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1.1 
Introduction 
 
Multiple pharmaceuticals, herbicides, fragrances and flavors manufactured on an 
industrial scale are known to involve a transition metal-catalyzed reaction in their 
synthesis.[1] Among these reactions, the most prominent reaction is the asymmetric 
hydrogenation catalyzed by a transition metal. The relevance of these products can be 
noticed by the fact that numerous non-specialists are familiar with their names (e.g.              
L-DOPA, ibuprofen and vitamin E). The metal-catalyzed hydrogenation is an attractive 
reaction for asymmetric synthesis, since it combines highly desirable advantages such as 
perfect atom economy, high conversions, low catalyst loadings and mild reaction 
conditions.[2] All these characteristics are well appreciated in modern organic synthesis 
and explain the various applications of metal-catalyzed asymmetric hydrogenation, not 
only in academic research but also in industrial synthesis. Although this reaction has been 
explored for many years and an impressive number of enantioselective catalysts have 
been developed it is still investigated today. The main goals in this field today are to find 
solutions to render this reaction more universal, meaning applicable to a wider range of 
substrates, or to discover more generally applicable, effective, inexpensive and readily 
available catalysts.[3] 
 
This first chapter of this thesis will show the ongoing need to design novel catalysts for 
iridium-catalyzed hydrogenation. First, the milestones set to reach today’s knowledge in 
asymmetric hydrogenation reactions catalyzed by a transition metal will be summarized. 
The subsequent sections will then mainly focus on iridium catalysts for asymmetric 
hydrogenation, by showing their successful applications in industrial processes 
(see section 1.3.2) and in natural product synthesis (see section 1.4.2). This perspective 
will also allow to present many of the designed ligands for iridium-catalyzed asymmetric 
hydrogenations as well as the broad variety of the substrates they have been applied to 
(see section 1.4.1). Today’s challenges in asymmetric metal-catalyzed hydrogenation, 
                                                             
[1] a) Asymmetric Catalysis on Industrial Scale: Challenges, Approaches and Solutions (eds. H.-U. Blaser 
and H.-J. Federsel), Wiley, Verlag GmbH & Co. KGaA, Weinheim, 2010; b) J. W. Scott, Topics in 
Stereochem. 1989, 19, 209-226; c) H.-U. Blaser, F. Spindler, M. Studer, Applied Catalysis A: General 2001, 
221, 119-143. 
[2] G Shang, W. Li, X. Zhang, Transition Metal-Catalyzed Homogeneous Asymmetric Hydrogenation in 
Catalytic Asymmetric Synthesis (ed. I. Ojima), Wiley, Hoboken, 2010, 3rd Ed., pp. 343-436. 
[3] a) H.-U. Blaser, B. Pugin, F. Spindler, Chemistry Today 2008, 26, 37-38; b) J. M. Hawkins, 
T. J. N. Watson, Angew. Chem. Int. Ed. 2004, 43, 3224-3228. 
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will then be discussed in section 1.5; prior to the presentation of the ligand scaffolds that 
have been investigated as part of the project described in this thesis (see section 1.6). 
 
1.2 
Transition Metal-Catalyzed Asymmetric Hydrogenation: a 
Historical Perspective 
 
The first active catalyst for homogeneous hydrogenation was the rhodium complex 
discovered by WILKINSON (Nobel Prize 1973, [(PPh3)3Rh]Cl, Figure 1) and COFFEY.[4] 
Not much earlier, methods to prepare optically active phosphines were reported by 
HORNER et al. and MISLOW et al.[5] The remarkable idea to replace triphenylphosphine by 
chiral phosphines was obvious to many researchers, but it was first realized by HORNER 
and KNOWLES, who developed the first asymmetric hydrogenation using a rhodium 
complex.[6] The enantioselectivities were low, but promising. KNOWLES optimized this 
catalytic system until it led to the enantioselective synthesis of the rare amino acid               
L-DOPA ((S)-3), which was already known at that time to be active in the treatment of 
Parkinson’s disease (Scheme 1).[7] This synthesis and the discovery in 1968 that a chiral 
rhodium catalyst can be used for catalytic and asymmetric hydrogenation earned 
KNOWLES the Nobel Prize in Chemistry in 2001 (shared with NOYORI and SHARPLESS).[8] 
 
 
Scheme 1. Monsanto synthesis of L-DOPA: the process has been in operation since 1978 and 
was the first transition metal-catalyzed asymmetric synthesis of a commercialized product.[8] 
                                                             
[4] a) J. A. Osborn, F. H. Jardine, Y. F. Young, G. Wilkinson, J. Chem. Soc. A 1966, 1711-1732; 
b) R. S. Coffey, Imperial Chemical Industries, Brit. Pat. 1965, 1121642. 
[5] a) L. Horner, H. Winkler, A. Rapp, A. Mentrup, H. Hoffmann, P. Beck, Tetrahedron Lett. 1961, 2, 161-166; 
b) O. Korpiun, K. Mislow, J. Am. Chem. Soc. 1967, 89, 4784-4786. 
[6] a) W. S. Knowles, Chem. Commun. 1968, 1445-1446; b) B. D. Vineyard, W. S. Knowles, M. J. Sabacky, 
G. L. Bachman, D. J. Weinkauff, J. Am. Chem. Soc. 1977, 99, 5946-5952; c) L. Horner, H. Büthe, H. Siegel, 
Tetrahedron Lett. 1968, 37, 4023-4026; d) L. Horner, H. Siegel, H. Büthe, Angew. Chem. Int. Ed. Engl. 1968, 
7, 942-942. 
[7] a) W. S. Knowles, M. J. Sabacky, B. D. Vineyard, J. Chem. Soc., Chem. Commun. 1972, 10-11; 
b) W. S. Knowles, Acc. Chem. Res. 1983, 16, 106-112. 
[8] W. S. Knowles, Angew. Chem. Int. Ed. 2002, 41, 1998-2007. 
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Since the discovery that a metal complex can be used as a homogeneous catalyst for 
hydrogenations, many important achievements were reported, resulting in today’s state-
of-the-art in transition metal-catalyzed asymmetric hydrogenations. Figure 1 does not 
describe the chronological history of progresses accomplished in asymmetric 
hydrogenation, it is rather thought to give a figurative overview of how a discovery 
stimulated the next one to reach standards of reactivity. Nowadays countless 
combinations of ligands and transition metals have been reported to give good to high 
selectivities in the asymmetric hydrogenation of a myriad of substrates, but Figure 1 is 
only meant to show the most important compounds that represent landmarks in 
organometallic chemistry. 
 
Shortly after KNOWLES’and HORNER’s discovery, other researchers brought similar 
contributions and achieved the synthesis of various ligands for transition metals.[9] 
KAGAN et al. introduced C2-symmetric diphosphines, such as DIOP                                
(2,3-O-isopropylidene-2,3-dihydroxy-1,4-bis(diphenylphosphino)butane, (R,S)-LDIOP, 
Figure 1) as ligands and showed their synthesis to be practicable.[9a-b] 
 
Another pioneer in this field, awarded with the Nobel Prize together with KNOWLES, is 
NOYORI.[10] He discovered the C2-chiral diphosphine ligand BINAP                                 
(2,2'-bis(diphenylphosphino)-1,1'-binaphthyl, (Sa)-LBINAP, Figure 1) as a versatile and 
efficient ligand for various metal-catalyzed transformations, including the asymmetric 
hydrogenation of α-(acylamino)acrylic acids or esters.[11] BINAP/ruthenium-complexes 
proved to be more efficient than their rhodium analogues for a broader range of 
substrates. Besides the C−C double bond reduction of functionalized alkenes, they also 
allow for the reduction of the C−O double bond in a wide range of ketones.[12] Important 
industrial syntheses, involving a transformation catalyzed by a BINAP/ruthenium or 
/rhodium catalyst as key step will be described in more detail in section 1.3.1. 
 
                                                             
[9] a) T. P. Dang, H. B. Kagan, J. Chem. Soc. D 1971, 481-481; b) H. B. Kagan, T.-P. Dang, J. Am. Chem. 
Soc. 1972, 94, 6429-6433; c) J. D. Morrison, R. E. Burnett, A. M. Aguiar, C. J. Morrow, C. Phillips, J. Am. 
Chem. Soc. 1971, 93, 1301-1303. 
[10] R. Noyori, Angew. Chem. Int. Ed. 2002, 41, 2008-2022. 
[11] A. Miyashita, A. Yasuda, H. Takaya, K. Toriumi, T. Ito, T. Souchi, R. Noyori, J. Am. Chem. Soc. 1980, 
102, 7932-7934. 
[12] a) M. Kitamura, T. Ohkuma, S. Inoue, N. Sayo, H. Kumobayashi, S. Akutagawa, T. Ohta, H. Takaya, 
R. Noyori, J. Am. Chem. Soc. 1988, 110, 629-631; b) T. Ohta, H. Takaya, R. Noyori, Inorg. Chem. 1988, 27, 
566-569. 
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Ligand design for asymmetric hydrogenation catalyzed by a transition metal continued to 
be the main focus of research for several years and many modifications of the structural 
environment around the metal center were investigated. BURK et al. for instance, designed 
the bis(phospholane) ligand DuPhos for the rhodium-catalyzed hydrogenation of various 
olefins ((S,S)-LDuPhos, Figure 1).[13] For a long time C2-symmetric P,P ligands dominated 
in asymmetric transition metal catalysis. In the 90s, the planar chiral and non-symmetric 
ferrocene-based ligands Josiphos were discovered ((R,SFc)-LJosiphos, Figure 1).[14] After 
the discovery of sterically and electronically non-symmetric P,N ligands by PFALTZ, and 
independently by HELMCHEN and WILLIAMS, a change in the course of research in chiral 
ligands could be observed; many ligands that were introduced later on for asymmetric 
catalysis were non-symmetric.[15] Although the concept of C2-symmetry has been very 
successful, the introduction of the non-symmetrical PHOX ligands proved that two 
electronically and sterically divergent coordinating units can be more effective than       
C2-symmetric ligands. PHOX ligands, which were developed originally for palladium-
catalyzed allylic substitutions, were also deployed to other transition metal-catalyzed 
reactions. Excellent enantiomeric excesses and turn over numbers were obtained in the 
iridium-catalyzed asymmetric hydrogenation of trisubstituted alkenes by the use of these 
P,N ligands. PHOX/iridium complexes were shown not require a polar coordinating 
group near to the C−C double bond that is reduced, contrarily to rhodium and ruthenium 
catalysts. 
 
CRABTREE et al. reported already in 1979 that [Ir(cod)(PCy3)(Py)]PF6 was a highly active 
catalyst for the hydrogenation of alkenes (CRABTREE’s catalyst, Figure 1).[16] This 
complex hydrogenated alkenes more rapidly than WILKINSON’s catalyst. However, 
deactivation of the catalyst due to the formation of inactive hydride-bridged trinuclear 
complexes was observed.[16b] Such a trinuclear PHOX/iridium hydride complex was 
isolated and characterized.[17]  
                                                             
[13] a) M. J. Burk, J. Am. Chem. Soc. 1991, 113, 8518-8519; b) M. J. Burk, J. E. Feaster, W. A. Nugent, 
R. L. Harlow, J. Am. Chem. Soc. 1993, 115, 10125-10138; c) M. J. Burk, Acc. Chem. Res. 2000, 33, 363-
372. 
[14] a) A. Togni, C. Breutel, A. Schnyder, F. Spindler, H. Landert, A. Tijani, J. Am. Chem. Soc. 1994, 116, 
4062-4066; b) H.-U. Blaser, W. Brieden, B. Pugin, F. Spindler, M. Studer, A. Togni, Top. Catal. 2002, 19, 3-
16. 
[15] a) A. Pfaltz, W. J. Drury III., PNAS 2004, 101, 5723-5726; b) G. Helmchen, A. Pfaltz, Acc. Chem. Res. 
2000, 33, 336-345; c) J. M. J. Williams, Synlett 1996, 8, 705-710. 
[16] a) R. H. Crabtree, H. Felkin, G. E. Morris, J. Organomet. Chem. 1977, 141, 205-215; b) R. Crabtree, 
Acc. Chem. Res. 1979, 12, 331-337. 
[17] S. P. Smidt, A. Pfaltz, E. Martínez-Vivente, P. S. Pregosin, A. Albinati, Organometallics 2003, 22, 1000-
1009. 
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Figure 1. Figurative representation of milestones in metal-catalyzed asymmetric hydrogenation. 
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The catalyst deactivation was circumvented replacing the PF6-anion with the weakly 
coordinating, bulky and apolar BArF-couteranion (tetrakis[3,5-bis(trifluoromethyl) 
phenyl]borate, Figure 1).[18] However, it seems that only this accumulation of different 
findings (non-symmetric ligands, solvent and counterion effects and the success of the 
Josiphos ligands in industry) permitted to show that iridium is an interesting alternative to 
rhodium and ruthenium for the catalytic enantioselective hydrogenation.  
 
The mechanism of the rhodium/phosphine-complex catalyzed asymmetric hydrogenation 
has been elucidated. Detailed mechanistic studies of the DiPAMP/rhodium-catalyzed 
asymmetric hydrogenation of acetamidocinnamates were performed by HALPERN and 
BROWN et al.[19] The mechanism of the asymmetric hydrogenation of ketones using a 
BINAP/ruthenium complex was elucidated by NOYORI et al.[20] A definitive rationale of 
the mechanism of the iridium-catalyzed hydrogenation of C−C double bonds has not been 
proposed yet.[21] Although several studies have been undertaken, experimental evidence 
about each step of the catalytic cycle is still lacking and, according to computational 
studies, it seems that several pathways are possible.[21] 
 
 
 
 
 
                                                             
[18] a) A. Lightfoot, P. Schnider, A. Pfaltz, Angew. Chem. Int. Ed. 1998, 37, 2897-2899; b) S. J. Roseblade, 
A. Pfaltz, Acc. Chem. Res. 2007, 40, 1402-1411; c) I. Krossing, I. Raabe, Angew. Chem. Int. Ed. 2004, 43, 
2066-2090. 
[19] a) J. Halpern, Science 1982, 217, 401-407; b) J. Halpern, Asymmetric Catalytic Hydrogenation: 
Mechanism and Origin of Enantioselection, in Asymmetric Synthesis (ed. J. D. Morrison), Academic Press, 
New York, 1985, Vol. 5, pp. 41-69; c) J. M. Brown, P. A. Chaloner, Tetrahedron Lett. 1978, 21, 1877-1880; 
d) J. M. Brown, P. A. Chaloner, J. Chem. Soc., Chem. Commun. 1980, 344-346; e) J. M. Brown, D. Parker, 
Organometallics 1982, 1, 950-956; f) J. M. Brown, L. R. Canning, A. J. Downs, A. M. Forster, J. Organomet. 
Chem. 1983, 255, 103-111; g) A. S. C. Chan, J. J. Pluth, J. Halpern, Inorg. Chim. Acta 1979, 37, 477-479; 
h) A. S. C. Chan, J. J. Pluth, J. Halpern, J. Am. Chem. Soc. 1980, 102, 5952-5954; i) A. S. C. Chan, 
J. Halpern, J. Am. Chem. Soc. 1980, 102, 838-840; j) C. Landis, J. Halpern, J. Am. Chem. Soc. 1987, 109, 
1746-1754; k) I. D. Gridnev, T. Imamoto, Acc. Chem. Res. 2004, 37, 633-644. 
[20] C. A. Sandoval, T. Ohkuma, K. Muñiz, R. Noyori, J. Am. Chem. Soc. 2003, 125, 13490-13503. 
[21] a) R. H. Crabtree, P. C. Demou, D. Eden, J. M. Mihelcic, C. A. Parnell, J. M. Quirk, G. E. Morris, J. Am. 
Chem. Soc. 1982, 104, 6994-7001; b) C. Mazet, S. P. Smidt, M. Meuwly, A. Pfaltz, J. Am. Chem. Soc. 2004, 
126, 14176-14181; c) M. J. Burk, M. P. McGrath, R. Wheeler, R. H. Crabtree, J. Am. Chem. Soc. 1988, 110, 
5034-5039; d) R. Dietiker, P. Chen, Angew. Chem. Int. Ed. 2004, 43, 5513-516; e) X. Cui, K. Burgess, 
Chem. Rev. 2005, 105, 3272-3296; f) Y. Zhu, Y. Fan, K. Burgess, J. Am. Chem. Soc. 2010, 132, 6249-6253; 
g) Y. Fan, X. Cui, K. Burgess, M. B. Hall, J. Am. Chem. Soc. 2004, 126, 16688-16689; h) J. Zhou, 
J. W. Ogle, Y. Fan, V. Banphavichit(Bee), Y. Zhu, K. Burgess, Chem. Eur. J. 2007, 13, 7162-7170; 
i) C. Hedberg, K. Källström, P. Brandt, L. K. Hansen, P. G. Andersson, J. Am. Chem. Soc. 2006, 128, 2995-
3001; j) T. L. Church, T. Rasmussen, P. G. Andersson, Organometallics 2010, 29, 6769-6781; k) P. Brandt, 
C. Hedberg, P. G. Andersson, Chem. Eur. J. 2003, 9, 339-347; l) K. H. Hopmann, A. Bayer, Organometallics 
2011, 30, 2483-2497; m) K. Källström, I. Munslow, P. G. Andersson, Chem. Eur. J. 2006, 12, 3194-3200. 
IRIDIUM-CATALYZED ASYMMETRIC HYDROGENATION AS A TOOL FOR ORGANIC SYNTHESIS 
 
13 
1.3 
Metal-Catalyzed Asymmetric Hydrogenation in Industrial 
Processes 
 
A major concern for chemical processes is efficiency. Catalysis can be highly productive 
and economical, as it reduces the waste deriving from racemate resolution in 
enantioselective synthesis. The asymmetric hydrogenation reaction is fundamental for the 
manufacturing of fine and industrial chemicals and has found application in the industrial 
synthesis of pharmaceuticals, agrochemicals, flavors and fragrances. Selected examples 
of transition metal-catalyzed asymmetric hydrogenation for industrial processes will be 
presented below. 
 
1.3.1 
Rhodium and Ruthenium Catalysts for Asymmetric Hydrogenation 
in Industrial Processes 
 
Most of the asymmetric hydrogenations in industry involve chiral phosphorus ligands and 
are rhodium- or ruthenium-catalyzed. As described above, the first industrial application 
of a metal-catalyzed asymmetric hydrogenation was found in the synthesis of L-DOPA 
(Scheme 1). The catalyst developed by KNOWLES, not only proved to be efficient in the 
enantioselective synthesis of L-DOPA, but also led to the synthesis of several amino 
acids, such as phenylalanine, tryptophan and alanine with enantiomeric excess higher 
than 90%. This application of diphosphine/rhodium catalysts became a standard method 
for the production of enantiomerically pure amino acids. Although KNOWLES’ 
DiPAMP ligand was efficient, the chiral phospholane DuPhos introduced later on 
replaced it since this ligand proved to be more convenient hydrogenation of                   
(E)/(Z)-mixtures of olefins.[13c] 
 
Another significant example of a pharmaceutically important compound that can be 
synthesized by asymmetric hydrogenation of a C−C double bond using this time a 
ruthenium-based BINAP catalyst is (S)-ibuprofen ((S)-4, Figure 2). This                       
anti-inflammatory drug was obtained quantitatively from 2-(4-isobutylphenyl)propenoic 
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acid with 97% ee.[22] The synthesis of (S)-naproxen ((S)-5), a chiral anti-inflammatory 
drug) involves as well an enantioselective hydrogenation that can be catalyzed effectively 
by the BINAP/ruthenium catalysts developed by NOYORI et al.[23] Despite the good 
results obtained with several catalysts in terms of enantioselectivity, the asymmetric 
synthesis of (S)-naproxen ((S)-5) by asymmetric hydrogenation is still not valuable for 
industry. For economical reasons, (S)-naproxen is still produced on a large scale by the 
resolution of a racemate.[1c] 
 
 
[a] (S)-Naproxen is still produced on a large scale by the resolution of a racemate. 
Figure 2. Asymmetric hydrogenation products produced in large scale by the use of chiral 
ruthenium and rhodium catalysts.[1c,23-26] 
 
Some other compounds synthesized by asymmetric C−C double bond reduction are: 
citronellol ((R)-6) by Takasago;[1c,24] the intermediate (R,S,R)-7 for biotin by Lonza;[1c,25] 
and the intermediate (S)-8 in the synthesis of aspartame (sweetener) by 
Enichem/Anic[1c,26] (Figure 2). Whereas, the synthesis of citronellol involves as well a 
BINAP/ruthenium catalyst, the asymmetric hydrogenations affording (R,S,R)-7 and (S)-8 
are rhodium-catalyzed. 
 
                                                             
[22] a) K. Mashima, K. Kusano, N. Sato, Y. Matsumura, K. Nozaki, H. Kumobayashi, N. Sayo, Y. Hori, 
T. Ishizaki, S. Akutagawa, H. Takaya, J. Org. Chem. 1994, 59, 3064-3076; b) H. Kumobayashi, T. Miura, 
N. Sayo, T. Saito, X. Zhang, Synlett 2001, 1055-1064. 
[23] a) T. Ohta, H. Takaya, R. Noyori, Inorg. Chem. 1988, 27, 566-569; b) T. Ohta, H. Takaya, M. Kitamura, 
K. Nagai, R. Noyori, J. Org. Chem. 1987, 52, 3174-3176. 
[24] S. Akutagawa, Appl. Catal. A: General 1995, 128, 171-207. 
[25] R. Imwinkelried, Chimia 1997, 51, 300-302. 
[26] a) I. Ojima, N. Clos, C. Bastos, Tetrahedron 1989, 45, 6901-6939; b) M. Fiorini, M. Riocci, M. Giongo, 
Eur. Pat. Appl. 1983, EP 77099 A2. 
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1.3.2 
Iridium Catalysts for Asymmetric Hydrogenation in Industrial Processes 
 
Among all the production processes known to involve an asymmetric hydrogenation as 
the key step, only one of them employs an iridium catalyst (Scheme 2).[1c] In fact, iridium 
catalysts have found so far no commercially important application in the reduction of 
C−C double bonds, however the Josiphos 1/iridium complex has been applied 
successfully to the industrial synthesis of the herbicide (S)-metolachlor ((S)-11, 
Scheme 2). The active ingredient of the grass herbicide, commercialized as Dual®, was 
first sold as a racemate, until it was found in 1982 that only the (S)-enantiomer of 
metolachlor is bioactive. The iridium/ferrocenyl bisphosphine catalyst found its utility in 
the asymmetric reduction of the C−N double bond of the imine intermediate: 2-methyl-6-
ethylphenyl-1'-methyl-2'-methoxyethylimine (MEA-imine, (9)). The Josiphos 1/iridium 
catalyst showed extremely high activities and high enantioselectivities in the presence of 
acid and iodine, compared to all the other rhodium/ or iridium/P,P ligand combinations 
previously tested.[27] Solvias AG (formerly Ciba-Geigy/Novartis) demonstrated that 
enantioselective hydrogenation can compete against other methods (such as classical 
resolution, chromatographic separation or biocatalysis) in the production of 
enantiomerically enriched chiral compounds. 
 
Scheme 2. (S)-Metolachlor process.[27] 
The Solvias Josiphos ligand family is today almost as successful as the BINAP ligand 
family and has been reported to induce high enantioselectivities in a wide variety of 
transformations.[28] 
                                                             
[27] H.-U. Blaser, R. Hanreich, H.-D. Schneider, F. Spindler, B. Steinacher,The Chiral Switch of Metolachlor: 
The Development of a Large-Scale Enantioselective Catalytic Process, in Asymmetric Catalysis on Industrial 
Scale: Challenges, Approaches and Solutions (eds. H.-U. Blaser and E. Schmidt), Wiley-VCH Verlag GmbH 
& Co. KGaA, Weinheim, FRG, 2004. 
[28] a) H.-U. Blaser, W. Brieden, B. Pugin, F. Spindler, M. Studer, A. Togni, Top. Catal. 2002, 19, 3-16; 
b) H.-U. Blaser, B. Pugin, F. Spindler, M. Thommen, Acc. Chem. Res. 2007, 40, 1240-1250. 
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However, the enantioselective reduction of C−C double bonds in production is still 
dominated by rhodium and ruthenium catalysts, most likely due to their high efficiency, 
extensively reported in the literature. This observation is very surprising, considering the 
fact that iridium complexes can be more reactive than rhodium and ruthenium catalysts 
and, in contrast to rhodium and ruthenium complexes do not require an additional 
coordinating functional group close to the C−C double bond to promote its 
reduction.[19a,29] Further to these observations and considering the advantageous price of 
iridium compared to rhodium, efforts are being made to increase the number of industrial 
processes involving an iridium-catalyzed asymmetric hydrogenation. For instance, in a 
pilot process at Lonza, a Josiphos ligand has been used in combination with iridium in the 
reduction of the imine intermediate 12 for the preparation of dextromethorphan          
((S,S,S)-14), an antitussive (Scheme 3).[1c,25] Unfortunately though, the catalyst efficiency 
was reported to be rather low (ton 1 500; compared to 2 000 000 in the hydrogenation of 
the (S)-metolachlor intermediate, Scheme 2). 
 
 
Scheme 3. Pilot process at Lonza: asymmetric hydrogenation of imine 12 to amine (S)-13, an 
intermediate in the synthesis of dextromethorphan. 
 
In order to encourage process chemists to consider asymmetric catalysis for the large 
scale manufacturing of low cost products, the chiral ligands need either to be available in 
large quantities or at least involve short synthesis. Today’s challenges can be seen in two 
different ways, either researchers seek for the right substrate and catalyst combination 
using for example high-throughput methods, or go on seeking for more broadly 
applicable catalysts, that are readily available. 
 
                                                             
[29] A. Pfaltz, J. Blankenstein, R. Hilgraf, E. Hörmann, S. McIntyre, F. Menges, M. Schönleber, S. P. Smidt, 
B. Wüstenberg, N. Zimmermann, Adv. Synth. Catal. 2003, 345, 33-43. 
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1.4 
Iridium-Catalyzed Asymmetric Hydrogenation in Natural Product 
Synthesis 
 
Many iridium catalysts have been designed and deployed to hydrogenate 
enantioselectively a broad variety of substrates. As depicted in Figures 3 and 4, a certain 
type of substrate can often be associated with a type of ligand structure depending on 
their electronic and steric features. This association can rarely be predicted and a 
thorough substrate screening is often required to identify the best catalyst for a defined 
substrate class. Moreover, one should also keep in mind that a substrate class that can be 
hydrogenated with good enantioselectivities, using already known catalysts is not always 
tested for each new catalyst system, since researchers try to fill the existing gaps. 
Therefore, a comparison between all the existing catalysts for each substrate class is not 
possible. Nevertheless, the iridium-catalyzed asymmetric hydrogenation of C−N and C−C 
double bonds has proved to be very efficient in academia. In this case, once a catalyst has 
been found to be active and selective in the hydrogenation of a specific substrate, it 
becomes an interesting tool for synthesis. Herein, privileged ligands for each class of 
substrate for the iridium-catalyzed asymmetric hydrogenation will first be described 
(see section 1.4.1). Next, ligands that were applied successfully to natural product 
syntheses featuring an asymmetric iridium-catalyzed hydrogenation will be presented 
(see section 1.4.2). 
 
1.4.1 
Privileged Chiral Bidentate Ligands for Iridium 
 
Many ligands have been elaborated and the design of new ligand structures is still 
ongoing. This section describes bidentate ligands that were applied to the asymmetric 
hydrogenation of C−C, C−N and C−O double bonds. The discussion will be limited to 
bidentate ligands coordinating to iridium, even though a large number of monodentate 
ligands was as well developed for iridium-catalyzed asymmetric hydrogenation.[30] 
                                                             
[30] a) N. Mrsic, L. Lefort, J. A. F. J. Boogers, A. J. Minnaard, B. L. Feringa, J. G. de Vries, Adv. Synth. 
Catal. 2008, 350, 1081-1089; b) G. Erre, K. Junge, S. Enthaler, D. Addis, D. michalik, A. Spannenberg, 
M. Beller, Chem. Asian J. 2008, 3, 887-894; c) X.-B. Jiang, M. van den Berg, A. J. Minnaard, B. L. Feringa, 
J. G. de Vries, Tetrahedron: Asymmetry 2004, 15, 2223-2229; d) X.-B. Jiang, A. J. Minnaard, B. Hessen, 
B. L. Feringa, A. L. L. Duchateau, J. G. O. Andrien, J. A. F. Boogers, J. G. de Vries, Org. Lett. 2003, 5, 1503-
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1.4.1.1 
Bidentate Ligands for Asymmetric Hydrogenation of C−C Double Bonds 
 
Figure 3 shows ligand structures, which allowed to broaden the substrate scope for 
enantioselective hydrogenation of C−C double bonds employing iridium complexes. This 
figure offers an overview of the substrates that were efficiently hydrogenated using chiral 
iridium complexes and shows, at the same time, that the asymmetric hydrogenation 
reaction is a substrate specific reaction. Each ligand type performs best for a specific 
substrate class. This does not mean that a specific ligand is not applicable to another 
substrate class, but that it performs better in the reduction of a particular substrate type it 
is associated to than others tested previously.  
 
Trisubstituted functionalized and unfunctionalized alkenes can be hydrogenated 
selectively with a large number of P,N ligands and NHC ligands.[31] In contrast, 
unfunctionalized tetrasubstituted alkenes could only be hydrogenated successfully using 
iridium catalysts derived from phosphinooxazolines (S)-L8 with up to 97% ee 
(see Figure 3).[32] 
 
For the hydrogenation of 1,1-disubstituted alkenes, phosphinite–oxazoline ligands derived 
from threonine ((S,S)-LThrePHOX) were shown to be highly selective (up to 94% ee).[33a-b] 
A broader range of highly functionalized 1,1-disubstituted alkenes were asymmetrically 
hydrogenated with up to 99% ee with chiral phosphite oxazoline ligands L1*.[33c] A new 
class of bulky chiral pyranoside phosphite-oxazoline ligands (L2*) designed by 
ANDERSSON et al. showed as well remarkable enantioselectivities for some                         
1,1-disubstituted alkenes (up to 99% ee).[33d-e] 
 
                                                                                                                                                                                      
1506; e) M. T. Reetz, X. Li, Chem. Commun. 2006, 2159-2160; e) A. J. Minnard, B. L. Feringa, L. Lefort, 
J. G. de Vries, Acc. Chem. Res. 2007, 40, 1267-1277. 
[31] D. H. Woodmansee, A. Pfaltz, Chem. Commun. 2011, 47, 7912-7916. 
[32] M. G. Schrems, E. Neumann, A. Pfaltz, Angew. Chem. Int. Ed. 2007, 46, 8274-8276. 
[33] a) S. McIntyre, E. Hörmann, F. Menges, S. P. Smidt, A. Pfaltz, Adv. Synth. Catal. 2005, 347, 282-288; 
b) F. Menges, A. Pfaltz, Adv. Synth. Catal. 2002, 344, 40-44; c) J. Mazuela, J. J. Verendel, M. Coll, 
B. Schäffner, A. Börner, P. G. Andersson, O. Pàmies, M. Diéguez, J. Am. Chem. Soc. 2009, 131, 12344-
12353; d) M. Diéguez, J. Mazuela, O. Pàmies, J. J. Verendel, P. G. Andersson, J. Am. Chem. Soc. 2008, 
130, 7208-7209; e) J. Mazuela, P.-O. Norrby, P. G. Andersson, O. Pàmies, M. Diéguez, J. Am. Chem. Soc. 
2011, 133, 13634-13645. 
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Fewer examples of the successful hydrogenation of C−C double bonds of α,β-unsaturated 
ketones are reported.[34]. Both phosphinooxazolines ligands ((S)-LPHOX and (S)-L3) 
allowed for the hydrogenation of α,β-disubstituted enones, with enantiomeric excesses of 
up to 99%.[34a-c] However, for the selective C−C double bond hydrogenation of               
β,β-disubstituted enones, sulfoximine-derived P,N ligands (S)-L4 gave up to           
97% ee depending on the substituents.[34d] Ferrocenyl-PHOX iridium catalysts                   
((S,SFc)-LFc-PHOX ligands) reduce α,β-unsaturated amides with up to 98% ee.[35] Only 
iridium complexes of the spiro ligands, (S,Sa)-LSpinPHOX and (S,Sa)-LSiPHOX, are reported 
to reduce enantioselectively α,β- and β,γ-unsaturated carboxylic acids.[36] Iridium 
complexes with biphenylphosphine oxazoline ligands ((S,Sa)-L5) are the only ones which 
were reported to achieve the asymmetric hydrogenation of α,β-unsaturated lactones and 
lactames with high enantioselectivities (up to 98% ee).[34e] Moreover, these ligands were 
also applied to the asymmetric reduction of the to exocyclic C−C double bond of               
α,β-unsaturated ketones.[34e] 
 
Di- and trisubstituted enol phosphinates can be hydrogenated with up to 99% ee by 
iridium complexes bearing P,N ligands (S,S,R,R)-L6.[37] (S,S,R,R)-L6 ligands, also 
furnished high enantioselectivities in the iridium-catalyzed reduction of vinyl boronates 
(up to 98% ee).[38] Iridium complexes derived from (R)-L7 proved to be selective in the 
asymmetric hydrogenation of a few fluorinated alkenes.[39] The same ligand (R)-L7 
allowed for high enantioselectivities in the asymmetric hydrogenation of several 
diphenylvinylphosphine oxides and vinylphosphonates.[40] Very recently (1-chloro-1-
alkenyl)boronic esters were hydrogenated with moderate to high enantioselectivities, 
using Ferrocenyl-PHIM  ligands ((R,R,SFc)-LFc-PHIM).[41] 
 
                                                             
[34] a) W.-J. Lu, Y.-W. Chen, X.-L. Hou, Adv. Synth. Catal. 2010, 352, 103-107; b) S.-M. Lu, C. Bolm, 
Angew. Chem. Int. Ed. 2008, 47, 8920-8923; c) W.-J. Lu, Y.-W. Chen, X.-L. Hou, Angew. Chem. Int. Ed. 
2008, 47, 10133-10136; d) S.-M. Lu, C. Bolm, Chem. Eur. J. 2008, 14, 7513-7516; e) F. Tian, D. Yao, Y. Liu, 
F. Xie, W. Zhang, Adv. Synth. Catal. 2010, 352, 1841-1845. 
[35] W.-J. Lu, X.-L. Hou, Adv. Synth. Catal. 2009, 351, 1224-1228. 
[36] a) S. Li, S.-F. Zhu, C.-M. Zhang, S. Song, Q.-L. Zhou, J. Am. Chem. Soc. 2008, 130, 8584-8585; 
b) Y. Zhang, Z. Han, F. Li, K. Ding, A. Zhang, Chem. Commun. 2010, 46, 156-158; c) S. Song, S.-F. Zhu, 
S. Yang, S. Li, Q.-L Zhou, Angew. Chem. Int. Ed. 2012, 51, 2708-2711. 
[37] a) P. Cheruku, S. Gohil, P. G. Andersson, Org. Lett. 2007, 9, 1659-1661; b) P. Cheruku, J. Diesen, 
P. G. Andersson, J. Am. Chem. Soc. 2008, 130, 5595-5599. 
[38] A. Paptchikhine, P. Cheruku, M. Engman, P. G. Andersson, Chem. Commun. 2009, 5996-5998. 
[39] M. Engman, J. S. Diesen, A. Paptchikhine, P. G. Andersson, J. Am. Chem. Soc. 2007, 129, 4536-4537. 
[40] P. Cheruku, A. Paptchikhine, T. L. Church, P. G. Andersson, J. Am. Chem. Soc. 2009, 131, 8285-8289. 
[41] I. Gazić Smilović, E. Casas-Arcé, S. J. Roseblade, U. Nettekoven, A. Zanotti-Gerosa, M. Kovačevič, 
Z. Časar, Angew. Chem. Int. Ed. 2012, 51, 1014-1018. 
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Protected and unprotected allylic alcohols were reduced with high enantioselectivities 
using the ligand type (R)-L9 developed by PFALTZ et al., but also using and the 
carbene oxazoline ligand (S)-L10 designed by BURGESS et al.[42] In addition, BURGESS’ 
iridium catalyst ((S)-L10/iridium complex) permits the asymmetric hydrogenation of 
vinyl ethers with up to 98% ee, a transformation which is so far not achievable with 
P,N ligands.[43] This same carbene-oxazoline catalyst allows for the asymmetric 
hydrogenation of dienes.[44]  
 
Bicyclic pyridine phosphinite (R)-L9 are valuable ligands for the iridium-catalyzed 
asymmetric hydrogenation of a broad range of substrates, but remarkable is their 
application in the reduction of furane and benzofurane derivatives (up to 99% ee), for 
which no precedent was reported before.[45] These same ligands proved highly efficient in 
the asymmetric hydrogenation of purely alkyl-substituted alkenes.[46] Chromenes were 
hydrogenated with excellent enantioselectivities using iridium complexes chelated with 
phosphinite oxazoline ligands derived from threonine ((S,S)-LThrePHOX).[47]  
 
Screening P,N iridium catalysts developed previously, unfunctionalized enamines were 
hydrogenated with up to 91% ee, using a phosphinooxazoline ligand ((S)-LPHOX).[48a] The 
well known PHOX ligands provided the best results for a larger amount of substrates but 
also other P,N ligands were shown to be effective for the iridium-catalyzed asymmetric 
hydrogenation of enamines.[48] N-Protected indole derivatives were reduced 
enantioselectively with (S,S)-LThrePHOX and bicyclic pyridine phosphinite (R)-L9 (up to 
99% ee) but the scope of indoles that underwent selective reduction is very narrow.[49] 
 
 
 
 
                                                             
[42] a) A. Wang, B. Wüstenberg, A. Pfaltz, Angew. Chem. Int. Ed. 2008, 47, 2298-2300; b) J. Zhou, 
K. Burgess, Angew. Chem. Int. Ed. 2007, 46, 1129-1131; c) J. Zhao, K. Burgess, J. Am. Chem. Soc. 2009, 
131, 13236-13237. 
[43] Y. Zhu, K. Burgess, Adv. Synth. Catal. 2008, 350, 979-983. 
[44] X. Cui, K. Burgess, J. Am. Chem. Soc. 2003, 125, 14212-14213. 
[45] S. Kaiser, S. P. Smidt, A. Pfaltz, Angew. Chem. Int. Ed. 2006, 45, 5194-5197. 
[46] S. Bell, B. Wüstenberg, S. Kaiser, F. Menges, T. Netscher, A. Pfaltz, Science 2006, 311, 642-644. 
[47] C. Valla, A. Baeza, F. Menges, A. Pfaltz, Synlett 2008, 20, 3167-3171. 
[48] a) A. Baeza, A. Pfaltz, Chem. Eur. J. 2009, 15, 2266-2269; b) P. Cheruku, T. L. Church, A. Trifonova, 
T. Wartmann, P. G. Andersson, Tetrahedron Lett. 2008, 49, 7290-7293; c) G.-H. Hou, J.-H. Xie, P.-C. Yan, 
Q.-L. Zhou, J. Am. Chem. Soc. 2009, 131, 1366-1367. 
[49] A. Baeza, A. Pfaltz, Chem. Eur. J. 2010, 16, 2036-2039. 
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Figure 3. Privileged ligands for iridium-catalyzed asymmetric hydrogenation of C−C double bond. 
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Figure 3. (continued) 
 
Besides P,N ligands constituted from a heterocyclic sp2-hybridized nitrogen donor in 
combination with a trisubstituted phosphorus atom, also a C,N ligand ((S)-L10) having a 
coordinating N-heterocyclic carbene unit was designed and gave astonishingly high 
selectivities in the iridium-catalyzed asymmetric reduction of several substrates (vinyl 
ethers, allylic alcohols and dienes, Figure 3). 
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1.4.1.2 
Bidentate Ligands for the Asymmetric Hydrogenation of C−N Double Bonds 
 
In the iridium-catalyzed asymmetric hydrogenations of C−N double bonds not only 
bidentate P,N ligands proved to be efficient but also P,P ligands. In Figure 4 are depicted 
selected ligands, which gave high enantioselectivities in the iridium-catalyzed 
hydrogenation of C−N double bonds. 
 
Besides the Josiphos ligand family presented previously, an impressive amount of various 
P,N and P,P ligands have been applied to the iridium-catalyzed hydrogenation of various 
imines.[34a,50] The ligands designed by KNOCHEL et al. ((S,SFc)-L11) and those developed 
by YOSHIDA et al. ((S,S)-L12) allow for enantioselectivities up to 99% in the reduction of 
aromatic N-aryl imines, whereas with SpinPHOX ligands ((S,Sa)-LSpinPHOX) the 
hydrogenation of aromatic N-benzyl imines can be achieved with up to 98% ee.[50g-i] The 
chiral 1,1-bisphosphanoferrocene ligands (Sa,Sa)-Lf-binaphane led to the hydrogenation of 
acyclic imines with up to > 99% ee and of N−H imines with up to 94% ee.[50k] 
 
Quinolines were hydrogenated with the use of sulfoximine-derived P,N ligands ((S)-L4) 
for iridium, achieving enantiomeric excesses of up to 92%.[51a] Ferrocenyl-based 
P,N ligands furnished similar enantioselectivities,[51b] whereas MeO-Biphep ligand, a 
P,P chelating ligand gave slightly higher enantioselectivities (up to 96%).[51c] Many other 
P,P ligands were successfully employed for the iridium-catalyzed asymmetric 
hydrogenation of quinolines.[51d-e]  
 
                                                             
[50] a) A. Baeza, A. Pfaltz, Chem. Eur. J. 2010, 16, 4003-4009; b) P. Schnider, G. Koch, R. Prétôt, G. Wang, 
F. M. Bohnen, C. Krüger, A. Pfaltz, Chem. Eur. J. 1997, 3, 887-892; c) A. Trifonova, J. S. Diesen, 
C. J. Chapman, P. G. Andersson, Org. Lett. 2004, 6, 3825-3827; d) A. Trifonova, J. S. Diesen, 
P. G. Andersson, Chem. Eur. J. 2006, 12, 2318-2328., e) C. Moessner, C. Bolm, Angew. Chem. Int. Ed. 
2005, 44, 7564-7567; f) S.-F. Zhu, J.-B. Xie, Y.-Z. Zhang, S. Li, Q.-L. Zhou, J. Am. Chem. Soc. 2006, 128, 
12886-12891; g) M. N. Cheemala, P. Knochel, Org. Lett. 2007, 9, 3089-3092; h) Z. Han, Z. Wang, X. Zhang, 
K. Ding, Angew. Chem. Int. Ed. 2009, 48, 5345-5349; i) T. Imamoto, N. Iwadate, K. Yoshida, Org. Lett. 2006, 
8, 2289-2292; j) D. Xiao, X. Zhang, Angew. Chem. Int. Ed. 2001, 40, 3425-3428; k) G. Hou, F. Gosselin, 
W. Li, J. C. McWilliams, Y. Sun, M. Weisel, P. D. O’Shea, C. Y. Chen, I. W. Davies, X. Zhang, J. Am. Chem. 
Soc. 2009, 131, 9882-9883. 
[51] a) S.-M. Lu, C. Bolm, Adv. Synth. Catal. 2008, 350, 1101-1105; b) S.-M. Lu, X.-W. Han, Y.-G. Zhou, 
Adv. Synth. Catal. 2004, 346, 909-912; c) W.-B. Wang, S.-M. Lu, P.-Y. Yang, X.-W. Han, Y.-G. Zhou, J. Am. 
Chem. Soc. 2003, 125, 10536-15037; d) S. H. Chan, K. H. Lam, Y.-M. Li, L. Xu, W. Tang, F. L. Lam, 
W. H. Lo, W. Y. Yu, Q. Fan, A. S. C. Chan, Tetrahedron: Asymmetry 2007, 18, 2625-2631; e) F.-R. Gou, 
W. Li, X. Zhang, Y.-M. Liang, Adv. Synth. Catal. 2010, 352, 2441-2444. 
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Figure 4. Privileged ligands for iridium-catalyzed asymmetric hydrogenation of C−N double 
bonds. 
 
Even though enantioselectivities are excellent, the range of imines and quinolines that 
undergo highly enantioselective iridium-catalyzed asymmetric hydrogenation remains 
limited. 
 
1.4.1.3 
Bidentate Ligands for the Asymmetric Hydrogenation of C−O Double Bonds 
 
Most of the iridium catalysts developed hitherto display moderate selectivities in the 
asymmetric hydrogenation of C−O double bonds. The first successful example of a C−O 
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double bond reduction was reported by DAHLENBURG et al.[52] The iridium-catalyzed 
hydrogenation of ketones with P,N ligands afforded the resulting alcohols with poor 
enantioselectivities (up to 68% ee). For cyclic α,β-unsaturated ketones, with an exocyclic 
C−C double bond, ZHOU et al. achieved up to 97% ee in the selective C−O double bond 
reduction with iridium complexes derived from chiral spiro aminophosphine ligands 
((Sa)-LSpiroAP, Scheme 4).[53] 
 
 
Scheme 4. Asymmetric hydrogenation of exocyclic α,β-unsaturated ketones.[53] 
 
1.4.2 
Natural Product Syntheses Involving an Iridium-Catalyzed 
Asymmetric Hydrogenation 
 
Several total syntheses of natural products featuring an iridium-catalyzed asymmetric 
hydrogenation as the key step have been reported and some of them are depicted in 
Scheme 5. 
 
Shortly after the discovery that pyridylphosphine ligands (R)-L9 allow for the 
asymmetric hydrogenation of unfunctionalized trialkyl-substituted C−C double bonds, a 
first example of the enantio- and diastereoselective hydrogenation of farnesol, an 
important building block for nature but also for organic synthesis was reported.[42a,45-46,54] 
This type of pyridylphosphine/iridium catalyst could also be applied to the asymmetric 
hydrogenation of an intermediate in the total synthesis of mutisianthol (19)[55] and of 
macrocidin A (22)[57] (Scheme 5).  
 
                                                             
[52] L. Dahlenburg, R. Götz, Eur. J. Inorg. Chem. 2004, 888-905. 
[53] J.-B. Xie, J.-H. Xie, X.-Y. Liu, W.-L. Kong, S. Li, Q.-L. Zhou, J. Am. Chem. Soc. 2010, 132, 4538-4539. 
[54] a) R. Schmid, S. Antoulas, R. Rüttimann, M. Schmid, M. Vecchi, H. Weiser, Helv. Chim. Acta 1990, 73, 
1276-1299; b) N. Cohen, B. Schaer, J. Org. Chem. 1992, 57, 5783-5785; c) D. R. Threlfall in Secondary 
Plant Products (eds. E. A. Bell, B. V. Charlwood), Springer, Berlin 1980, pp. 292-298. 
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Scheme 5. Examples of iridium catalysts used in the total synthesis of natural products (for 
reaction conditions see the references). 
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Mutisianthol (19) is a sesquiterpene, both its enantiomers were isolated from the roots of 
Mutisia homoeantha and show moderate antitumor activity.[55,56] Macrocidin A (22) is a 
cyclophane tetramic acid that was identified as plant pathogen and represents a potential 
lead compound for herbicide design.[57,58] The total and enantioselective synthesis of     
(+)-torrubiellone C (25) was also accomplished with a pyridylphosphine/iridium catalyst 
(Scheme 5).[59] 
 
Subsequent to the identification of NeoPHOX ligands as valuable ligands for the iridium-
catalyzed asymmetric hydrogenation of both unfunctionalized and functionalized olefins, 
they were employed in the total synthesis of the antitumor natural product                     
(R)-(+)-7-demethyl-2-methoxycalamenene ((R)-28).[60] This same ligand class was later 
used in the stereoselective total synthesis of pyridone alkaloid militarinone D (31).[61] 
 
The development of iridium complexes of spiro phosphoramidites as highly 
enantioselective catalysts for the asymmetric hydrogenation of cyclic enamines led to the 
synthesis of the biologically active isoquinoline alkaloid crispine A ((R)-34, 
Scheme 5).[48c,62] For this transformation the monodentate spiro phosphoramidite ligand 
(S,Sa)-L13 showed better enantioselectivities than bidentate ligands.[48c]  
 
The formal total synthesis of platensimycin (35), showing potent activity as new type of 
antibiotic, was achieved by performing two asymmetric hydrogenations catalyzed by           
P,N iridium complexes in the key steps (Figure 5).[63] BURGESS et al. could apply their 
NHC ligand/iridium complex in the total synthesis of (−)-spongidepsin (36), a cytotoxic 
marine natural product (Figure 5).[64] 
 
                                                             
[55] G. G. Bianco, H. M. C. Ferraz, A. M. Costa, L. V. Costa-Lotufo, C. Pessoa, M. O. de Moraes, 
M. G. Schrems, A. Pfaltz, L. F. Silva, Jr. J. Org. Chem. 2009, 74, 2561-2566. 
[56] F. Bohlmann, C. Zdero, N. Le Van, Phytochemistry 1979, 18, 99-102. 
[57] T. Yoshinari, K. Ohmori, M. G. Schrems, A. Pfaltz, K. Suzuki, Angew. Chem. Int. Ed. 2010, 49, 881-885. 
[58] P. R. Graupner, A. Carr, E. Clancy, J. Gilbert, K. L. Bailey, J.-A. Derby, B. Clifford Gerwick, J. Nat. Prod. 
2003, 66, 1558-1561. 
[59] H. J. Jessen, A. Schumacher, F. Schmid, A. Pfaltz, K. Gademann, Org. Lett. 2011, 13, 4368-4370. 
[60] a) M. G. Schrems, A. Pfaltz, Chem. Commun. 2009, 6210-6212; b) F. Bohlmann, C. Zdero, 
H. Robinson, R. King, Phytochemistry 1979, 18, 1675-1680. 
[61] H. J. Jessen, A. Schumacher, T. Shaw, A. Pfaltz, K. Gademann, Angew. Chem. Int. Ed. 2011, 50, 4222-
4226. 
[62] Q. Zhang, G. Tu, Y. Zhao, T. Cheng, Tetrahedron 2002, 58, 6795-6798. 
[63] a) K. Tiefenbacher, L. Tröndlin, J. Mulzer, A. Pfaltz, Tetrahedron 2010, 66, 6508-6513; b) D. Häbich, F. 
von Nussbaum, ChemMedChem 2006, 1, 951-954. 
[64] a) Y. Zhu, A. Loudet, K. Burgess, Org. Lett. 2010, 12, 4392-4395; b) A. Grassia, L. Bruno, C. Debitus, 
S. Marzocco, A. Pino, L. Gomez-Paloma, R. Riccio, Tetrahedron 2001, 57, 6257-6260. 
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Figure 5. Structure of platensimycin and (−)-spongidepsin. 
 
All these reports involving an iridium-catalyzed asymmetric hydrogenation in the total 
synthesis of natural products are recent. This trend shows the slow establishment of 
iridium as the metal of choice for certain type of asymmetric hydrogenation and suggest 
that iridium could also find its place as the metal of choice for industrial applications. 
 
1.5 
Challenges for Metal-Catalyzed Asymmetric Hydrogenations 
 
As it was shown by history, for example in the synthesis of chiral (S)-metolachlor, the 
quest for new transition metal-catalysts is still a valuable goal in order to optimize the 
synthesis of enantiomerically pure active compounds by asymmetric hydrogenation. 
Between the discovery of the biological activity of metolachlor in 1970 and the start of 
the production of (S)-metolachlor on a ton-scale in 1996, many attempts were made to 
optimize its enantioselective synthesis. These efforts required first the screening of 
different metals and then of different ligands, followed by optimization of the reaction 
conditions.[65] This example, among many other, illustrates well the substrate dependence 
of metal-catalyzed hydrogenations and the need to discover other active and selective 
catalysts in order to make asymmetric reduction of double bonds more universal. 
 
Another trend that can be noticed examining more recent reports about asymmetric 
hydrogenations, is the re-introduction of chiral monodentate phosphorus ligands.[30] 
Phosphites, phosphonites and phosphoroamidates were reported as interesting and cheap 
alternative ligands for the iridium-catalyzed asymmetric hydrogenation of alkenes. Their 
lower cost might compensate for their reduced activity. However, the development of 
                                                             
[65] H.-U. Blaser, Adv. Synth. Catal. 2002, 344, 17-31. 
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ligands that are both, efficient and cheap is required. A valuable approach to fulfill these 
requirements still probably is the design of ligands which are derived from amino acids. 
 
1.6 
Objectives of this Work 
 
The main aim of the research project described in this thesis was to develop and optimize 
easily accessible ligands that can be applied to the iridium-catalyzed asymmetric 
hydrogenation of various substrates. In the field of asymmetric catalysis, two different 
approaches can be pursued: (1) a substrate of interest needs to be hydrogenated 
enantioselectively and the goal of research is to develop a catalyst that fulfills this 
particular need; or (2) one develops and elaborates new catalyst systems based on today’s 
knowledge and then find an interesting substrate type which could reveal the advantages 
of this catalyst by comparing its selectivity with previously tested catalysts. This second 
approach is most used in methodological research and is also how it was proceeded 
herein. Given the goal to seek for a novel type of catalyst for the asymmetric 
hydrogenation, three parameters are variable excluding the optimization of the reaction 
conditions: the metal, the ligand structure and the substrate type. This thesis deals with 
the ligand structure optimization. The important variations in ligand structure are the 
following: coordination mode of the ligand (bidentate or monodentate), the atoms that 
coordinate the metal (P, N, S, C and their substituents influencing the electronic property 
of the ligand), the size of the metallacycle formed upon coordination (influencing the bite 
angle in a bidentate coordination manner) and the general steric hindrance generated by 
the ligand around the active site. 
 
The general scaffold of choice for this project was proline. All ligands that were 
developed are proline-based (Figure 6).  
 
Figure 6. Ligand scaffolds presented herein. 
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In chapter 2, proline-based P,O ligands will be described in more detail. Amido-, 
carbamato- as well as ureaphophines were investigated as novel types of ligands. In the 
following chapters, two different proline-based P,N ligands scaffolds will be presented 
(chapters 3 and 4). The state-of-the-art ligands for iridium-catalyzed asymmetric 
hydrogenation are P,N bidentates. The idea to combine the advantages of proline-based 
ligands with the traditional coordination mode was obvious: proline-based P,N ligands 
were therefore investigated. Finally, in chapter 5, an attempt to discover further 
applications of proline-based P,O ligands for transition metal-catalyzed reactions will be 
described. 
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2.1   
Metal-Catalyzed Asymmetric Reactions Involving Bidentate 
P,O Ligands 
 
As described in chapter 1, a series of ligands was designed and applied successfully to 
iridium-catalyzed asymmetric hydrogenation of C−C and C−N double bonds. Although 
an appreciable variety in ligand structure was achieved, most ligands are bidentate 
P,N ligands. They coordinate to iridium via a nitrogen atom and a phosphorus donor. 
Herein, proline-based ligands will be described which bind to the transition metal via a 
carbonyl oxygen atom and a phosphorus atom. Their synthesis and the analysis of their 
coordination mode to iridium(I) will be discussed. Furthermore, the results will be shown, 
which were obtained, when the ligands were applied to the iridium-catalyzed asymmetric 
hydrogenation of functionalized and unfunctionalized alkenes, as well as a standard imine 
substrate. Prior to this, previous reports involving P,O ligands in metal-catalyzed 
reactions will be summarized. 
 
In the field of asymmetric metal catalysis, only a few ligands which are coordinated to the 
transition metal by a carbonyl oxygen atom have been reported. TOMIOKA et al. described 
amidophosphines as ligands for the asymmetric rhodium-catalyzed 1,4-addition of 
arylboronic acids to enones with high enantioselectivities (Scheme 6).[66] 
Amidophosphine (S)-LA1 was reported to behave as a hemilabile ligand for 
rhodium(I).[67] 
 
 
Scheme 6. Rhodium-catalyzed asymmetric 1,4-addition of arylboronic acids to cyclohexenone 
(37) using amidophosphine (S)-LA1 as ligand.[66a] 
 
                                                             
[66] a) M. Kuriyama, K. Nagai, K.-I. Yamada, Y. Miwa, T. Taga, K. Tomioka, J. Am. Chem. Soc. 2002, 124, 
8932-8939; b) Q. Chen, M. Kuriyama, X. Hao, T. Soeta, Y. Yamamoto, K.-I. Yamada, K. Tomioka, Chem. 
Pharm. Bull. 2009, 57, 1024-1027. 
[67] For reviews on hemilabile ligands see: a) P. Braunstein, F. Naud, Angew. Chem. Int. Ed. 2001, 40, 680–
699; b) P. Braunstein, J. Organomet. Chem. 2004, 689, 3953-3967; c) A. Bader, E. Lindner, Coord. Chem. 
Rev. 1991, 108, 27-110. 
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These amidophosphines were used as chiral ligands for the enantioselective conjugate 
addition of various organocopper reagents to cyclic and acyclic α,β-unsaturated carbonyl 
compounds, too.[68] Moderate to excellent enantioselectivities were achieved. One 
example of a catalytic reaction of this type using butylmagnesium chloride and copper 
iodide in the presence of ligand (S)-LA1 is depicted in Scheme 7. 
 
 
Scheme 7. Example of the asymmetric conjugate addition of Grignard reagents to cyclic                 
α,β-unsaturated carbonyl compounds.[68b] 
 
When, alkoxyarylphosphines were investigated as ligands, it was found in the beginning 
that P,O ligands decrease the reaction rate of the rhodium-catalyzed hydrogenation of      
1-hexene.[67c,69] However, REEK et al. applied recently a novel type of ureaphosphine 
P,O ligands that coordinate to rhodium in a bidentate fashion.[70] This system allowed for 
the asymmetric hydrogenation of cyclic enamides with moderate to good 
enantioselectivities (Scheme 8). 
 
 
Scheme 8. Rhodium-catalyzed asymmetric hydrogenation of cyclic enamides using a bidentate 
P,O ligand.[70b] 
                                                             
[68] a) Y. Nakagawa, K. Matsumoto, K. Tomioka, Tetrahedron 2000, 56, 2857-2863; b) M. Kanai, 
Y. Nakagawa, K. Tomioka, Tetrahedron 1999, 55, 3843-3854; c) Y. Nakagawa, M. Kanai, Y. Nagaoka, 
K. Tomioka, Tetrahedron 1998, 54, 10295-10307; d) Y. Nakagawa, M. Kanai, Y. Nagaoka, K. Tomioka, 
Tetrahedron Lett. 1996, 37, 7805-7808; e) M. Kanai, K. Koga, K. Tomioka, Tetrahedron Lett. 1992, 33, 7193-
7196; f) M. Kanai, Y. Nakagawa, K. Tomioka, Tetrahedron 1999, 55, 3831-3842; g) K. Nagai, H. Fujihara, 
M. Kuriyama, K.-i. Yamada, K. Tomioka, Chem. Lett. 2002, 8-9. 
[69] L. Horner, G. Simons, Z. Naturforsch. Teil B 1984, 39B, 497-503. 
[70] a) J. Meeuwissen, R. Detz, A. J. Sandee, B. de Bruin, M. A. Siegel, A. L. Spek, J. N. H. Reek, Eur. J. 
Inorg. Chem. 2010, 2992-2997; b) J. Meeuwissen, R. J. Detz, A. J. Sandee, B. de Bruin, J. N. H. Reek, 
Dalton Trans. 2010, 39, 1929-1931. 
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2.2 
An Amidophosphine Representing Proline-Based P,O Ligands for 
Iridium-Catalyzed Asymmetric Hydrogenation 
 
In a broad automated screening of various combinations of metals and ligands carried out 
at Solvias AG an iridium complex formed in situ from bis-(η4-1,5-cyclooctadiene) 
iridium(I) tetrakis[3,5-bis(trifluoromethyl)phenyl]borate ([Ir(cod)2]BArF) and 
amidophosphine (R)-LA1 was discovered to give promising results.[71] In the asymmetric 
hydrogenation of (E)-1,2-diphenyl-1-propene (S1) this (R)-LA1/iridium catalyst furnished 
68% ee (Scheme 9). 
 
 
Scheme 9. Iridium-catalyzed asymmetric hydrogenation of (E)-1,2-diphenyl-1-propene (S1) using 
a catalyst formed in situ by complexation of [Ir(cod)2]BArF with (R)-LA1.[71,72] 
 
This result triggered the start of the project presented in this chapter in collaboration with 
Solvias AG. The ligand (R)-LA1 was provided by Solvias AG. The questions which had 
primarily to be addressed were: (1) the identification of the coordination mode of this 
ligand to the transition metal (see section 2.2.2), and (2) the optimization of the 
selectivities in the asymmetric hydrogenation of alkenes. Therefore, the reaction 
conditions were studied in detail and afterwards it was investigated, whether this catalytic 
system can also be applied to the asymmetric hydrogenation of substrates different from 
the unfunctionalized trisubstituted alkene S1. 
 
 
 
 
 
                                                             
[71] Unplublished results from Solvias AG. 
[72] These results were obtained in an automated screening at Solvias AG, the detailed reaction conditions 
are not known. 
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2.2.1 
Initial Results 
 
After the discovery of amidophosphine (R)-LA1 as ligand for iridium of some preliminary 
screening experiments were carried out. First, the optimization of the reaction conditions 
for the iridium-catalyzed asymmetric hydrogenation of (E)-1,2-diphenyl-1-propene (S1) 
was pursed. The results from this screening using amidophosphine (R)-LA1 and (S)-LA1 
as ligand are summarized in Table 1. 
 
Table 1. Iridium-catalyzed asymmetric hydrogenation of (E)-1,2-diphenyl-1-propene (S1).[a] 
 
Entry Ligand LA1/Ir (ratio) Solvent p [bar] t [h] Yield [%][b] ee [%][c] 
1   (R)-LA1 1:2[d] CH2Cl2 50 2    90 58 (S) 
2   (R)-LA1 1:1   CH2Cl2 50 2 > 99 70 (S) 
3   (R)-LA1 2:1[e] CH2Cl2 50 2    79 62 (S) 
4[f] (R)-LA1 1:1   CH2Cl2 50 2 > 99 70 (S) 
5[f] (S)-LA1 1:1   CH2Cl2 50 2 > 99 68 (R) 
6[f] (R)-LA1 1:1[g] CH2Cl2 50 2    93 60 (S) 
7   (R)-LA1 1:1   CH2Cl2 50 1    92 64 (S) 
8   (R)-LA1 1:1   CH2Cl2  5 2    55 65 (S) 
9   (R)-LA1 1:1   CH2Cl2  5 1    48 64 (S) 
10   (R)-LA1 1:1   PhCH3 50 2    15 53 (S) 
11   (R)-LA1 1:1   tBuOMe 50 2    79 62 (S) 
12   (R)-LA1 1:1   n-C5H12 50 2    15 50 (S) 
13   (R)-LA1 1:1   CF3CH2OH 50 2    29 rac 
[a] Reaction scale: [Ir(cod)2]BArF (2.50 μmol), ligand (2.50 μmol), solvent (0.5 mL), substrate (250 μmol), rt; [b] Yields were 
determined by GC analysis (see experimental part); [c] Enantioselectivities were determined by HPLC analysis using a 
chiral stationary phase (see experimental part); [d] (R)-LA1 (1.25 μmol) and [Ir(cod)2]BArF (2.50 μmol);                            
[e] (R)-LA1 (5.00 μmol) and [Ir(cod)2]BArF (2.50 μmol); [f] The reaction was not prepared in a glove box; [g] Results 
obtained with the isolated precatalyst (R)-CA1 ([((R)-LA1)Ir(cod)]BArF). 
 
Entries 1 to 3 show the results obtained by variation of the ligand to metal ratio. These 
experiments were thought to give an initial indication, whether the ligand behaves as a 
bidentate P,O ligand. Indeed, the best result concerning both activity and selectivity were 
observed, when a 1:1 ratio of ligand to metal was used (entry 2). If the ligand would 
behave as monodentate phosphine donor, the active catalyst formed by complexation of 
two equivalents of (R)-LA1 to one equivalent of the metal, entry 3 should show superior 
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results compared to entry 2. In addition, the 31P NMR spectra after the in situ 
complexation but prior to the hydrogenation reaction of entry 3 clearly showed a 1:1 
mixture of complex (R)-CA1 ([((R)-LA1)Ir(cod)]BArF; δ = 9.1 ppm) and free ligand          
(R)-LA1 (δ = − 25.3 ppm, see also Table 2). The conversion and selectivity were 
significantly lower, when a 1:2 ratio of ligand to metal was used (entry 1). 
 
By comparing the results in entries 4 and 5 it can be seen that under identical reaction 
condition the use of the corresponding (S)-enantiomer of LA1* as ligand causes the almost 
perfect inversion of selectivity and the (R)-configured product is obtained with 68% ee. 
When the precatalyst was isolated prior to the hydrogenation reaction, the 
enantioselectivity was slightly lower (entry 6). The synthesis and isolation of the 
precatalyst will be discussed below in section 2.2.2. 
 
The results in entries 7 to 9, show the influence of hydrogen pressure and reaction time on 
the activity of the catalytic system. After applying 50 bar hydrogen pressure for 1 hour, 
the reaction yielded 92% of the product with 64% ee (entry 7). At 5 bar hydrogen 
pressure the reaction did not go to completion (entries 8 and 9). The screening of various 
solvents for this asymmetric hydrogenation reaction did not improve the catalyst 
efficiency (entries 10 to 13). The use of toluene, tert-butylmethylether, n-pentane and                      
2,2,2-trifluoroethanol resulted in reduced yields and enantioselectivities. 
 
Therefore, the appropriate reaction conditions were determined to be the initial 
conditions, utilizing: 1 mol% of catalyst at 50 bar hydrogen pressure for 2 hours in 
dichloromethane at room temperature. These conditions were used for almost all iridium-
catalyzed asymmetric hydrogenations presented in this chapter. If parameters are varied, 
this change will be noted. The product yields obtained in the hydrogenation of any 
substrate presented herein were determined by GC analysis and the products were not 
isolated. 
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2.2.2 
Analysis of the Coordination Mode to Iridium 
 
In order to investigate the coordination mode of the amidophosphine ligand (R)-LA1 to 
iridium(I) in the precatalyst structure a series of analytical experiments was carried out. 
These are described below, involving NMR, IR and X-ray spectroscopy. 
 
Analysis of the coordination mode of amidophosphine (R)-LA1 to the iridium center in 
solution was achieved by employing nuclear magnetic resonance (NMR) spectroscopy, 
measuring the chemical shifts for the free ligand and the in situ complexed ligand in 
deuterated dichloromethane (Table 2). The 31P NMR signals of the phosphorus atom in 
(R)-CA1 ([((R)-LA1)Ir(cod)]BArF) and in (R)-LA1 clearly prove its coordination to the 
metal center ((R)-CA1, δ = 9.1 ppm versus (R)-LA1, δ = − 25.3 ppm). This observation 
was not surprising, but a similar chemical shift of the 13C NMR signal for the quaternary 
carbon of the amide functionality was also observed (Table 2). This signal is shifted 
downfield by 8.8 ppm, when the ligand is complexed to iridium ((R)-CA1, δ = 184.7 ppm 
and (R)-LA1, δ = 175.9 ppm). The absence of a second quaternary signal for the carbonyl 
functionality in the measured sample of (R)-CA1 indicates the complete binding of the 
amide carbonyl oxygen to iridium. In the isostructural rhodium(I) complex studied by 
TOMIOKA et al. the ligand was described to behave as a hemilabile ligand.[66a] When 
complexed to iridium(I), the ligand (R)-LA1 binds in a bidentate manner, however it is 
possible that an average chemical shift of two different species is measured, if the rate of 
exchange is faster than NMR time scale. 
 
Table 2. Comparison of the spectroscopic properties of ligand (R)-LA1 and complex (R)-CA1. 
 
  
 (R)-LA1 (R)-CA1[a] 
31P NMR [δ (P)] − 25.3 ppm    9.1 ppm 
13C NMR [δ (C=O)]  175.9 ppm 184.7 ppm 
IR [ߥ෤ (C=O)]  1615 cm−1 1535 cm−1 
[a] The in situ complexed ligand was analyzed [Ir(cod)2]BArF/(R)-LA1 (1:1) in CD2Cl2. 
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Stronger evidence for the bidentate chelation of (R)-LA1 to iridium was obtained from 
infrared (IR) spectroscopy (Table 2). The IR spectrum of the free ligand (R)-LA1 shows a 
strong absorption at 1615 cm−1, which was assigned to the C−O bond stretching mode. 
Lowering of the analogous wavenumber in the IR spectra of (R)-CA1 to 1535 cm−1, 
unambiguously confirms the coordination of the carbonyl group to the metal through 
π* back-donation. 
 
Summarizing the results of the analyses shown above, it is clear that the amidophosphine 
(R)-LA1 coordinates in a bidentate fashion to iridium(I). The carbonyl oxygen and the 
phosphorus atom both coordinate to the metal center via σ-donation of electron density. In 
addition, the carbonyl oxygen is bound by π back-donation from the metal to the            
π*-orbital of the carbonyl functionality (Figure 7). Taken together, the interaction between 
iridium(I) and the carbonyl oxygen of the amidophosphine ligand was shown to be 
stronger than the analogous rhodium(I) carbonyl ligand interaction.[66a] 
 
 
Figure 7. Simplified binding modes of the carbonyl functionality to iridium. 
 
In order to analyze this P,O ligand/iridium complex (R)-CA1 also in its solid state, the 
precatalyst (R)-CA1 was synthesized and isolated. The preparation of complex (R)-CA1 is 
depicted in Scheme 10. [Ir(cod)2]BArF was treated with free ligand (R)-LA1 in 
dichloromethane and stirred at room temperature for 30 minutes.[73] After evaporation of 
the solvent the residue was triturated several times with n-pentane, whereupon the desired 
                                                             
[73] For the synthesis of [Ir(cod)2]BArF see: V. Semeniuchenko, T E. Exner, V. Khilya, U. Groth, Appl. 
Organometal. Chem. 2011, 25, 804-809. The compound is commercially available. 
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complex (R)-CA1 was obtained (for the detailed procedure see the experimental part). 
This procedure differed slightly from the standard complexation method described for the 
isolation of P,N ligand/iridium complexes.[74] For the isolation of precatalyst (R)-CA1, 
this standard method did not prove to be suitable, since (R)-CA1 can not be purified by 
column chromatography. Several attempts were made, but in all cases decomposition of 
the complex was observed, probably due to the weaker Ir−O bond compared to the Ir−N 
interaction in the corresponding P,N ligand/iridium complexes. 
 
N
P
O
(R)-LA1
BArF
N
O
Ir
P Ph
Ph
(R)-CA1
[Ir(cod)2]BArF
CH2Cl2,
rt, 30 min,
98%
 
Scheme 10. Synthesis of the P,O ligand/iridium complex (R)-CA1. 
 
Crystals suitable for X-ray diffraction were obtained by recrystallization from 
dichloromethane solution layered with n-pentane in a NMR tube. The solid state structure 
shows the expected bidentate coordination of the planar amide group and the phosphorus 
atom to the iridium center. 
 
 
Figure 8. Crystal structure of complex [((R)-LA1)Ir(cod)]BArF. The counterion has been omitted for 
clarity (red O, blue N, magenta P, dark gray Ir, light gray C).[75] 
 
                                                             
[74] For a standard method for the complexation of P,N ligands with iridium(I) see: A. Franzke, Dissertation, 
University of Basel, 2006, pp. 167-167. 
[75] Crystallographic data (excluding structure factors) have been deposited with the Cambridge 
Crystallographic Data Center. The deposition number is 829325. 
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The conformation of the seven-membered metallacycle formed by chelation of the ligand 
to iridium(I) can be seen to be boat-like. One of the phenyl substituents of the 
diphenylphosphino group is oriented in a pseudo-axial and the other in a pseudo-
equatorial fashion (Figure 8). The pseudo axial phenyl substituent extends into the same 
direction as the tert-butyl substituent of the amide functionality. The bite angle of the 
ligand was measured to be 89.31° and the Ir−P and Ir−O distances are 2.295 Å and 
2.081 Å respectively. 
 
Amidophosphine (R)-LA1 clearly represents a stable bidentate P,O ligand, when it is 
coordinated to iridium(I). Both in solution and in the solid state the amide oxygen atom is 
bonded to the metal center of the complex. Further analysis of the carbonyl 
functionality’s coordinating behavior during a hydrogenation reaction was carried out by 
online IR spectroscopy, which allows to measure spectra during the course of the 
reaction. Strong support was gained that the carbonyl group remains bonded to the 
transition metal in the active catalyst during the reaction, but the quality of the recorded 
spectra does not afford a definite proof and therefore, they are not presented here. 
 
After the coordination mode of this first amidophosphine ligand had been clarified and 
the reaction conditions for the use of this P,O ligand in the iridium-catalyzed 
hydrogenation of alkenes had been optimized, further derivatives were investigated. This 
ligand scaffold is highly modular, and therefore various functionalities were introduced. 
The results of the application of these ligands in the iridium-catalyzed asymmetric 
hydrogenation of several alkenes as well as in the reduction of an exemplary imine 
substrate will be described. A separate section will be dedicated to each type of oxygen 
functionality investigated, starting with carbamatophosphine ligands ((S)-LC), followed 
by amidophosphines ((S)-LA) and finally ureaphosphines ((S)-LU3 and (S)-LU4). 
 
 
Figure 9. Ligand scaffolds presented herein. 
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2.3   
Proline-Based Carbamatophosphines Ligands 
 
The preparation of the (S)-enantiomer of the initially tested chiral ligand LA1* was 
previously reported by TOMIOKA et al.[68b] During the synthesis of amidophosphines 
substituted with various moieties in the amide and at the phosphorus atom, carbamates 
became available as well (Scheme 11). These carbamatophosphines were tested in the 
iridium-catalyzed hydrogenation of unfunctionalized and functionalized alkenes too, as 
they were thought to have the same potential as the corresponding bidentate amide-based 
P,O ligands. The results are described below. 
 
2.3.1 
Synthesis of Proline-Based Carbamatophosphines 
 
All P,O ligands synthesized and described herein are readily available from the naturally 
occurring amino acid L-proline. The preparations started from commercially available         
N-(tert-butoxycarbonyl)-L-proline ((S)-44) as depicted in Scheme 11. The reduction of 
the carboxylic acid using borane as reducing agent via a reported procedure led to the 
desired N-(tert-butoxycarbonyl)-L-prolinol ((S)-45) in good yield.[76] 
 
Scheme 11. Synthesis of carbamatophosphine ligand (S)-LC1. 
 
Subsequent transformation of the alcohol into a better leaving group was achieved by 
either an Appel reaction, replacing the alcohol by bromine, or conversion of the alcohol 
into a tosylate.[76,77] Both reactions were performed and are depicted in Scheme 12. 
                                                             
[76] For the synthesis of N-(tert-butoxycarbonyl)-L-prolinol ((S)-45) and (S)-tert-butyl 2-
[(tosyloxy)methyl]pyrrolidine-1-carboxylate ((S)-47) see: G. Bartoli, M. Bosco, R. Dalpozzo, A. Giuliani, 
E. Marcantoni, T. Mecozzi, L. Sambri, E. Torregiani, J. Org. Chem. 2002, 67, 9111-9114. 
[77] For the synthesis of (S)-tert-butyl 2-(bromomethyl)pyrrolidine-1-carboxylate ((S)-46) see: B. Hinzen, 
H. Broetz, R. Endermann, K. Henninger, H. Paulsen, S. Raddatz, S. Anlauf, Ger. Offen. 2004, 
DE 10308107 A1. 
PROLINE-BASED P,O LIGANDS FOR IRIDIUM-CATALYZED ASYMMETRIC HYDROGENATION 
 
45 
Displacement of the bromide in (S)-46 by the diphenylphosphide anion, in analogy to the 
previously reported procedure of TOMIOKA et al. furnished the first carbamatophosphine 
(S)-LC1 in good overall yield (Scheme 12).[68b] 
 
 
Scheme 12. Synthesis of carbamatophosphines with aryl substituents at the phosphorus atom. 
 
Variation of the phosphorus substituents was carried out using different phosphide anions 
in the final substitution reaction (Scheme 12). The ortho-tolyl-substituted 
carbamatophosphine (S)-LC2 was obtained from the bromine precursor (S)-46 in 
83% yield in the same manner as (S)-LC1. However, sodium di-ortho-tolylphosphide is 
not commercially available and was obtained in situ by the reaction of sodium with              
chlorodi-ortho-tolylphosphine in analogy to the reported in situ generation of sodium 
diphenylphosphide.[68b] In contrast, the di-(2-furyl)-phosphine derivative (S)-LC3 was 
obtained from tosylate (S)-47 in only moderate yield. The nucleophilic                             
di-(2-furyl)-phosphide anion was generated by the reaction of sodium and                
chlorodi-(2-furyl)-phosphine. The synthesis of (S)-LC3 starting from (S)-46 was not tried, 
but the synthesis of di-ortho-tolylphosphine (S)-LC3 from tosylate (S)-47 proved to be as 
well possible in the same range of yield. 
 
In contrast, the synthesis of carbamatophosphines bearing alkyl substituents at the 
phosphorus atom was not possible from the tosylate precursor (S)-47. Like (S)-LC1, 
dialkylphosphines (S)-LC4 and (S)-LC5 were synthesized from                                             
(S)-tert-butyl 2-(bromomethyl)pyrrolidine-1-carboxylate ((S)-46, Scheme 13). The 
protected phosphides for the displacement of the bromide leaving group were generated 
in situ by deprotonation of the respective phosphine borane adducts using n-butyllithium. 
Finally the desired P,O ligands for the generation of iridium complexes were obtained by 
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deprotection under standard conditions. This deprotection was carried out by reacting the 
protected ligands (S)-LC4∙BH3 and (S)-LC5∙BH3 with diethylamine (Scheme 13). The 
extended reaction times required for complete deprotection are a serious drawback in the 
synthesis of these dialkyl-substituted P,O ligands. Heating of the reaction mixture slightly 
reduced the reaction time. However, compared to other deprotection methods this method 
can clearly be qualified as cleaner, because simple evaporation of all volatiles under 
reduced pressure led to the quantitative isolation of the desired P,O ligands (for detailed 
procedures see the experimental part). Due to this advantage this deprotection method 
was used as standard protocol even when it was rather slow. 
 
 
Scheme 13. Synthesis of carbamatophosphines with alkyl substituents at the phosphorus atom. 
 
All four carbamatophosphines (S)-LC1 to (S)-LC4, were used to synthesize 
amidophosphines ((S)-LA) and ureaphosphines ((S)-LU3 and (S)-LU4). These subsequent 
synthetic steps will be depicted in the corresponding sections (see sections 2.4.1, 2.5.1.1 
and 2.5.2.1). 
 
Derivatives of the carbamatophosphine (S)-LC1 bearing R1-substituents different from 
tert-butyl were also synthesized (Scheme 14). This was achieved after deprotection of the 
tert-butyl carbamate (S)-LC1 under acidic conditions to obtain (S)-52∙HCl and 
subsequent reaction of the resulting pyrrolidinium salt with different chloroformates 
R1OCOCl. For example, (S)-LC7 was isolated after the reaction of (S)-52∙HCl with 
commercially available 9-fluorenylmethyl chloroformate (FmocCl) in 73% yield. 
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Scheme 14. Synthesis of carbamatophosphines with different carbamate moieties (abbreviations: 
1-Adm for 1- adamantyl, (9-Fl)CH2 for 9-fluorenylmethyl and (2,6-Me2)Ph for 2,6-dimethylphenyl). 
 
The other chloroformates 54 and 56 are not commercially available and were synthesized 
according to literature-known procedures (Scheme 15).[78,79] Both were obtained from 
their alcohol precursors 53 and 55, respectively, using triphosgene and pyridine as base. 
Reacting these chloroformates with pyrrolidinium salt (S)-52∙HCl furnished the 
carbamatophosphines (S)-LC6 and (S)-LC8 in good yields of 85% and 80%, respectively, 
(see Scheme 14). 
 
 
Scheme 15. Synthesis of chloroformates 54 and 56, using triphosgene.[78,79] 
 
 
 
 
                                                             
[78] For the synthesis of 1-adamantyl chloroformate (54) see: R. A. Moos, J. Tian, R. R. Sauers, Org. Lett. 
2004, 6, 4293-4296. This compound was synthesized in analogy to the procedure reported for the synthesis 
of 3-homoadamantyl chloroformate. 
[79] For the synthesis of 2,6-dimethylphenyl chloroformate (56) see: M. W. Martin, J. Newcomb, J. J. Nunes, 
D. C. McGowan, D. M. Armistead, C. Boucher, J. L. Buchanan, W. Buckner, L. Chai, D. Elbaum, L. F. 
Epstein, T. Faust, S. Flynn, P. Gallant, A. Gore, Y. Gu, F. Hsieh, X. Huang, J. H. Lee, D. Metz, S. Middleton, 
D. Mohn, K. Morgenstern, M. J. Morrison, P. M. Novak, A. Oliveira-dos-Santos, D. Powers, P. Rose, S. 
Schneider, S. Sell, Y. Tudor, S. M. Turci, A. A. Welcher, R. D. White, D. Zack, H. Zhao, L. Zhu, X. Zhu, C. 
Ghiron, P. Amouzegh, M. Ermann, J. Jenkins, D. Johnston, S. Napier, E. Power, J. Med. Chem. 2006, 49, 
4981-4991. 
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2.3.2 
Iridium-Catalyzed Asymmetric Hydrogenations with Carbamatophosphine 
Ligands 
 
As shown above several carbamatophosphines were easily synthesized. The potential of 
these compounds as P,O ligands for iridium catalysis was investigated next. The results of 
the asymmetric hydrogenation of various alkenes are reported in the tables below and will 
be discussed. The precatalysts were formed by in situ complexation prior to the 
hydrogenation reactions and the hydrogenation reactions were performed under the 
optimized conditions as described in section 2.2.1. 
 
All eight carbamatophosphines (S)-LC1 to (S)-LC8 were tested in the iridium-catalyzed 
asymmetric hydrogenation of the unfunctionalized alkene (E)-1,2-diphenyl-1-propene 
(S1), first. The results are summarized in Table 3. These ligands did not prove to be very 
effective in this transformation. Only the use of ligand (S)-LC5 allowed for complete 
conversion (entry 5). The other catalysts showed only moderate activities (27% to 
86% yield). Concerning the use of ligands (S)-LC6 and (S)-LC8, average yields and 
enantioselectivities are given, since the reactions were carried out several times (entries 6 
and 8). 
 
Table 3. Iridium-catalyzed asymmetric hydrogenation of (E)-1,2-diphenyl-1-propene (S1).[a] 
 
Entry Ligand R1 R2 Yield [%][b] ee [%][c] 
1 (S)-LC1 tBu Ph    49 66 (R) 
2 (S)-LC2 tBu oTol    86 41 (R) 
3 (S)-LC3 tBu 2-Fur    29 45 (R) 
4 (S)-LC4 tBu tBu    87 95 (R) 
5 (S)-LC5 tBu Cy > 99 92 (R) 
6 (S)-LC6 1-Adm Ph    73[d] 76 (R)[d] 
7 (S)-LC7 (9-Fl)CH2 Ph    66 15 (S) 
8 (S)-LC8 (2,6-Me2)Ph Ph    50[d] 54 (R)[d] 
[a] Reaction scale: [Ir(cod)2]BArF (2.50 μmol), ligand (2.50 μmol), solvent (0.5 mL), substrate (250 μmol); [b] Yields were 
determined by GC analysis (see experimental part); [c] Enantioselectivities were determined by HPLC analysis using a 
chiral stationary phase (see experimental part); [d] Average of 2-3 experiments. 
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The results varied slightly from one experiment to the other. This observation in 
combination with the low yields obtained with several other (S)-LC ligands suggest that 
these carbamatophosphine/iridium complexes partially decompose during the course of 
the reaction. Moreover, only moderate enantioselectivities were obtained compared to the 
best P,N ligand complexes. The dialkyl-substituted phosphine derivatives (S)-LC4 and 
(S)-LC5 furnished the highest enantiomeric excesses of 95% and 92% respectively. As in 
the case of the initially studied amidophosphine the use of the (S)-configured 
carbamatophosphine ligands afforded the (R)-configured product P1 in excess. 
 
Given the rather disappointing results in terms of activity and selectivity in the 
hydrogenation of substrate S1, these carbamatophosphines were screened only randomly 
in the iridium-catalyzed hydrogenation of other substrates. In the reduction of other 
trisubstituted unfunctionalized alkenes, such as 6-methoxy-1-methyl-3,4-
dihydronaphthalene (S2), (E)- and (Z)-2-(4-methoxyphenyl)-2-butene ((E)-and (Z)-S3), 
these P,O ligand/iridium catalysts furnished even lower enantiomeric excesses 
(Scheme 16 and Table 4). The best result was obtained in the hydrogenation of (E)-S3 
employing the 1-adamantyl-substituted carbamate (S)-LC6 (76% yield and 30% ee, 
entry 5). 
 
Table 4. Iridium-catalyzed asymmetric hydrogenation of (E)- and (Z)-2-(4-methoxyphenyl)-2-
butene ((E)- and (Z)-S3).[a] 
 
Entry Substrate Ligand R1 R2 Yield [%][b] ee [%][c] 
1 (Z)-S3 (S)-LC1 tBu Ph 77   9 (S) 
2 (Z)-S3 (S)-LC2 tBu oTol 82 rac 
3 (E)-S3 (S)-LC3 tBu 2-Fur 95 rac 
4 (Z)-S3 (S)-LC3 tBu 2-Fur 91 rac 
5 (E)-S3 (S)-LC6 1-Adm Ph 76 30 (R) 
6 (Z)-S3 (S)-LC6 1-Adm Ph 98   3 (R) 
[a] Reaction scale: [Ir(cod)2]BArF (2.50 μmol), ligand (2.50 μmol), solvent (0.5 mL), substrate (250 μmol); [b] Yields were 
determined by GC analysis (see experimental part); [c] Enantioselectivities were determined by HPLC or GC analysis 
using a chiral stationary phase (see experimental part). 
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Several other substrates were hydrogenated in the course of the screening of 
carbamatophosphines. The best results for each substrate are depicted in Scheme 16.  
 
 
 
[a] Reaction scale: [Ir(cod)2]BArF (2.50 μmol), ligand (2.50 μmol), solvent (0.5 mL), substrate (250 μmol); [b] Yields were 
determined by GC analysis (see experimental part); [c] Enantioselectivities were determined by HPLC analysis using a 
chiral stationary phase (see experimental part); [d] Formation of side products was observed (conversion > 99%); [e] The 
reactions were carried out at 5 bar H2. 
Scheme 16. Iridium-catalyzed asymmetric hydrogenations using carbamatophosphines.[a-c] 
 
No enantioselectivity at all was induced in the reduction of 6-methoxy-1-methyl-3,4-
dihydronaphthalene (S2). The same results were obtained from the reduction of the                
1,1-disubstituted alkene S12, where only carbamatophosphine (S)-LC1 gave a slight 
enantiomeric excess of 9%. The carbamatophosphine complexes showed only moderate 
performance in the reduction of C−N double bonds. When imine S11 was hydrogenated, 
only low yields of up to 29% were obtained. The highest enantiomeric excess was 24% in 
this case. At least, 63% ee were obtained in the hydrogenation of the allylic alcohol S5, 
when the (S)-LC1/iridium complex was used. In this case, complete conversion of the 
starting material was observed too, but this was accompanied by the formation of side 
products (> 99% conversion but only 90% yield of the desired hydrogenation product 
P5). 
 
Slightly better yields were achieved, when the trisubstituted functionalized alkene S4 was 
reduced (Table 5). An enantiomeric excess of up to 78% of the (R)-configured product 
ethyl 3-phenylbutanoate (P4) was obtained using (S)-LC4 and up to 99% yield were 
observed using (S)-LC5 (entries 3 and 4). 
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Table 5. Iridium-catalyzed asymmetric hydrogenation of (E)-ethyl 3-phenylbut-2-enoate (S4).[a] 
 
Entry Ligand R1 R2 Yield [%][b] ee [%][c] 
1 (S)-LC1 tBu Ph 95 41 (R) 
2 (S)-LC2 tBu oTol 99   9 (R) 
3 (S)-LC4 tBu tBu 80 78 (R) 
4 (S)-LC5 tBu Cy 99 75 (R) 
5 (S)-LC6 1-Adm Ph 39 53 (R) 
[a] Reaction scale: [Ir(cod)2]BArF (2.50 μmol), ligand (2.50 μmol), solvent (0.5 mL), substrate (250 μmol); [b] Yields were 
determined by GC analysis (see experimental part); [c] Enantioselectivities were determined by GC analysis using a chiral 
stationary phase (see experimental part). 
 
From the results obtained in the iridium-catalyzed asymmetric hydrogenation of C−C and 
C−N double bonds with carbamatophosphines as P,O ligands it can be seen that these 
derivatives are not well suited for these applications. Therefore, carbamatophosphines 
(S)-LC were not investigated further and the focus was turned to proline-based 
amidophosphines (S)-LA. 
 
2.4 
Proline-Based Amidophosphines Ligands 
 
Several amidophosphines (S)-LA bearing various substitution patterns within their 
carbonyl and phosphine functionalities were synthesized and tested as P,O ligands in the 
iridium-catalyzed asymmetric hydrogenation of different substrates. The goal was to 
optimize the ligand structure by introducing different electronic and steric properties, in 
order to surpass the results obtained with the initial ligand (R)-LA1 (section 2.2.1). The 
ligand’s scaffold proved highly modular and led to the synthesis of a wide ligand library 
(see section 2.4.1). The ligands are numbered according to their carbonyl moieties, 
starting with alkyl groups and followed by aromatic groups, and, within each carbonyl 
subgroup, according to their phosphorus substituents. This classification allows for a 
better analysis of the influence of each substituent on the results in the iridium-catalyzed 
asymmetric hydrogenation reactions. The hydrogenation results varied significantly from 
substrate to substrate and are described in section 2.4.2. Substrate dependency of the 
catalyst’s selectivity is a well-known phenomenon in asymmetric catalysis and was 
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already pointed out in chapter 1. This is why many combinations of ligands and substrates 
were thoroughly screened. 
 
2.4.1 
Synthesis of Proline-Based Amidophosphines 
 
The synthesis of amidophosphine ligands (S)-LA was carried out following the same 
strategy used for the synthesis of carbamatophosphines (S)-LC described above 
(see section 2.3.1). Depending on the phosphorus atom substituents the preparation of 
aryl- and alkyl-substituted amidophosphines will be described separately (see Schemes 17 
and 19). Starting from the already described carbamates (S)-LC1 to (S)-LC3 (Schemes 11 
and 12), the corresponding pyrrolidinium salts (S)-52∙HCl, (S)-57∙HCl and (S)-58∙HCl 
were obtained in quantitative yields, with different aryl substituents on the 
phosphorus moiety after removal of the Boc-protecting group (Scheme 17). Reaction of 
these deprotected amines with acyl chloride derivatives under basic conditions gave rise 
to a small library of amidophosphines with various substituents R1 and R2. 
 
 
Scheme 17. Synthesis of amidophosphines with aryl substituents at the phosphorus atom. 
 
This synthetic route is very similar to that used for the synthesis of carbamatophosphines 
and to the route reported in the literature by TOMIOKA et al.[68b] Ligands (S)-LA1 to       
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(S)-LA3, (S)-LA6 to (S)-LA9, (S)-LA12 to (S)-LA15 and (S)-LA18 were obtained in 
moderate to excellent yields (24% to 98%). Both alkyl and aryl substituents were easily 
introduced in the amide functionality and the steric hindrance was varied by substitution 
with tBu ≈ 1-Adm < CPh3. 
 
Most of the acyl chlorides R1COCl used for amide formation are commercially available. 
Only the compounds 60 (R1 = (1-Adm)CH2) and 62 (R1 = CPh3) had to be synthesized 
prior to their transformation into an amide (Scheme 18). Reacting their carboxylic acid 
precursors with thionyl chloride at reflux gave the desired acyl chloride derivatives in 
quantitative yields. 
 
 
Scheme 18. Synthesis of not commercially available acyl chlorides 60 and 62. 
 
The synthesis of amidophosphines bearing alkyl substituents at the phosphorus atom is 
shown in Scheme 19. The carbamatophosphines (S)-LC4∙BH3 and (S)-LC5∙BH3 were 
deprotected and the resulting amines treated with the respective acyl chlorides that were 
already used for the synthesis of the previous diarylphosphine library (see Scheme 17).  
 
 
Scheme 19. Synthesis of amidophosphines with alkyl substituents at the phosphorus atom. 
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For this substitution reaction potassium carbonate was used as base, since triethylamine 
promotes the deprotection of the phosphorus atom. In general, the borane adducts of the 
amidophosphines were obtained in moderate to good yields, although slightly lower 
efficiencies were observed for fully alkyl-substituted ligands like (S)-LA4∙BH3 and               
(S)-LA10∙BH3 (24% and 43%, respectively, see Scheme 19). Quantitative protecting 
group removal was carried out with the help of diethylamine, before these 
amidophosphines were employed as ligands. 
 
In order to obtain the isolated precatalyst (S)-CA16 and (S)-CA17, ligands (S)-LA16 and 
(S)-LA17 were reacted with [Ir(cod)2]BArF. These complexations were carried out as in 
the case of (R)-CA1 and all three reactions are depicted in Scheme 20. All precatalysts 
were obtained in excellent yields. 
 
 
Scheme 20. Synthesis of amidophosphine/iridium complexes. 
 
2.4.2  
Iridium-Catalyzed Asymmetric Hydrogenations with Amidophosphine 
Ligands 
 
The amidophosphines were screened systematically in the iridium-catalyzed asymmetric 
hydrogenation of exemplary unfunctionalized and functionalized trisubstituted alkenes. 
Since these ligands showed excellent selectivities in the hydrogenation of the standard 
α,β-unsaturated ester S4, other α,β-unsaturated carbonyl compounds were investigated as 
substrates, too. These results will be shown below in separate tables for each substrate. 
 
Table 6 summarizes the results obtained in the iridium-catalyzed asymmetric 
hydrogenation of the initially studied substrate (E)-1,2-diphenyl-1-propene (S1). Ligand 
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(R)-LA1 from the automated screening at Solvias AG is also included for comparison; it 
gave > 99% conversion and an enantiomeric excess of 70% (entry 1).  
 
Table 6. Iridium-catalyzed asymmetric hydrogenation of (E)-1,2-diphenyl-1-propene (S1).[a] 
 
Entry Ligand R1 R2 Yield [%][b] ee [%][c] 
1 (R)-LA1 tBu Ph > 99 70 (S) 
2 (S)-LA2 tBu oTol > 99 48 (R) 
3 (S)-LA3 tBu 2-Fur    83 45 (R) 
4 (S)-LA4  tBu tBu    99 89 (R) 
5 (S)-LA5 tBu Cy    99 83 (R) 
6 (S)-LA6 (tBu)CH2 Ph > 99   6 (R) 
7 (S)-LA7 1-Adm Ph    73 54 (R) 
8 (S)-LA8 1-Adm oTol > 99 37 (R) 
9 (S)-LA9 1-Adm 2-Fur    95 19 (R) 
10 (S)-LA10 1-Adm tBu > 99 86 (R) 
11 (S)-LA11 1-Adm Cy > 99 76 (R) 
12 (S)-LA12 (1-Adm)CH2 Ph    97 10 (R) 
13 (S)-LA13 CPh3 Ph    71 90 (R) 
14 (S)-LA14 CPh3 oTol    80 80 (R) 
15 (S)-LA15 CPh3 2-Fur    63 90 (R) 
16 (S)-LA16 CPh3 tBu > 99 98 (R) 
17 (S)-LA17 CPh3 Cy > 99 96 (R) 
18 (S)-LA18 Ph Ph    90   2 (S) 
[a] Reaction scale: [Ir(cod)2]BArF (2.50 μmol), ligand (2.50 μmol), solvent (0.5 mL), substrate (250 μmol); [b] Yields were 
determined by GC analysis (see experimental part); [c] Enantioselectivities were determined by HPLC analysis using a 
chiral stationary phase (see experimental part). 
 
Several new ligands, such as (S)-LA10 and (S)-LA13 to (S)-LA17 furnished substantially 
higher selectivities (entries 10 and 13 to 17). It can be easily seen that ligands with more 
sterically demanding amides in combination with electron-donating dialkyl phosphines 
furnished higher enantioselectivities. In addition, the steric demands of the amide groups 
seem to have a bigger impact on the enantioinduction of the catalysts than the electronic 
properties of the coordinating phosphorus atom. All trityl (CPh3)-substituted 
amidophosphines induced enantiomeric excesses of higher than 80% (entries 13 to 17). 
The lowest selectivities were obtained with ligands (S)-LA6, (S)-LA12 and (S)-LA18 
(entries 6, 12 and 18). Whereas (S)-LA18 comprises a planar phenyl substituent, the other 
two ligands have a methylene group in α-position to the carbonyl moiety. Both 
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substitution patterns allow an increased rotational flexibility of the ligand and reduce the 
steric crowding around the active site of the catalysts, which might explain the lower 
selectivities. The conversion of the starting material S1 was not always complete, but 
overall good yields from 63% to > 99% were obtained in most cases. 
Dialkylphosphine/iridium catalysts generally exhibited higher activities than their        
aryl-substituted structural analogs (entries 10, 11, 16 and 17). 
 
Further unfunctionalized trisubstituted alkenes were tested (see Tables 7 and 8). With 
amidophosphines as P,O ligands only poor to moderate enantioselectivities were 
achieved. The results for the asymmetric hydrogenation of 6-methoxy-1-methyl-3,4-
dihydronaphthalene (S2) are shown in Table 7 and the respective data for (E)- and              
(Z)-2-(4-methoxyphenyl)-2-butene ((E)-and (Z)-S3) are summarized in Table 8.  
 
Table 7. Iridium-catalyzed asymmetric hydrogenation of 6-methoxy-1-methyl-3,4-
dihydronaphthalene (S2).[a] 
 
Entry Ligand R1 R2 Yield [%][b] ee [%][c] 
1 (S)-LA1  tBu Ph 97 [> 99]   2 (S) 
2 (S)-LA2  tBu oTol 77 [83] rac 
3 (S)-LA8  1-Adm oTol 82 [88] rac 
4 (S)-LA10 1-Adm tBu 97 [> 99] 29 (S) 
5 (S)-LA11 1-Adm Cy 53 [> 99] 11 (S) 
6 (S)-LA13 CPh3 Ph 96 [> 99]   2 (S) 
7 (S)-LA14 CPh3 oTol 56 [73]   4 (S) 
8 (S)-LA15 CPh3 2-Fur 96 [> 99] rac 
9 (S)-LA16 CPh3 tBu 96 [> 99] 16 (S) 
10 (S)-LA17 CPh3 Cy 95 [> 99]   3 (S) 
[a] Reaction scale: [Ir(cod)2]BArF (2.50 μmol), ligand (2.50 μmol), solvent (0.5 mL), substrate (250 μmol); [b] Yields were 
determined by GC analysis (see experimental part), conversions are given in parenthesis; [c] Enantioselectivities were 
determined by HPLC analysis using a chiral stationary phase (see experimental part). 
 
In the reduction of S2 dialkylphosphines again provided complete conversions, albeit 
these were accompanied by the formation of a small amount of side product. The 
enantiomeric excesses measured for product P2 were unsatisfying (ees < 29%). Even the 
sterically hindered trityl-substituted amides did not achieve enantiomeric excesses higher 
than 16% (entries 6 to 10). 
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Taking into account the poor results obtained in the asymmetric reduction of the cyclic 
substrate S2 only a few ligands were tested in the hydrogenation of the isomeric 
substrates (E)-S3 and (Z)-S3 (Table 8). Albeit good yields higher than 83% were 
measured, only low to moderate selectivities were obtained for both isomers. The best 
enantioselectivity in the reduction of the (E)-isomer was achieved with the trityl-
substituted ligand (S)-LA13 (53% ee, entry 8). The selectivity in the reduction of the        
(E)-isomer was always higher than in the corresponding reduction of the (Z)-isomer. 
 
Table 8. Iridium-catalyzed asymmetric hydrogenation of (E)- and (Z)-2-(4-methoxyphenyl)-2-
butene ((E)- and (Z)-S3).[a] 
 
Entry Substrate Ligand R1 R2 Yield [%][b] ee [%][c] 
1 (E)-S3 (R)-LA1 tBu Ph > 99 44 (S) 
2 (Z)-S3 (R)-LA1 tBu Ph > 99   7 (R) 
3 (E)-S3 (S)-LA2  tBu oTol > 99 35 (R) 
4 (Z)-S3 (S)-LA2  tBu oTol > 99 12 (S) 
5 (E)-S3 (S)-LA8  1-Adm oTol    88 20 (R) 
6 (Z)-S3 (S)-LA8  1-Adm oTol > 99 15 (S) 
7 (Z)-S3 (S)-LA9  1-Adm 2-Fur > 99 rac 
8 (E)-S3 (S)-LA13 CPh3 Ph    83 53 (R) 
9 (Z)-S3 (S)-LA13 CPh3 Ph    99 rac 
10 (E)-S3 (S)-LA14 CPh3 oTol    88 46 (R) 
11 (Z)-S3 (S)-LA14 CPh3 oTol > 99   5 (R) 
12 (E)-S3 (S)-LA15 CPh3 2-Fur    95 29 (R) 
13 (Z)-S3 (S)-LA15 CPh3 2-Fur    94 rac 
[a] Reaction scale: [Ir(cod)2]BArF (2.50 μmol), ligand (2.50 μmol), solvent (0.5 mL), substrate (250 μmol); [b] Yields were 
determined by GC analysis (see experimental part); [c] Enantioselectivities were determined by HPLC or GC analysis 
using a chiral stationary phase (see experimental part). 
 
When functionalized trisubstituted alkenes were tested, amidophosphines proved to be 
significantly more efficient. The reduction of (E)-ethyl 3-phenylbut-2-enoate (S4) 
furnished up to 98% ee and complete conversion (entry 14). All amidophosphines (S)-LA 
gave good to excellent conversions of S4. The selectivities varied depending on the 
substituents R1 and R2. As observed in the asymmetric reduction of S1, sterically more 
demanding R1-substituents in the ligand gave better enantiomeric excesses (entries 11 to 
15) and R2-alkyl substituents afforded higher selectivities than R2-aryl substituents. When 
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amidophosphines bearing a trityl substituent as R1 were used, enantiomeric excesses of 
higher than 84% (R) were achieved, with di-ortho-tolylphosphine ligand (S)-LA14 being 
the only exception (57% ee (R), entry 12). The use of di-ortho-tolylphosphine (S)-LA8 
furnished the (S)-configured product P4 with 30% ee (entry 7). 
 
Table 9. Iridium-catalyzed asymmetric hydrogenation of (E)-ethyl 3-phenylbut-2-enoate (S4).[a] 
 
Entry Ligand R1 R2 Yield [%][b] ee [%][c] 
1 (S)-LA1  tBu Ph    65 33 (R) 
2 (S)-LA2  tBu oTol    99 13 (R) 
3 (S)-LA3  tBu 2-Fur    99 40 (R) 
4 (S)-LA4  tBu tBu    98 51 (R) 
5 (S)-LA5  tBu Cy    95 33 (R) 
6 (S)-LA7  1-Adm Ph    96 15 (R) 
7 (S)-LA8  1-Adm oTol    97 30 (S) 
8 (S)-LA9  1-Adm 2-Fur    85 14 (R) 
9 (S)-LA10 1-Adm tBu > 99 50 (R) 
10 (S)-LA11 1-Adm Cy    98 26 (R) 
11 (S)-LA13 CPh3 Ph    88 89 (R) 
12 (S)-LA14 CPh3 oTol > 99 57 (R) 
13 (S)-LA15 CPh3 2-Fur    86 84 (R) 
14 (S)-LA16 CPh3 tBu > 99 98 (R) 
15 (S)-LA17 CPh3 Cy > 99 94 (R) 
16 (S)-LA18 Ph Ph    99 12 (S) 
[a] Reaction scale: [Ir(cod)2]BArF (2.50 μmol), ligand (2.50 μmol), solvent (0.5 mL), substrate (250 μmol); [b] Yields were 
determined by GC analysis (see experimental part); [c] Enantioselectivities were determined by GC analysis using a chiral 
stationary phase (see experimental part). 
 
Another standard substrate to evaluate the potential of novel catalysts for the asymmetric 
hydrogenation of alkenes is the allylic alcohol S5. The results obtained from the 
asymmetric reduction of this trisubstituted functionalized alkene by 
amidophosphine/iridium complexes are presented in Table 10. Conversions were 
generally higher than 95% throughout the complete ligand set, although the reaction was 
sometimes accompanied by the formation of decomposition side products (entries 1, 2, 7 
and 8). The product P5 was formed with lower enantioselectivities than observed for P1 
or P4 (Tables 6 and 9 respectively). The highest enantiomeric excess for the 
hydrogenation of S5 was obtained with the di-ortho-tolylphosphine (S)-LA2 (69% ee, 
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entry 2). In contrast to the substrates tested above, the selectivity was superior, when     
di-ortho-tolylphosphines (S)-LA2, (S)-LA8 and (S)-LA14 were used (entries 2, 3 and 8). 
This observation indicates that this substrate approaches the active site of the catalyst in 
different way (for a qualitative model rationalizing the enantioselectivity effected by 
P,O ligand/iridium complexes see section 2.7). 
 
Table 10. Iridium-catalyzed asymmetric hydrogenation of (E)-2-methyl-3-phenylprop-2-en-1-ol 
(S5).[a] 
 
Entry Ligand R1 R2 Yield [%][b] ee [%][c] 
1 (S)-LA1  tBu Ph    88 [95] 26 (S) 
2 (S)-LA2  tBu oTol    56 [96] 69 (S) 
3 (S)-LA8  1-Adm oTol > 99 60 (S) 
4 (S)-LA9  1-Adm 2-Fur    99 17 (S) 
5 (S)-LA10 1-Adm tBu > 99 63 (S) 
6 (S)-LA11 1-Adm Cy > 99 35 (S) 
7 (S)-LA13 CPh3 Ph    97 [> 99] 17 (S) 
8 (S)-LA14 CPh3 oTol    96 [> 99] 37 (S) 
9 (S)-LA15 CPh3 2-Fur > 99 13 (S) 
10 (S)-LA16 CPh3 tBu > 99 48 (S) 
11 (S)-LA17 CPh3 Cy > 99 20 (R) 
[a] Reaction scale: [Ir(cod)2]BArF (2.50 μmol), ligand (2.50 μmol), solvent (0.5 mL), substrate (250 μmol); [b] Yields were 
determined by GC analysis (see experimental part), conversions are given in parenthesis; [c] Enantioselectivities were 
determined by HPLC analysis using a chiral stationary phase (see experimental part). 
 
Considering the higher efficiency of amidophosphines (S)-LA compared to 
carbamatophosphines (S)-LC as P,O ligands for the iridium-catalyzed asymmetric 
hydrogenation of standard substrates, selected additional substrates were investigated. 
However, this second screening involved only amidophosphines, which exhibited good 
selectivities in the asymmetric hydrogenation of the previous substrates, namely the   
trityl-substituted ligands (S)-LA13, (S)-LA16 and (S)-LA17. Since excellent selectivities 
up to 98% ee were obtained for the reduction of S4, other trisubstituted α,β-unsaturated 
esters were studied next (Tables 11 to 13). 
 
The results obtained in the asymmetric hydrogenation of the more challenging                     
α-methyl-substituted esters S6a and S6b are summarized in Table 11. Pyridyl 
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phosphonite-based P,N catalysts have previously been reported to reduce these esters with 
excellent enantioselectivities up to 97% for S6a and 99% for S6b.[80] Using the                
trityl-substituted amidophosphines (S)-LA13, (S)-LA16 and (S)-LA17 showing similar 
efficiencies for ester S4 slightly lower enantioselectivities were obtained, but nevertheless 
(S)-LA17 furnished up to 95% ee for S6b (entry 6).  
 
Table 11. Iridium-catalyzed asymmetric hydrogenation of (E)-ethyl-2-methyl-3-phenylacrylate 
(S6a) and (E)-isopropyl 2-methyl-3-phenylacrylate (S6b).[a] 
 
Entry R3 Ligand R1 R2 Yield [%][b] ee [%][c] 
1 Et (S)-LA13 CPh3 Ph    54 66 (R) 
2 iPr (S)-LA13 CPh3 Ph    57 77 (R) 
3 Et (S)-LA16 CPh3 tBu > 99 90 (R) 
4 iPr (S)-LA16 CPh3 tBu > 99 89 (R) 
5 Et (S)-LA17 CPh3 Cy > 99 87 (R) 
6 iPr (S)-LA17 CPh3 Cy > 99 95 (R) 
[a] Reaction scale: [Ir(cod)2]BArF (1.25 μmol), ligand (1.25 μmol), solvent (0.25 mL), substrate (125 μmol); [b] Yields were 
determined by GC analysis (see experimental part); [c] Enantioselectivities were determined by HPLC analysis using a 
chiral stationary phase (see experimental part). 
 
Generally, the ligands achieved better results for the sterically more demanding isopropyl 
ester S6b compared with the ethyl ester S6a (entries 1 and 5 versus 2 and 6). The use of 
(S)-LA16 gave the (R)-configured product P6a with 90% ee, whereas (S)-LA17 permitted 
to reduce S6b to P6b with 95% ee (R). 
 
The reduction of α,β-unsaturated esters S7 and S8, by the use of amidophosphine ligands 
proceeded with conversions greater than 96% and moderate enantiomeric excesses of 
55% to 85% (Table 12). The α-methyl-substituted ester S7 was reduced with up to 
85% ee, while the β-methyl-substituted ester S8 was reduced with only 55% ee at best. 
The decreased enantioselectivity of the catalysts in the reduction of these esters may be 
rationalized by the greater flexibility of substrate S7 and S8, attributed to the longer alkyl 
chains in β-position. 
 
                                                             
[80] D. H. Woodmansee, M.-A. Müller, M. Neuburger, A. Pfaltz, Chem. Sci. 2010, 1, 72-78. 
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Table 12. Iridium-catalyzed asymmetric hydrogenation of (E)-ethyl 2-methyl-5-phenylpent-2-
enoate (S7) and (E)-ethyl 3-methyl-5-phenylpent-2-enoate (S8).[a] 
 
Entry Substrate Ligand R1 R2 Yield [%][b] ee [%][c] 
1 S7 (S)-LA13 CPh3 Ph    96 74 (−) 
2 S7 (S)-LA16 CPh3 tBu > 99 84 (−) 
3 S7 (S)-LA17 CPh3 Cy > 99 85 (−) 
4 S8 (S)-LA13 CPh3 Ph > 99 48 (S) 
5 S8 (S)-LA16 CPh3 tBu > 99 55 (S) 
[a] Reaction scale: [Ir(cod)2]BArF (1.25 μmol), ligand (1.25 μmol), solvent (0.25 mL), substrate (125 μmol); [b] Yields were 
determined by GC analysis (see experimental part); [c] Enantioselectivities were determined by HPLC analysis using a 
chiral stationary phase (see experimental part). 
 
The very challenging α-aryl ester S9 was reduced in moderate yields and selectivities 
(Table 13). Although the closely related α-methyl-substituted analog S6a was obtained in 
> 99% yield and with 90% ee (R) using ligand (S)-LA16 (Table 11), for ester S9 the 
ligand (S)-LA17 furnished the highest selectivity of 84% ee albeit with a slightly 
diminished conversion of 63% (entry 3). 
 
Table 13. Iridium-catalyzed asymmetric hydrogenation of (E)-ethyl 2,3-diphenylacrylate (S9).[a] 
 
Entry Ligand R1 R2 Yield [%][b] ee [%][c] 
1 (S)-LA13 CPh3 Ph 16 65 (+) 
2 (S)-LA16 CPh3 tBu 62 76 (+) 
3 (S)-LA17 CPh3 Cy 63 84 (+) 
[a] Reaction scale: [Ir(cod)2]BArF (1.25 μmol), ligand (1.25 μmol), solvent (0.25 mL), substrate (125 μmol); [b] Yields were 
determined by GC analysis (see experimental part); [c] Enantioselectivities were determined by HPLC analysis using a 
chiral stationary phase (see experimental part). 
 
Certainly more impressive is the level of enantioselectivity obtained in the reduction of 
α,β-unsaturated ketones S10a and S10b utilizing several amidophosphine/iridium 
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catalysts, where the selectivities exceeded the values previously reported for P,N-based 
systems (Table 14).[81] Sulfoximine-derived P,N ligand/iridium complexes catalyzed the 
reduction of these substrates with enantiomeric excesses up to 81%. Both di-tert-
butylphosphine (S)-LA16 and dicyclohexylphosphine (S)-LA17 catalysts yielded P10a 
with 96% ee (R) (entries 3 and 5). Substrate S10b bearing an R3-phenyl substituent was 
reduced with up to 95% ee (R) (entry 6). Conversions in the hydrogenation of S10b 
ranged from 71% to 98%. Even though the enantioselectivities were excellent for this 
substrate class, the complete conversion of substrate S10a using (S)-LA16 and (S)-LA17 
was accompanied by minor formation of the saturated alcohol. To overcome this issue the 
reaction was carried out with isolated, preformed catalysts instead of using the in situ 
complexation method (entries 3 and 5). By using this procedure less overreduction was 
observed in the case of (S)-LA17 (98% versus 95% yield), but the selectivity decreased 
(98% versus 89% ee in entry 5). 
 
Table 14. Iridium-catalyzed asymmetric hydrogenation of (E)-4-phenylpent-3-en-2-one (S10a) 
and (E)-1,3-diphenylbut-2-en-1-one (S10b).[a] 
 
Entry R3 Ligand R1 R2 Yield [%][b] ee [%][c] 
1 Me (S)-LA13 CPh3 Ph 85 79 (R) 
2 Ph (S)-LA13 CPh3 Ph 71 87 (R) 
3 Me (S)-LA16 CPh3 tBu 98[d] [98][e] 96 (R) [94 (R)][e] 
4 Ph (S)-LA16 CPh3 tBu 99 94 (R) 
5 Me (S)-LA17 CPh3 Cy 95[d] [98][e] 96 (R) [89 (R)][e] 
6 Ph (S)-LA17 CPh3 Cy 98 95 (R) 
[a] Reaction scale: [Ir(cod)2]BArF (1.25 μmol), ligand (1.25 μmol), solvent (0.25 mL), substrate (125 μmol); [b] Yields were 
determined by GC analysis (see experimental part); [c] Enantioselectivities were determined by HPLC analysis using a 
chiral stationary phase (see experimental part); [d] Formation of side products was observed (conversions > 99%); 
[e] Results obtained with the isolated precatalyst. 
 
To address the undesired overreduction of S10a different reaction conditions were 
screened using the (S)-LA17/iridium catalyst system (Table 15). The influence of the 
prior isolation of the precatalyst compared to the in situ complexation method was 
investigated, as well as the impact of the reaction time and the hydrogen pressure. At 
                                                             
[81] S.-M. Lu, C. Bolm, Chem. Eur. J. 2008, 14, 7513-7516. 
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lower hydrogen pressure both yields and enantioselectivities dropped but no 
overreduction was observed (entry 5).  
 
Table 15. Optimization of reaction conditions for the iridium-catalyzed asymmetric hydrogenation 
of (E)-4-phenylpent-3-en-2-one (S10a) with (S)-LA17.[a] 
 
Entry p [bar] t [h] Complex Conv. [%][b] Yield [%][b] ee [%][c] 
1 50 2 A > 99 93[d] 96 (R) 
2 50 2 B > 99 98 89 (R) 
3 50 1 A > 99 97 96 (R) 
4 50 1 B > 99 98 90 (R) 
5   5 2 B    83 83 86 (R) 
[a] Reaction scale: catalyst (1.25 μmol), solvent (0.25 mL), substrate (125 μmol); [b] Conversions and yields were 
determined by GC analysis (see experimental part); [c] Enantioselectivities were determined by HPLC analysis using a 
chiral stationary phase (see experimental part); [d] Average of 2 experiments. 
 
Using the isolated complex (S)-CA17 ([((S)-LA17)Ir(cod)]BArF) as catalyst no influence 
of the reaction time could by observed and the same results were obtained 1 or 2 hours 
reaction time (entries 2 and 4). When the in situ complexation method was used, no 
influence of the reaction time on the enantioselectivity of the reaction was observed, 
either (entries 1 and 3). Comparison of the influence of the catalyst’s provenance (isolated 
(S)-CA17 versus in situ complexed (S)-LA17) shows that the isolation of the precatalyst 
renders a slight decrease of the amount of overreduced product possible but also impacts 
the enantiomeric excess (entries 1 and 3 versus 2 and 4). 
 
Finally, the imine substrate S11 was also tested (Table 16), but the 
amidophosphine/iridium catalysts proved to be not suitable for the reduction of C−N 
double bonds. Diarylphosphines did not give yields higher than 57% and the selectivities 
were of 26% ee at best. Moreover, the reduction was accompanied by major formation of 
hydrolysis products. Dialkylphosphines were not tested at all in the hydrogenation of S11. 
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Table 16. Iridium-catalyzed asymmetric hydrogenation of N-(1-phenylethylidene)-aniline (S11).[a] 
 
Entry Ligand R1 R2 Yield [%][b] ee [%][c] 
1 (R)-LA1 tBu Ph 12 [56] 14 (S) 
2 (S)-LA2  tBu oTol 37 [92] 25 (R) 
3 (S)-LA8  1-Adm oTol 27 [91] 18 (R) 
4 (S)-LA9  1-Adm 2-Fur 15 [66]   7 (R) 
5 (S)-LA13 CPh3 Ph   9 [64] 11 (R) 
6 (S)-LA14 CPh3 oTol 57 [95] 13 (R) 
7 (S)-LA15 CPh3 2-Fur 18 [93]   5 (R) 
[a] Reaction scale: [Ir(cod)2]BArF (2.50 μmol), ligand (2.50 μmol), CH2Cl2 (0.5 mL), substrate (250 μmol); [b] Yields were 
determined by GC analysis (see experimental part), conversions are given in parenthesis; [c] Enantioselectivities were 
determined by HPLC analysis using a chiral stationary phase (see experimental part). 
 
Sterically hindered proline-based P,O ligands with alkyl substituents at the phosphorus 
moiety allowed for the enantioselective hydrogenation of the unfunctionalized 
trisubstituted alkene S1 with higher enantiomeric excesses than the initially discovered 
ligand (R)-LA1. In addition, these ligands were applied to the iridium-catalyzed 
asymmetric hydrogenation of α,β-unsaturated ketones and excellent enantiomeric 
excesses of up to 96% were achieved. 
 
2.5   
Proline-Based Ureaphosphines Ligands 
 
Based on the results of the previous section, ureaphosphines were prepared and tested as 
ligands in the iridium-catalyzed asymmetric hydrogenation of the exemplar substrates 
presented above. Again, only the best ureaphosphines were applied to the hydrogenation 
of the more challenging α,β-unsaturated esters and ketones. The same phosphorus 
substituents were introduced in the ureaphosphines, which were already contained in the 
amidophosphines, namely diphenyl-, di-ortho-tolyl-, di-(2-furyl)-, di-tert-butyl- and 
dicyclohexylphosphines were prepared. The incorporation of an urea moiety instead of an 
amide carbonyl functionality was thought to make an optimization of the electronic as 
well as steric characteristics of the coordinating oxygen possible, since the adjacent 
nitrogen atom can be substituted with two groups. The ureaphosphines synthesized and 
presented below are divided into two classes, namely trisubstituted ureaphosphines             
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(S)-LU3 and tetrasubstituted ureaphosphines (S)-LU4 (see Figure 9). First, their synthesis 
is described and the results of their application as ligand in the asymmetric hydrogenation 
are summarized, later. 
 
2.5.1 
Trisubstituted Ureaphosphines Ligands 
 
A series of trisubstituted ureaphosphine ligands was prepared, which is depicted in 
Schemes 21 and 23. The urea moiety consists of the pyrrolidine ring (which incorporates 
the first nitrogen atom) and a second substituent, which is derived from a primary amine 
(aryl or alkyl substituent as R1-group). 
 
2.5.1.1 
Synthesis of Trisubstituted Ureaphosphines 
 
In the following, the synthesis of ureaphosphine ligands is depicted in two schemes: while 
Scheme 21 shows all diaryl-substituted phosphines that were prepared, the                    
dialkyl-substituted phosphine ligands are presented in Scheme 23. 
 
Ureaphosphine ligands were easily prepared from the previously synthesized carbamates 
(S)-LC1, (S)-LC2 and (S)-LC3 with different substituents at the phosphorus atom as 
starting materials (Schemes 11 and 12). Form the respective deprotected salts (S)-52∙HCl, 
(S)-57∙HCl and (S)-58∙HCl, several trisubstituted ureaphosphines (S)-LU3 were obtained. 
The urea functionalities were introduced using isocyanates (R1NCO) or the succinimidyl 
carbamate of aniline (70) as reagent. Good to excellent yields were achieved for this 
substitution reaction representing the last step of the ligand synthesis (34% to 92%). 
 
The majority of the isocyanates were commercially available, only triphenylmethyl 
isocyanate (66) and 2,4,6-tri-tert-butylmethylphenyl isocyanate (68) had to be 
synthesized (Scheme 22). These were prepared following a literature-known procedures 
involving the reaction of triphosgene with the respective primary amine.[82,83] 
                                                             
[82] For the synthesis of triphenylmethyl isocyanate (66) see: A. G. S. Blommert, J.-H. Weng, A. Dorville, 
I. McCort, B. Ducos, C. Durieux, B. P. Roques, J. Med. Chem. 1993, 36, 2868-2877. 
[83] For the prodecure followed to prepare 2,4,6-tri-tert-butylmethylphenyl isocyanate (68) see: H.-J. Knölker, 
T. Braxmeier, G. Schlechtingen, Angew. Chem. Int. Ed. Engl. 1995, 34, 2497-2500. 
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Scheme 21. Synthesis of trisubstituted ureaphosphines with aryl substituents at the phosphorus 
atom (abbreviations: Mes for mesityl, (2,4,6-tBu3)Ph for 2,4,6-tri-tert-butylphenyl and 1-Naph for 1-
naphthyl). 
 
 
Scheme 22. Synthesis of the isocyanates 66 and 68 and of the succinimidyl carbamate 70.[82,83] 
 
Additionally, 2,5-dioxopyrrolidin-1-yl phenylcarbamate (70) was prepared from aniline 
(69), by reacting it with N,N'-disuccinimidyl carbonate (DSC) in the presence of 
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triethylamine (Scheme 22). The desired product was obtained in 82% yield after only 
30 minutes. The conditions were not optimized and the reaction was deliberately stopped 
after 30 minutes to avoid the subsequent formation of 1,3-diphenylurea, that was 
observed after longer reaction times. The utilization of 70 and phenyl isocyanate proved 
to be equally effective. 
 
The synthesis of dialkyl-substituted phosphines is depicted in Scheme 23. These ligands 
comprise the same urea moieties as the derivatives shown in Scheme 21 in combination 
with either a di-tert-butyl- or dicyclohexylphosphine moiety.  
 
 
Scheme 23. Synthesis of trisubstituted ureaphosphines with alkyl substituents at the phosphorus 
atom. 
 
Ligand precursors (S)-LU3∙BH3 were obtained in good yields by reaction of the 
pyrrolidinium salts (S)-63∙HCl and (S)-64∙HCl containing the desired borane-protected 
phosphine moieties with the respective isocyanates (51% to 90% yield, Scheme 23). 
Potassium carbonate had to be used as base to avoid the premature deprotection of the 
phosphorus atom. The free ligands were obtained by deprotection with diethylamine as 
described in the synthesis of dialkyl-substituted amidophosphines, and the ligands were 
converted to their respective iridium complexes in the same way as shown in Scheme 20. 
 
A representative example for the complexation of ureaphosphines is depicted in 
Scheme 24. [Ir(cod)2]BArF was stirred with the trisubstituted ureaphosphine (S)-LU315 in 
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a 1:1 ratio at room temperature. After evaporation of the solvent and trituration with              
n-pentane the complex (S)-CU315 was obtained as a yellowish solid in 97% yield. 
 
 
Scheme 24. Synthesis of ureaphosphine/iridium complex (S)-CU315. 
 
The coordination mode of (S)-LU315 to iridium was investigated in order to confirm that 
similar to amidophosphines, ureaphosphines behave as bidentate P,O ligands. The 
spectroscopic data in Table 17 confirm a bidentate coordination.  
 
Table 17. Comparison of the spectroscopic properties of ligand (S)-LU315 and complex (S)-CU315. 
 
  
 (S)-LU315 (S)-CU315 
31P NMR [δ (P)] − 21.6 ppm 11.2 ppm 
13C NMR [δ (C=O)] 154.5 ppm 163.7 ppm 
IR [ߥ෤ (C=O)] 1663 cm−1 1569 cm−1 
 
The NMR signals of both the phosphorus and the quaternary carbonyl carbon are shifted 
downfield, when the ligand is bound to iridium ((S)-CU315). Furthermore, the IR 
spectroscopic data also support that the urea moiety is coordinated to iridium by showing 
the typical shift of the vibrational wavenumber for the coordinated urea C−O double bond 
to lower values (ߥ෤ = 1663 cm−1 for (S)-LU315 versus ߥ෤ = 1569 cm−1 for (S)-CU315). These 
results are very similar to those obtained in the analysis of amidophosphine coordination 
to iridium (see Table 2). 
 
The solid state structure of complex (S)-CU315 is shown in Figure 10. Since the 
crystallization of the presented BArF complexe proved to be difficult, the growth of 
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suitable single crystals was pursed for the corresponding PF6 derivative (S)-CU315. The 
procedure for its preparation is basically the same as described in Scheme 24, but instead 
of [Ir(cod)2]BArF, [Ir(cod)2]PF6 was used. Looking at this structure it can be seen that the 
trityl group acts like a shield for one side of the metal center. This observation explains 
the better enantioselectivities obtained with trityl-substituted ureaphosphine ligands in the 
asymmetric hydrogenation of several substrates described below (Tables 18 and 21). The 
same is probably true for the good results obtained with trityl-substituted 
amidophosphines (Tables 6 and 9). In both cases the trityl group might occupy a wider 
space near the active site of the catalyst and therefore forces the substrates to coordinate 
in a more defined, less flexible way. 
 
 
Figure 10. Crystal structure of complex [((S)-LU315)Ir(cod)]PF6.The counterion has been omitted 
for clarity (red O, blue N, magenta P, dark gray Ir, light gray C).[84] 
 
No significant differences in the bond lengths can be noticed when the values obtained 
with the help of the X-ray structures for (R)-CA1 and (S)-CU315 are compared 
(Figures 8 and 10). The Ir−P bond lengths are almost equal in both complexes and the           
Ir−O bond lengths are just slightly different (Ir−P bonds 2.29 Å for (S)-CU315 and 2.30 Å 
for (R)-CA1, Ir−O bonds 2.10 Å for (S)-CU315 and 2.08 Å for (R)-CA1). However, more 
pronounced differences between both precatalysts can be seen concerning their bite 
angles of 93.3° for (S)-CU315 and 89.3° for (R)-CA1. 
 
 
 
 
                                                             
[84] Crystallographic data (excluding structure factors) have been deposited with the Cambridge 
Crystallographic Data Center. The deposition number is 829326. 
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2.5.5.2 
Iridium-Catalyzed Asymmetric Hydrogenations with Trisubstituted Ureaphosphine 
Ligands 
 
The standard substrate S1 ((E)-1,2-diphenyl-1-propene) was investigated first, once again 
(Table 18). As it was the case for amidophosphines, (S)-configured 
ureaphosphine/iridium catalysts gave the (R)-configured product P1 in excess. The 
highest enantiomeric excess obtained with amidophosphines in section 2.4.2 involved 
ligand (S)-LA16, a di-tert-butylphosphine with a trityl-substituted amide (98% ee). The 
asymmetric hydrogenation of alkene S1 using ligands (S)-LU313, (S)-LU315, (S)-LU317 
and (S)-LU318 afforded the product (R)-P1 with the same or even better enantiomeric 
excesses of 98% and more (entries 13, 15, 17 and 18). Overall, several quite efficient 
ureaphosphine ligands for the iridium-catalyzed asymmetric hydrogenation of S1 were 
developed that furnished selectivities of 90% ee and more. The same correlations between 
catalyst structures and selectivities were observed for ureaphosphines and 
amidophosphines. Interestingly in the case of the urea-based derivatives, also the ligands 
substituted with a planar R1-mesityl group (S)-LU323 and (S)-LU324 furnished 
selectivities of 90% ee and 92% ee (entries 23 and 24). In contrast, the structurally related 
ligand (S)-LU325 with a more bulky 2,4,6-tri-tert-butyl-phenyl-substituted urea, reduced 
the alkene S1 with only 86% conversion and 40% ee (entry 25). The steric hindrance of 
this urea moiety is probably too pronounced and causes overcrowding around the active 
site of the catalyst making it more difficult for the substrate to bind to the metal center in 
a defined way. 
 
Comparison of the results obtained for (S)-LU319, (S)-LU321 and (S)-LU326 with 
R1 = phenyl, mesityl and naphtyl, respectively, with (S)-LU315 with R1 = trityl indicates 
that diaryl-substituted ureaphosphines can provide excellent results, when they exhibit 
increased steric bulk at the carbonyl functionality, while planar substituents are not 
equally suited as R1-groups. Taken together, a trityl-substituted urea once again proved to 
be optimal for obtaining high selectivities, while dialkylphosphines/iridium catalysts gave 
better results than their structural diaryl analogs in most cases. 
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Table 18. Iridium-catalyzed asymmetric hydrogenation of (E)-1,2-diphenyl-1-propene (S1).[a] 
 
Entry Ligand R1 R2 Yield [%][b] ee [%][c] 
1 (S)-LU31  tBu Ph > 99 73 (R) 
2 (S)-LU32  tBu oTol    50 54 (R) 
3 (S)-LU33  tBu 2-Fur > 99 62 (R) 
4 (S)-LU34  tBu tBu    70 93 (R) 
5 (S)-LU35  tBu Cy > 99 88 (R) 
6 (S)-LU36  iPr Ph > 99 17 (R) 
7 (S)-LU37  Cy Ph > 99 36 (R) 
8 (S)-LU38  Cy oTol > 99   6 (R) 
9 (S)-LU39  Cy tBu    96 77 (R) 
10 (S)-LU310 Cy Cy > 99 63 (R) 
11 (S)-LU311 1-Adm Ph > 99 89 (R) 
12 (S)-LU312 1-Adm oTol    99 79 (R) 
13 (S)-LU313 1-Adm tBu > 99 98 (R) 
14 (S)-LU314 1-Adm Cy > 99 96 (R) 
15 (S)-LU315 CPh3 Ph > 99 99 (R) 
16 (S)-LU316 CPh3 oTol > 99 97 (R) 
17 (S)-LU317 CPh3 tBu > 99 98 (R) 
18 (S)-LU318 CPh3 Cy > 99 99 (R) 
19 (S)-LU319 Ph Ph    95 77 (R) 
20 (S)-LU320 Ph 2-Fur    64 70 (R) 
21 (S)-LU321 Mes Ph > 99 87 (R) 
22 (S)-LU322 Mes oTol > 99 69 (R) 
23 (S)-LU323 Mes tBu > 99 92 (R) 
24 (S)-LU324 Mes Cy > 99 90 (R) 
25 (S)-LU325 (2,4,6-tBu3)Ph Ph    86 40 (R) 
26 (S)-LU326 1-Naph Ph > 99 80 (R) 
[a] Reaction scale: [Ir(cod)2]BArF (2.50 μmol), ligand (2.50 μmol), solvent (0.5 mL), substrate (250 μmol); [b] Yields were 
determined by GC analysis (see experimental part); [c] Enantioselectivities were determined by HPLC analysis using a 
chiral stationary phase (see experimental part). 
 
Unfortunately, trisubstituted ureaphosphine/iridium catalysts were not more selective in 
the asymmetric hydrogenation of the unfunctionalized trisubstituted alkene S2 compared 
with the corresponding amidophosphine derivatives (Table 19). Throughout the whole 
screening of various ureaphosphines involving both dialkyl- and diarylphosphines and 
various amide R1-substituents the selectivities in the reduction of cyclic substrate S2 
remained below 23% ee. Although the yields in these reactions were good to excellent 
(75% to 98%), the conversion of S2 and yields of P2 were not always identical, since up 
to 9% of by-products were observed (entry 22). 
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Table 19. Iridium-catalyzed asymmetric hydrogenation of 6-methoxy-1-methyl-3,4-
dihydronaphthalene (S2).[a] 
 
Entry Ligand R1 R2 Yield [%][b] ee [%][c] 
1 (S)-LU31  tBu Ph    88 [91] rac 
2 (S)-LU32  tBu oTol    93 23 (S) 
3 (S)-LU34  tBu tBu    96 [98] 20 (S) 
4 (S)-LU35  tBu Cy    92 [> 99] 10 (S) 
5 (S)-LU36  iPr Ph    93 [96]   2 (R) 
6 (S)-LU37  Cy Ph    87 [90]   2 (R) 
7 (S)-LU38  Cy oTol    98 rac 
8 (S)-LU39  Cy tBu    75 [78]   4 (S) 
9 (S)-LU310 Cy Cy    89 [> 99] rac 
10 (S)-LU311 1-Adm Ph    99   4 (S) 
11 (S)-LU312 1-Adm oTol    99 23 (S) 
12 (S)-LU313 1-Adm tBu    98   6 (R) 
13 (S)-LU314 1-Adm Cy    91 [98]   3 (S) 
14 (S)-LU315 CPh3 Ph    87 rac 
15 (S)-LU316 CPh3 oTol    86   2 (R) 
16 (S)-LU318 CPh3 Cy    93 [> 99]   5 (R) 
17 (S)-LU317 CPh3 tBu    95 [> 99] 17 (S) 
18 (S)-LU319 Ph Ph    97 [> 99]   2 (S) 
19 (S)-LU321 Mes Ph > 99 14 (S) 
20 (S)-LU322 Mes oTol    98   9 (S) 
21 (S)-LU323 Mes tBu    96 [> 99] 10 (S) 
22 (S)-LU324 Mes Cy    91 [> 99]   4 (S) 
23 (S)-LU325 (2,4,6-tBu3)Ph Ph    79 [81]   4 (S) 
24 (S)-LU326 1-Naph Ph    93 14 (S) 
[a] Reaction scale: [Ir(cod)2]BArF (2.50 μmol), ligand (2.50 μmol), solvent (0.5 mL), substrate (250 μmol); [b] Yields were 
determined by GC analysis (see experimental part), conversions are given in parenthesis; [c] Enantioselectivities were 
determined by HPLC analysis using a chiral stationary phase (see experimental part). 
 
Although the results of the screening shown, above, in Table 19 were not very 
encouraging to pursue the iridium-catalyzed asymmetric hydrogenation of more 
demanding unfunctionalized alkenes, the reduction of (E)-S3 and (Z)-S3 was attempted 
with several trisubstituted ureaphosphine ligands ((S)-LU3) (Table 20). The screening was 
rather unsystematic, since no clear trends concerning the preferred electronic and steric 
properties of the catalysts in order to achieve high enantioinduction was obtained from 
the previous screening, using S2. The reduction of (E)-S3 with (S)-LU319 as ligand led to 
(R)-P3 in > 99% yield and 41% ee (entry 12). (S)-LU32 permitted to obtain (S)-P3 in 
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99% yield and 55% ee from (Z)-S3 (entry 3). In these reductions involving the (Z)-isomer 
of S3, di-ortho-tolylphosphines ligands generally induced higher enantiomeric excesses 
than the respective diphenylphosphine ligands (entries 1, 3, 8 and 10). 
 
Table 20. Iridium-catalyzed asymmetric hydrogenation of (E)- and (Z)-2-(4-methoxyphenyl)-2-
butene ((E)-and (Z)-S3).[a] 
 
Entry Substrate Ligand R1 R2 Yield [%][b] ee [%][c] 
1 (Z)-S3 (S)-LU31  tBu Ph > 99 16 (S) 
2 (E)-S3 (S)-LU32  tBu oTol    51   3 (R) 
3 (Z)-S3 (S)-LU32  tBu oTol    99 55 (S) 
4 (E)-S3 (S)-LU36  iPr Ph > 99   7 (R) 
5 (Z)-S3 (S)-LU36  iPr Ph > 99 14 (S) 
6 (E)-S3 (S)-LU37  Cy Ph > 99 17 (R) 
7 (Z)-S3 (S)-LU37  Cy Ph > 99 17 (S) 
8 (Z)-S3 (S)-LU311 1-Adm Ph > 99 21 (S) 
9 (E)-S3 (S)-LU312 1-Adm oTol    65 rac 
10 (Z)-S3 (S)-LU312 1-Adm oTol > 99 35 (S) 
11 (Z)-S3 (S)-LU315 CPh3 Ph > 99 18 (S) 
12 (E)-S3 (S)-LU319 Ph Ph > 99 41 (R) 
13 (Z)-S3 (S)-LU319 Ph Ph > 99   8 (R) 
14 (E)-S3 (S)-LU321 Mes Ph    90 19 (R) 
15 (Z)-S3 (S)-LU321 Mes Ph > 99 15 (S) 
16 (Z)-S3 (S)-LU325 (2,4,6-tBu3)Ph Ph > 99   6 (S) 
[a] Reaction scale: [Ir(cod)2]BArF (2.50 μmol), ligand (2.50 μmol), solvent (0.5 mL), substrate (250 μmol); [b] Yields were 
determined by GC analysis (see experimental part); [c] Enantioselectivities were determined by HPLC or GC analysis 
using a chiral stationary phase (see experimental part). 
 
All the synthesized trisubstituted ureaphosphines were tested in the asymmetric 
hydrogenation of the functionalized alkenes S4 and S5. The results obtained in the ligand 
screening for the α,β-unsaturated ester (E)-ethyl 3-phenylbut-2-enoate (S4) are shown in 
Table 21. Unlike in the asymmetric reduction of the unfunctionalized alkene S1 only one 
ligand furnished an excellent enantiomeric excess, namely the dicyclohexylphosphine 
(S)-LU318 with a trityl-substituted urea functionality. The (R)-configured product P4 was 
obtained with > 99% yield and 98% ee (entry 18). 
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Table 21. Iridium-catalyzed asymmetric hydrogenation of (E)-ethyl 3-phenylbut-2-enoate (S4).[a] 
 
Entry Ligand R1 R2 Yield [%][b] ee [%][c] 
1 (S)-LU31  tBu Ph > 99 83 (R) 
2 (S)-LU32  tBu oTol    52 19 (R) 
3 (S)-LU33  tBu 2-Fur    60 50 (R) 
4 (S)-LU34  tBu tBu    58 53 (R) 
5 (S)-LU35  tBu Cy > 99 78 (R) 
6 (S)-LU36  iPr Ph > 99   7 (R) 
7 (S)-LU37  Cy Ph > 99 40 (R) 
8 (S)-LU38  Cy oTol    99   8 (R) 
9 (S)-LU39  Cy tBu    69 40 (R) 
10 (S)-LU310 Cy Cy > 99 48 (R) 
11 (S)-LU311 1-Adm Ph > 99 83 (R) 
12 (S)-LU312 1-Adm oTol    99 71 (R) 
13 (S)-LU313 1-Adm tBu > 99 92 (R) 
14 (S)-LU314 1-Adm Cy > 99 93 (R) 
15 (S)-LU315 CPh3 Ph    99 92 (R) 
16 (S)-LU316 CPh3 oTol    99 85 (R) 
17 (S)-LU317 CPh3 tBu    99 93 (R) 
18 (S)-LU318 CPh3 Cy > 99 98 (R) 
19 (S)-LU319 Ph Ph > 99 74 (R) 
20 (S)-LU320 Ph 2-Fur    48 41 (R) 
21 (S)-LU321 Mes Ph    99 87 (R) 
22 (S)-LU322 Mes oTol    99 49 (R) 
23 (S)-LU323 Mes tBu > 99 88 (R) 
24 (S)-LU324 Mes Cy > 99 90 (R) 
25 (S)-LU325 (2,4,6-tBu3)Ph Ph > 99 57 (R) 
26 (S)-LU326 1-Naph Ph    99 77 (R) 
[a] Reaction scale: [Ir(cod)2]BArF (2.50 μmol), ligand (2.50 μmol), solvent (0.5 mL), substrate (250 μmol); [b] Yields were 
determined by GC analysis (see experimental part); [c] Enantioselectivities were determined by GC analysis using a chiral 
stationary phase (see experimental part). 
 
Several other ligands furnished selectivities of more than 90% (entries 13 to 15, 17, 18 
and 24), though these derivatives incorporate bulky adamantyl, trityl or mesityl groups as 
R1-substituent. Isopropyl or cyclohexyl substituents at this position proved not to be 
suitable and only 7% to 48% ee were achieved in these cases (entries 6 to 10). For a given           
R1-group the combination with R2-alkyl substituents proved to be more efficient 
concerning enantioselectivities than the respective combination with R2-aryl substituents 
(entries 13 and 14 versus 11 and 12, as well as 17 and 18 versus 15 and 16). The ligand 
with tert-butyl substituents as R1-groups represents the only exception to this observation: 
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while 83% ee was achieved for the diphenylphosphine all other ureaphosphines in this 
subgroup showed lower selectivities (entries 1 to 5). In general, conversions were 
excellent except for di-ortho-tolylphosphine (S)-LU32, for di-(2-furyl)-phosphines               
(S)-LU33 and (S)-LU320 and di-tert-butylphosphines (S)-LU34 and (S)-LU39 (entries 2 to 
4, 9 and 20). 
 
At this stage the influence of the catalyst loading on the activity and selectivity of the 
complexes was investigated (Table 22). For this purpose (S)-LU315 was chosen as ligand 
for these test reactions, since it gave complete conversions and good selectivities in the 
asymmetric reduction of both the unfunctionalized alkene S1 and the ester substrate S4. 
With 1 mol% of catalyst loading 99% ee was obtained in the hydrogenation of S1 and 
92% ee in the reduction of S4 (entries 1 and 4). 
 
Table 22. Influence of the catalyst loading using (S)-LU315.[a] 
 
Entry Substrate Loading Yield [%][b] ee [%][c] 
1 S1   1 mol% > 99 99 (R) 
2 S1 0.5 mol%    97 95 (R) 
3 S1 0.1 mol%    65 82 (R) 
4 S4   1 mol%    99 92 (R) 
5 S4 0.5 mol%    99 90 (R) 
6 S4 0.1 mol%    21 86 (R) 
[a] Reaction scale: substrate (125 μmol), solvent (0.25 mL); [b] Yields were determined by GC analysis (see experimental 
part); [c] Enantioselectivities were determined by HPLC or GC analysis using a chiral stationary phase (see experimental 
part). 
 
Reduction of the catalyst loading to 0.5 mol% resulted in a slight decrease of the 
selectivities for both products P1 and P4 (entries 2 and 5). An additional reduction of the 
catalyst loading to 0.1 mol% impaired the enantioselectivities even more and also caused 
a drastic decrease of the conversions of starting materials S1 and S4 (entries 3 and 6). 
Since the observed trends were consistent for both investigated substrates, no further 
investigations concerning the lowering of catalyst loadings were carried out, and in all 
following hydrogenation reactions 1 mol% of catalyst was used. 
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Table 23. Iridium-catalyzed asymmetric hydrogenation of (E)-2-methyl-3-phenylprop-2-en-1-ol 
(S5).[a] 
 
Entry Ligand R1 R2 Yield [%][b] ee [%][c] 
1 (S)-LU31  tBu Ph    91 [> 99] 54 (S) 
2 (S)-LU32  tBu oTol > 99 57 (S) 
3 (S)-LU34  tBu tBu > 99 47 (S) 
4 (S)-LU35  tBu Cy > 99 32 (S) 
5 (S)-LU36  iPr Ph    95 [> 99] 32 (S) 
6 (S)-LU37  Cy Ph    87 [> 99] 32 (S) 
7 (S)-LU38  Cy oTol > 99 40 (S) 
8 (S)-LU39  Cy tBu > 99 59 (S) 
9 (S)-LU310 Cy Cy > 99 44 (S) 
10 (S)-LU311 1-Adm Ph    20 [25] 73 (S) 
11 (S)-LU312 1-Adm oTol    89 [95] 72 (S) 
12 (S)-LU313 1-Adm tBu > 99 61 (S) 
13 (S)-LU314 1-Adm Cy > 99 39 (S) 
14 (S)-LU315 CPh3 Ph > 99 71 (S) 
15 (S)-LU316 CPh3 oTol > 99 71 (S) 
16 (S)-LU317 CPh3 tBu > 99 20 (S) 
17 (S)-LU318 CPh3 Cy > 99 38 (S) 
18 (S)-LU319 Ph Ph    83 [> 99] 11 (S) 
19 (S)-LU321 Mes Ph > 99   9 (S) 
20 (S)-LU322 Mes oTol > 99 34 (S) 
21 (S)-LU323 Mes tBu > 99    7(S) 
22 (S)-LU324 Mes Cy > 99 10 (R) 
23 (S)-LU325 (2,4,6-tBu3)Ph Ph > 99 26 (R) 
24 (S)-LU326 1-Naph Ph > 99 14 (R) 
[a] Reaction scale: [Ir(cod)2]BArF (2.50 μmol), ligand (2.50 μmol), solvent (0.5 mL), substrate (250 μmol); [b] Yields were 
determined by GC analysis (see experimental part), conversions are given in parenthesis; [c] Enantioselectivities were 
determined by HPLC analysis using a chiral stationary phase (see experimental part). 
 
Most ureaphosphine/iridium catalysts gave more or less quantitative conversions for 
allylic alcohol S5 (see Table 23). Although the activities were excellent, these complexes 
showed rather moderate selectivities. The best enantiomeric excess measured for the 
reduction of allylic alcohol S5 was 73% ee (S), but unfortunately the lowest conversion of 
the whole series was obtained in this case (entry 10). Some other ligands also showed 
selectivities of more than 70% ee, namely (S)-LU312, (S)-LU315 and (S)-LU316 
(entries 11, 14 and 15). These ligands once again bear bulky urea substituents, like 
adamantyl or trityl moieties, but interestingly resemble diarylphosphine derivatives. 
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Therefore, this substrate is reduced with higher selectivities when aryl-substituted rather 
than alkyl-substituted phosphines are used. This observation was already made, when 
amidophosphines were used as P,O ligands in this transformation (see Table 10). 
 
Because of the excellent results for ester substrate S4 (Table 21), selected trisubstituted 
ureaphosphines were as well screened in the asymmetric hydrogenation of other 
trisubstituted α,β-unsaturated esters S6a, S6b, S7, S8 and S9 as well as the                          
α,β-unsaturated ketones S10a and S10b. The results for these investigations are shown 
below. High enantioselectivities were obtained for the iridium-catalyzed asymmetric 
hydrogenation of the α-methyl-substituted α,β-unsaturated esters S6a and S6b (Table 24). 
 
Table 24. Iridium-catalyzed asymmetric hydrogenation of (E)-ethyl 2-methyl-3-phenylacrylate 
(S6a) and (E)-isopropyl 2-methyl-3-phenylacrylate (S6b).[a] 
 
Entry R3 Ligand R1 R2 Yield [%][b] ee [%][c] 
1 Et (S)-LU313 1-Adm tBu > 99 90 (R) 
2 iPr (S)-LU313 1-Adm tBu > 99 92 (R) 
3 Et (S)-LU315 CPh3 Ph > 99 86 (R) 
4 iPr (S)-LU315 CPh3 Ph > 99 95 (R) 
5 Et (S)-LU317 CPh3 tBu    79 84 (R) 
6 iPr (S)-LU317 CPh3 tBu    87 87 (R) 
7 Et (S)-LU318 CPh3 Cy    98 68 (R) 
8 iPr (S)-LU318 CPh3 Cy > 99 71 (R) 
[a] Reaction scale: [Ir(cod)2]BArF (1.25 μmol), ligand (1.25 μmol), solvent (0.25 mL), substrate (125 μmol); [b] Yields were 
determined by GC analysis (see experimental part); [c] Enantioselectivities were determined by HPLC analysis using a 
chiral stationary phase (see experimental part). 
 
Interestingly, the trisubstituted ureaphosphine (S)-LU318, which afforded the highest 
enantiomeric excess in the reduction of the β-methyl-substituted α,β-unsaturated ester S4 
(see Table 21) afforded, compared with the other ligands, the lowest selectivities in this 
case (entries 7 and 8). The isopropyl ester S6b was always hydrogenated with higher 
enantiomeric excesses to P6b than S6a to the corresponding product P6a probably as a 
consequence of the increased steric bulk of the ester functionality. The asymmetric 
reduction of both substrates afforded the respective (R)-configured products in excesses. 
Noteworthy is the observation that, the R1-adamantyl-substituted ligand (S)-LU313 
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furnished the highest enantiomeric excess in the reduction of S6a (92% ee, entry 2) and 
not one of the R1-trityl-substituted derivatives (90% ee, entry 1). Substrate S6b was 
reduced with 95% ee by using the trityl-substituted ligand (S)-LU315 (entry 4). 
 
α,β-Unsaturated esters S7 and S8, with an additional ethylene bridge in the β-position 
were both hydrogenated with complete conversions within 2 hours with all tested 
trisubstituted ureaphosphines (Table 25).  
 
Table 25. Iridium-catalyzed asymmetric hydrogenation of (E)-ethyl 2-methyl-5-phenylpent-2-
enoate (S7) and (E)-ethyl 3-methyl-5-phenylpent-2-enoate (S8).[a] 
 
Entry Substrate Ligand R1 R2 Yield [%][b] ee [%][c] 
1 S7 (S)-LU313 1-Adm tBu > 99 87 (−) 
2 S7 (S)-LU315 CPh3 Ph > 99 89 (−) 
3 S7 (S)-LU317 CPh3 tBu > 99 86 (−) 
4 S7 (S)-LU318 CPh3 Cy > 99 78 (−) 
5 S8 (S)-LU313 1-Adm tBu > 99 70 (S) 
6 S8 (S)-LU315 CPh3 Ph > 99 77 (S) 
7 S8 (S)-LU317 CPh3 tBu > 99 68 (S) 
8 S8 (S)-LU318 CPh3 Cy > 99 68 (S) 
[a] Reaction scale: [Ir(cod)2]BArF (1.25 μmol), ligand (1.25 μmol), solvent (0.25 mL), substrate (125 μmol); [b] Yields were 
determined by GC analysis (see experimental part); [c] Enantioselectivities were determined by HPLC analysis using a 
chiral stationary phase (see experimental part). 
 
The α-methyl-substituted substrate S7 was reduced with slightly better selectivities (78% 
to 89% ee) than the β-methyl-substituted substrate S8 (68% to 77% ee). In both cases, the 
highest enantioselectivities were induced by the R1-trityl-substituted diphenylphosphine 
ligand (S)-LU315, with 89% ee for the reduction of S7 and 77% ee for P8 (entries 2 and 
6). Compared with the results obtained with amidophosphines in section 2.4.2 the 
selectivities were better for both substrates, when trisubstituted ureaphosphines were used 
(Table 12 versus 25). 
 
PROLINE-BASED P,O LIGANDS FOR IRIDIUM-CATALYZED ASYMMETRIC HYDROGENATION 
 
79 
Comparing the results obtained in the asymmetric hydrogenation of the                                 
α-phenyl-substituted ester S9 utilizing amidophosphine/iridium catalysts and 
trisubstituted ureaphosphines the later yielded lower selectivities (Table 13 versus 26).  
 
Table 26. Iridium-catalyzed asymmetric hydrogenation of (E)-ethyl 2,3-diphenylacrylate (S9).[a] 
 
Entry Ligand R1 R2 Yield [%][b] ee [%][c] 
1 (S)-LU313 1-Adm tBu > 99 55 (+) 
2 (S)-LU315 CPh3 Ph    66 79 (+) 
3 (S)-LU317 CPh3 tBu     6 11 (+) 
4 (S)-LU318 CPh3 Cy    83 10 (−) 
[a] Reaction scale: [Ir(cod)2]BArF (1.25 μmol), ligand (1.25 μmol), solvent (0.25 mL), substrate (125 μmol); [b] Yields were 
determined by GC analysis (see experimental part); [c] Enantioselectivities were determined by HPLC analysis using a 
chiral stationary phase (see experimental part). 
 
Only ligand (S)-LU315 furnished (+)-P9, with an enantiomeric excess of 79% (entry 2). 
(S)-LU313 and (S)-LU318, both being substituted with R2-alkyl groups, showed higher 
conversions albeit with only moderate enantiomeric excesses (entries 1 and 4). In 
contrast, the iridium complex chelated by di-tert-butylphosphine (S)-LU317 converted 
only 6% of S9 into the respective product (entry 3). Interestingly, the use of the two trityl 
derivatives, di-tert-butylphosphine (S)-LU317 and dicyclohexylphosphine (S)-LU318 gave 
excesses of the opposite product enantiomers, although the absolute values were very low 
(11% ee (+) for (S)-LU317 and 10% ee (−) for (S)-LU318, entries 3 and 4). 
 
However, in the iridium-catalyzed asymmetric hydrogenation of α,β-unsaturated ketones 
trisubstituted ureaphosphines/iridium complexes furnished excellent enantioselectivities 
(Table 27). The most selective catalyst was found to be the (S)-LU315/iridium complex 
(entries 3 and 4). It performed the reduction of S10a with 93% ee and of the                 
phenyl-substituted compound S10b with 95% ee. 
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Table 27. Iridium-catalyzed asymmetric hydrogenation of (E)-4-phenylpent-3-en-2-one (S10a) 
and (E)-1,3-diphenylbut-2-en-1-one (S10b).[a] 
 
Entry R3 Ligand R1 R2 Yield [%][b] ee [%][c] 
1 Me (S)-LU313 1-Adm tBu    87[d] 86 (R) 
2 Ph (S)-LU313 1-Adm tBu    98 82 (R) 
3 Me (S)-LU315 CPh3 Ph    98[d] [99][e] 93 (R) [91 (R)][e] 
4 Ph (S)-LU315 CPh3 Ph > 99 95 (R) 
5 Me (S)-LU317 CPh3 tBu    86[f] 79 (R)[f] 
6 Ph (S)-LU317 CPh3 tBu    86 80 (R) 
7 Me (S)-LU318 CPh3 Cy    95[d] 82 (R) 
8 Ph (S)-LU318 CPh3 Cy    98 90 (R) 
[a] Reaction scale: [Ir(cod)2]BArF (1.25 μmol), ligand (1.25 μmol), solvent (0.25 mL), substrate (125 μmol); [b] Yields were 
determined by GC analysis (see experimental part); [c] Enantioselectivities were determined by HPLC analysis using a 
chiral stationary phase (see experimental part); [d] Formation of the saturated alcohol was observed (conversions > 99%); 
[e] Results obtained with the isolated precatalyst; [f] Average of 2 experiments. 
 
As shown in Table 27, the conversions of S10a were complete (except for the use of             
(S)-LU317), but the reactions were accompanied by the reduction to the saturated alcohol 
in variable and uncontrolled amounts (entries 1, 3 and 7). To address this issue a 
screening of reaction conditions was carried out using the trisubstituted ureaphosphines 
(S)-LU315 as chiral ligand (Table 28).  
 
Table 28. Optimization of reaction conditions for the iridium-catalyzed asymmetric hydrogenation 
of (E)-4-phenylpent-3-en-2-one (S10a) with (S)-LU315.[a] 
 
Entry p [bar] t [h] Complex Conv. [%][b] Yield [%][b] ee [%][c] 
1 50 2 A > 99    98 93 (R) 
2 50 2 B > 99    99 91 (R) 
3 50 1 B > 99 > 99 90 (R) 
4  5 2 A    46    45 76 (R) 
5  5 2 B    80    80 86 (R) 
[a] Reaction scale: catalyst (1.25 μmol), solvent (0.25 mL), substrate (125 μmol); [b] Conversions and yields were 
determined by GC analysis (see experimental part); [c] Enantioselectivities were determined by HPLC analysis using a 
chiral stationary phase (see experimental part). 
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Appling the isolated (S)-LU315/iridium complex as catalyst in the reduction of S10a did 
not give any overreduction after one hour reaction time (> 99% conversion and 
> 99% yield, entry 3), but the enantioselectivity decreased slightly compared to the value 
obtained, when the complex was formed in situ (entry 1). Lowering the hydrogen 
pressure resulted in reduced enantioselectivities and conversions, independent of the 
precatalyst’s provenance (entries 4 and 5). Therefore, for this particular reaction, the 
conditions described in entry 1 are best suited; the amount of overreduction product is 
minimal and the enantioselectivity is excellent (2% of the respective saturated alcohol and 
93% ee of (R)-P10a). 
 
In the asymmetric reduction of C−N double bonds ureaphosphines showed similar 
unsatisfying results as their amidophosphines congeners. The results of the ligand 
screening in the hydrogenation of imine S11 are shown in Table 29. In general good 
conversions of the starting material S11 were measured, but the yields of P11 were low, 
mostly hydrolysis products were obtained. Nevertheless, the usage of                               
di-ortho-tolylphosphine (S)-LU312 furnished P11 with 59% ee of the (R)-configured 
product (entry 6). 
 
Table 29. Iridium-catalyzed asymmetric hydrogenation of N-(1-phenylethylidene)-aniline (S11).[a] 
*
 
Entry Ligand R1 R2 Yield [%][b] ee [%][c] 
1 (S)-LU31  tBu Ph 15 [90] 24 (R) 
2 (S)-LU32  tBu oTol 46 [97] 37 (R) 
3 (S)-LU36  iPr Ph   8 [90]   7 (R) 
4 (S)-LU37  Cy Ph   5 [85] 19 (R) 
5 (S)-LU311 1-Adm Ph 24 [93]   2 (S) 
6 (S)-LU312 1-Adm oTol 30 [95] 59 (R) 
7 (S)-LU315 CPh3 Ph   5 [62]   2 (R) 
8 (S)-LU319 Ph Ph 23 [90]   2 (R) 
9 (S)-LU321 Mes Ph 22 [95]   4 (R) 
10 (S)-LU325 (2,4,6-tBu3)Ph Ph   5 [48] 19 (S) 
11 (S)-LU326 1-Naph Ph 18 [90]   4 (R) 
[a] Reaction scale: [Ir(cod)2]BArF (2.50 μmol), ligand (2.50 μmol), solvent (0.5 mL), substrate (250 μmol); [b] Yields were 
determined by GC analysis (see experimental part): conversions are given in parenthesis; [c] Enantioselectivities were 
determined by HPLC analysis using a chiral stationary phase (see experimental part). 
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Trisubstituted dialkylphosphines with sterically hindered urea substituents were 
successfully used as ligands for the iridium-catalyzed asymmetric hydrogenation of 
several trisubstituted alkenes. In particular, excellent enantiomeric excesses were 
achieved in the asymmetric reduction of α,β-unsaturated esters and ketones. 
 
2.5.2  
Tetrasubstituted Ureaphosphines Ligands 
 
In this section proline-based ligands with tetrasubstituted urea moieties will be described. 
These differ from trisubstituted ligands described in section 2.5.1 only in bearing an 
additional substituent at the second urea nitrogen atom. 
 
2.5.2.1 
Synthesis of Tetrasubstituted Ureaphosphines 
 
The synthesis of tetrasubstituted proline-based ureaphosphines is described below. These 
compounds were prepared following similar procedures as in the synthesis of 
trisubstituted ureaphosphines (Scheme 21), but carbamoyl chlorides (R2R1NCOCl) 
instead of isocyanates were used for urea formation. These ligands were isolated in 
variable yields ranging from 39 to 93%, depending on the carbamoyl chlorides used. 
 
 
Scheme 25. Synthesis of tetrasubstituted ureaphosphines with aryl substituents at the 
phosphorus atom. 
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Many carbamoyl chlorides shown above are commercially available, but carbamoyl 
chloride 72 was synthesized from dicyclohexyl amine (71) and triphosgene.                     
N,N-Dicyclohexylcarbamoyl chloride (72) was obtained in 45% yield in analogy to a 
literature-known procedure.[85] 
 
 
Scheme 26. Synthesis of N,N-Dicyclohexylcarbamoyl chloride (72).[85] 
 
For the preparation of the diastereoisomeric derivatives (S,R,R)-LU415 and (S,S,S)-LU415 
a different procedure was developed (Scheme 27).  
 
 
Scheme 27. Synthesis of diastereoisomeric ureaphosphines (S,R,R)-LU415 and (S,S,S)-LU415. 
 
Bis[(R)-1-phenylethyl]amine ((R,R)-73) could not be converted into the respective 
carbamoyl chloride (R,R)-74 in the same way than the secondary amine 71 into 
carbamoyl chloride 72 (Scheme 26). Therefore, the amine (R,R)-73 was first 
                                                             
[85] N,N-Dicyclohexylcarbamoyl chloride (72) was prepared in analogy to the procedure reported for the 
synthesis of N,N-di-isopropylcarbamoyl chloride: D. Hoppe, R. Hanko, A. Brönneke, F. Lichtenberg, 
E. van Hülsen, Chem. Ber. 1985, 118, 2822-2851. 
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deprotonated by n-butyllithium to increase its nucleophilicity and then reacted with 
triphosgene. The resulting carbamoyl chloride (R,R)-74 was not isolated and 
subsequently reacted with the pyrrolidinium chloride (S)-52∙HCl under basic conditions. 
The desired ligand (S,R,R)-LU415 was obtained in 24% yield via this sequence 
(Scheme 27). These reaction conditions were not optimized and a different procedure was 
used for the synthesis of the diastereomeric ligand (S,S,S)-LU415.  
 
It was thought that better yields might be achieved by using directly phosgene instead of 
triphosgene, which generates only a small amount of phosgene in situ. For that reason 
amine (S,S)-73 was treated with a solution of phosgene in toluene. To the crude reaction 
mixture pyrrolidinium salt (S)-52∙HCl was added, and then the reaction was heated at 
reflux overnight. The yield of (S,S,S)-LU415 (27%) was not significantly improved by the 
use of this method, though, and does not justify the application of the highly toxic 
phosgene as reagent in this case. 
 
Tetrasubstituted ureaphosphines bearing alkyl substituents at the phosphorus atom were 
synthesized from the borane-protected dialkylphosphines (S)-63∙HCl and (S)-64∙HCl 
(Scheme 28).  
 
 
Scheme 28. Synthesis of tetrasubstituted ureaphosphines with alkyl substituents at the 
phosphorus atom. 
 
Only urea functionalities with two identical substituents at the second nitrogen atom 
introduced (R1 = isopropyl, cyclohexyl or phenyl) and the desired protected ligands were 
isolated in moderate to excellent yields (43% to 92%). 
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Again an exemplary complexation reaction using one of these tetrasubstituted ligands was 
carried out (Scheme 29). With the same procedure as in the syntheses of (R)-CA1 and      
(S)-CU315 depicted in Schemes 10 and 24, the corresponding complex (S)-CU48 was 
isolated as yellowish solid in 98% yield. 
 
 
Scheme 29. Synthesis of ureaphosphine/iridium complex (S)-CU48. 
 
2.5.2.2 
Iridium-Catalyzed Asymmetric Hydrogenations with Tetrasubstituted 
Ureaphosphine Ligands 
 
All tetrasubstituted ureaphosphine ligands were applied to the iridium-catalyzed 
asymmetric hydrogenation of (E)-1,2-diphenyl-1-propene (S1, Table 30).  
 
Overall, moderate to excellent enantioselectivities and conversions were achieved. 
Remarkably, identical results were obtained, when the structurally                                   
di-tert-butylphosphines (S)-LU43 and (S)-LU47 were used, both gave > 99% yield and 
enantiomeric excesses of 99% for the (R)-configured alkane P1 (entries 3 and 7). The use 
of related di-ortho-tolylphosphines (S)-LU42 and (S)-LU46 furnished identical selectivities 
(79% (R)) and similar conversions, too (94% versus 92%, entries 2 and 6). 
Dialkylphosphines performed better than the structurally related diarylphosphines in all 
cases. Ureaphosphine (S)-LU414 with different substituents at the second nitrogen atom 
provided only 94% yield and 42% ee the iridium-catalyzed asymmetric hydrogenation of 
S1 (entry 14).  
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Table 30. Iridium-catalyzed asymmetric hydrogenation of (E)-1,2-diphenyl-1-propene (S1).[a] 
S1
*
P1
[Ir(cod)2]BArF (1 mol%)
then (S)-LU4 (1 mol%)
H2 (50 bar), CH2Cl2, rt, 2 h
(S)-LU4
N
O
P
R3
R3N
R2
R1
 
Entry Ligand R1 R2 R3 Yield [%][b] ee [%][c] 
1 (S)-LU41  iPr iPr Ph    67 90 (R) 
2 (S)-LU42  iPr iPr oTol    94 79 (R) 
3 (S)-LU43  iPr iPr tBu > 99 99 (R) 
4 (S)-LU44  iPr iPr Cy > 99 94 (R) 
5 (S)-LU45  Cy Cy Ph    64 81 (R) 
6 (S)-LU46  Cy Cy oTol    92 79 (R) 
7 (S)-LU47  Cy Cy tBu > 99 99 (R) 
8 (S)-LU48  Cy Cy Cy > 99 97 (R) 
9 (S)-LU49  Ph Ph Ph    97 63 (R) 
10 (S)-LU410 Ph Ph oTol    99 43 (R) 
11 (S)-LU411 Ph Ph tBu > 99 90 (R) 
12 (S)-LU412 Ph Ph Cy > 99 78 (R) 
13 (S)-LU413 R1R2N = Morpholine Ph    69 29 (R) 
14 (S)-LU414 Ph Me Ph    94 42 (R) 
15 (S,R,R)-LU415 (R)-CHMePh (R)-CHMePh Ph    70 64 (R) 
16 (S,S,S)-LU415 (S)-CHMePh (S)-CHMePh Ph    32 37 (R) 
[a] Reaction scale: [Ir(cod)2]BArF (2.50 μmol), ligand (2.50 μmol), solvent (0.5 mL), substrate (250 μmol); [b] Yields were 
determined by GC analysis (see experimental part); [c] Enantioselectivities were determined by HPLC analysis using a 
chiral stationary phase (see experimental part). 
 
The hydrogenations with the diastereoisomeric derivatives (S,R,R)-LU415 and            
(S,S,S)-LU415 as ligands showed a moderate match/mismatch effect. Although both 
catalysts yielded an excess of the (R)-configured product, very different catalyst activities 
were observed (70% yield for (S,R,R)-LU415 and 32% yield for (S,S,S)-LU415, entries 15 
and 16). 
 
Investigating 6-methoxy-1-methyl-3,4-dihydronaphthalene (S2) in the iridium-catalyzed 
hydrogenation involving tetrasubstituted ureaphosphines ligands resulted in low 
enantioinductions throughout (Table 31). 28% ee (S) were achieved with the                        
di-ortho-tolylphosphine (S)-LU42, representing the best value (entry 2). In general the use 
of diarylphosphines resulted in moderate yields, whereas dialkyl-substituted phosphines 
led to excellent conversions (entries 3, 4, 7, 8, 11 and 12). 
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Table 31. Iridium-catalyzed asymmetric hydrogenation of 6-methoxy-1-methyl-3,4-
dihydronaphthalene (S2).[a] 
 
Entry Ligand R1 R2 R3 Yield [%][b] ee [%][c] 
1 (S)-LU41  iPr iPr Ph 79 [85]   6 (S) 
2 (S)-LU42  iPr iPr oTol 58 [62] 28 (S) 
3 (S)-LU43  iPr iPr tBu 98   6 (S) 
4 (S)-LU44  iPr iPr Cy 97 [> 99]    4(R) 
5 (S)-LU45  Cy Cy Ph 36 [39]   8 (S) 
6 (S)-LU46  Cy Cy oTol 64 [70] 19 (S) 
7 (S)-LU47  Cy Cy tBu 97 [> 99]   5 (R) 
8 (S)-LU48  Cy Cy Cy 97 [> 99] 13 (R) 
9 (S)-LU49  Ph Ph Ph 98 rac 
10 (S)-LU410 Ph Ph oTol 74 [84]   3 (S) 
11 (S)-LU411 Ph Ph tBu 94 [> 99] 19 (S) 
12 (S)-LU412 Ph Ph Cy 98 [> 99]   5 (S) 
13 (S)-LU414 Ph Me Ph 85 [93] rac 
[a] Reaction scale: [Ir(cod)2]BArF (2.50 μmol), ligand (2.50 μmol), solvent (0.5 mL), substrate (250 μmol); [b] Yields were 
determined by GC analysis (see experimental part), conversions are given in parenthesis; [c] Enantioselectivities were 
determined by HPLC analysis using a chiral stationary phase (see experimental part). 
 
The results for the reduction of both isomers of S3, namely (E)- and (Z)-S3, are shown in 
Table 32. Slightly higher enantiomeric excesses were observed than in the reduction of 
S2, although these were still disappointingly low. Selectivities of more than 40% ee (R) 
were achieved by the ligands (S)-LU41, (S)-LU42, (S)-LU45 and (S)-LU410 in the 
asymmetric hydrogenation of the (E)-isomer (entries 1, 3, 5 and 10). The reduction of the 
(Z)-isomer generally resulted in the formation of an excess of the (S)-enantiomeric 
product, although the absolute values were even lower. The highest value with 25% ee 
was accomplished by the (S)-LU46/iridium catalyst (entry 8). None of the proline-based 
P,O ligand/iridium catalyst presented above gave satisfactory selectivities in the 
asymmetric hydrogenation of the trisubstituted unfunctionalized alkenes S2, (E)-S3 and 
(Z)-S3. This fact indicates that all these P,O ligand/iridium catalysts can be applied 
efficiently only in the hydrogenation of sterically more encumbered substrates. 
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Table 32. Iridium-catalyzed asymmetric hydrogenation of ((E)- and (Z)-2-(4-methoxyphenyl)-2-
butene ((E)- and (Z)-S3).[a] 
 
Entry Substrate Ligand R1 R2 Yield [%][b] ee [%][c] 
1 (E)-S3 (S)-LU41  iPr Ph    48 45 (R) 
2 (Z)-S3 (S)-LU41  iPr Ph    90 19 (S) 
3 (E)-S3 (S)-LU42  iPr oTol    87 42 (R) 
4 (Z)-S3 (S)-LU42  iPr oTol    93 24 (S) 
5 (E)-S3 (S)-LU45  Cy Ph    79 43 (R) 
6 (Z)-S3 (S)-LU45  Cy Ph    84 23 (S) 
7 (E)-S3 (S)-LU46  Cy oTol    55 37 (R) 
8 (Z)-S3 (S)-LU46  Cy oTol    93 25 (S) 
9 (Z)-S3 (S)-LU49  Ph Ph    99   5 (S) 
10 (E)-S3 (S)-LU410 Ph oTol    92 42 (R) 
11 (Z)-S3 (S)-LU410 Ph oTol > 99   4 (S) 
12 (E)-S3 (S,R,R)-LU415 (R)-CHMePh Ph    99 25 (R) 
13 (E)-S3 (S,S,S)-LU415 (S)-CHMePh Ph    99 21 (R) 
[a] Reaction scale: [Ir(cod)2]BArF (2.50 μmol), ligand (2.50 μmol), solvent (0.5 mL), substrate (250 μmol); [b] Yields were 
determined by GC analysis (see experimental part); [c] Enantioselectivities were determined by HPLC or GC analysis 
using a chiral stationary phase (see experimental part). 
 
In contrast, the suitability of these catalysts for the enantioselective hydrogenation of 
trisubstituted α,β-unsaturated esters was also observed, when tetrasubstituted 
ureaphosphines were used as ligands for the reduction of S4 (Table 33). As it was the 
case in the asymmetric hydrogenation of S1, the di-tert-butylphosphines with isopropyl 
and cyclohexyl substituents at the nitrogen atom ((S)-LU43 and (S)-LU47) achieved 
complete conversions and the highest enantiomeric excesses (entries 3 and 7). A similar 
enantiomeric excess was measured for the electronically and sterically closely related 
ligand (S)-LU48 with four cyclohexyl substituents in total (entry 8). Interesting is the 
comparison of the results obtained with the two pairs of diphenylphosphine ligands            
(S)-LU319 (R1 = phenyl and R2 = H)/(S)-LU49 (R1 = R2 = phenyl) and (S)-LU37 
(R1 = cyclohexyl and R2 = H)/(S)-LU45 (R1 = R2 = cyclohexyl) (Tables 21 and 33). While 
the presence of the second R2-phenyl moiety in the urea functionality did not give any 
increase of selectivity, the introduction of a second R2-cyclohexyl substituent did. The use 
of (S)-LU45 afforded an enantiomeric excess of 69% for the (R)-configured product P4, 
while (S)-LU37 gave only 40% ee (R) (see Table 33, entry 5 and see Table 21, entry 7). In 
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contrast, no improvement was observed going from ligand (S)-LU49 to (S)-LU319 (70% ee 
for (S)-LU49, see Table 33, entry 9 versus 74% ee for (S)-LU319, see Table 21, entry 9). 
 
Table 33. Iridium-catalyzed asymmetric hydrogenation of (E)-ethyl 3-phenylbut-2-enoate (S4).[a] 
 
Entry Ligand R1 R2 R3 Yield [%][b] ee [%][c] 
1 (S)-LU41  iPr iPr Ph    26 66 (R) 
2 (S)-LU42  iPr iPr oTol > 99 44 (R) 
3 (S)-LU43  iPr iPr tBu > 99 97 (R) 
4 (S)-LU44  iPr iPr Cy > 99 90 (R) 
5 (S)-LU45  Cy Cy Ph    53 69 (R) 
6 (S)-LU46  Cy Cy oTol    99 50 (R) 
7 (S)-LU47  Cy Cy tBu > 99 99 (R) 
8 (S)-LU48  Cy Cy Cy > 99 97 (R) 
9 (S)-LU49  Ph Ph Ph    99 70 (R) 
10 (S)-LU410 Ph Ph oTol    98 45 (R) 
11 (S)-LU411 Ph Ph tBu > 99 86 (R) 
12 (S)-LU412 Ph Ph Cy > 99 80 (R) 
13 (S)-LU413 R1R2N = Morpholine Ph    68 43 (R) 
14 (S)-LU414 Ph Me Ph    99 29 (R) 
15 (S,R,R)-LU415 (R)-CHMePh (R)-CHMePh Ph    69 59 (R) 
16 (S,S,S)-LU415 (S)-CHMePh (S)-CHMePh Ph    27 51 (R) 
[a] Reaction scale: [Ir(cod)2]BArF (2.50 μmol), ligand (2.50 μmol), solvent (0.5 mL), substrate (250 μmol); [b] Yields were 
determined by GC analysis (see experimental part); [c] Enantioselectivities were determined by GC analysis using a chiral 
stationary phase (see experimental part). 
 
The C−C double bond of the allylic alcohol S5 was reduced with slightly better 
enantioselectivities, when tetrasubstituted ureaphosphines were used compared with the 
results of the P,O ligands presented in the previous sections (Table 34 versus Tables 10 
and 23). While trisubstituted ureaphosphines (S)-LU315 and (S)-LU316, both bearing 
diarylphosphine and trityl-substituted urea units allowed for 71% ee (S) and > 99% yield 
of P5 as the best results (see Table 23, entries 14 and 15), tetrasubstituted ureaphosphines 
furnished up to 83% ee (Table 34, entry 6). In addition, the use of other diarylphosphines 
yielded selectivities of 80%, containing for example di-isopropyl-substituted ureas 
(entries 1 and 2). Rather surprising were the high enantiomeric excesses measured for           
di-tert-butylphosphines (S)-LU43 and (S)-LU47 (78% ee (S) and 81% ee (S), respectively, 
entries 3 and 7). Finally, the complete conversion of S5 without formation of any side 
products for almost all catalysts has to be pointed out. 
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Table 34. Iridium-catalyzed asymmetric hydrogenation of (E)-2-methyl-3-phenylprop-2-en-1-ol 
(S5).[a] 
 
Entry Ligand R1 R2 R3 Yield [%][b] ee [%][c] 
1 (S)-LU41  iPr iPr Ph > 99 80 (S) 
2 (S)-LU42  iPr iPr oTol > 99 80 (S) 
3 (S)-LU43  iPr iPr tBu > 99 78 (S) 
4 (S)-LU44  iPr iPr Cy > 99 51 (S) 
5 (S)-LU45  Cy Cy Ph > 99 74 (S) 
6 (S)-LU46  Cy Cy oTol > 99 83 (S) 
7 (S)-LU47  Cy Cy tBu > 99 81 (S) 
8 (S)-LU48  Cy Cy Cy > 99 49 (S) 
9 (S)-LU49  Ph Ph Ph > 99 18 (S) 
10 (S)-LU410 Ph Ph oTol > 99 29 (S) 
11 (S)-LU411 Ph Ph tBu > 99 15 (S) 
12 (S)-LU412 Ph Ph Cy > 99   8 (S) 
13 (S)-LU413 R1R2N = Morpholine Ph    99 34 (S) 
14 (S)-LU414 Ph Me Ph > 99 33 (S) 
15 (S,R,R)-LU415 (R)-CHMePh (R)-CHMePh Ph    96 55 (S) 
16 (S,S,S)-LU415 (S)-CHMePh (S)-CHMePh Ph > 99 46 (S) 
[a] Reaction scale: [Ir(cod)2]BArF (2.50 μmol), ligand (2.50 μmol), solvent (0.5 mL), substrate (250 μmol); [b] Yields were 
determined by GC analysis (see experimental part); [c] Enantioselectivities were determined by HPLC analysis using a 
chiral stationary phase (see experimental part). 
 
Because of the fact that tetrasubstituted ureaphosphines/iridium catalysts furnish 
enantiomeric excesses up to 99% in the asymmetric hydrogenation of the C−C double 
bond of α,β-unsaturated esters (see Table 33), other α,β-unsaturated esters were 
investigated as substrates. The results for the reduction of (E)-ethyl 2-methyl-3-
phenylacrylate (S6a) and (E)-isopropyl 2-methyl-3-phenylacrylate (S6b) are summarized 
in Table 35. Good to excellent selectivities were obtained in the iridium-catalyzed 
hydrogenation of these α-methyl-substituted esters using the new P,O ligands. 
Conversions were complete for all the tested tetrasubstituted ureaphosphines and the ethyl 
ester S6a was hydrogenated with up to 91% ee (entry 3). The same catalyst which 
achieved this result gave the highest enantiomeric excess of 90% in the hydrogenation of 
the isopropyl ester S6b, too. The trisubstituted ureaphosphine (S)-LU315 with a trityl 
moiety performed even better, though, and 95% ee was obtained in the reduction of S6b 
for this ligand (see Table 24, entry 4). 
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Table 35. Iridium-catalyzed asymmetric hydrogenation of (E)-ethyl 2-methyl-3-phenlacrylate (S6a) 
and (E)-isopropyl 2-methyl-3-phenylacrylate (S6b).[a] 
 
Entry R3 Ligand R1 R2 Yield [%][b] ee [%][c] 
1 Et (S)-LU43  iPr tBu > 99 81 (R) 
2 iPr (S)-LU43  iPr tBu > 99 88 (R) 
3 Et (S)-LU47  Cy tBu > 99 91 (R) 
4 iPr (S)-LU47  Cy tBu > 99 90 (R) 
5 Et (S)-LU48  Cy Cy > 99 83 (R) 
6 iPr (S)-LU48  Cy Cy > 99 87 (R) 
[a] Reaction scale: [Ir(cod)2]BArF (1.25 μmol), ligand (1.25 μmol), solvent (0.25 mL), substrate (125 μmol); [b] Yields were 
determined by GC analysis (see experimental part); [c] Enantioselectivities were determined by HPLC analysis using a 
chiral stationary phase (see experimental part). 
 
Table 36 summarizes the results obtained from the iridium-catalyzed asymmetric 
hydrogenation of substrates S7 an S8. 
 
Table 36. Iridium-catalyzed asymmetric hydrogenation of (E)-ethyl 2-methyl-5-phenylpent-2-
enoate (S7) and (E)-ethyl 3-methyl-5-phenylpent-2-enoate (S8).[a] 
 
Entry Substrate Ligand R1 R2 Yield [%][b] ee [%][c] 
1 S7 (S)-LU43 iPr tBu > 99 73 (−) 
2 S7 (S)-LU47 Cy tBu > 99 91 (−) 
3 S7 (S)-LU48 Cy Cy > 99 86 (−) 
4 S8 (S)-LU47 Cy tBu > 99 76 (S) 
5 S8 (S)-LU48 Cy Cy > 99 66 (S) 
[a] Reaction scale: [Ir(cod)2]BArF (1.25 μmol), ligand (1.25 μmol), solvent (0.25 mL), substrate (125 μmol); [b] Yields were 
determined by GC analysis (see experimental part); [c] Enantioselectivities were determined by HPLC analysis using a 
chiral stationary phase (see experimental part). 
 
The α-methyl-substituted ester S7 and the β-methyl-substituted ester S8, bearing an alkyl-
chain as β-substituent, were as well reduced with excellent conversions with the help of 
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tetrasubstituted ureaphosphines as P,O ligands for iridium (Table 36). The highest 
enantiomeric excess for the iridium-catalyzed reduction of S7 was obtained with (S)-LU47 
(entry 2). This di-tert-butylphosphine/iridium catalyst gave 91% ee of (−)-P7. In the 
reduction of S8 up to 76% ee was achieved. This result compares favorably with the best 
selectivities, which were obtained with trisubstituted ureaphosphines (see Table 25, 
entry 6).  
 
In the asymmetric reduction the bulky β-phenyl-substituted α,β-unsaturated ester S9 
dialkylphosphines gave only good to moderate enantioselectivities (34% to 75% ee, 
Table 37). The conversions of S9 were never complete and, curiously the                       
(S)-LU43/iridium catalyst yielded only 30% of P9. This result is remarkable, since in the 
previous screenings the closely related (S)-LU43/ and (S)-LU47/iridium catalysts showed 
similar activities and selectivities in most cases. 
 
Table 37. Iridium-catalyzed asymmetric hydrogenation of (E)-ethyl 2,3-diphenylacrylate (S9).[a] 
 
Entry Ligand R1 R2 Yield [%][b] ee [%][c] 
1 (S)-LU43  iPr tBu 30 34 (+) 
2 (S)-LU47  Cy tBu 88 75 (+) 
3 (S)-LU48  Cy Cy 94 41 (+) 
[a] Reaction scale: [Ir(cod)2]BArF (1.25 μmol), ligand (1.25 μmol), solvent (0.25 mL), substrate (125 μmol); [b] Yields were 
determined by GC analysis (see experimental part); [c] Enantioselectivities were determined by HPLC analysis using a 
chiral stationary phase (see experimental part). 
 
Finally, enones S10a and S10b were also investigated as substrates for the asymmetric 
hydrogenation using tetrasubstituted ureaphosphine/iridium catalysts (Table 38). 
Conversions of the α,β-unsaturated ester S10a were complete for all the tested ligands, 
but once again overreduction was observed (entries 1, 2 and 4). Especially the reduction 
utilizing ligand (S)-LU47 was prone to this unwanted side reaction. The amount of 
saturated alcohol obtained varied between individual repetitions of this reaction. 
Therefore, the average result is presented (entry 2). S10a was reduced with an 
enantiomeric excess of up to 94% with (S)-LU43 (entry 1). In the reduction of the             
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phenyl-substituted substrate S10b no overreduction was observed. S10b was transformed 
with 94% yield into P10b and 84% ee using (S)-LU47 (entry 3). 
 
Table 38. Iridium-catalyzed asymmetric hydrogenation of (E)-4-phenylpent-3-en-2-one (S10a) 
and (E)-1,3-diphenylbut-2-en-1-one (S10b).[a] 
 
Entry R3 Ligand R1 R2 Yield [%][b] ee [%][c] 
1 Me (S)-LU43  iPr tBu 88[d] 94 (R) 
2 Me (S)-LU47  Cy tBu 68[d,f] [94][e] 92 (R)[f] [94 (R)][e] 
3 Ph (S)-LU47  Cy tBu 94 84 (R) 
4 Me (S)-LU48  Cy Cy 88[d]  [94][e] 87 (R)  [87 (R)][e] 
5 Ph (S)-LU48  Cy Cy 96 82 (R) 
[a] Reaction scale: [Ir(cod)2]BArF (1.25 μmol), ligand (1.25 μmol), solvent (0.25 mL), substrate (125 μmol); [b] Yields were 
determined by GC analysis (see experimental part); [c] Enantioselectivities were determined by HPLC analysis using a 
chiral stationary phase (see experimental part); [d] Formation of the saturated alcohol was observed (conversions > 99%); 
[e] Results obtained with the isolated precatalyst; [f] Average of 3 experiments. 
 
Since the results above indicated that completely alkyl-substituted ureaphosphines 
promote the overreduction of S10a, different reaction conditions were tested (Table 39).  
 
Table 39. Iridium-catalyzed asymmetric hydrogenation of (E)-4-phenylpent-3-en-2-one (S10a): 
reaction condition optimisation with (S)-LU48.[a] 
 
Entry p [bar] t [h] Complex Conv. [%][b] Yield [%][b] ee [%][c] 
1 50 2 A > 99 88 87 (R) 
2 50 2 B > 99 94 87 (R) 
3 50 1 B > 99 95 87 (R) 
4 5 2 A    65 64 20 (R) 
5 5 2 B > 99 97 56 (R) 
[a] Reaction scale: catalyst (1.25 μmol), solvent (0.25 mL), substrate (125 μmol); [b] Conversions and yields were 
determined by GC analysis (see experimental part); [c] Enantioselectivities were determined by HPLC analysis using a 
chiral stationary phase (see experimental part). 
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The exemplary ligand (S)-LU48 bearing four cyclohexyl substituents was used for this 
purpose. By applying the previously isolated, preformed precatalyst (S)-CU48                    
([((S)-LU48)Ir(cod)]BArF, Scheme 29) the yield of the desired product P10a was 
increased from 88% to 94%, without detectable decrease in the selectivity (entries 1 and 
2). The yield was still 95%, when the reaction was run for half of the time and the 
enantiomeric excess did not change (entry 3). These results prove that longer reaction 
times are not responsible for increased amounts of overreduction. When lower hydrogen 
pressure was utilized the hydrogenation was also complete after 2 hours as long the 
isolated precatalyst was used, but conversion was lower, when the in situ generated 
precatalyst was used (entries 4 and 5).  
 
In addition, the standard imine S11 was again tested using several tetrasubstituted 
ureaphosphines (Table 40). Interestingly, the use of di-ortho-tolylphosphine (S)-LU42 
resulted in 98% yield (entry 2). This same ligand achieved the best enantiomeric excess 
of 38% for product P11, too. This value is certainly not impressive, but compared to the 
previous results in the reduction of S11 (see Tables 16 and 29, as well as Scheme 16) for 
the other classes of P,O ligands, it is quite remarkable (entry 2). Although the measured 
selectivities in Table 40 are small, it can be seen that ortho-tolyl-substituted ligands favor 
the formation of the opposite product enantiomers compared with their relatives, with 
phenyl moieties. 
 
Table 40. Iridium-catalyzed asymmetric hydrogenation of N-(1-phenylethylidene)-aniline (S11).[a] 
N
S11
N
H
*
P11
[Ir(cod)2]BArF (1 mol%)
then (S)-LU4 (1 mol%)
H2 (50 bar), CH2Cl2, rt, 2 h
(S)-LU4
N
O
P
R2
R2N
R1
R1
 
Entry Ligand R1 R2 Yield [%][b] ee [%][c] 
1 (S)-LU41  iPr Ph 36 [89] 11 (S) 
2 (S)-LU42  iPr oTol 98 [98] 39 (R) 
3 (S)-LU45  Cy Ph 40 [90] 15 (S) 
4 (S)-LU46  Cy oTol 64 [92] 24 (R) 
5 (S)-LU49  Ph Ph 18 [91]   4 (S) 
6 (S)-LU410 Ph oTol 34 [92]   6 (S) 
[a] Reaction scale: [Ir(cod)2]BArF (2.50 μmol), ligand (2.50 μmol), solvent (0.5 mL), substrate (250 μmol); [b] Yields were 
determined by GC analysis (see experimental part), conversions are give in parenthesis; [c] Enantioselectivities were 
determined by HPLC analysis using a chiral stationary phase (see experimental part). 
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In summary, slightly lower enantiomeric excesses were achieved with tetrasubstituted 
ureaphosphines than with trisubstituted ureaphosphines. Nevertheless all developed 
ligands could be applied to the iridium-catalyzed asymmetric hydrogenation of various 
trisubstituted functionalized alkenes and enantiomeric excesses up to 99% could be 
achieved. 
 
2.6   
Iridium-Catalyzed Asymmetric Hydrogenation of Other 
Substrates, Using Proline-Based P,O Ligands 
 
In the course of this project several other alkenes were as well tested as substrates for the 
iridium-catalyzed asymmetric hydrogenation with proline-based P,O ligands. These 
additional reactions involving the use of amidophosphines, trisubstituted and 
tetrasubstituted ureaphosphines as ligands are summarized below. 
 
Table 41. Iridium-catalyzed asymmetric hydrogenation of 2-(4-methoxyphenyl)-1-butene (S12).[a] 
 
Entry Ligand R1 R2 Yield [%][b] ee [%][c] 
1   (R)-LA1 tBu Ph > 99 31 (R) 
2[d] (R)-LA1 tBu Ph > 99 19 (R) 
3[e] (R)-LA1 tBu Ph > 99 19 (R) 
4   (S)-LA2 tBu oTol > 99 27 (S) 
5[e] (S)-LA7 1-Adm Ph > 99   6 (S) 
6   (S)-LA8 1-Adm oTol > 99 14 (S) 
7[e] (S)-LA9 1-Adm 2-Fur > 99 rac 
8   (S)-LA13 CPh3 Ph > 99 65 (S) 
9   (S)-LU31 tBuNH Ph > 99   3 (R) 
10  (S)-LU36 iPrNH Ph > 99   7 (R) 
11  (S)-LU311 1-AdmNH Ph > 99   3 (S) 
12  (S)-LU45 Cy2N Ph > 99 23 (S) 
13  (S)-LU49 Ph2N Ph > 99 10 (S) 
[a] Reaction scale: [Ir(cod)2]BArF (1.25 μmol), ligand (1.25 μmol), solvent (0.25 mL), substrate (125 μmol); [b] Yields were 
determined by GC analysis (see experimental part); [c] Enantioselectivities were determined by HPLC analysis using a 
chiral stationary phase (see experimental part); [d] The reaction was carried out at 5 bar H2; [e] The reactions were stirred 
for 1 hour under 5 bar hydrogen pressure. 
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In Table 41 shows the results obtained in the asymmetric hydrogenation of the terminal 
double bond of 2-(4-methoxyphenyl)-1-butene (S12). This substrate is known to be 
hydrogenated with higher selectivities at lower hydrogen pressures. Therefore, the 
reductions were carried out either at atmospheric pressure or at 5 bar. S12 was fully 
converted into P3 independently of the iridium catalyst, which was used. The obtained 
enantiomeric excesses were rather low. The highest value was obtained with ligand            
(S)-LA13 and 65% ee (R) was achieved (entry 8). As expected, the enantioselectivity 
decreased with increasing hydrogen pressure (entries 1 to 3). 
 
Furthermore, lactones and chromenes were tested as substrates for the iridium-catalyzed 
asymmetric hydrogenation using several proline-based P,O ligands (Scheme 30). 
Although these P,O ligand-based iridium catalysts showed higher activities in the 
reduction of several substrates than previously reported P,N ligand/iridium catalysts, no 
conversion of the chromenes S14 and S15 was observed with these derivatives. 
Nevertheless, in the hydrogenation of lactone S13 bearing an exocyclic C−C double bond 
61% conversion and 61% ee (R) were achieved with the trisubstituted ureaphosphine          
(S)-LU315. These results are not competitive with the selectivities that were obtained with 
other iridium catalysts.[34e,47] Tetrasubstituted alkenes, which were previously 
hydrogenated with excellent enantioselectivities using phosphinooxazoline/iridium 
complexes, are not suitable substrates for this novel type of catalysts.[32] No conversion of 
1-methoxy-4-(3-methylbut-2-en-2-yl)-benzene (S16) was achieved with any of the tested 
catalysts. 
 
Amidophosphine/ and trisubstituted ureaphosphine/iridium catalysts were applied to the 
asymmetric hydrogenation of boronic esters derivatives within the PFALTZ group by 
ADNAN GANIĆ, too. Complete conversions were observed in the reduction of S17 
(Scheme 30). Only low to moderate enantiomeric excesses were determined, though. The 
reduction of S17 was accomplished with 55% ee using the amidophosphine ligand       
(S)-LA7. In contrast, excellent enantioselectivities were achieved by the use of other 
iridium catalysts bearing P,N ligands.[86] 
 
                                                             
[86] A. Ganić, A. Pfaltz, Chem. Eur. J. 2012, 18, 6724-6728. 
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[a] Reaction conditions: 0.5 M in substrate, 2 h; [b] Reaction conditions: 0.5 M in substrate, > 12 h; [c] Yields were 
determined by GC analysis; [d] Enantioselectivities were determined by GC or HPLC analysis using a chiral stationary 
phase (see experimental part for S13 and S16; and reference [86] for S17). 
Scheme 30. Iridium-catalyzed asymmetric hydrogenations of various substrates with proline-
based P,O ligands.[c-d] 
 
Finally, proline-based/iridium complexes were screened among other catalysts in the 
asymmetric hydrogenation of dienes within the PFALTZ group by DR. ANDREAS 
SCHUMACHER (Table 42). The reduction of (2E,4E)-methyl 2,4-dimethylhexa-2,4-
dienoate (S18) was achieved with excellent conversions using these catalysts. No 
reduction of only one C−C double bond was observed and both bonds were efficiently 
hydrogenated. Moderate diastereo- and enantioselectivities were achieved. The use of the 
tetrasubstituted ureaphosphine (S)-LU45 induced a diastereoisomeric ratio of 60:40, in 
combination with 89% ee for the syn-product and 41% ee for the anti-product (entry 3). 
Other P,O ligand/iridium catalysts were also tested but did not provide efficient 
reductions of diene S18 to P18. Better results were obtained with C,N ligand/iridium 
catalysts.[87]  
                                                             
[87] A. Schumacher, Dissertation, University of Basel, 2012. 
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Table 42. Iridium-catalyzed asymmetric hydrogenation of (2E, 4E)-methyl-2,4-dimethylhexa-2,4-
dienoate (S18).[87] 
 
Entry 
 
Ligand 
 
R1 
 
R2 
 
Yield [%][a] 
 
ee [%][b] 
syn/anti 
dr [%][b] 
syn:anti 
1 (S)-LA7 1-Adm Ph > 99 28/20 43:57 
2 (S)-LA13 CPh3 Ph > 99 84/26 60:40 
3 (S)-LU45 Cy2N Ph > 99 89/41 60:40 
[a] Yields were determined by GC analysis; [b] Diastereo- and enantioselectivities were determined by GC analysis using 
a chiral stationary phase. 
 
2.7  
Model Rationalizing the Enantioselectivity 
 
A potential short explanation for the excellent enantioselectivities furnished by these 
catalysts for certain substrate classes will be given below. Although experimental 
structural information concerning the intermediates in the catalytic cycle is still scarce, 
computational studies of P,N ligand/iridium and C,N ligand/iridium catalysts suggest that 
the enantiodiscrimination takes place during the migratory insertion step.[21b,21e-l] In a 
PHOX/iridium complex as well as in a P,O ligand-based catalyst, the olefin is proposed to 
coordinate trans to the phosphorus atom as shown in Figure 11.  
 
Generally, proline-based iridium catalysts bearing bulky amido or urea functionalities 
furnished higher enantioselectivities. In Figure 11 a model is presented, which compares a 
PHOX/iridium complex with an ureaphosphine/iridium catalyst, for which a crystal 
structure of the precatalyst was obtained (see Figure 10). Assuming an analogous 
coordination mode for P,O ligands as for PHOX ligands, a steric repulsion between the 
substrates and the bulky urea moiety of the ligand is expected as drawn in Figure 11. The 
large substituent of the urea group (or amide group in other P,O ligands) occupies a 
similar region in space like the substituent at the oxazoline ring of a PHOX ligand, 
namely the lower right quadrant. This is the reason, why the smallest substituent of the 
coordinated alkene substrate, which in most cases is a hydrogen atom, is oriented towards 
this crowded area in both complexes. 
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Figure 11. Qualitative model rationalizing the enantioselectivity of P,O ligand/iridium and 
P,N ligand/iridium catalysts. 
 
This qualitative model explains, why rather bulky amide or urea groups are necessary for 
an efficient discrimination of transition states and therefore high enantioselectivities, and 
rationalizes the sense of asymmetric induction. In accordance with the crystal structures 
obtained for the precatalyst (R)-CA1 and (S)-LU315 the rather big pocket at the active 
metal center might be the reason, why only sterically quite demanding substrates can be 
oriented efficiently for selective reduction by coordinating to iridium. 
 
2.8   
Conclusion 
 
In conclusion, a new ligand system for the iridium-catalyzed asymmetric hydrogenation 
of trisubstituted functionalized and unfunctionalized alkenes was developed. Starting 
from a known amidophosphine, discovered by high-throughput screening and based on a 
highly modular and readily available proline scaffold, a wide range of structurally related 
ligands were synthesized. The flexibility of the synthetic approach enabled the extensive 
structural tuning by variation of the coordinating phosphorus and oxygen donors. It was 
shown that proline-derived phosphines bearing bulky amide or urea groups at the 
pyrrolidine nitrogen form efficient catalysts for the asymmetric reduction of various 
alkenes. Most notably are the results achieved for α,β-unsaturated carboxylic esters and 
ketones, where these novel catalysts compare favorably with or even surpass the 
enantioselectivities reported for the best P,N and C,N ligands.  
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3.1   
P,N Ligands for Iridium-Catalyzed Asymmetric Hydrogenation 
 
All bidentate P,N ligands applied to iridium-catalyzed asymmetric hydrogenation were 
designed to bind to the metal through a heterocyclic sp2-hybridized nitrogen donor in 
combination with a trisubstituted phosphorus atom. Unfortunately, no single 
P,N ligand/iridium catalyst performs efficiently in the asymmetric hydrogenation of all 
type of substrates. However, modifications of the P,N ligand scaffolds led to highly 
selective catalysts for specific targets.[88] This trend was already described in chapter 1, 
and explains the large number of P,N ligands that were designed. In this chapter, some 
P,N ligands will be described in more detail. Particular attention will be given to the size 
of the metallacycles that are formed upon coordination of the P,N ligands to iridium 
(see sections 3.1.1 and 3.1.2). This analysis, will permit to rationalize the choice of the 
proline-based scaffold that was investigated in this work for the development of novel 
P,N ligands forming a seven-membered metallacycle with iridium. Finally, the use of 
several proline-based P,N ligands for the iridium-catalyzed asymmetric hydrogenation of 
alkenes will be discussed (see section 3.2.2). 
 
3.1.1  
P,N Ligands Forming a Six-Membered Metallacycle with Iridium 
 
In order to create a well-defined chiral environment in close proximity to the iridium 
center of a catalyst, several characteristics of the ligand structure were shown to be 
important: (1) the substituents of both coordinating atoms (nitrogen and phosphorus), 
which influence the electronic properties of the catalyst; (2) the steric hindrance generated 
by the ligand around the metal, which favors the approach of one of the enantiotopic faces 
of the substrate towards the active site of the catalyst; and (3) the size of the metallacycle 
formed by coordination of the ligand, which influences the bite angle and the general 
shape of the catalyst. Moreover, chirality was incorporated in all the regions of the 
metallacycle backbone. Many of the P,N ligands that were reported to afford high 
enantioselectivities in the iridium-catalyzed hydrogenation form a six-membered 
metallacycle when bound to the transition metal (Figure 12). 
                                                             
[88] a) D. H. Woodmansee, A. Pfaltz, Top. Organomet. Chem. 2011, 34, 71-76; b) W. Tang, X. Zhang, 
Chem. Rev. 2003, 103, 3029-3069; see also references [18b, 21e, 21m, 31]. 
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Figure 12. Figurative representation of efficient P,N ligand/iridium complexes used in iridium-
catalyzed asymmetric hydrogenation and forming a six-membered metallacycle. 
 
Several P,N ligands forming a six-membered metallacycle with iridium such as, 
phosphinooxazolines ((S)-LPHOX[89] and (S,SFc)-LFc-PHOX[90]) or pyridylphosphine ligands 
(R)-L9,[91] were already shown in chapter 1 (see Figures 3 and 4, and Scheme 5). 
Figure 13 shows further P,N ligands, which were designed for enantioselective iridium-
catalyzed hydrogenation.  
 
 
Figure 13. Further P,N ligands forming a six-membered metallacycle with iridium, and used in 
iridium-catalyzed asymmetric hydrogenation. 
 
All of them coordinate to iridium through a nitrogen atom, which is part of a heterocycle 
and a phosphorus atom, but display different electronic properties and introduce unequal 
                                                             
[89] a) D. G. Blackmond, A. Lightfoot, A. Pfaltz, T. Rosner, P. Schnider, N. Zimmermann, Chirality 2000, 12, 
442-449; b) S. P. Smidt, N. Zimmermann, M. Studer, A. Pfaltz, Chem. Eur. J. 2004, 10, 4685-4693; 
c) C. Valla, A. Pfaltz, Chemistry Today 2004, 4-7; d) S. P. Smidt, F. Menges, A. Pfaltz, Org. Lett. 2004, 6, 
2023-2026; e) A. Franzke, F. Voss, A. Pfaltz, Tetrahedron 2011, 67, 4358-4363; see also references [15b, 
18a, 31, 33a, 34b-c, 35, 48a, 49, 50a-b]. 
[90] X. Li, Q. Li, X. Wu, Y. Gao, D. Xu, L. Kong, Tetrahedron: Asymmetry 2007, 18, 629-634; see also 
references [35, 51b]. 
[91] Q. B. Liu, C. B. Yu, Y.-G. Zhou, Tetrahedron Lett. 2006, 47, 4733-4736; see also references [42a, 45, 
46, 48a, 49]. 
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levels of steric hindrance around the transition metal. Another important feature of these 
ligands is the rigidity of the backbone, which influences the enantioinduction in the 
hydrogenation reaction. 
 
All of these P,N ligands achieved high enantioselectivities in the iridium-catalyzed 
hydrogenation, but most of them were not employed so broadly as the structures shown in 
chapter 1. For example, PHIM ligands ((S)-LPHIM) were mostly applied to 
unfunctionalized alkenes and in several cases better enantioselectivities were obtained 
than with analogous PHOX ligands.[92] Zwitterionic iridium complexes with PHOX and 
PHIM ligands have also been investigated.[93] SimplePHOX ligands induced good 
enantioselectivities in the reduction of a broad range of standard substrates (e.g. terminal 
alkenes, trisubstituted functionalized and unfunctionalized alkenes, imines and 
enamines).[94] Chiral bis(N-sulfonylamino)- and bis(N-arylamino)-phosphine-oxazolines 
(S,S,S)-L15 were also designed as bidentate P,N ligands for iridium.[95] In particular 
bis(N-arylamino)phosphine oxazolines showed good enantioselectivities in the reduction 
of unfunctionalized olefins and α,β-unsaturated carboxylic esters.[95a] SerPHOX ligands 
are closely related to ThrePHOX ligands and allowed for excellent enantiomeric excesses 
in the asymmetric reduction of trisubstituted and terminal alkenes (Figures 3 and 13).[96] 
Similar results, were obtained when PyrPHOX ligands were employed in the reduction of 
standard trisubstituted olefins, but they found no other application so far.[97] NeoPHOX 
ligands were also used in the asymmetric reduction of trisubstituted alkenes and imines, 
but found more fruitful application in the synthesis of natural products 
(Scheme 5).[50a,60a,61] JM-Phos were employed as P,N ligand for iridium for the 
enantioselective hydrogenation of trisubstituted alkenes and for some arylakene substrates 
high enantioselectivities were obtained.[98] Pinene-derived ligands (S,S,S)-L16 and 
(S,S,S)-L17[99] and phosphinite ligands L18[100] were applied to the iridium-catalyzed 
                                                             
[92] F. Menges, M. Neuburger, A. Pfaltz, Org. Lett. 2002, 4, 4713-4716; see also reference [50a]. 
[93] A. Franzke, A. Pfaltz, Chem. Eur. J. 2011, 17, 4131-4144. 
[94] M. Harmata, X. Hong, Org. Lett. 2005, 7, 3581-3581; see also references [31, 33a, 48a, 50a, 89c, 89d]. 
[95] a) M. Schönleber, R. Hilgraf, A. Pfaltz, Adv. Synth. Catal. 2008, 350, 2033-2038; b) R. Hilgraf, A. Pfaltz, 
Synlett 1999, 11, 1814-1816. 
[96] J. Blankenstein, A. Pfaltz, Angew. Chem. Int. Ed. 2001, 40, 4445-4447; see also references [33a, 89c] 
[97] P. G. Cozzi, N. Zimmermann, R. Hilgraf, S. Schaffner, A. Pfaltz, Adv. Synth. Catal. 2001, 343, 450-454; 
see also reference [31]. 
[98] D.-R. Hou, J. Reibenspies, T. J. Colacot, K. Burgess, Chem. Eur. J. 2001, 7, 5391-5400. 
[99] a) J. J. Verendel, P. G. Andersson, Dalton Trans. 2007, 47, 5603-5610; b) X. Meng, X. Li, D. Xu, 
Tetrahedron: Asymmetry 2009, 20, 1402-1406. 
[100] K. Kallström, C. Hedberg, P. Brandt, A. Bayer, P. G. Andersson, J. Am. Chem. Soc. 2004, 126, 14308-
14309; see also reference [39]. 
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asymmetric hydrogenation of a wide range of trisubstituted functionalized and 
unfunctionalized alkenes, and furnished good to excellent enantioselectivities depending 
on the substrate. Thiazole derived P,N ligands (S)-L19 [101] and (R)-L7[39,40] are closely 
related (Figures 3 and 13). However, whilst (R)-L7 permitted the asymmetric reduction of 
fluorinated alkenes,[39] (S)-L19 gave high enantioselectivities in the reduction of 
trifluoromethyl alkenes.[101] 
 
3.1.2  
P,N Ligands Forming a Non-Six-Membered Metallacycle with Iridium 
 
Even though, Figures 3 and 13 show that most of the P,N ligands applied successfully to 
the iridium-catalyzed asymmetric hydrogenation bind to the metal center by forming a 
six-membered metallacycle with iridium, other P,N ligands forming either smaller or 
larger metallacycles have been investigated (Figure 14.). 
 
An impressive example showing the influence of the metallacycle size was the 
development and application of phosphinooxazolines (S)-L8.[32] These P,N ligands 
allowed for the reduction of tetrasubstituted alkenes with excellent enantioselectivities, 
whereas for example PHOX ligands ((S)-LPHOX) performed poorly. In contrast, these 
phophanyl oxazolines (S)-L8, forming a five-membered metallacycle with iridium 
delivered poor selectivities with trisubstituted alkenes.[32] 
 
 
Figure 14. Efficient P,N ligands forming a non-six-membered metallacycle with iridium, and 
exploited for iridium-catalyzed asymmetric hydrogenation. 
 
Chiral substituted P,N ligands (S)-L3, derived from the well-known PHOX ligands, 
permit the highly enantioselective iridium-catalyzed hydrogenation of trisubstituted 
                                                             
[101] M. Engman, P. Cheruku, P. Tolstoy, J. Berquist, S. F. Völker, P. G. Andersson, Adv. Synth. Catal. 
2009, 351, 375-378; see also references [21i, 39]. 
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functionalized and unfunctionalized alkenes, α,β-unsaturated ketones and amides, as well 
as imines.[34a,34c,35] This ligand system allows to analyze the influence of the ring-size of 
the iridacycle formed by chelation of the bidentate ligand. By comparing the results 
obtained in the iridium-catalyzed asymmetric hydrogenation of α,β-unsaturated ketones 
with (S)-LPHOX and (S)-L3 ligands, bearing the same R-substituent, no general trend in 
the influence of the chelating ring size was found (Scheme 31).  
 
The α,β-unsaturated ketone 75, was reduced with 98% ee by the (S)-CPHOX1 complex, 
whilst lower enantioselectivity was achieved employing the analogous complex (S)-C3a. 
In contrast, when the corresponding isopropyl-substituted ligands were used, (S)-C3b 
induced higher enantiomeric excess than (S)-CPHOX2 (91% ee versus 79 ee). In the 
iridium-catalyzed asymmetric hydrogenation of the α,β-unsaturated amide shown below, 
the PHOX/iridium complex (S)-CPHOX1 gave higher enantiomeric excess than (S)-C3a 
(81% ee for (S)-CPHOX1 and 70% ee for (S)-C3a). 
 
 
Scheme 31. Comparison of the asymmetric hydrogenation results obtained using PHOX ligands 
and their phosphinooxazoline analogs (S)-L3.[34c,35] 
 
The spirocycles SpinPHOX ((S,Sa)-LSpinPHOX) and the spiroindanes SIPHOX               
((S,Sa)-LSIPHOX), both of them bearing a rather rigid backbone, from a seven- and a nine-
membered metallacycle, respectively, when bound to iridium (see Figure 14). SpinPHOX 
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and SIPHOX ligands were employed for the iridium-catalyzed hydrogenation of              
α,β-unsaturated carboxylic esters and imines.[36a-b,50f,50h] SpinPHOX ligands induced up to 
99% ee in the iridium-catalyzed hydrogenation of cinnamic and tiglic acid derivatives,[36a] 
and SIPHOX ligands for the reduction of acrylic acid derivatives with up to 96% ee.[36b] 
PHOX/iridium catalysts reduced α,β-unsaturated carboxylic acids with moderate 
enantioselectivity (81% ee).[102] Although this is the only report of the reduction of           
α,β-unsaturated acids by a PHOX/iridium complex to take for comparison, SIPHOX and 
SpinPHOX furnished excellent enantioselectivities in this reduction. Both             
SIPHOX/ and SpinPHOX/iridium catalysts were also used successfully in the asymmetric 
hydrogenation of imines, affording excellent enantioselectivities of up to 97%.[50f,50h] 
However, the asymmetric imine reduction can also be achieved with high 
enantioselectivities, using for example PHOX, SimplePHOX and NeoPHOX ligands 
(Figures 3 and 13).[50a] 
 
In summary, it can be seen that the size of the iridacycle has an impact on the selectivity 
of the catalyst, but a rationale accounting for such an effect has not yet been proposed, 
and the level of enantioinduction of catalysts with different iridacycles can not be 
anticipated a priori. 
 
3.2   
Proline-Based P,N Ligands 
 
Many P,N ligands applied to the iridium-catalyzed asymmetric hydrogenation are derived 
from naturally occurring amino acids (e.g. PHOX, ThrePHOX, SerPHOX and 
SimplePHOX). Nevertheless, only a few P,N ligands derived from proline have been 
investigated for this asymmetric transformation. One example is the ligand (R,S)-L20a 
designed by GILBERTSON, forming a six-membered metallacycle with iridium 
(Scheme 32).[103] The iridium complexes of such proline-derived phosphinooxazoline 
ligands were applied to the asymmetric hydrogenation various functionalized and 
unfunctionalized aromatic alkenes and gave good enantioselectivities, although overall 
they were less effective than analogous PHOX ligands.[31,103] 
 
                                                             
[102] A. Scrivanti, S. Bovo, A. Ciappa, U. Matteoli, Tetrahedron Lett. 2006, 47, 9261-9265. 
[103] G. Xu, S. R Gilbertson, Tetrahedron Lett. 2003, 44, 953-955. 
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Scheme 32. Iridium-catalyzed asymmetric hydrogenation of (E)-1,2-diphenyl-1-propene (S1) with 
GILBERTSON’s ligand ((R,S)-L20a).[103] 
 
Other proline-based P,N ligands have been investigated, by SARAH WEHLE, within the 
PFALTZ group.[104] These ligands were designed to form a nine-membered metallacycle 
with iridium. However, low selectivities and activities were observed in the iridium-
catalyzed hydrogenation of alkenes (Scheme 33). Higher catalyst’s activities were 
observed in the reduction of imines.[104] 
 
 
Scheme 33. Iridium-catalyzed asymmetric hydrogenation of (E)-1,2-diphenyl-1-propene (S1) with 
proline-based ligands forming a nine-membered metallacycle.[104] 
 
Figure 15 presents the proline-based P,N ligands investigated herein. Since proline-based 
P,O ligands were shown to be efficient in the enantioselective iridium-catalyzed 
hydrogenation of several substrate classes (chapter 2), it became obvious to develop 
related P,N versions of these. In fact, P,N ligands/iridium complexes represent the most 
reliable class of catalysts for asymmetric hydrogenation of C−C double bonds. Therefore, 
it was thought to combine both, the well-known chelation of bidentate P,N ligands and 
the advantage of the high modularity of proline-based scaffolds (Figure 15). It is 
interesting to note that, even if a series of P,N ligands has already been designed, only a 
                                                             
[104] S. Wehle, Masterarbeit, University of Basel 2011. 
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few of them form a seven-membered metallacycle with iridium. Moreover, as shown 
above, a bigger ring-size of the metallacycle can be advantageous. 
 
 
Figure 15. Ligand scaffolds presented herein. 
 
First the synthesis of P,N proline-based ligands will be presented (see section 3.2.1) and 
then the results obtained in the iridium-catalyzed asymmetric hydrogenation of various 
alkenes will be discussed (see section 3.2.2). The ligands are named depending on their 
heterocyclic moiety in order to allow for a better comparison of the results achieved when 
these ligands were employed for the iridium-catalyzed asymmetric hydrogenation 
(see section 3.2.2). 
 
3.2.1  
Synthesis of Proline-Based P,N Ligands 
 
The synthesis of proline-based P,N ligands was thought to be straightforward starting 
from the carbamatophosphines (S)-LC presented in chapter 1. Carbamatophosphines, 
bearing aryl substituents at the phosphorus atom were obtained from L-proline 
(Schemes 11 and 12). Diphenylphosphines (S)-LOx1, (S)-LTh1 and (S)-LIm1 were 
obtained from compound (S)-LC1 after Boc-deprotection under acidic conditions 
(Scheme 34). The resulting pyrrolidinium salt (S)-52∙HCl was deprotonated, by means of 
n-butyllithium and then reacted with the respective heterocyclic moiety:                               
2-chlorobenzoxazole, 2-chlorobenzothiazole and 2-chloro-1-methyl-1H-benzo[d] 
imidazole (83). The reactions led to the isolation of benzoxazole (S)-LOx1, benzothiazole 
(S)-LTh1 and benzimidazole (S)-LIm1 in good yields (75% to 83%, Scheme 34). 
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Scheme 34. Synthesis of proline-based P,N ligands, varying the heterocyclic moiety. 
 
2-Chlorobenzoxazole and 2-chlorobenzothiazole are commercially available, whilst the 
related 2-chloro-1-methyl-1H-benzo[d]imidazole (83) was prepared according to a known 
procedure.[105] 2-Chlorobenzimidazol (85) was methylated using iodomethane in the 
presence of sodium hydroxide, the product 83 was obtained in 67% yield (Scheme 35). 
 
 
Scheme 35. Synthesis of 2-chloro-1-methyl-1H-benzo[d]imidazole (83).[105] 
 
The respective iridium complexes (S)-COx1, (S)-CTh1 and (S)-CIm1 were obtained in 
excellent yields (81% to 92%) according to the standard method reported for the 
complexation of P,N ligands to iridium (Scheme 36).[74] The ligands were transformed 
into their respective iridium complexes by reacting them with [Ir(cod)Cl]2                                                  
(bis(1,5-cyclooctadiene)diiridium(I) dichloride). After the exchange of the chloride 
counterion, for BArF, the complexes were purified by column chromatography on silica 
gel. This purification method was possible for P,N ligand/iridium complexes, in contrast 
to proline-based P,O ligand/iridium complexes (see section 2.2.2). 
 
 
                                                             
[105] R. Lemura, T. Kawashima, T. Fukuda, K. Ito, G. Tsukamoto, J. Med. Chem. 1986, 29, 1178-1183. 
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Scheme 36. Synthesis of diphenylphosphine P,N ligand/iridium complexes: (S)-COx1, (S)-CTh1, 
and (S)-CIm1. 
 
Since the synthesis of diphenyphosphine-substituted ligands ((S)-LOx1, (S)-LTh1, and          
(S)-LIm1) was straightforward, the synthesis of proline-based P,N ligands bearing 
different substituents at the phosphorus atom was attempted using the same procedure 
(Scheme 37). However, when the borane-protected aminophosphine (S)-63∙HCl was tried 
to be substituted with 2-chlorobenzoxazole, the desired compound (S)-LOX3∙BH3 could 
not be obtained.  
 
 
Scheme 37. Attempted synthesis of the benzoxazoline ligand (S)-LOx3∙BH3. 
 
No consumption of 2-chlorobenzoxazole was observed under the reaction conditions 
shown above. Longer reaction times did not promote the reaction, and when heated at 
reflux, decomposition of the pyrrolidine (S)-63∙HCl was observed. Since n-butyllithium 
is known to be compatible with borane-protected phosphines, it is likely that the steric 
bulk of the phosphorus substituents inhibits the reaction. 
 
Consequently, a second synthetic approach to the desired proline-based P,N ligands was 
attempted. The synthesis of all the ligands prepared so far herein, involved the 
substitution at the pyrrolidine nitrogen atom in the last synthetic step. An obvious 
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alternative approach would introduce the pyrrolidine nitrogen substituents prior to the 
phosphine group in order to avoid the issues described above. 
 
This second synthetic route to proline-based P,N ligands is depicted in Scheme 38. 
Starting from commercially available L-prolinol these ligands were obtained in five or six 
steps depending on the phosphorus moiety (Schemes 38, 39 and 40). 
 
 
Scheme 38. First steps of the second synthetic route to proline-based P,N ligands. 
 
The oxygen atom of L-prolinol was first protected with tert-butyldimethylsilyl 
(TBDMS).[106] The pyrrolidine (S)-87 was then deprotonated and reacted with the 
corresponding 2-chloro-substituted heterocycle (benzoxazole and benzothiazole) under 
the same conditions described for the synthesis of (S)-LOx1 and (S)-LTh1 (Scheme 38). 
Benzothiazole (S)-89 was obtained in 69% yield by this route. The next synthetic step 
involved the removal of the TBDMS protecting group. Standard procedure using 
tetrabutylammonium fluoride (TBAF) was followed for deprotection and permitted the 
isolation of compounds (S)-90 and (S)-91. The benzoxazole (S)-88 was not isolated, prior 
to its deprotection. In fact, several attempts to purify (S)-88 by column chromatography 
on silica gel resulted in cleavage of the TBDMS ether and thus in a loss in yield. 
                                                             
[106] For the synthesis of (S)-2-{[(tert-butyldimethylsilyl)oxy]methyl}pyrrolidine ((S)-87) see: J. Mařĺk, 
B. Bennettová, R. Tykva, M. Budĕšĺnsky, J. Hlaváček, J. Peptide Res. 2001, 57, 401-408. 
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Therefore, the crude compound (S)-88 was directly subjected to deprotection conditions 
and the resulting benzoxazole (S)-90 was isolated in 57% yield over three steps. 
Surprisingly, purification of the benzothiazole (S)-89 was not problematic and the 
TBDMS protecting group was removed after purification. Compounds (S)-90 and (S)-91 
were both transformed into their respective bromides (S)-92 and (S)-93, through an Appel 
reaction, under the same conditions described for the synthesis of proline-based 
P,O ligands (Schemes 11 and 12). 
 
Bromides (S)-92 and (S)-93 were subsequently displaced by phosphides (Scheme 39 and 
40). Di-ortho-tolylphosphine substituents were introduced by substitution of bromides 
(S)-92 and (S)-93 with di-ortho–tolylphosphide, generated in situ by deprotonation of                   
di-ortho-tolylphosphine (94) by n-butyllithium. In this way, di-ortho-tolylphosphines   
(S)-LOx2 and (S)-LTh2 were isolated in 83% and 59% yield respectively.  
 
 
Scheme 39. Synthesis of di-ortho-tolylphosphine P,N ligands: (S)-LOx2, and (S)-LTh2. 
 
The synthesis of these compounds in the way depicted in Scheme 34 for the synthesis of 
diphenylphosphines was not attempted, but it seems likely that it would also be 
appropriate for ligands (S)-LOx2 and (S)-LTh2. 
 
Dialkylphosphines were used as borane adducts (50∙BH3 and 51∙BH3) in order to prevent 
undesired oxidation of the phosphorus atom. Di-tert-butyl- and dicyclohexylphosphines 
were deprotonated in situ and then reacted with the respective bromides in order to get 
(S)-LOx3 and (S)-LOx4, as well as (S)-LTh3 and (S)-LTh4 as borane adducts. The products 
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were isolated in moderate to good yields (66% to 89%, Scheme 40). Removal of the 
borane protecting group with diethylamine was carried out in analogy to the procedure 
described above (Schemes 19, 23 and 28, for the detailed procedure see the experimental 
part). 
 
Scheme 40. Synthesis of proline-based P,N ligands with alkyl-substituted phosphine moieties. 
 
Further derivatives of the benzimidazole ligand (S)-LIm1 were not prepared. This ligand 
induced lower selectivities compared to benzoxazole and benzimidazole derivatives, 
when tested in the iridium-catalyzed asymmetric hydrogenation (see section 3.2.2.2). 
 
These proline-based P,N ligands were transformed into their corresponding iridium 
complexes (Scheme 41). The complexes (S)-COx2 to (S)-COx4 and (S)-CTh2 to (S)-CTh4 
were obtained by complexation with [Ir(cod)2]BArF in generally excellent yields (> 84%). 
 
 
Scheme 41. Synthesis of proline-based P,N ligand/iridium complexes. 
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3.2.2  
Iridium-Catalyzed Asymmetric Hydrogenations with Proline-Based 
P,N Ligands 
 
In order to determine the efficiency of these novel ligands, all the precatalysts obtained 
above were tested in the asymmetric hydrogenation of various substrates. The results are 
shown below. In contrast, to when proline-based P,O ligands were tested, all the 
hydrogenation reactions using P,N ligands were set up outside of a glove box, as all the 
precatalysts that were isolated proved to be stable for storage (Schemes 36 and 41). As in 
the previous chapter, if not otherwise noted in the corresponding table, the conversion of 
starting material is identical to the yield of product. Both yield and conversion were 
determined by GC analysis, and the products were not isolated. 
 
3.2.2.1  
Initial Results 
 
Initially, the optimization of the reaction conditions was investigated. Different reaction 
conditions were tested for two catalysts in the asymmetric hydrogenation of the 
trisubstituted substrates (E)-1,2-diphenyl-1-propene (S1) and (E)-ethyl 3-phenylbut-2-
enoate, using (S4) (see Tables 43 and 44). The reaction conditions optimized for the 
iridium-catalyzed asymmetric hydrogenation involving P,O ligands, were also found to be 
optimal, when (S)-LTh1 was used as P,N ligand (see Table 44, entries 1 and 5). The 
reaction was complete within 2 hours at room temperature. When the reactions were 
carried out at 50 °C, the enantiomeric excesses obtained in the reduction of S1 and S4 
were identical (entries 1 and 5 versus 4 and 6). No considerable impact of the reaction 
temperature on the selectivity of this catalyst could be observed. 
 
Interestingly, the concentration of both the substrate and catalyst had a dramatic effect on 
the conversion of the starting material S1 and on the enantiomeric excess of the product 
P1 (entry 1 versus 2). At a substrate concentration of 200 μmol∙mL−1, also longer reaction 
time did not improve the conversion of alkene S1 (entry 3). 
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Table 43. Optimization of the reaction conditions for the iridium-catalyzed asymmetric 
hydrogenation of (E)-1,2-diphenyl-1-propene (S1) and (E)-ethyl 3-phenylbut-2-enoate (S4) with 
(S)-LTh1.[a] 
 
Entry Substrate T [°C] t [h] cSubstrate [μmol∙mL−1] Yield [%]
[b] ee [%][c] 
1 S1 rt 2 500 > 99 80 (R) 
2 S1 rt 2 200    49 77 (R) 
3 S1 rt 18 200    50 68 (R) 
4 S1 50 2 500 > 99 80 (R) 
5 S4 rt 2 500 > 99 76 (R) 
6 S4 50 2 500 > 99 75 (R) 
[a] Reaction scale: [Ir(cod)2]BArF (2.50 μmol), ligand (2.50 μmol), substrate (250 μmol), the reactions were prepared 
outside of a glove box; [b] Yields were determined by GC analysis (see experimental part); [c] Enantioselectivities were 
determined by GC analysis using a chiral stationary phase (see experimental part). 
 
The same trend was observed, when (S)-LOx1 was used as ligand (see Table 44). Both 
substrates S1 and S4, were reduced with the same selectivity regardless of the reaction 
temperature. Nevertheless, in the reduction the α,β-unsaturated ester S4, the use of ligand 
(S)-LOx1 did not result in full conversion of the substrate (87% and 96% yield). 
 
Table 44. Optimization of the reaction conditions for the iridium-catalyzed asymmetric 
hydrogenation of (E)-1,2-diphenyl-1-propene (S1) and (E)-ethyl 3-phenylbut-2-enoate (S4) with 
(S)-LOx1.[a] 
 
Entry Substrate T [° C] Yield [%][b] ee [%][c] 
1 S1 rt > 99 81 (R) 
2 S1 50 > 99 81 (R) 
3 S4 rt    87 81 (R) 
4 S4 50    96 80 (R) 
[a] Reaction scale: [Ir(cod)2]BArF (2.50 μmol), ligand (2.50 μmol), solvent (0.5 mL), substrate (250 μmol), the reactions 
were prepared outside of a glove box; [b] Yields were determined by GC analysis (see experimental part);                              
[c] Enantioselectivities were determined by GC analysis using a chiral stationary phase (see experimental part). 
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Since the reaction temperature was shown not to impact on the enantioselectivity of the 
reaction and changes in the concentration of the reagents had a negative impact on the 
selectivity of the catalyst, the initially tested reaction conditions were chosen for further 
screening reactions. No other parameters were varied since most of the reactions above 
showed full conversion. All the reactions below were carried out with 1 mol% of catalyst 
at 50 bar hydrogen pressure for 2 hours in dichloromethane at room temperature. 
 
3.2.2.2  
Screening of Various Hydrogenation Substrates 
 
Table 45 summarizes the results obtained in the iridium-catalyzed asymmetric 
hydrogenation of (E)-1,2-diphenyl-1-propene (S1). The results obtained under the 
optimized conditions for the use of ligands (S)-LOx1 and (S)-LTh1 are reported again for 
comparison (entries 1 and 5). The starting material S1 was converted completely with all 
the tested complexes, with the exception of (S)-LIm1/iridium complex (entry 9). The 
iridium catalyst chelated by (S)-LIm1 gave 82% conversion and only 52% ee. All other 
catalysts furnished higher enantioselectivities (≥ 80%). When ligand (S)-LOx3 was used, 
99% ee (R) was recorded. 
 
Table 45. Iridium-catalyzed asymmetric hydrogenation of (E)-1,2-diphenyl-1-propene (S1).[a] 
 
Entry Ligand Y R Yield [%][b] ee [%][c] 
1 (S)-LOx1 O Ph > 99 81 (R) 
2 (S)-LOx2 O oTol > 99 97 (R) 
3 (S)-LOx3 O tBu > 99 99 (R) 
4 (S)-LOx4 O Cy > 99 97 (R) 
5 (S)-LTh1 S Ph > 99 80 (R) 
6 (S)-LTh2 S oTol    90 88 (R) 
7 (S)-LTh3 S tBu > 99 95 (R) 
8 (S)-LTh4 S Cy > 99 80 (R) 
9 (S)-LIm1 NMe Ph    82 52 (R) 
[a] Reaction scale: [Ir(cod)2]BArF (2.50 μmol), ligand (2.50 μmol), solvent (0.5 mL), substrate (250 μmol), the reactions 
were prepared outside of a glove box; [b] Yields were determined by GC analysis (see experimental part); 
[c] Enantioselectivities were determined by HPLC analysis using a chiral stationary phase (see experimental part). 
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In general, comparing ligands substituted with the same phosphine substituents, 
benzoxazoline ligands ((S)-LOx1 to (S)-LOx4) gave better enantioselectivities than 
benzothiazole ligands ((S)-LTh1 to (S)-LTh4, entries 1 to 4 versus 5 to 8).                              
Di-tert-butylphosphines achieved the highest enantiomeric excesses compared to 
analogous ligands, bearing the same heterocyclic moiety (entries 3 and 7). But also        
(S)-LOx2 and (S)-LOx4 induced high enantioselectivities (97% ee, entries 2 and 4). 
 
Diphenylphosphine ligands were tested in the iridium-catalyzed asymmetric 
hydrogenation of the cyclic unfunctionalized alkene S2 (Table 46). Moderate to good 
yields were obtained by the use of these ligands (71 to 90%). However, the 
enantioselectivities achieved were low (2% to 23% ee). As proline-based P,O ligands, 
these P,N ligands seem not to be suited for the asymmetric reduction of this substrate 
type. Therefore, substrate S2 was not further investigated. 
 
Table 46. Iridium-catalyzed asymmetric hydrogenation of 6-methoxy-1-methyl-3,4-
dihydronaphthalene (S2).[a] 
 
Entry Ligand Y R Yield [%][b] ee [%][c] 
1 (S)-LOx1 O Ph    90 [> 99] 23 (S) 
2 (S)-LTh1 S Ph    89 27 (S) 
3 (S)-LIm1 NMe Ph    71   2 (S) 
[a] Reaction scale: [Ir(cod)2]BArF (2.50 μmol), ligand (2.50 μmol), solvent (0.5 mL), substrate (250 μmol); [b] Yields were 
determined by GC analysis (see experimental part), conversions are given in parenthesis; [c] Enantioselectivities were 
determined by HPLC analysis using a chiral stationary phase (see experimental part). 
 
In the iridium-catalyzed asymmetric hydrogenation of the unfunctionalized alkenes           
(E)- and (Z)-S3, proline-based P,N ligands showed to be better suited than their related 
proline-based P,O ligands. The P,O ligands presented in chapter 2, induced only low to 
moderate enantiomeric excesses in this transformation (see Tables 4, 8, 20, and 32). 
When proline-based P,N ligands were tested, moderate to good enantioselectivities were 
measured (40% to 86% ee, Table 47). Enantiomeric excesses up to 86% were obtained in 
the asymmetric hydrogenation of the (E)-isomer of S3 and up to 76% were achieved in 
the enantioselective reduction of the (Z)-isomer (entries 3 and 8). In general, the           
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(E)-isomer was reduced with higher enantioselectivities than the (Z)-isomer, except for 
the reaction with the catalyst derived from (S)-LTh1 (entry 8). Conversions of 99% and 
more were obtained with all the catalysts and for both substrates, (E)-S3 and (Z)-S3. 
 
Table 47. Iridium-catalyzed asymmetric hydrogenation of (E)- and (Z)-2-(4-methoxyphenyl)-2-
butene ((E)- and (Z)-S3).[a] 
 
Entry Substrate Ligand Y R Yield [%][b] ee [%][c] 
1 (E)-S3 (S)-LOx1 O Ph    99 72 (R) 
2 (Z)-S3 (S)-LOx1 O Ph > 99 50 (S) 
3 (E)-S3 (S)-LOx2 O oTol    99 86 (R) 
4 (Z)-S3 (S)-LOx2 O oTol > 99 67 (S) 
5 (Z)-S3 (S)-LOx3 O tBu > 99 42 (S) 
6 (Z)-S3 (S)-LOx4 O Cy > 99 40 (S) 
7 (E)-S3 (S)-LTh1 S Ph    99 56 (R) 
8 (Z)-S3 (S)-LTh1 S Ph > 99 76 (S) 
9 (E)-S3 (S)-LTh2 S oTol    98 64 (R) 
10 (Z)-S3 (S)-LTh2 S oTol > 99 55 (S) 
11 (Z)-S3 (S)-LTh3 S tBu > 99 51 (S) 
12 (Z)-S3 (S)-LTh4 S Cy > 99 55 (S) 
13 (Z)-S3 (S)-LIm1 NMe Ph    99 49 (S) 
[a] Reaction scale: [Ir(cod)2]BArF (2.50 μmol), ligand (2.50 μmol), solvent (0.5 mL), substrate (250 μmol), the reactions 
were prepared outside of a glove box; [b] Yields were determined by GC analysis (see experimental part);                               
[c] Enantioselectivities were determined by HPLC or GC analysis using a chiral stationary phase (see experimental part). 
 
The reduction of the trisubstituted functionalized alkene S4 proceeded with excellent 
conversions and good selectivities (Table 48). Only the iridium catalyst derived from the 
imidazole ligand (S)-LIm1, afforded low ee-values (29%, entry 9). Several ligands 
furnished ee ≥ 90% (entries 1, 3, 4, 7, and 8). The highest enantioselectivities were 
provided by di-tert-butylphosphine ligands: (S)-LOx3 and (S)-LTh3 (entries 3 and 7). As 
for the reduction of the unfunctionalized alkene S1, substrate S4 was also reduced 
preferentially to the (R)-configured alkane by the use of these (S)-configured P,N ligands. 
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Table 48. Iridium-catalyzed asymmetric hydrogenation of (E)-ethyl 3-phenylbut-2-enoate (S4).[a] 
 
Entry Ligand Y R Yield [%][b] ee [%][c] 
1 (S)-LOx1 O Ph    87 81 (R) 
2 (S)-LOx2 O oTol > 99 92 (R) 
3 (S)-LOx3 O tBu > 99 98 (R) 
4 (S)-LOx4 O Cy > 99 95 (R) 
5 (S)-LTh1 S Ph > 99 76 (R) 
6 (S)-LTh2 S oTol > 99 85 (R) 
7 (S)-LTh3 S tBu > 99 96 (R) 
8 (S)-LTh4 S Cy > 99 90 (R) 
9 (S)-LIm1 NMe Ph > 99 29 (R) 
[a] Reaction scale: [Ir(cod)2]BArF (2.50 μmol), ligand (2.50 μmol), solvent (0.5 mL), substrate (250 μmol), the reactions 
were prepared outside of a glove box; [b] Yields were determined by GC analysis (see experimental part); 
[c] Enantioselectivities were determined by GC analysis using a chiral stationary phase (see experimental part). 
 
The results obtained from the asymmetric reduction of the allylic alcohol S5 are shown in 
Table 49. The conversion of (E)-2-methyl-3-phenylprop-2-en-1-ol (S5) was mostly 
complete with all the catalysts tested.  
 
Table 49. Iridium-catalyzed asymmetric hydrogenation of (E)-2-methyl-3-phenylprop-2-en-1-ol 
(S5).[a] 
 
Entry Ligand Y R1 Yield [%][b] ee [%][c] 
1 (S)-LOx1 O Ph    42 [55] 47 (S) 
2 (S)-LOx2 O oTol > 99 72 (S) 
3 (S)-LOx4 O Cy    85 [> 99] 40 (S) 
4 (S)-LTh1 S Ph    96 [> 99] 87 (S) 
5 (S)-LTh2 S oTol > 99 89 (S) 
6 (S)-LTh4 S Cy    92 [> 99] 63 (S) 
7 (S)-LIm1 NMe Ph    94 [> 99] 25 (S) 
[a] Reaction scale: [Ir(cod)2]BArF (2.50 μmol), ligand (2.50 μmol), solvent (0.5 mL), substrate (250 μmol), the reactions 
were prepared outside of a glove box; [b] Yields were determined by GC analysis (see experimental part), conversions are 
given in parenthesis; [c] Enantioselectivities were determined by HPLC analysis using a chiral stationary phase (see 
experimental part). 
 
CHAPTER 3 
 
122 
However, reduction to the saturated alcohol was often accompanied by the formation of 
side products (entries 3, 4, 6 and 7). Ligands bearing di-ortho-tolylphosphines gave 
higher enantioselectivities, compared to their analogues substituted with other phosphines 
(72% ee for (S)-LOx2 and 89% ee for (S)-LTh2, entries 2 and 5). Nevertheless, also the 
use of (S)-LTh1 as ligand permitted to hydrogenate substrate S5 with 87% ee (S) (entry 4). 
The (S)-configured product P5 was formed preferentially with the tested (S)-configured 
catalysts. However, benzothiazole/iridium catalysts gave better enantiomeric excesses 
than their analogous benzoxazoles, whereas in the previous examples generally slightly 
better selectivities were achieved by benzoxazole/iridium catalysts (see Tables 45 and 
48). 
 
The iridium-catalyzed hydrogenation of 1-methoxy-4-(3-methylbut-2-en-2-yl)benzene 
(S16) was as well attempted with proline-based P,N ligands (Table 50). Unfortunately, 
these catalysts did not prove to be more suitable for the asymmetric reduction of 
tetrasubstituted alkenes, than proline-based P,O ligands (Table 50 versus Schemes 16 and 
30). Low conversions (13% to 30%) and enantioselectivities (up to 12% ee) were 
obtained. No other P,N ligand-based catalyst of this type was tested for the iridium-
catalyzed hydrogenation of S16. 
 
Table 50. Iridium-catalyzed asymmetric hydrogenation of 1-methoxy-4-(3-methylbut-2-en-2-
yl)benzene (S16).[a] 
 
Entry Ligand Y R Yield [%][b] ee [%][c] 
1 (S)-LOx1 O Ph    36 rac 
2 (S)-LTh1 S Ph    13 12 (−) 
3 (S)-LIm1 NMe Ph    20   4 (−) 
[a] Reaction scale: [Ir(cod)2]BArF (2.50 μmol), ligand (2.50 μmol), solvent (0.5 mL), substrate (250 μmol), the reactions 
were prepared outside of a glove box; [b] Yields were determined by GC analysis (see experimental part); 
[c] Enantioselectivities were determined by GC analysis using a chiral stationary phase (see experimental part). 
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Proline-based P,N ligands were also applied to the iridium-catalyzed asymmetric 
hydrogenation of furanes within the PFALTZ group by LARISSA PAULI (Scheme 42).[107] 
 
 
 
[a] Conversions were determined by GC analysis; [b] Enantioselectivities were determined by GC or HPLC analysis using 
a chiral stationary phase. 
Scheme 42. Iridium-catalyzed asymmetric hydrogenations of furanes with proline-based 
P,N ligands.[a-b] 
 
All tested furanes S19 to S21 gave the corresponding tetrahydrofuranes in very poor 
yields and unsatisfying selectivities (8% to 13% conversion and 16% to 22% ee), even 
though the chosen reaction conditions were harsher than those used for the reduction of 
alkenes. Furanes and benzofuranes were hydrogenated previously with enantiomeric 
excesses of up to 99% and more using pyridylphosphine ((R)-L9)/iridium catalyst 
(Figure 3).[45] 
 
3.3   
Conclusions and Outlook 
 
In conclusion, a novel type of P,N ligands was developed for the iridium-catalyzed 
asymmetric hydrogenation of trisubstituted unfunctionalized and functionalized alkenes. 
These chiral P,N ligands were readily prepared in enantiomerically pure form starting 
from the amino acid L-prolinol. As the proline-based P,O ligands presented in chapter 2, 
these ligands are highly modular and their structures can be easily tuned by variation of 
the coordinating nitrogen and phosphorus units. Moreover, these scaffolds represent 
further examples of ligands forming a seven-membered metallacycle with iridium.  
                                                             
[107] L. Pauli, unpublished results. 
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The ligands prepared involved different heterocylic moieties, such as benzoxazoline, 
benzothiazole and benzimidazole. However, other heterocyclic moieties could be 
introduced as substituents at the pyrrolidine nitrogen. An example of further ligands 
which could be synthesized, is depicted in Scheme 43. 
 
Scheme 43. Outlook: further proline-based P,N ligands derived from amino alcohol (S)-98. 
 
This substitution of the pyrrolidine nitrogen would allow to generate a greater variety in 
the structure of proline-based P,N ligands. Moreover, these derivatives would be derived 
from readily available amino acids with a wide variety of R1-groups. 
 
In addition, a broader substrate screening with the prepared proline-based P,N ligands 
should be carried out in order to determine both their further potential but also their 
limitations. So far, these ligands were shown to be efficient in the asymmetric reduction 
of certain trisubstituted functionalized and unfunctionalized alkenes and inefficient in the 
iridium-catalyzed reduction of tetrasubstituted alkenes and furanes. Although other 
P,N ligands gave as good or even better results in the iridium-catalyzed asymmetric 
hydrogenation of the same substrates, it is possible that these ligands perform better in the 
reduction of substrates not tested so far. 
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4.1   
SAMP/RAMP Hydrazones in Asymmetric Synthesis 
 
(S)-(−)-1-Amino-2-(methoxymethyl)pyrrolidine (SAMP) and its (R)-stereoisomer 
(RAMP) have been widely used as chiral auxiliaries in the enantioselective synthesis of 
many compounds. First, a brief summary of diastereoselective methodologies based on 
these auxiliaries will be given and examples of applications will be shown. Moreover, 
proline-based phosphinohydrazones and other phosphinohydrazones were also used as 
ligands for transition metal-catalysis. Only a few palladium-catalyzed reactions involving 
phosphinohydrazones ligands are known and will be described below. These reports 
inspired the development of proline-based phosphinohydrazones, which were 
investigated. Their synthesis and attempts to obtain their respective iridium complexes 
will be discussed in more details in section 4.2.1. Furthermore, initial results of the 
application of these phosphinohydrazones as chiral ligands for the iridium-catalyzed 
asymmetric hydrogenation of alkenes will be shown (see section 4.2.2). 
 
4.1.1  
The SAMP/RAMP Hydrazone Methodology 
 
The SAMP/RAMP hydrazone methodology has found many applications and is 
commonly used in asymmetric synthesis. ENDERS et al. discovered SAMP and RAMP as 
chiral auxiliaries for the α-alkylation of ketones and aldehydes in 1976 
(see Scheme 44).[108] The chiral hydrazones (S)-101 are obtained by mixing the chiral 
auxiliary (SAMP, (S)-100) with a carbonyl compound 99. While aldehydes react without 
difficulty, ketones need to be refluxed with catalytic amounts of acid in benzene or 
cyclohexane under water separation conditions. The hydrazone intermediates (S)-101 are 
then deprotonated (mostly by means of LDA (lithium di-isopropylamide)) to obtain 
azaenolates (S)-102. Mechanistic investigations showed that only one geometrical isomer 
is formed upon deprotonation (Scheme 44).[109] Electrophilic attack proceeds with high 
                                                             
[108] a) D. Enders, H. Eichenauer, Angew. Chem. Int. Ed. Engl. 1976, 15, 549-551; b) D. Enders, 
H. Eichenauer, Tetrahedron Lett. 1977, 2, 191-194; c) D. Enders, P. Fey, H. Kipphardt, Org. Synth. 1987, 65, 
173-182; d) D. Enders, H. Kipphardt, P. Fey, Org. Synth. 1987, 65, 183-202. 
[109] a) K. G. Davenport, H. Eichenauer, D. Enders, M. Newcomb, D. E. Bergbreiter, J. Am. Chem. Soc. 
1979, 101, 5654-5659; b) D. Enders, G. Bachstädter, K. A M. Kremer, M. Marsch, K. Harms, G. Boche, 
Angew. Chem. Int. Ed. Engl. 1988, 27, 1522-1524; c) W. Bauer, D. Seebach, Helv. Chim. Acta 1984, 67, 
1972-1988. 
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diastereofacial differentiation, as shown in Scheme 44. The stereochemical outcome of 
the reaction can therefore be controlled by the use of either SAMP or RAMP as auxiliary. 
 
 
Scheme 44. α-Alkylation of ketones and aldehydes, using SAMP ((S)-100) as a chiral auxiliary. 
 
Both enantiomers of this chiral auxiliary are readily available from the amino acid 
proline.[108c] Many electrophiles, such as alkyl halides, but also Michael acceptors, 
carbonyl compounds, halide-substituted esters, oxiranes and aziridines are tolerated and 
illustrate the broad applicability of this methodology.[110] Subsequent hydrolysis permits 
to obtain the original carbonyl functionality, but other cleavage reactions can as well 
introduce further functionalities, such as amino groups.[110] 
 
Since the discovery of this methodology, many alkylations of this type were achieved 
with excellent enantioselectivities and allowed for the asymmetric synthesis of numerous 
natural products. An example is shown in Scheme 45.[111] ENDERS’ hydrazines were 
deployed in the alkylation of propionaldehyde to obtain the 1,3-dimethyl-substituted 
hydrazone 105 with 92% de in the synthesis of the C6 side chain of zaragozic acid A 
(107). Subsequent ozonolysis of the crude hydrazone 105 and Wittig olefination gave the 
desired ester 106 in 30% overall yield and 92% de. This synthetic sequence was achieved 
by NICOLAOU et al. and applied to the total synthesis to zaragozic acid A (107). 
 
 
 
 
                                                             
[110] A. Job, C. F. Janeck, W. Bettray, R. Peters, D. Enders, Tetrahedron 2002, 58, 2253-2329. 
[111] a) K. C. Nicolaou, E. W. Yue, S. L. Greca, A. Nadin, Z. Yang, J. E. Leresche, T. Tsuri, Y. Naniwa, 
F. De Riccardis, Chem. Eur. J. 1995, 1, 467-494; b) A. Nadin, K. C. Nicolaou, Angew. Chem. Int. Ed. Engl. 
1996, 35, 1622-1656. 
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Scheme 45. Application of the SAMP hydrazone methodology to the total synthesis of 
zaragozic acid A (107).[111] 
 
When introduced these chiral hydrazone intermediates were mostly subjected to 
alkylation reactions, but since then many alternative transformations were accomplished 
such as aldol reactions, Michael reactions, rearrangements and Diels−Alder reactions.[110] 
 
4.1.2  
SAMP Hydrazones as Ligands in Organometallic Chemistry 
 
Whilst SAMP hydrazines were used successfully as chiral auxiliaries for asymmetric 
syntheses, only a few publications report the use of SAMP hydrazones as chiral ligands 
for asymmetric catalysis.[108,112] Nevertheless, hydrazones (S,SFc)-L22, (S)-L23, (S)-L24 
and (Ra)-L25 were all used as ligands in the palladium-catalyzed allylic alkylation 
reaction (Scheme 46). In the palladium-catalyzed allylic alkylation of                            
(E)-1,3-diphenylallyl-acetate (108) with dimethyl malonate (109) enantiomeric excesses 
up to 93% were obtained using ferrocene phosphinohydrazone ((S,SFc)-L22). SAMP 
hydrazone (S)-L23 was as well used as P,N ligand for this reaction; the alkylation product 
                                                             
[112] a) T. Mino, W. Imiya, M. Yamashita, Synlett 1997, 583-584; b) T. Mino, M. Shiotsuki, N. Yamamoto, 
T. Suenaga, M. Sakamoto, T. Fujita, M. Yamashita, J. Org. Chem. 2001, 66, 1795-1797; c) D. Enders, 
R. Peters, R. Lochtman, J. Runsink, Eur. J. Org. Chem. 2000, 2839-2850; d) D. Enders, R. Peters, 
R. Lochtman, J. Runsink, Synlett 1997, 1462-1464. 
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was obtained with excellent yield and an enantiomeric excess of 90%. The closely related 
SAMP hydrazone (S)-L24, was employed as N,N ligand in the same catalytic 
transformation. Although the product was obtained in nearly quantitative yield, only an 
enantiomeric excess of 38% was achieved. WIDHALM et al. reported binaphthyl-based 
azepine derivatives, such as (Ra)-L25 and their use as ligands in the same reaction, 
achieving an enantiomeric excess of 95%.[113] 
 
 
Scheme 46. Hydrazones ligands for the palladium-catalyzed allylic alkylation reaction.[108b,112,113] 
 
Very recently, phosphinohydrazones were reported as suitable ligands for the asymmetric 
Suzuki−Miyaura cross-coupling reaction.[114] Excellent to good yields and 
enantioselectivities were obtained in the asymmetric cross-coupling of functionalized aryl 
bromides and triflates to afford axially chiral biaryls. An example is shown in Scheme 47. 
                                                             
[113] M. Widhalm, M. Abraham, V. B. Arion, S. Saarsalu, U. Maeorg, Tetrahedron: Asymmetry 2010, 21, 
1971-1982. 
[114] A. Ros, B. Estepa, A. Bermejo, E. Álvarez, R. Fernández, J. M. Lassaletta, J. Org. Chem. 2012, 77, 
4740-4750. 
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Scheme 47. SAMP Hydrazones as ligands for the palladium-catalyzed cross-coupling 
reaction.[114] 
 
4.2   
Phosphinohydrazones Ligands 
 
Inspired by both, the structure of SAMP hydrazones (see section 4.1) and the proline-
based ligands presented earlier herein (see chapters 2 and 3), proline-based 
phosphinohydrazones (S)-LH were investigated as ligands for iridium (Figure 16). These 
phosphinohydrazone ligands (S)-LH were thought to form a six-membered metallacycle 
with iridium, like many other P,N ligands reported in literature (see section 3.1.1). The 
synthesis of these ligands and their respective iridium complexes are described below 
(see section 4.2.1). Initial results obtained when these phosphinohydrazones were used as 
ligands in the iridium-catalyzed asymmetric hydrogenation will be shown in section 4.2.2. 
 
Figure 16. Ligand scaffolds presented herein. 
 
4.2.1  
Synthesis of Phosphinohydrazones Ligands and Iridium Complexes 
 
Different synthetic strategies were attempted for the synthesis of phosphinohydrazones 
(S)-LH. The syntheses of ketohydrazones and aldhydrazones will be described separately 
(Figure 17). The complexation of the prepared ligands to iridium will be discussed 
directly after the description of the synthetic methods attempted. 
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Figure 17. Phosphinohydrazone ligand structures. 
 
4.2.1.1  
Ketohydrazone Ligands 
 
The retrosynthetic approach depicted in Scheme 48 was first considered to synthesize 
these phosphinohydrazones (S)-LH. This strategy would allow to use all the 
intermediates, which were involved in the synthesis of proline-based P,O ligands 
(see section 2.3.1).  
 
 
Scheme 48. 1st Retrosynthetic analysis to phosphinohydrazones (S)-LH. 
 
In addition, it permits to introduce the hydrazone functionality in the last synthetic step so 
that various R1- and R2-substituents can be easily installed on a common intermediate and 
the synthesis of a small library of (S)-LH ligands could be rapidly achieved. Hydrazones 
(S)-LH were thought to be accessible from the hydrazine (S)-114, via condensation with a 
variety of ketones. Hydrazine (S)-114 would be obtained from pyrrolidinium salt           
(S)-52∙HCl. 
 
N-substituted oxaziridines were used as source of electrophilic nitrogen in the synthesis of 
hydrazines and alkoxyl amines.[115] In fact, one method to introduce the hydrazine moiety 
on a proline-derived compound using 1-oxa-2-azaspiro[2.5]octane (117) was reported 
                                                             
[115] S. Andreae, E. Schmitz, Synthesis 1991, 327-341. 
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previously (Scheme 49).[116] Hydroxylamine-O-sulfonic acid (120) as well has been 
widely used as reagent for the N-amination of various heterocycles, like for example 
pyrroles and aziridines.[117] Therefore, the N-substitution of (S)-52 was attempted using 
both reagents, 117 and 120 as sources of electrophilic nitrogen (Scheme 50). 
 
 
Scheme 49. Synthesis of 1-(3,3-dimethyl-butylamino)-pyrrolidine-2-carboxylic acid methyl ester 
(119), involving 117 as electrophilic nitrogen source. 
 
However, when used for the N-amination of pyrrolidine (S)-52, none of these reagents 
prooved to be effective. Various reaction conditions were tested, involving the screening 
of solvents, temperatures and bases, but hydrazine (S)-121 was never obtained 
(Scheme 50). The compatibility of these reagents (117 and 120) with the phosphine 
moiety is therefore doubted. 
 
 
Scheme 50. Attempted synthesis of hydrazine (S)-121 from pyrrolidinium salt (S)-52∙HCl. 
 
                                                             
[116] F. Ruebsam, Z. Sun, B. Ayida, Y. Zhou, A. X. Xiang, PCT Int. Appl. 2008073987, 2008. 
[117] a) J. T. Hunt, T. Mitt, R. Borzilleri, J. Gullo-Brown, J. Fargnoli, B. Fink, W.-C. Han, S. Mortillo, G. Vite, 
B. Wautlet, T. Wong, C. Yu, X. Zheng, R. Bhide, J. Med. Chem. 2004, 47, 4054-4059; b) S. J. Brois, 
Tetrahedron Lett. 1968, 57, 5997-6000. 
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Instead of screening further reaction conditions or additional N-amination reagents 
different from 117 and 120, an alternative retrosynthetic approach was proposed 
(Scheme 51). In order to avoid, possible issues concerning the stability of the phosphine 
moiety, this second retrosynthesis suggests the formation of the N−N bond prior to the 
introduction of the phosphine functionality. 
 
 
Scheme 51. 2nd Retrosynthetic analysis to phosphinohydrazones (S)-LH, starting from L-prolinol 
((S)-98). 
 
Nitrosamine (S)-124 was obtained in quantitative yield, starting from L-prolinol ((S)-98) 
that was reacted with tert-butylnitrite, as described in the literature.[118] This nitrosamine 
was then converted into compound (S)-122, under reaction conditions similar to those 
described previously (see section 2.3.1). The desired nitrosamine (S)-122 was obtained in 
excellent yields via an Appel reaction, followed by displacement of the bromine of            
(S)-123 by diphenylphosphide (Scheme 52). Nitrosamine (S)-122 was then reduced to the 
desired hydrazine (S)-114 in quantitative yield with lithium aluminum hydride as 
reducing agent. 
 
 
Scheme 52. Synthesis of hydrazine (S)-114. 
 
Hydrazine (S)-114 was finally condensated with cyclohexanone (125) and                         
1-(4-methoxyphenyl)ethanone (126) (Scheme 53). The reaction of (S)-114 with the 
ketone 125 proceeded smoothly affording phosphinohydrazone (S)-LH1 in 80% yield, 
whereas the condensation with 126 proceeded poorly (17% yield for (S)-LH2). 
                                                             
[118] R. Lazny, A. Nodzewska, B. Zabicka, J. Comb. Chem. 2008, 10, 986-991. 
PHOSPHINOHYDRAZONE LIGANDS FOR IRIDIUM-CATALYZED ASYMMETRIC HYDROGENATION 
 
137 
 
 
Scheme 53. Synthesis of phosphinohydrazones (S)-LH1 and (S)-LH2. 
 
Both phosphinohydrazones (S)-LH1 and (S)-LH2 were complexed to iridium, but the 
isolation of the desired phosphinohydrazone/iridium precatalyst proved not possible 
(Schemes 54 and 55). Two different issues arised and will be described separately below. 
 
Both the complexation methods (A and B) used for the complexation of (S)-LH1 afforded 
a mixture of iridium complexes (Scheme 54).  
 
 
Scheme 54. Complexation of phosphinohydrazone (S)-LH1 with iridium. 
 
The mixture of complexes obtained was identical in both cases and the products could not 
be separated by column chromatography on silica gel (Figure 18, NMR spectra in red). 
Although only the expected mass was measured for the mixture by ESI-MS, the analytical 
data were not conclusive about the structure of these iridium species. The 31P NMR 
spectrum is shown in Figure 18.  
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Figure 18. 31P NMR Analysis of the iridium complexes formed by coordination of (S)-LH1. 
In black: free ligand (S)-LH1 in CD2Cl2; and in red: (S)-LH1/Ir complex in CD2Cl2. 
 
In the 31P NMR spectrum of the free ligand (S)-LH1, two rotamers were observed 
(δ = − 21.6 and − 22.0 ppm). These rotamers were thought to be able to interconvert 
under the complexation conditions or, if they can not convert into each other, that one 
conformer would be favored for complexation. However, the fact that both complexation 
methods, involving different iridium precursors and also different reaction temperatures, 
afforded an identical mixture of iridium complexes suggests that these conformers do not 
interconvert or that in both cases a thermodynamic product mixture is formed. Further 
analyses were not carried out, as the separation of a single iridium complex for 
asymmetric hydrogenation seems not possible. Phosphinohydrazone (S)-LH1 was not 
further investigated. 
 
When phosphinohydrazone (S)-LH2 was complexed to iridium another issue arised: a 
mixture of three iridium/hydride species was obtained, resulting from C−H insertion of 
iridium into the ortho-position of the phenyl-ring of the hydrazone and again these 
complexes could not be separated (Scheme 55). At least, this characteristic is not 
unexpected as it has already been observed in the iridium-catalyzed asymmetric 
hydrogenation of imines within the PFALTZ group.[119] 
 
                                                             
[119] Unpublished results. 
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Scheme 55. Complexation of phosphinohydrazone (S)-LH2 with iridium. 
 
The presence of more than one phosphine species in the 31P NMR spectra was assigned to 
the formation of several diastereomeric C−H insertion complexes 127 (see Figure 22). 
Both, the 31P and the 1H NMR spectra show the presence of three iridium/hydride 
complexes (see Figures 19 and 20). Although, the corresponding m/z was not observed by 
ESI-MS, the unusual signal at δ = 27.5 ppm may also originate from the iridium complex 
of the phosphine oxide of (S)-LH2. 
 
 
Figure 19. 31P NMR Analysis of the iridium complexes formed by coordination of (S)-LH2. 
 
Three hydride signals can be observed in the 1H NMR spectrum: one singlet and two 
doublets (Figure 20). This observation suggests that only two of the three iridium 
complexes obtained have the phosphorus atom and the inserted hydrogen atoms in close 
enough proximity to allow for coupling. The coupling constants for the doublets at 
δ = − 14.9 and – 15.7 ppm in the 1H NMR spectrum (J = 7.7 and 8.6 Hz respectively), 
suggest that the corresponding two complexes have both their phosphorus and hydride 
atoms cis to each other. Typical coupling values are: 2JH,P(cis) = 10-30 Hz, and 
2JH,P(trans) = 90-160 Hz. 
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Figure 20. 1H NMR Analysis of the iridium complex formed by coordination of (S)-LH2. 
Three hydride signals are observed: δ = − 14.6 (s), − 14.9 (d, J = 7.7 Hz), − 15.7 (d, 
J = 8.6 Hz) ppm. 
 
However, the 2D-NMR experiment allowing for the correlation of 1H and 31P NMR 
spectra, does not support the assumption that the third signal in the 31P NMR spectrum 
(δ = 27.5 ppm) is due to an impurity (Figure 21).  
 
Figure 21. 2D NMR Analysis of the iridium complex formed by coordination of (S)-LH2: correlation 
of 1H and 31P NMR spectra. 
 
In fact, although the chemical shift of this signal is shifted atypically in the 31P NMR 
spectrum, it is clearly correlated to a hydride signal on the basis of the 1H NMR shift. 
 
All the iridium/hydride species, which can possibly be formed by the complexation and 
insertion of (S)-LH2 to iridium are depicted in Figure 22. First of all, the two coordination 
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sites occupied by 1,5-cyclooctadiene need to be cis to each other. Structures 127a and 
127b can most likely be assigned to the two doublets observed in the 1H NMR spectrum 
(Figure 20). However, the structure of the complex showing a singlet in this same 
spectrum remains unclear. While, structures 127c and 127d are unlikely, due to the 
absence of the typical trans coupling constant between the hydride and phosphorus 
atoms, structures 127e and 127f are also unlikely due to the distorted and planar bidentate 
chelation mode of ligand (S)-LH2. In addition, complexes 127e and 127f should display a 
doublet as signal with a similar cis coupling constant in the 1H NMR spectrum. 
 
 
Figure 22. Possible iridium/hydride species formed by the complexation of (S)-LH2. 
 
Another possibility could be that the ligand coordination does not occur as assumed, 
which would mean: (1) the pyrrolidine nitrogen atom could coordinate as nitrogen donor, 
or (2) the ligand chelates only through the phosphorus atom and the inserted C−H bond 
CHAPTER 4 
 
142 
and a solvent molecule occupies the last coordination site. These coordination modes 
could explain the highly different chemical shifts of the hydride and phosphorus signals. 
 
No further analyses were carried out. Based on these results phosphinohydrazone ligands 
with ortho-substituted phenyl substituents were investigated in order to avoid C−H 
insertion. Therefore the synthesis of phosphinohydrazone (S)-LH3 was attempted 
(Scheme 56). This ligand was thought to be accessible from the condensation of the 
pyrrolidine (S)-114 with 1-mesitylethanone (128), in the same way as (S)-LH1 and           
(S)-LH2 (see Scheme 53). However, none of the tested reaction conditions led to the 
formation of the desired phosphinohydrazone (S)-LH3. 
 
 
Scheme 56. Attempted synthesis of the ketohydrazone ligand (S)-LH3. 
 
A third synthetic pathway was developed: the retrosynthetic strategy is depicted in 
Scheme 57. This synthesis involves again the formation of the N−N bond prior to the 
introduction of the phosphine moiety, but also the condensation reaction prior to the 
introduction of the phosphine. The synthesis of the nitrosamine (S)-124 was already 
described above. 
 
 
Scheme 57. 3rd Retrosynthetic analysis to phosphinohydrazones (S)-LH, starting from nitrosamine 
(S)-124. 
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The reduction of nitrosamine (S)-124 was carried out by the use of lithium aluminum 
hydride, in the same way than in the reduction of (S)-122 (see Schemes 52 and 58). 
However, the condensation of hydrazine (S)-131 with the desired ketone 128 was not 
achieved. Probably, the steric hindrance around the electrophilic carbonyl group in 128 
does not allow for the nucleophilic attack of the hydrazine (S)-131. 
 
 
Scheme 58. Attempted synthesis of proline-based hydrazone ligands from ketones. 
 
Ketohydrazones were abandoned as targets for the development of phosphinohydrazone 
ligands. Not only their synthesis proved difficult, but also the problems encountered 
during their complexation to iridium made this approach unattractive. Therefore, the 
synthesis of aldhydrazones was investigated. 
 
4.2.1.2  
Aldhydrazone Ligands 
 
For the synthesis of aldhydrazones the synthetic route depicted in Scheme 59 was 
followed. Nitrosamine (S)-124 was reduced to hydrazine (S)-131 as described above. 
Compound (S)-131 was condensated with 2,4,6-trimethylbenzaldehyde (133) under 
refluxing conditions in toluene and the aldhydrazone (S)-134 was isolated in 49% yield 
(Scheme 59). Subsequently, the alcohol (S)-134 was converted to its bromine derivative 
(S)-135 through an Appel reaction (69% yield). Finally, the phosphinohydrazone ligand 
(S)-LH4 was isolated, after displacement of the bromine by diphenylphosphide in 
96% yield. In contrast to the synthesis of ketohydrazones, the synthesis of aldhydrazone 
(S)-LH4 proceeded smoothly in good overall yield. 
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Scheme 59. Synthesis of proline-based hydrazone ligand (S)-LH4 from aldehydes. 
 
Since the condensation of the hydrazine (S)-131 with aldehyde (133) was straightforward 
(Scheme 59), other aldhydrazones were prepared (Scheme 61). The synthesis of 
aldhydrazones was carried out from hydrazine (S)-114, following the retrosynthetic 
analysis depicted in Scheme 51. Aldhydrazones (S)-LH4, (S)-LH5 and (S)-LH6 were 
prepared by this method. The yields for the condensation reactions were moderate and 
ranged from 49% to 62% (Scheme 61). 
 
 
Scheme 61. Synthesis of proline-based aldhydrazones (S)-LH4, (S)-LH5 and (S)-LH6. 
 
Complexation of (S)-LH4 to iridium was carried out in situ (Scheme 60). In contrast to 
phosphinohydrazones (S)-LH1 and (S)-LH2, ligand (S)-LH4 formed only one iridium 
species upon complexation (see Figure 23). ESI-MS measurements supported the 
formation of the desired compound (S)-CH4 (m/z = 715). 
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Scheme 60. Complexation of phosphinohydrazone (S)-LH4 with iridium. 
 
Figure 23 shows the 31P NMR spectra of the free phosphinohydrazone ligand (S)-LH4 
(black trace) and that of the corresponding (S)-LH4/iridium complex (red trace). While 
the free ligand showed a chemical shift of δ = − 22.6 ppm, the signal was shifted 
downfield upon addition of the iridium source. Only one peak was observed when the 
ligand was complexed in situ with [Ir(cod)2]BArF in CD2Cl2: δ = − 13.4 ppm (red trace). 
 
  
Figure 23. 31P NMR Analysis of the iridium complex formed by coordination of (S)-LH4. 
In black: free ligand (S)-LH4 in CD2Cl2; and in red: (S)-LH4/Ir complex in CD2Cl2. 
 
However, complex (S)-CH4 proved very sensitive to moisture and could not be isolated. 
All attempts to purify the compound by: (1) column chromatography; (2) recrystalization 
or (3) washing of the crude product with n-pentane in order to remove the free 
cyclooctadiene, resulted in partial decomposition of (S)-CH4. 
 
In addition, the complex (S)-CH4 formed by in situ complexation with [Ir(cod)2]BArF in 
absolute CD2Cl2 was shown to form a different species over time (Figure 24). Even 
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tough, the solvent was treated with basic aluminum oxide prior to use. Upon 
decomposition of (S)-CH4, the formation of a broad signal (δ = 28.8 ppm) was observed 
(blue trace). The same signal was observed, when the purification and isolation of the 
complex was attempted. Further investigations to identify this second species were not 
conclusive. 
 
 
Figure 24. 31P NMR Analysis revealing the decomposition of the iridium complex (S)-CH4. 
In red: freshly prepared complex in CD2Cl2; and in blue: the same complex approximately 2 hours 
after preparation. 
 
The complexation of (S)-LH5 and (S)-LH6 showed similar characteristics to the 
complexation of ligand (S)-LH4. Therefore, these complexes were not isolated and 
prepared in situ for an initial screening as catalysts for the iridium-catalyzed asymmetric 
hydrogenation. 
 
The complex (S)-CH6 formed by in situ complexation with [Ir(cod)2]BArF in absolute 
CD2Cl2 showed as well two signals in the 31P NMR spectra: δ = 10.7 ppm and 
δ = 38.8 ppm in a ratio close to 4:1. Nevertheless, crystals suitable for X-ray analysis 
were obtained by crystallization from the stock solution of precatalyst prepared by in situ 
complexation and layered with n-pentane (see Figure 25). The solid state structure shows 
the expected bidentate coordination. The ligand forms a six-membered metallacycle upon 
coordination through the second hydrazone nitrogen and the phosphorus atom to the 
iridium center.  
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Figure 25. Crystal structure of complex [((S)-LH6)Ir(cod)]BArF. The counterion has been omitted 
for clarity (blue N, magenta P, dark gray Ir, light gray C; Ir−P bond (2.27 Å), Ir−N bond (2.13 Å), 
N−N bond (1.40 Å), and P−Ir−N angle (84.7°)). 
 
4.2.2 
Iridium-Catalyzed Asymmetric Hydrogenations with Proline-Based 
Phosphinohydrazones Ligands 
 
As described above, three aldhydrazones ((S)-LH4, (S)-LH5 and (S)-LH6) were prepared 
and complexed in situ to iridium. Next, the potential of these chiral phosphinohydrazones 
as ligands for iridium catalysis was investigated. The catalysts were formed in situ by 
complexation prior to the hydrogenation reaction, but were used directly after 
preparation, in order to minimize the formation of the unknown second species 
(see Figure 24). 
 
The results of the iridium-catalyzed asymmetric hydrogenation of alkenes S1 and S4 are 
reported in Table 51. Excellent conversions were obtained by the use of these 
phosphinohydrazones (S)-LH4 to (S)-LH6 as chiral ligands for iridium; conversions of 
99% and more were measured in all cases after only 2 hours. However, the 
enantioselectivities achieved in this catalytic transformation were fluctuating. In fact, for 
a same test reaction, the values were not reproducible and varied over a large range of 
values. For example in the asymmetric reduction of S1, the use of ligand (S)-LH4 
afforded up to 91% ee of the (R)-configured alkane P1 (entry 1). When the same reaction 
was repeated several times, the values were never consistent, ranging from 23% ee (R) to 
91% ee (R). 
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Table 51. Iridium-catalyzed asymmetric hydrogenation of (E)-1,2-diphenyl-1-propene (S1) and 
(E)-ethyl 3-phenylbut-2-enoate (S4), using proline-based hydrazone ligands (S)-LH.[a] 
 
Entry Substrate Ligand R Yield [%][b] ee [%][c] 
1 S1 (S)-LH4 Mes > 99 61 (R)[d] [91 (R)][e] 
2 S4 (S)-LH4 Mes > 99 54 (R)[d] [84 (R)][e] 
3 S1 (S)-LH5 tBu > 99 24 (S)[d] [29 (S)][e] 
4 S4 (S)-LH5 tBu > 99 12 (S) 
5 S1 (S)-LH5 Cy > 99 23 (R)[d] [34 (R)][e] 
6 S4 (S)-LH6 Cy > 99 21 (R) 
[a] Reaction scale: [Ir(cod)2]BArF (1.25 μmol), ligand (1.25 μmol), solvent (0.25 mL), substrate (125 μmol); [b] Yields were 
determined by GC analysis (see experimental part); [c] Enantioselectivities were determined by GC analysis using a chiral 
stationary phase (see experimental part); [d] Average of 2-4 experiments; [e] Best enantiomeric excess obtained. 
 
Irreproducibility of the results was also observed with the other catalysts in the 
asymmetric hydrogenation of S1 and S4. Therefore, the average ee-value obtained is 
given and in brackets the best enantiomeric excess obtained for each test reaction is 
shown. Although, the enantiomeric excesses showed large fluctuations, it seems that the 
mesityl-substituted ligand (S)-LH4 furnishes higher enantioinduction than its tert-butyl- 
and cyclohexyl-substituted analogues ((S)-LH5 and (S)-LH6). 
 
These results indicate that decomposition of the complex occurs faster than the 
hydrogenation reaction with (S)-CH4. In addition, the unidentified species might as well 
be an active reducing agent, which would explain the complete conversions and 
fluctuating selectivities. 
 
4.3   
Conclusion 
 
Only a few proline-based phosphinohydrazones derived from aldehydes were 
synthesized. The synthesis of phosphinohydrazones from ketones proved to be difficult. 
Both types of compounds, ketohydrazones and aldhydrazones, were complexed to iridium 
but different issues arised. Whereas the in situ complexation of aldhydrazones was 
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successful, ketohydrazones formed only mixtures of several iridium species, which could 
not be separated and clearly identified. 
 
Aldhydrazone iridium complexes, were not stable and decomposed. Nevertheless, they 
were tested in the iridium-catalyzed asymmetric hydrogenation of alkenes. Full 
conversions to the desired reduction product were obtained. The enantioselectivities are 
fluctuating and it is likely that the decomposition process is fast and interferes with the 
desired asymmetric reduction of the substrate. The decomposition process was not 
investigated. These initial results suggest that these ligands are too sensitive to be 
practical. 
 
However, an X-ray structure of a phosphinohydrazone/iridium complex was obtained and 
confirms the expected bidentate coordination mode of aldhydrazones to iridium.  
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5.1   
Privileged Chiral Ligands for Asymmetric Catalysis 
 
So called, privileged ligands, are chiral ligands, which can be applied to various 
asymmetric catalytic reactions.[120] As described in chapter 2, proline-based 
amidophosphines and ureaphosphines were applied successfully in the iridium-catalyzed 
asymmetric hydrogenation of trisubstituted alkenes and furnished high 
enantioselectivities for certain classes of substrates. Because palladium complexes with 
P,N ligands have proved to be efficient catalysts for allylic substitution, it was explored 
whether these proline-based ligands can also be applied to these reactions. First in this 
chapter, will be given an overview of privileged ligands for metal catalysis which are 
known today (see section 5.1) and then the results obtained when these proline-based 
ligands were applied to palladium catalysis will be presented (see section 5.3.2). 
Moreover, attempts to elucidate the coordination mode of these ligands to palladium will 
be discussed. 
 
Several ligand classes have been shown to have a general scope and were applied to more 
than one transition metal-catalyzed reaction. To these chiral ligands was given the status 
of privileged ligands. Figure 26 shows some of these privileged chiral ligands and gives 
an overview of the reactions they were used in. Only the most common enantioselective 
transition metal-catalyzed transformations are depicted. 
 
The non-symmetrical and modular phosphinooxazolines (S)-LPHOX for example were 
applied as P,N ligands in various metal-catalyzed reactions.[121] They were not only 
applied to iridium-catalyzed enantioselective hydrogenation of imines and trisubstituted 
alkenes, but also in the palladium-catalyzed allylic alkylation and Heck reaction and in 
the iridium-catalyzed intramolecular Pauson−Khand reaction.[121] 
 
                                                             
[120] a) T. P. Yoon, E. N. Jacobsen, Science 2003, 299, 1691-1693; b) Privileged Chiral Ligands and 
Catalysts (ed. Q.-L. Zhou), Wiley-VCH, Weinheim, 2011. 
[121] For catalytic asymmetric reactions involving PHOX ligands see: a) P. Von Matt, A. Pfaltz, Angew. 
Chem. Int. Ed. Engl. 1993, 32, 566-568; b) J. Sprinz, G. Helmchen, Tetrahedron Lett. 1993, 34, 1769-1772; 
c) G. J. Dawson, C. G. Frost, J. M. Williams, S. J. Coote, Tetrahedron Lett. 1993, 34, 3149-3150; 
d) O. Loiseleur, P. Meier, A. Pfaltz, Angew. Chem. Int. Ed. Engl. 1996, 35, 200-202; e) O. Loiseleur, 
M. Hayashi, N. Schmees, A. Pfaltz, Synthesis 1997, 1338-1345; f) Z.-L. Lu, E. Neumann, A. Pfaltz, Eur. J. 
Org. Chem. 2007, 4189-4192. 
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Other ligands, which have been presented previously herein as important ligands for 
transition metal-catalyzed asymmetric hydrogenations are: BINAP or SEGPHOS, and 
DuPhos or BPE phospholanes. BINAP and SEGPHOS ligands form two large families of 
related ligands. Both are based on a biphenyl architecture with a C2 axial chirality; 
BINAP is based on a bisnaphthalene backbone and SEGPHOS on a bis(1,3-benzodioxole) 
backbone. Nevertheless, SEGPHOS ligands lead often to higher enantioselectivities and 
therefore SEGPHOS ((Ra)-LSEGPHOS) is depicted in Figure 26. SEGPHOS not only 
proved to be efficient in the enantioselective hydrogenation of amino ketones,[122a] but 
also in 1,4-additions of arylboronic acids to coumarins (rhodium-catalyzed);[122b] 
hydrosilylations of ketones (copper-catalyzed);[122c-d] and in reductive aminations 
(ruthenium-catalyzed).[122e] C2-Symmetric bis(phospholanes), (R,R)-LDuPhos and              
(R,R)-LBPE form as well an extensive ligand library. They have proven to be efficient in 
the rhodium-catalyzed asymmetric hydrogenation of enamides, enol esters, ketoesters, 
imines and other substrates,[123a-d] as well as in the copper-catalyzed allylboration of 
ketones.[123f] 
 
Chiral bisoxazolines ((S,S)-LBOX) promote a great number of asymmetric reactions, 
involving various transition metals.[124] BOX ligand and their derivatives were used 
mostly in copper-catalyzed reactions, as: cyclopropanation of alkenes,[124d-f] and 
aziridination of styrenes.[124g] BOX ligands were also applied to Diels−Alder 
reactions.[124i-j]  
                                                             
[122] For catalytic asymmetric reactions involving SEGPHOS ligands see: a) T. Ohkuma, D. Ishii, H. Takeno, 
R. Noyori, J. Am. Chem. Soc. 2000, 122, 6510-6511; b) G. Chen, N. Tokunaga, T. Hayashi, Org. Lett. 2005, 
7, 2285-2288; c) D. Tomita, R. Wada, M. Kanai, M. Shibasaki, J. Am. Chem. Soc. 2005, 127, 4138-4139; 
d) B. H. Lipshutz, A. Lower, R. J. Kucejko, K. Noson, Org.Lett. 2006, 8, 2969-2972; e) H. Shimizu, 
I. Nagasaki, K. Matsumura, N. Sayo, T. Saito, Acc. Chem. Res. 2007, 40, 1385-1393. 
[123] For catalytic asymmetric reactions involving DuPhos and BPE phospholane ligands see: a) M. J. Burk, 
J. E. Feaster, J. Am. Chem. Soc. 1992, 114, 6266-6267; b) M. J. Burk, J G. Allen, W. F. Kiesman, J. Am. 
Chem. Soc. 1998, 120, 657-663; c) M. J. Burk, T. G. P. Harper, C. S. Kalberg, J. Am. Chem. Soc. 1995, 117, 
4423-4424; d) M. J. Burk, F. Bienewald, S. Challenger, A. Derrick, J. A. Ramsden, J. Org. Chem. 1999, 64, 
3290-3298; e) C. González-Arellano, A. Corma, M. Iglesias, F. Sánchez, Chem. Commun. 2005, 3451-3451; 
f) R. Wada, K. Oisaki, M. Kanai, M. Shibasaki, J. Am. Chem. Soc. 2004, 126, 8910-8911;  g) A. Côté, 
V. N. G. Lindsay, A. B. Charrette, Org. Lett. 2007, 9, 85-87. 
[124] For catalytic asymmetric reactions involving BOX ligands see: a) G. Desimoni, G. Faita, 
K. A. Jørgensen, Chem. Rev. 2006, 106, 3561‑3651; b) A. K. Ghosh, P. Mathivanan, J. Cappiello, 
Tetrahedron: Asymmetry 1998, 9, 1-45; c) J. S. Johnson, D. A. Evans, Acc. Chem. Res. 2000, 33, 325‑335; 
d) D. A. Evans, K. A. Woerpel, M. M. Hinman, M. M. Faul, J. Am. Chem. Soc. 1991, 113, 726-728; 
e) E. Jezek, A. Schall, P. Kreitmeier, O. Reiser, Synlett 2005, 915‑918; f) R. B. Chor, B. Nosse, S. Sörgel, 
C. Böhm, M. Seitz, O. Reiser, Chem. Eur. J. 2003, 9, 260‑270; g) D. A. Evans, M. M. Faul, M. T. Bilodeau, 
B. A. Anderson, D. M. Barnes, J. Am. Chem. Soc. 1993, 115, 5328‑5329; h) Z. Sun, S. Yu, Z. Ding, D. Ma, 
J. Am. Chem. Soc. 2007, 129, 9300‑9301; i) D. A. Evans, S. J. Miller, T. Lecta, J. Am. Chem. Soc. 1993, 
115, 6460‑6461; j) E. J. Corey; N. Imai, H.-Y. Zhang, J. Am. Chem. Soc. 1991, 113, 728-729; k) K. Juhl, 
N. Gathergood, K. A. Jørgensen, Angew. Chem. Int. Ed. 2001, 40, 2995-2997. 
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Figure 26. Privileged ligands for asymmetric catalysis.[120] 
 
PYBOX ligands ((S,S)-LPYBOX), which are constituted of a pyridine-ring flanked by two 
oxazoline groups are related to BOX ligands.[125a-b] They were applied to the rhodium-
                                                             
[125] For catalytic asymmetric reactions involving PYBOX ligands see: a) G. Desimoni, G. Faita, 
P. Quadrelli, Chem. Rev. 2003, 103, 3119‑3154; b) H. Nishiyama, H. Sakaguchi, T. Nakamura, M. Horihata, 
M. Kondo, K. Itoh, Organometallics 1989, 8, 846‑848; c) H. Nishiyama, S.-B. Park, K. Itoh, Tetrahedron: 
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catalyzed hydrosilylation of ketones,[125c] and to the copper-catalyzed addition of terminal 
alkynes to imines.[125d] 
 
BINOL and its related axially chiral biaryl ligands form a widely used class of ligands in 
asymmetric synthesis and were applied to many reactions, such as Diels−Alder reaction, 
carbonyl additions and reductions and Michael addition. Herein, VAPOL                        
(3-3’-biphenantrol) is depicted as a representative axially chiral biaryl ligand. This ligand 
has proven to be highly efficient in catalytic asymmetric Diels−Alder, aldol and 
aziridination reactions.[126] 
 
C2-symmetric diaminocyclohexyl ligands ((S,S)-LDACH), were designed for asymmetric 
allylic alkylation reactions.[127] Many nucleophiles can be employed to form multiple 
types of bonds (carbon, oxygen and nitrogen nucleophiles). DACH ligands were used 
efficiently for this reaction, both palladium and molybdenum catalysts can be employed. 
 
Many other ligands have been used in many asymmetric reactions.[120] Although, 
TADDOLs (α,α,α,α-tetraaryl-1,3-dioxolane-4,5-dimethanols, (R,R)-LTADDOL) have found 
numerous applications in asymmetric synthesis, generally their titanium complexes were 
used.[128] 
                                                                                                                                                                                      
Asymmetry 1992, 3, 1029‑1034; d) C. Wei, C.-J. Li, J. Am. Chem. Soc. 2002, 124, 5638‑5639; e) J. Lu, M.-
L. Hong, S.-J. Ji, T.-P. Loh, Chem. Commun. 2005, 1010‑1012. 
[126] For catalytic asymmetric reactions involving VAPOL ligands see: a) J. Bao, W. D. Wulff, 
A. L. Rheingold, J. Am. Chem. Soc. 1993, 115, 3814-3815; b) J. Bao, W. D. Wulff, Tetrahedron Lett. 1995, 
36, 3321-3324; c) D. P. Heller, D. R. Goldberg, W. D. Wulff J. Am. Chem. Soc. 1997, 119, 10551-10552; 
d) J. C. Antilla, W. D. Wulff, Angew. Chem. Int. Ed. 2000, 39, 4518-4521; e) C. Loncaric, W. D. Wulff, Org. 
Lett. 2001, 3, 3675-3678; f) A. P. Patwardhan, V. R. Pulgam, Y. Zhang, W. D. Wulff, Angew. Chem. Int. Ed. 
2005, 44, 6169-6172; g) A. P. Patwardhan, Z. Lu, V. R. Pulgam, W. D. Wulff, Org. Lett. 2005, 7, 2201-2204; 
h) S. Xue, S. Yu, Y. Deng, W. D. Wulff, Angew. Chem. Int. Ed. 2001, 40, 2271-2274. 
[127] For catalytic asymmetric reactions involving DACH ligands see: a) B. M. Trost, D. L. Van Vranken, 
Chem. Rev. 1996, 96, 395-422; b) B. M. Trost, M. R. Machacek, A. Aponick, Acc. Chem. Res. 2006, 39, 
747-760; c) B. M. Trost, M. L. Crawley, Chem. Rev. 2003, 103, 2921-2943; d) B. M. Trost, Acc. Chem. Res. 
1996, 29, 355-364; e) B. M. Trost, R. C. Bunt, J. Am. Chem. Soc. 1994, 116, 4089-4090; f) M. Ernst, 
G. Helmchen, Angew. Chem. Int. Ed. 2002, 41, 4054-4056; g) B. M. Trost, F. D. Toste, J. Am. Chem. Soc. 
1999, 121, 3543-3544; h) B. M. Trost, F. D. Toste, J. Am. Chem. Soc. 2003, 125, 3090-3100; i) B. M. Trost, 
M. L. Crawley, J. Am. Chem. Soc. 2002, 124, 9328-9329; j) B. M. Trost, M. J. Krische, R. Radinov, 
G. Zanoni, J. Am. Chem. Soc. 1996, 118, 6297-6298; k) B. M. Trost, S. R. Pulley, J. Am. Chem. Soc. 1995, 
117, 10143-10144; l) B. M. Trost, D. L. Van Vranken, J. Am. Chem. Soc. 1993, 115, 444-458; m) B. M. Trost, 
D. L. Van Vranken, C. Bingel, J. Am. Chem. Soc. 1992, 114, 9327-9343; n) B. M. Trost, K. Dogra, Org. Lett. 
2007, 9, 861-863. 
[128] For catalytic asymmetric reactions involving TADDOL ligands see: a) D. Seebach, A. K. Beck, 
A. Heckel, Angew. Chem., Int. Ed. 2001, 40, 92-138; b) R. O. Duthaler, A. Hafner, Chem. Rev. 1992, 92, 
807‑832; c) D. Seebach, G. Jaeschke, Y. M. Wang, Angew. Chem. Int. Ed. Engl. 1995, 34, 2395‑2396; 
d) G. Jaeschke, D. Seebach, J. Org. Chem. 1998, 63, 1190‑1197; e) D. Seebach, R. Dahinden, R. E. Marti, 
A. K. Beck, D. A. Plattner, F. N. M. Kühnle, J. Org. Chem. 1995, 60, 1788‑1799; f) A. Cuenca, M. Medio-
Simón, G. Asensio Aguilar, D. Weibel, A. K. Beck, D. Seebach, Helv. Chim. Acta 2000, 83, 3153-3162; 
g) L. Hintermann, A Togni, Angew. Chem. Int. Ed. 2000, 39, 4359‑4362. 
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5.2   
Palladium-Catalyzed Allylic Alkylation Reaction 
 
The palladium-catalyzed asymmetric allylic alkylation has proven to be an exceptionally 
powerful method for the construction of stereogenic centers (Scheme 62). This method 
permits to form multiple types of bond (C−C, C−O, C−S and C−N bonds). The allylic 
alkylation methodology has been intensively studied and can be catalyzed by various 
transition metals, such as palladium, iridium, nickel, molybdenum or platinum.[129] In 
addition, a large number of ligands have been developed and optimized for this 
asymmetric transformation. Nevertheless, the most import examples have been shown in 
Figure 26 above to be PHOX and DACH ligands derivatives.[126a,129] 
 
 
Scheme 62. Palladium-catalyzed allylic alkylation reaction. 
 
5.3   
Palladium-Catalyzed Allylic Alkylation Reaction with Proline-
Based Ligands 
 
Although, chiral proline-based ligands have been applied as ligands in asymmetric 
palladium-catalyzed allylic alkylation reactions, the selectivities were lower than with 
state-of-the-art ligands. GILBERTSON et al. studied the proline-based phosphinooxazoline 
(R,S)-L20b, as a ligand for the palladium-catalyzed alkylation of dimethyl malonate 
(Scheme 63).[130] SHIBASAKI et al. tested the well known BPPM ligand ((S,S)-LBPPM) in 
the palladium-catalyzed alkylation of cyclopentene diol derivatives to form 
cyclopentanoids.[131] High yields of the cyclized product were obtained, but no selectivity 
was observed (Scheme 63). 
 
                                                             
[129] a) A. Pfaltz, M. Lautens, Allylic Substitution Reactions in Comprehensive Asymmetric Catalysis (ed. 
E. N. Jacobsen, A. Pfaltz, and H. Yamamoto), Springer, Berlin, 1999, 1st Ed., Vol. 2, pp. 833-884; 
b) B. M. Trost, Asymmetric Allylic Alkylation Reactions in Catalytic Asymmetric Synthesis (ed. I. Ojima), 
Wiley-VCH, New York, 2000, 2nd Ed., pp. 593-649. 
[130] G. Xu, R. Gilbertson, Tetrahedron Lett. 2002, 43, 2811-2814. 
[131] M. Mori, S. Nukui, M. Shibasaki, Chem. Lett. 1991, 1797-1800. 
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Scheme 63. Palladium-catalyzed allylic alkylation reaction with proline-based chiral ligands. 
 
As shown by TOMIOKA et al. amidophosphine (S)-LA1 can be applied to rhodium-
catalyzed 1,4-addition of boronic esters to enones, but also in the copper-catalyzed         
1,4-addition of Grignard reagents to cyclic α,β-unsaturated carbonyl compounds 
(Figure 27).[66a,68a]. Derivatives of (S)-LA1, were found to be efficient P,O ligands for the 
iridium-catalyzed asymmetric hydrogenation of various trisubstituted alkenes 
(see chapter 2). 
 
 
Figure 27. Applications of proline-based amidophosphine (S)-LA1 in asymmetric catalysis. 
 
Therefore, these same proline-based P,O ligands, described in chapter 2, were applied to 
the palladium-catalyzed allylic alkylation. This reaction was chosen to evaluate the 
potential of these ligands, since the privileged PHOX ligand was highly efficient in both, 
the iridium-catalyzed asymmetric hydrogenation and the palladium-catalyzed allylic 
alkylation reaction. In addition, it was thought to be more interesting to investigate a 
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transition metal, different from those that were already investigated for this ligand type, 
namely rhodium, copper and iridium. This project was carried out in collaboration with 
DR. CHRISTIAN EBNER within the PFALTZ group. 
 
5.3.1  
Initial Results 
 
In an initial experiment the tetrasubstituted ureaphosphine ligand (S)-LU49 was tested in 
the palladium-catalyzed allylic alkylation of (E)-1,3-di-para-tolylallyl-benzoate (S23) 
(Scheme 64). The tested tetrasubstituted ureaphosphine (S)-LU49 gave product P23 in 
90% yield with an enantiomeric excess of 60%. This result was encouraging for further 
investigations. As this reaction is known to proceed with high enantioselectivity using for 
example PHOX ligands, it was chosen as test reaction for the screening of further proline-
based ligands. All the screening reactions were carried out by DR. CHRISTIAN EBNER. 
 
 
Scheme 64. Initial testing of proline-based ligands in the palladium-catalyzed allylic alkylation. 
 
5.3.2  
Palladium-Catalyzed Allylic Alkylation with Amido- and Ureaphosphine 
Ligands 
 
Several other proline-based ligands were tested in the palladium-catalyzed allylic 
substitution of (E)-1,3-di-para-tolylallyl-acetate (S22) with dimethyl malonate as carbon 
nucleophile (Table 52). At least one representative of the different proline-based ligands 
described in chapter 2 was tested, namely, tetrasubstituted ureaphosphines ((S)-LU49 and 
(S)-LU410), trisubstituted ureaphosphines ((S)-LU319) and amidophosphines ((S)-LA13 
and (S)-LA14). 
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Table 52. Palladium-catalyzed allylic alkylation of (E)-1,3-diphenylallyl-acetate (S22), using 
proline-based ligands. 
 
Entry Ligand R1 R2 t [h] Yield [%][a] ee [%][b] 
1   (S)-LU319 NHPh Ph 24 92 47 (R) 
2   (S)-LU49  NPh2 Ph 17 94 54 (R) 
3[c] (S)-LU49  NPh2 Ph 17 56 52 (R) 
4[d] (S)-LU49  NPh2 Ph 89 70 62 (R) 
5   (S)-LU410 NPh2 oTol 42 28 62 (S) 
6   (S)-LA13  CPh3 Ph 16 92 49 (R) 
7   (S)-LA14  CPh3 oTol 39 26 50 (S) 
[a] Yields were isolated; [b] Enantioselectivities were determined by HPLC analysis using a chiral stationary phase (see 
experimental part); [c] 5 mol% NaBArF was used as an additive; [d] The reaction was carried out in toluene. 
 
In all cases conversion to the desired compound was found. Furthermore all catalysts led 
to enantioenriched product in the range of 50 to 60% ee. Diphenylphosphines as ligands 
allowed for higher activity of the catalyst compared to di-ortho-tolylphosphines 
(entries 1, 2, 6 versus 5, 7). Interestingly, whenever the di-ortho-tolylphosphine 
derivatives were used the reaction resulted in the formation of the other product 
enantiomer compared to the reactions using the diphenylphosphine derivatives although 
the configuration of the stereogenic center of the ligand was the same for all ligands.  
 
When it was tried to optimize the reaction conditions in order to increase the selectivity of 
the catalysts, both, a change in solvent and the addition of an additive did not lead to the 
desired effect. The use of toluene as solvent, instead of dichloromethane resulted in a 
slight increase in selectivity (62% ee versus 54% ee), but reduced the activity of the 
catalyst (70% versus 94% yield, entries 2 and 4). The addition of NaBArF as additive, 
which is known to accelerate the reaction via anion exchange as reported by                 
LLOYD-JONES et al. had a negative impact on both, activity and selectivity of the catalyst 
(entry 3).[132] 
 
                                                             
[132] L. A. Evans, N. Fey, J. N. Harvey, D. Hose, G. C. Lloyd-Jones, P. Murray, A. G. Orpen, R. Osborne, 
G. J. J. Owen-Smith, M. Purdie, J. Am. Chem. Soc. 2008, 130, 14471-14473. 
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In order to test a different nucleophile, (E)-1,3-diphenylallyl acetate (S22) was reacted 
with dimethyl malonate (109) using the tetrasubstituted ureaphosphine (S)-LU49 as ligand 
(Scheme 65). The desired reaction product P22a was formed and isolated in 78% yield 
with an enantiomeric excess of 49%.  
 
 
Scheme 65. Palladium-catalyzed allylic alkylation of (E)-1,3-diphenylallyl-acetate (S22) and 
cyclohex-2-en-1-yl-benzoate (S24), using the proline-based ligand (S)-LU49. 
 
Further, cyclohex-2-en-1-yl benzoate (S24) was tested as substrate (Scheme 65). Again 
dimethyl malonate was used as nucleophile. Unfortunately, using (S)-LU49, no conversion 
to the desired product was observed even after 3 days reaction time. 
 
5.3.3  
Analysis of the Coordination Mode to Palladium 
 
In order to determine, the coordination mode of these proline-based ligands to palladium, 
ESI-MS and NMR analyses were carried out for three ligands ((S)-LU319, (S)-LU410 and 
(S)-LA14). The main intention was to find out whether these ligands bind to palladium in 
a bidentate fashion, as it was shown to be the case with iridium or in a hemilabile manner, 
as it was shown to be the case for rhodium.[66,67] 
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First, ESI-MS analyses of the in situ prepared precatalysts performed (Scheme 66). When 
the ligands (S)-LU319, (S)-LU410 and (S)-LA14 were reacted with [(π-C3H5)PdCl]2 in 
dichloromethane and the resulting mixtures were analyzed by ESI-MS, a signal 
corresponding to the mass of the respective [(π-C3H5)Pd(L*)]+ complex was observed.  
 
 
Scheme 66. ESI-MS Analysis of in situ formed precatalysts. 
 
However, further signals with a lower mass were found, which could not be assigned. 
This finding does not prove that these ligands bind in a bidentate fashion palladium, but 
suggests that it is likely in order to occupy all coordination sites. 
 
In order to gain further information about the coordination mode of these ligands, NMR 
studies were carried out. First, it was tested whether the phosphorus atom is coordinated 
to the metal center in the palladium complex. For this purpose 31P NMR-spectra of the 
free ligands and the complexes were recorded to compare the corresponding chemical 
shifts. 
 
Figure 28 shows such spectra for the tetrasubstituted ureaphosphine ligand (S)-LU319. 
While the free ligand showed a chemical shift at δ = − 22.3 ppm (red trace), the signal 
was shifted downfield upon addition of the palladium source. In CD2Cl2 (blue trace) two 
signals were found due to restricted rotation of the allyl moiety in the complex. When the 
NMR spectra was measured in DMSO-d6 (the complexation was carried out in 
dichloromethane as before) only one signal was observed. This observation confirms that 
the two signals seen, when measured in dichloromethane, origin from the presence of 
rotamers. Comparable observations were made for the in situ complexation of ligands 
(S)-LU49 and (S)-LU410. Again a downfield shift of the signal of the phosphorus atom 
was observed upon coordination of the ligands to palladium. In CD2Cl2, rotamers were as 
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well observed and in DMSO-d6 only one signal was found for both complexes. These 
findings suggest that for all the tested ligands, coordination through the phosphorus atom 
takes place. 
 
 
Figure 28. 31P NMR Analysis of the palladium-precatalyst formed by coordination of (S)-LU319 (in 
black: free ligand (S)-LU319 in CD2Cl2; in blue: (S)-LU319/Pd complex in CD2Cl2; and in red:           
(S)-LU319/Pd complex in (CD3)2SO). 
 
Next it was examined whether the carbonyl oxygen atom is as well coordinating to the 
palladium center. If this would be the case a significant change of the signal of the 
quaternary carbonyl carbon atom should be observed in the 13C NMR spectra of the 
complexes. When, ureaphosphines and amidophosphines were found to coordinate to 
iridium as bidentate P,O ligands to iridium, the signal of the quaternary carbon atom was 
shifted by 9.2 ppm and 7.8 ppm downfield, respectively in the 13C NMR spectra 
(see Tables 17 and 2 in chapter 2). 
 
However, such a change in the chemical shift was not found, when the tested ligands 
were complexed to palladium (Table 53). In particular, the carbonyl function of the free 
ligands (S)-LU410 showed the same chemical shift as in its respective palladium complex 
(δ = 158.7 ppm). The same signals were found for the analysis of the coordination of 
ligand (S)-LU49 with the same chemical shift. For the trisubstituted ureaphosphine          
(S)-LU319 a slight highfield shift was observed for the corresponding palladium complex 
(δ = 153.8 ppm for the free ligand and δ = 151.0 ppm). However, this does not prove that 
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the chemical shift is originating from complete coordination of the oxygen atom towards 
the palladium center. 
 
Table 53. Comparison of the spectroscopic properties of the free ligands and their respective 
palladium precatalysts. 
 Compound[a-b]  13C NMR [δ (C=O)]  
 (S)-LU319  153.8 ppm  
 (S)-LU319/Pd complex  151.0 ppm  
 (S)-LU49  158.7 ppm  
 (S)-LU49/Pd complex  158.8 ppm  
 (S)-LU410  158.7 ppm  
 (S)-LU410/Pd complex  158.7 ppm  
[a] The in situ complexed ligands were analyzed: [(π-C3H5)PdCl]2/ligand (0.5:1) in CD2Cl2; [b] The free ligands were 
analyzed in CDCl3. 
 
The small differences in the chemical shifts of the quaternary carbonyl atom suggest that 
these proline-based ligands coordinate in a monodentate fashion and that one 
coordination site is occupied by the chloride anion. However this does not exclude a 
reactive cationic P,O ligand/iridium complex as the catalytic intermediate. Attempts to 
isolate, the precatalyst in its solid state failed. 
 
5.4   
Conclusions and Outlook 
 
In conclusion, the investigated proline-based ligands were shown to be applicable in the 
palladium-catalyzed allylic alkylation reaction. These palladium catalysts showed good 
activities but low selectivities. Considering, the high levels of enantioselectivities, which 
have been reported for these transformations, the catalyst tested herein are not 
competitive. Therefore, no further screening of ligands of this type and substrates were 
carried out. The analysis of the coordination manner, of these proline-based ligands to 
palladium was not conclusive. It was only confirmed that this ligands bind through their 
phosphorus atom to palladium. 
 
From the results obtained herein, these ligands are most likely not well-suited for 
asymmetric palladium catalysis. Nevertheless, they could be tested in many other 
transition metal-catalyzed reactions, in order to define their potential. In addition, it 
would be interesting to test them as well in the iridium- or copper-catalyzed allylic 
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alkylation reaction, since they are known to coordinate to both of them. Currently, these 
same P,O ligands are investigated as ligands for the iridium-catalyzed Heck-reaction. 
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6.1 
General Information 
 
6.1.1 
Working Techniques and Reagents 
 
Commercially available reagents were purchased from Acros, Aldrich or Fluka and used 
as received. Diethylamine was distilled from calcium hydride. 
 
All preparative reactions, involving a phosphine compound were carried out in flame-
dried glassware under inert atmosphere using Schlenk techniques, except for the 
compounds synthesized according to general procedure 2 (see section 6.1.2). All 
reactions were carried out in abs. solvents. 
 
The solvents were collected from a purification column system (PureSolv, 
Innovative Technology Inc.) or purchased from Aldrich or Fluka in sure/sealedTM bottles 
over molecular sieves. 
 
Column chromatographic purifications were performed on Fluka silica gel 60 (Buchs, 
particle size 40-63 nm). The eluents were of technical grade and distilled prior to use. 
 
The hydrogenation experiments were prepared under purified nitrogen in a glove box 
(MBraun Labmaster 130) and dichloromethane was purchased from Aldrich (≥ 99.5%, 
over molecular sieves). 
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6.1.2 
Analytical Methods 
 
Melting Points (m.p.): Melting points were determined on a Büchi 535 apparatus and are 
uncorrected. 
 
Thin Layer Chromatography (TLC): TLC plates were obtained from Machrey-Nagel 
(Polygram SIL/UV254, 0.2 mm silica with fluorescence indicator). UV light (254 nm) or 
basic permanganate solution were used to visualize the respective compounds. 
 
NMR-Spectroscopy (NMR): NMR spectra were measured either on a Bruker Avance 400 
(400 MHz) or a Bruker Avance 500 (500 MHz) spectrometer. The chemical shifts (δ) are 
given in ppm. The chemical shift δ values were corrected to the signal of the deuterated 
solvents: 7.26 ppm (1H NMR) and 77.16 ppm (13C NMR) for CDCl3; 5.32 ppm 
(1H NMR) and 53.5 ppm (13C NMR) for CD2Cl2; and 2.50 ppm (1H NMR) and 
39.52 ppm (13C NMR) for (CD3)2SO. 31P NMR spectra are calibrated relative to 85% 
phosphoric acid (δ = 0 ppm) and 19F NMR spectra relative to CFCl3 (δ = 0 ppm) as 
external standards. 13C and 31P NMR spectra were recorded 1H-decoupled. The 
assignment of 1H and 13C signals was accomplished, when needed by two-dimensional 
correlation experiments (COSY (correlation spectroscopy), HSQC (heteronuclear 
multiple quantum coherence) and HMBC (heteronuclear multiple quantum coherence)). 
Multiplets are assigned as: s (singlet), d (doublet), t (triplet), q (quartet), sept (septet) and 
m (multiplet). Broad signals are assigned with: br (broad). 
 
Infrared Spectroscopy (IR): Infrared spectra were collected on a Shimadzu FTIR-8400S 
spectrometer. The compounds were measured as pure substance via 
Specac ATR attachment. When, the solid samples were measured as potassium bromide 
discs, the spectra were collected on a Perkin Elmer 1600 series FTIR spectrometer. The 
absorption bands are given in wave numbers (ߥ෤ [cm−1]). The peak intensity is described 
by: s (strong), m (medium), w (weak). 
 
Mass Spectroscopy (MS): Mass spectra were measured by DR. HEINZ NADIG 
(Department of Chemistry, University of Basel) on a VG70-250 spectrometer (electron 
ionization (EI)) or on a MAR 312 spectrometer (fast atom bombardment (FAB)). FAB 
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was performed with 3-nitrobenzyl alcohol (NBA)) as matrix. ESI MS spectra were 
measured by DR. CHISTIAN EBNER and FLORIAN BÄCHLE (Department of Chemistry, 
University of Basel) on a Finnigan MAT LCQ. The signals are given in mass-to-charge 
ratios (m/z). The fragments and relative intensities are given in brackets. 
 
Optical Rotations ([ߙ]஽ଶ଴): Optical rotations were measured on a Perkin Elmer 
Polarimeter 341 (in a cuvette (l = 1 dm)) at 20 °C at 589 nm. The concentration (c) is 
given in g/100 mL. 
 
Elemental Analysis (EA): Elemental analyses were measured by WERNER KIRSCH and 
SYLVIE MITTELHEISSER (Department of Chemistry, University of Basel) on a Leco CHN-
900 (C-, H-, N-detection). The data are indicated in mass percent. 
 
High Resolution Mass Spectrometry (HRMS): High resolution mass spectra were 
recorded in the group of DR. STEFAN SCHÜRCH (Department for Chemistry and 
Biochemistry, University of Bern) on a Thermo Fisher Scientific LTQ Orbitrap XL (ESI-
MS) spectrometer. 
 
High Performance Liquid Chromatography (HPLC): HPLC analyses were performed 
on Shimadzu systems with SLC-10A system controller, CTO-10AC column oven, LC10-
AD pump system, DGU-14A degasser and SPD-M10A diode array- or UV/VIS detector. 
Chiral columns Chiracel AD-H, AS-H, OB-H, OD-H, OJ or OJ-H (4.6 x 250 mm) from 
Daicel Chemical Industries were used. 
 
Gas Chromatography (GC): Gas chromatograms were recorded on Carlo Erba HRGC 
Mega2 Series 800 (HRGS Mega2) instruments. Separations on achiral phases were 
performed on a Restek Rtx-1701 (30 m x 0.25 mm x 0.25 µmol) or a Macherey-Nagel 
Optima 5-Amin (0.25 mm x 0.25 µm x 30 m) column. Separations of enantiomers were 
achieved on a Chiraldex γ-cyclodextrin TFA G-TA (30 m x 0.25 mm x 0.12 µm) or a 
Brechbühler β-cyclodextrin DEtTButSil (SE54), (0.25 mm x 0.25 µm x 25 m) column. 
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6.2 
General Synthetic Procedures 
 
General procedure 1: synthesis of arylated phosphines[68c] 
Hydrogen chloride (4.0 M in 1,4-dioxane, > 3.0 eq.) was added drop wise at 0 °C to a 
solution of the (S)-Boc-(2-phosphino)pyrrolidine precursor ((S)-LC1, (S)-LC2, (S)-LC3, 
(S)-LC4∙BH3 or (S)-LC5∙BH3, 300-500µmol, 1.0 eq., 7.0 M) in 1,4-dioxane. The mixture 
was stirred at room temperature for 1.5-2 hours and then reduced to dryness. The 
resulting crude was treated three times with benzene (2 x 2 mL) and then concentrated 
under high vacuum to afford a colorless foam. A solution of NEt3 (> 3.0 eq.), the 
respective carbonyl compound (> 1.2 eq.) and the deprotected amine (2 M) in 
dichloromethane was stirred at 0 °C for 2 hours. The conversion was monitored by TLC 
analysis and in some cases the reaction mixture was allowed to warm to room 
temperature overnight. After addition of aqueous 10% Na2CO3, the mixture was extracted 
with dichloromethane (3 x). The combined extracts were washed successively with 
aqueous 10% HCl, aqueous saturated NaHCO3, H2O, brine, and then dried over MgSO4. 
The solvent was evaporated and the crude product purified by column chromatography on 
silica gel. Unless otherwise noted all the synthesized compounds, were isolated as 
colorless solid foam after freezing the compounds in liquid N2 and letting warm up under 
high vacuum for several hours. 
 
General procedure 2: synthesis of alkylated phosphine borane adducts 
The procedure is identical to general procedure 1 but involves the use of K2CO3 
(> 10 eq.) instead of NEt3. 
 
General procedure 3: deprotection of alkylated phosphine borane adducts 
Borane-protected phosphine (100 µmol) was dissolved in HNEt2 (3.0 mL) under argon 
and stirred at room temperature for 5-10 days. The conversion was monitored by 
31P NMR analysis. After completion of the reaction all volatiles were removed under high 
vacuum at 60 °C. 
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General procedure 4: synthesis of acyl chlorides from carboxylic acids 
Carboxylic acid (400-500 μmol) was mixed with thionyl chloride (1 mL) and heated at 
reflux for 3 hours under inert atmosphere. The reaction mixture was allowed to cool to 
room temperature, before the excess thionyl chloride was removed in vacuo to afford the 
desired acyl chloride in quantitative yield. The product was used in the next synthetic step 
without further purification. 
 
General procedure 5: synthesis of iridium complexes from [Ir(cod)2]BArF 
Ligand (50.0-100 mg, 1.0 eq.) and [Ir(cod)2]BArF (1.0 eq.)[73] were mixed in abs. 
CH2Cl2 (3-5 mL) and stirred for 30 minutes at room temperature. The solvent was 
evaporated and the residue was triturated with n-pentane (3 x 5 mL) before it was dried in 
vacuo for several hours. The desired complex was isolated as yellowish or orange solid.  
 
General procedure 6: synthesis of phosphines (S)-LOx1, (S)-LTh1, and (S)-LIm1 
Carbamatophosphine (S)-LC was Boc-deprotected as described in general procedure 1, 
to afford the respective salt (S)-52∙HCl, (S)-57∙HCl, or (S)-58∙HCl as a colorless foam. 
This salt (300-500 μmol, 1.0 eq.) was then dissolved in tetrahydrofuran (6 mL) and a 
1.6 M solution of n-butyllithium (1.5 eq.) in hexanes was slowly added at – 78 °C in a 
acetone/dry ice bath. The resulting solution was then stirred for 30 minutes at – 78 °C and 
for 1 hour at room temperature, where it turned yellow. After cooling the solution again 
to – 78 °C, the desired heteroaromatic compound (81, 82 or 83, 1.5 eq.) was added and 
the reaction mixture was allowed to warm to room temperature overnight. At 0 °C in an 
ice bath, aqueous saturated NaHCO3 (5 mL) was added drop wise. Ethyl acetate (10 mL) 
was added and the layers were separated. The aqueous layer was extracted with ethyl 
acetate (2 x 10 mL). The combined organic layers were washed with brine (20 mL), dried 
over MgSO4 and then reduced to dryness under reduced pressure. The crude was purified 
by column chromatography on silica gel. 
 
General procedure 7: synthesis of proline-based P,N ligands  
Phosphine (94, 50∙BH3 or 51∙BH3) was dissolved in tetrahydrofuran (10 M) and a 1.6 M 
solution of n-butyllithium (1.1-1.2 eq.) in hexanes was slowly added at – 78 °C in an 
acetone/dry ice bath. The resulting solution was stirred for 20 minutes at – 78 °C and then 
for 2 hours at room temperature. A solution of the desired bromide ((S)-92 or (S)-93, 
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1.0 eq.) in tetrahydrofuran (10 M) was added, after cooling the solution again to – 78 °C. 
The reaction mixture was allowed to warm to room temperature overnight. At 0 °C in an 
ice bath, aqueous saturated NaHCO3 was added drop wise to quench the reaction. Ethyl 
acetate was then added and the layers were separated. The aqueous layer was extracted 
with ethyl acetate (3 x). The combined organic layers were washed with brine, dried over 
MgSO4 and then reduced to dryness under reduced pressure. The crude was purified by 
column chromatography on silica gel. 
 
General procedure 8: synthesis of iridium complexes from [Ir(cod)Cl]2 
Ligand (S)-LOx1, (S)-LTh1 or (S)-LIm1 (200-300 μmol, 1.0 eq.) and bis(1,5-
cyclooctadiene)diiridium(I) dichloride (0.50 eq.) were dissolved in 
dichloromethane (5 mL). The resulting solution was heated at reflux for 2 hours, before it 
was allowed to cool to room temperature. At room temperature, NaBArF (1.3 eq.) was 
added and the resulting mixture was allowed to stir for 5 minutes. H2O (5 mL) was then 
added and the resulting biphasic mixture was vigorously stirred for 30 minutes. The 
layers were separated and the aqueous layer was extracted with 
dichloromethane (3 x 10 mL). The combined organic extracts were dried over MgSO4 
and the solvent was evaporated under reduced pressure. The product was purified by 
column chromatography on silica gel. Elution of the side products with 
cyclohexane/dichloromethane (100:0 → 1:1) and then of the product (1:1 → 0:100), 
afforded the desired complex (S)-COx1, (S)-CTh1 or (S)-CIm1 as an orange solid. 
 
General procedure 9: synthesis of iridium complexes from [Ir(cod)2]BArF 
Ligand (10.0-20.0 mg, 1.0 eq.) and [Ir(cod)2]BArF (1.0 eq.)[73] were mixed in abs. 
CH2Cl2 (1-2 mL) and stirred for 1 hour at room temperature. The solvent was evaporated 
and the residue was purified by column chromatography on silica gel. Elution of the side 
products with cyclohexane/dichloromethane (100:0 → 1:1) and then of the 
product (1:1 → 0:100), afforded the desired complexes (S)-COx or (S)-CTh, as an orange 
solid. 
 
General procedure 10: synthesis of aldhydrazone (S)-LH4, (S)-LH5 and (S)-LH6 
(S)-2-[(Diphenylphosphino)methyl]pyrrolidin-1-amine ((S)-114, 100 mg, 352 μmol, 
1.0 eq.) and the respective aldehyde (2.5 eq.) were mixed in abs. tetrahydrofuran (2 mL) 
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in a flame-dried Young tube. The resulting mixture was then heated at reflux for 
18 hours, before the solvent was removed in vacuo. The crude was purified by column 
chromatography on silica gel. 
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6.3 
Proline-Based P,O Ligands: Preparation and Analytical Data 
 
6.3.1 
Carbamatophosphines (S)-LC and Precursors 
 
(S)-tert-Butyl 2-[(diphenylphosphino)methyl]pyrrolidine-1-carboxylate ((S)-LC1) 
 
To a solution of (S)-tert-butyl 2-(bromomethyl)pyrrolidine-1-carboxylate ((S)-46, 2.00 g, 
5.63 mmol, 1.0 eq.)[77] in abs. tetrahydrofuran (10 mL) was added drop wise under argon 
atmosphere a 0.5 M solution of potassium diphenylphosphide in tetrahydrofuran 
(17.0 mL, 8.50 mmol, 1.5 eq.) at 0 °C in an ice bath. The reaction mixture was then 
allowed to stir at 0 °C for 30 minutes before it was filtered through celite. The solvent 
was removed in vacuo and the residue was purified by column chromatography on silica 
gel (5 x 19 cm), eluting with hexanes/ethyl acetate (9:1). The title compound (S)-LC1 was 
obtained as a colorless semisolid (2.01 g, 5.44 mmol, 97%). 
C22H28NO2P (369.44 g·mol−1):  
Rf = 0.24 (SiO2, hexanes/ethyl acetate 9:1).1H NMR (400 MHz, CDCl3): δ = 7.64-
7.22 (m, 10 H, Ph/Ph’-H), 4.10-3.77 (m, 1 H, Pyr-2-H), 3.50-3.19 (m, 2 H, Pyr-5-H), 
2.96-2.62 (m, 1 H, CHH’P), 2.15-1.69 (m, 5 H, CHH’P and Pyr-H), 1.41 (s, 9 H,             
tBu-H) ppm. 13C{1H} NMR (101 MHz, CDCl3): δ = 154.4 (s, C=O), 139.8-138.8 (br m, 
Ph-i-C), 138.1-137.4 (br m, Ph’-i-C), 133.1 (d, 2JC,P = 19 Hz, Ph-o-CH), 132.6 (d, 
2JC,P = 20 Hz, Ph’-o-CH), 128.9-128.4 (br m, Ph-CH), 79.5/78.9* (br s, tBu-C), 55.4 (d, 
2JC,P = 21 Hz, Pyr-2-CH), 46.9/46.3* (br s, Pyr-5-CH2), 34.1/33.2* (br, CH2P), 
31.5/31.0* (br s, Pyr-3-CH2), 28.7/28.6* (s, tBu-CH3), 24.0/23.1* (br s, Pyr-4-CH2) ppm. 
31P{1H} NMR (162 MHz, CDCl3): δ = – 21.0/– 21.6* (s) ppm. In the 13C and 31P NMR 
spectra the title compound can be seen as a mixture of rotamers in a ratio close to 1:1 and 
therefore nuclei, which are detected twice are marked with an asterisk. IR (KBr): 
ߥ෤ = 2975m, 2874m, 1687s, 1478m, 1391s, 1247m, 1172s, 1107s, 952w, 917w, 
857w cm−1. MS (+ EI): m/z (%) = 369 (1, M+), 313 (16), 312 (59), 296 (20), 285 (44), 
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284 (22), 216 (14), 215 (19), 203 (23), 202 (60), 201 (84), 200 (24), 199 (57), 186 (14), 
185 (29), 184 (10), 183 (54), 128 (16), 121 (48), 114 (38), 108 (18), 91 (15), 84 (100), 
83 (92), 77 (11), 70 (72), 57 (98), 41 (22). [ߙ]஽ଶ଴ = – 40.2 (c = 1.51, CHCl3). Elemental 
analysis: calc. C 71.52%, H 7.64%, N 3.79%; found: C 71.52%, H 7.70%, N 3.67%. 
 
(S)-tert-Butyl 2-[(di-ortho-tolylphosphino)methyl]pyrrolidine-1-carboxylate ((S)-LC2) 
 
To a suspension of sodium (370 mg, 16.1 mmol, 4.0 eq.) in abs. tetrahydrofuran (25 mL) 
was added chlorodi-(o-tolyl)phosphine (48, 1.50 g, 6.03 mmol, 1.5 eq.) under argon 
atmosphere and the mixture was heated at reflux for 3 hours. The resulting mixture was 
cooled to 0 °C and a solution of (S)-tert-butyl 2-(bromomethyl)pyrrolidine-1-carboxylate 
((S)-46)[77] (1.06 g, 4.01 mmol, 1.0 eq.) in abs. tetrahydrofuran (15 mL) was added drop 
wise. After stirring for 1 hour at 0 °C, the reaction mixture was filtered through celite 
before the solvent was removed in vacuo. Column chromatography on silica gel 
(5 x 17 cm), eluting with hexanes/ethyl acetate (4:1) afforded (S)-LC2 (1.32 g, 
3.32 mmol, 83%) as a colorless semisolid.  
C24H32NO2P (397.49 g·mol−1): 
Rf = 0.48 (SiO2, hexanes/ethyl acetate 4:1). 1H NMR (400 MHz, CDCl3): δ = 7.84-
6.95 (m, 8 H, oTol/oTol’-H), 4.22-3.82 (m, 1 H, Pyr-2-H), 3.44-3.19 (m, 2 H, Pyr-5-H), 
2.65-2.10 (m, 8 H, CH2P and oTol-CH3), 2.04-1.70 (m, 4 H, Pyr-H), 1.42 (s, 9 H,              
tBu-H) ppm. 13C{1H} NMR (101 MHz, CDCl3): δ = 154.4 (s, C=O), 141.8-141.4 (m, 
oTol/oTol’-2-C), 137.4-137.1 (br m, oTol-1-C), 136.1-135.5 (br m, oTol’-1-C), 132.0-
131.4 (br m, oTol/oTol’-6-CH), 130.2-129.9 (br m, oTol/oTol’-3-CH), 128.6-128.4 (br m, 
oTol/oTol’-4-CH), 126.3-125.6 (br m, oTol/oTol’-5-CH), 79.6/79.2* (br s, tBu-C), 
55.1/53.4* (br d, 2JC,P = 19/24 Hz, Pyr-2-CH), 46.6/46.2* (s, Pyr-5-CH2), 33.1-32.3 (m, 
CH2P), 31.4/30.9* (br s, Pyr-3-CH2), 28.7 (s, tBu-CH3), 23.8/23.1* (br s, Pyr-4-CH2), 
21.6-21.0 (br m, oTol/oTol’-CH3) ppm. 31P{1H} NMR (162 MHz, CDCl3): δ = – 41.5/          
– 41.9* (s) ppm. In the 13C and 31P NMR spectra the title compound can be seen as a 
mixture of rotamers in a ratio close to 1:1 and therefore nuclei, which are detected twice 
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are marked with an asterisk. IR (KBr): ߥ෤ = 2972m, 2875m, 1691s, 1590w, 1454m, 1393s, 
1250w, 1169s, 1108s, 1034w, 952w, 917w, 876w, 749m cm−1. MS (EI, 70 eV): 
m/z (%) = 397 (12, M+), 314 (17), 340 (62), 324 (20), 313 (24), 230 (23), 229 (56), 
228 (20), 227 (62), 215 (18), 214 (50), 213 (76), 211 (13), 197 (12), 196 (11), 165 (13), 
135 (11), 133 (15), 128 (15), 122 (18), 114 (46), 105 (14), 91 (13, C7H7+), 84 (100), 
83 (18), 70 (62), 57 (50), 41 (10). [ߙ]஽ଶ଴ = – 46.3 (c = 1.19, CHCl3). Elemental analysis: 
calc. C 72.52%, H 8.11%, N 3.52%; found: C 72.36%, H 8.52%, N 3.57%. 
 
(S)-tert-Butyl 2-{[di(furan-2-yl)phosphino]methyl}pyrrolidine-1-carboxylate ((S)-LC3) 
 
The synthesis was carried out in analogy to the preparation of (S)-LC3 using sodium 
(1.00 g, 43.5 mmol, 16 eq.), chlorodi(furan-2-yl)phosphine (49, 900 mg, 4.49 mmol, 
1.6 eq.), and (S)-tert-butyl-2-[(tosyloxy)methyl]pyrrolidine-1-carboxylate ((S)-47, 
836 mg, 2.81 mmol, 1.0 eq.). Column chromatography on silica gel (4 x 19 cm), eluting 
with dichloromethane (100%) yielded the title compound (S)-LC3 (561 mg, 1.61 mmol, 
57%), as a colorless solid. 
(S)-tert-butyl 2-[(tosyloxy)methyl]pyrrolidine-1-carboxylate ((S)-47),[76] was prepared 
according to the literature procedure and purified by column chromatography on silica 
gel, eluting with hexanes/ethyl acetate (7:3), Rf = 0.24). 
C18H24NO4P (349.36 g·mol−1): 
m.p. 111-113 °C. Rf = 0.43 (SiO2, CH2Cl2 100%). 1H NMR (400 MHz, CDCl3): 
δ = 7.61 (br s, 2 H, Fur/Fur’-5-H), 6.72 (m, 2 H, Fur/Fur’-3-H), 6.36 (m, 2 H,              
Fur/Fur’-4-H), 3.95-3.80 (br s, 1 H, Pyr-2-H), 3.40-3.22 (m, 2H, Pyr-5-H), 2.76 (“dt”, 
J = 13, 3.4 Hz, 1 H, CHH’P), 2.18 (“t”, J = 11 Hz, 1 H, CHH’P), 1.93-1.61 (m, 4 H,         
Pyr-H), 1.43 (s, 9 H, tBu-H) ppm. 13C{1H} NMR (101 MHz, CDCl3): δ = 154.4 (s, C=O), 
151.4 (“t”, 1JC,P = 16 Hz, Fur/Fur’-2-C), 147.1 (s, Fur/Fur’-5-CH), 120.2 (d, 2JC,P = 26 Hz, 
Fur/Fur’-3-CH), 110.8 (“t”, 3JC,P = 6.1 Hz, Fur/Fur’-4-CH), 79.3 (s, tBu-C), 55.3 (d, 
2JC,P = 22 Hz, Pyr-2-CH), 46.4 (s, Pyr-5-CH2), 31.0 (br s, Pyr-3-CH2), 28.7 (s, tBu-CH3), 
23.5 (s, Pyr-4-CH2) ppm. 31P{1H} NMR (162 MHz, CDCl3): δ = – 66.8 (s) ppm. 
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IR (KBr): ߥ෤ = 2927m, 2876m, 1676s, 1551w, 1455m, 1397s, 1365m, 1247w, 1175m, 
1119m, 1066w, 1002m, 953w, 904w, 876w cm−1. MS (EI, 70 eV): m/z (%) = 349 (6, M+), 
293 (21), 292 (56), 276 (23), 265 (35), 264 (14), 182 (14), 181 (46), 180 (28), 165 (66), 
150 (27), 136 (11), 128 (14), 114 (71), 109 (15), 84 (18), 83 (74), 81 (30), 70 (91), 
57 (100), 41 (23). [ߙ]஽ଶ଴ = – 31.6 (c = 1.00, CHCl3). Elemental analysis: calc. C 61.53%, 
H 7.46%, N 3.99%; found: C 61.79%, H 7.07%, N 3.74%. 
 
(S)-tert-Butyl 2-[(di-tert-butylphosphino)methyl]pyrrolidine-1-carboxylate borane 
adduct ((S)-LC4∙BH3) 
 
Di-tert-butylphosphine borane adduct (50∙BH3, 755 mg, 4.72 mmol, 1.1 eq.)[133] was 
dissolved in abs. tetrahydrofuran (15 mL) and cooled to – 78 °C, before a 1.6 M solution 
of n-butyllithium (2.95 mL, 4.72 mmol, 1.1 eq.) in hexanes was slowly added. The 
reaction mixture was then stirred for 20 minutes at – 78 °C and for 2 hours at room 
temperature. After cooling the solution again to – 78 °C, a solution of (S)-tert-butyl 2-
(bromomethyl)pyrrolidine-1-carboxylate ((S)-46, 1.13 g, 4.28 mmol, 1.0 eq.)[77] in abs. 
tetrahydrofuran (10 mL) was added via cannula. The reaction was monitored by 31P NMR 
analysis (the Rf-values of starting material and product are highly similar). The mixture 
was then stirred at – 78 °C for 1 hour before it was allowed to warm up to room 
temperature overnight. After completion of the reaction, the mixture was poured into 
aqueous saturated NaHCO3 (100 mL) and extracted with diethyl ether (3 x 200 mL). The 
combined organic extracts were dried over MgSO4 and the solvent was evaporated. 
Column chromatography on silica gel (4 x 18 cm), eluting with hexanes/ethyl acetate 
(19:1) afforded (S)-LC4∙BH3 (1.16 g, 3.38 mmol, 79%) as a colorless solid. 
C18H39BNO2P (343.29 g·mol−1): 
m.p. 140-142 °C. Rf = 0.17 (SiO2, hexanes/ethyl acetate 19:1). 1H NMR (400 MHz, 
CDCl3): δ = 4.13-4.05 (m, 1 H, Pyr-2-H), 3.42-3.26 (m, 2 H, Pyr-5-H2), 2.51-1.96 (m, 
3 H, CHH’P, Pyr-3-H2), 1.86-1.72 (m, 2 H, Pyr-4-H2), 1.54-1.40 (m, 1 H, CHH’P), 
                                                             
[133] For the synthesis of di-tert-butylphosphine borane adduct (50∙BH3) see: E. Neumann, Dissertation, 
University of Basel, 2006 pp.138-138; available from http://pages.unibas.ch/diss/2006/DissB_7467.htm. 
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1.45 (s, 9 H, OtBu-H), 1.35 (br d, 3JH,P = 12 Hz, 9 H, PtBu-H), 1.22 (d, 3JH,P = 13 Hz, 9 H, 
PtBu’-H), 0.89-0.05 (br m, 3 H, BH3) ppm. 13C{1H} NMR (101 MHz, CDCl3): 
δ = 154.4 (s, C=O), 79.6 (br s, OtBu-C), 55.4 (d, 2JC,P = 5.6 Hz, Pyr-2-CH), 46.7 (s,           
Pyr-5-CH2), 33.2 (d, 1JC,P = 27 Hz, PtBu-C), 32.1 (d, 1JC,P = 27 Hz, PtBu’-C), 31.9 (s,  
Pyr-3-CH2), 28.8 (s, OtBu-CH3), 28.3 (d, 2JC,P = 1.0 Hz, PtBu-CH3), 27.9 (d, 
2JC,P = 1.1 Hz, PtBu’-CH3), 23.1 (br s, Pyr-4-CH2), 22.1 (d, 1JC,P = 23 Hz, CH2P) ppm. 
31P{1H} NMR (162 MHz, CDCl3): δ = 39.6 (br d, 1JP,B = 67 Hz) ppm. IR (neat): 
ߥ෤ = 2966m, 2953m, 2873w, 2388w, 1682s, 1678m, 1645m, 1470m, 1386s, 1364m, 
1287w, 1161m, 1096s, 998s, 955m, 813s cm−1. MS (FAB, NBA): m/z (%) = 344 (10, 
[M + H]+), 342 (15), 330 (13), 287 (15), 286 (100), 285 (25), 240 (28), 216 (21), 57 (39). [ߙ]஽ଶ଴ = – 54.7 (c = 1.02, CHCl3). Elemental analysis: calc. C 62.98%, H 11.45%, 
N 4.08%; found: C 63.02%, H 11.19%, N 4.19%. 
 
(S)-tert-Butyl 2-[(di-tert-butylphosphino)methyl]pyrrolidine-1-carboxylate ((S)-LC4) 
 
Product (S)-LC4 was prepared according to general procedure 3 from (S)-LC4·BH3. 
C18H36NO2P (329.46 g·mol−1): 
31P{1H} NMR (162 MHz, CD2Cl2): δ = 20.8/20.1 (s) ppm. In the 31P NMR spectra the 
title compound can be seen as a mixture of rotamers in a ration close to 1:1. 
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(S)-tert-Butyl 2-[(dicyclohexylphosphino)methyl]pyrrolidine-1-carboxylate borane 
adduct ((S)-LC5∙BH3) 
 
The synthesis in analogy to the preparation of (S)-LC4∙BH3 using 
dicyclohexylphosphine borane adduct (51∙BH3, 1.59 g, 7.50 mmol, 1.1 eq.),[134] a 1.6 M 
solution of n-butyllithium (4.70 mL, 7.50 mmol, 1.1 eq.) in hexanes, and a solution of  
(S)-tert-butyl 2-(bromomethyl)pyrrolidine-1-carboxylate ((S)-46, 1.80 g, 6.81 mmol, 
1.0 eq.)[77] in abs. tetrahydrofuran allowed for the isolation of compound                       
(S)-LC5∙BH3 (1.46 g, 3.69 mmol, 54%) as a colorless solid. 
C22H43BNO2P (395.37 g·mol−1): 
m.p. 89-91 °C. Rf = 0.20 (SiO2, hexanes/ethyl acetate 19:1). 1H NMR (400 MHz, 
CDCl3): δ = 4.04 (br s, 1 H, Pyr-2-H), 3.32 (br s, 2 H, Pyr-5-H2), 2.40-1.17 (m, 37 H, 
CH2P, Cy-H, Pyr-H and tBu-H), 0.90-0.10 (br q, 3 H, BH3) ppm. 
13C{1H} NMR (101 MHz, CDCl3): δ = 154.3 (s, C=O), 79.3 (s, tBu-C), 53.8 (br d, 
2JC,P = 2.8 Hz, Pyr-2-CH), 46.4 (br s, Pyr-5-CH2), 34.5-33.5 (br m, Cy/Cy’-CH), 32.0 
(br s, Pyr-3-CH2), 28.7 (s, tBu-CH3), 28.4-26.0 (m, Cy/Cy’-CH2), 24.2-22.3 (m,              
Pyr-4-CH2 and CH2P) ppm. 31P{1H} NMR (162 MHz, CDCl3): δ = 21.2 (br d, 
1JP,B = 68 Hz) ppm. IR (neat): ߥ෤ = 2927m, 2853m, 2389w, 2352w, 2333w, 1684s, 1680s, 
1474w,1448m, 1388s, 1363m, 1355m, 1164m, 1105s, 1070m, 1082m, 1000m, 
813m cm−1. MS (FAB, NBA + KCl): m/z (%) = 434 (24, [M + K]+), 394 (23, [M – H]+), 
382 (19, [M – BH2]+), 339 (20), 338 (100), 292 (42), 291 (11), 242 (21), 192 (11), 
160 (13), 136 (12), 57 (22), 55 (14), 41 (12). [ߙ]஽ଶ଴ = – 33.5 (c = 1.04, CHCl3). Elemental 
analysis: calc. C 66.83%, H 10.96%, N 3.54%; found: C 66.82%, H 10.82%, N 3.66%. 
 
 
 
                                                             
[134] For the synthesis of dicyclohexylphosphine borane adduct (51∙BH3) see: C. A. Busacca, J. C. Lorenz, 
N. Grinberg, N. Haddad, H. Lee, Z. Li, M. Liang, D. Reeves, A. Saha, R. Varsolona, C. H. Senanayake, Org. 
Lett. 2008, 10, 341-344. 
CHAPTER 6 
 
182 
(S)-tert-Butyl 2-[(dicyclohexylphosphino)methyl]pyrrolidine-1-carboxylate ((S)-LC5) 
 
Product (S)-LC5 was prepared according to general procedure 3 from (S)-LC5·BH3. 
C22H40NO2P (381.53 g·mol−1): 
31P{1H} NMR (162 MHz, CD2Cl2): δ = − 11.4/ −11.6 (s) ppm. In the 31P NMR spectra 
the title compound can be seen as a mixture of rotamers in a ration close to 1:1. 
 
(S)-Adamantan-1-yl-2-[(diphenylphosphino)methyl]pyrrolidine-1-carboxylate       
((S)-LC6) 
 
Product (S)-LC6 (85%) was prepared according to general procedure 1 from (S)-LC1 
and 1-adamantyl chloroformate (54)[78] and isolated as a colorless semisolid. 
C28H34NO2P (447.55 g·mol−1): 
Rf = 0.27 (SiO2, hexanes/ethyl acetate 9:1). 1H NMR (400 MHz, CDCl3): δ = 8.04-
7.75 (m, 1 H, Ph-o-H), 7.75-7.19 (m, 9 H, Ph/Ph’-H), 4.10-3.79 (m, 1 H, Pyr-2-H), 3.46-
3.15 (m, 2 H, Pyr-5-H2), 2.96-2.64 (m, 1 H, CHH’P), 2.42-1.15 (m, 20 H, CHH’P, Pyr-H 
and Adm-H) ppm. 13C{1H} NMR (101 MHz, CDCl3): δ = 154.1 (s, C=O), 139.2-
138.9 (m, Ph-i-C), 138.2-137.3 (m, Ph’-i-C), 133.4-132.3 (m, Ph/Ph’-CH), 131.9-
130.3 (m, Ph/Ph’-CH), 129.1-128.3 (m, Ph/Ph’-CH), 78.9-78.6 (m, Adm-1-C), 
55.4/53.2* (br d, Pyr-2-CH), 46.8/46.2* (br s, Pyr-5-CH2), 42.0 (s, Adm-2/8/9-CH2), 
36.3 (s, Adm-4/6/10-CH2), 34.1/33.1* (br d, 1JC,P = 17 Hz, CH2P), 31.4/29.8* (br s,           
Pyr-3-CH2), 31.0 (s, Adm-3/5/7-CH), 23.9/23.1* (br s, Pyr-4-CH2) ppm. 31P{1H} NMR 
(162 MHz, CDCl3): δ = – 21.4/– 22.2* (s) ppm. In the 1H, 13C and 31P NMR spectra the 
title compound can be seen as a mixture of rotamers in a ratio close to 1:2 and therefore 
nuclei, which are detected twice are marked with an asterisk. IR (neat): ߥ෤ = 2918m, 
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2852m, 1727w, 1675s,1436m, 1393s, 1352m, 1298m, 1208m, 1187m, 1116s, 1056m, 
917w, 871w, 742m, 696m cm−1. MS (EI, 70 eV): m/z (%) = 447 (1, M+), 350 (11), 
312 (41), 285 (11), 284 (62), 211 (18), 201 (21), 183 (11), 136 (10), 135 (100), 93 (11). [ߙ]஽ଶ଴ = − 37.9 (c = 1.00, CHCl3). HRMS (ESI): calc. for C28H35NO2P ([M+H]+): 
448.2400; found: 448.2391. 
 
(S)-(9H-Fluoren-9-yl)methyl-2-[(diphenylphosphino)methyl]pyrrolidine-1-
carboxylate ((S)-LC7) 
 
Product (S)-LC7 (73%) was prepared according to general procedure 1 from (S)-LC1 
and 9-fluorenylmethyl chloroformate. 
C32H30NO2P (491.56 g·mol−1): 
m.p. 138-140 °C. Rf = 0.35 (SiO2, hexanes/ethyl acetate 8:2). 1H NMR (400 MHz, 
CD2Cl2): δ = 7.84-7.16 (m, 18 H, Ph/Ph’-H and Fl-H), 4.37-4.16 (m, 3 H, Fl-9-H and 
CH2O), 4.06-3.93 (m, 1 H, Pyr-2-H), 3.49-3.32 (m, 2 H, Pyr-5-H2), 2.95-2.82/2.65-
2.54* (m, 1 H, CHH’P), 2.22-1.73 (m, 5 H, CHH’P and Pyr-H) ppm. 13C{1H} NMR 
(101 MHz, CD2Cl2): δ = 154.5 (s, C=O), 144.4 (br s, Fl-8a/9a-C), 141.3 (br s,                 
Fl-4a/4b-C), 139.7-139.0 (m, Ph-i-C), 137.9 (d, 1JC,P = 14 Hz, Ph’-i-C), 132.9 (d, 
2JC,P = 19 Hz, Ph-o-CH), 132.7 (d, 2JC,P = 19 Hz, Ph’-o-CH), 128.8-128.2 (m,                
Ph/Ph’-CH), 127.6 (s, Fl-3/6-CH), 127.0 (br s, Fl-4/5-CH), 125.2 (br s, Fl-2/7-CH), 
119.9 (s, Fl-1/8-CH), 67.0/66.8* (s, CH2O), 56.0/55.4* (d, 2JC,P = 21 Hz, Pyr-2-CH), 
47.4 (s, Fl-9-CH), 46.9/46.5* (s, Pyr-5-CH2), 33.9/32.9* (d, 1JC,P = 15 Hz, CH2P), 
31.6/30.8* (d, 3JC,P = 8.1 Hz, Pyr-3-CH2), 24.0/23.2* (s, Pyr-4-CH2) ppm. 
31P{1H} NMR (162 MHz, CDCl3): δ = – 22.6/– 22.9* (s) ppm. In the 1H, 13C and 31P 
NMR spectra the title compound can be seen as a mixture of rotamers in a ratio close to 
2:3 and therefore nuclei, which are detected twice are marked with an asterisk. IR (neat): 
ߥ෤ = 3049w, 2960w, 2918w, 2903w, 2843w, 1674s, 1474m, 1417s, 1353m, 1332s, 1308m, 
1218w, 1191m, 1120s, 1101m, 1046w, 1025w, 996w, 970w, 916m, 822m, 746s, 
699s cm−1. MS (EI, 70 eV): m/z (%) = 491 (2, M+), 201 (17), 200 (88), 199 (29), 
CHAPTER 6 
 
184 
185 (14), 183 (20), 179 (32), 178 (100), 176 (14), 84 (13), 83 (15), 70 (66). [ߙ]஽ଶ଴ = – 75.5 
(c = 1.11, CHCl3). HRMS (ESI): calc. for C32H31NO2P ([M+H]+): 492.2087; found: 
492.2077. 
 
(S)-2,6-Dimethylphenyl-2-[(diphenylphosphino)methyl]pyrrolidine-1-
carboxylate ((S)-LC8) 
 
Product (S)-LC8 (80%) was prepared according to general procedure 1 from (S)-LC1 
and 2,6-dimethylphenyl chloroformate (56)[79] and isolated as a colorless semisolid. 
C26H28NO2P (417.48 g·mol−1): 
Rf = 0.40 (SiO2, hexanes/ethyl acetate 8:2). 1H NMR (400 MHz, CD2Cl2): δ = 7.63 (“t”, 
3JH,H = 7.3 Hz, 1 H, Ph-o-H), 7.52 (“t”, 3JH,H = 7.4 Hz, 1 H, Ph’-o-H), 7.43-7.26 (m, 7 H, 
Ph/Ph’-H), 7.26-7.21 (m, 1 H, Ph/Ph’-H), 7.08-6.95 (m, 3 H, Ar-H), 4.12-4.02 (m, 1 H, 
Pyr-2-H), 3.70-3.64 (m, 1 H, Pyr-5-HH’), 3.58-3.49 (m, 1 H, Pyr-5-HH’), 3.16-2.98 (m, 
1 H, CHH’P), 2.25-1.86 (m, 11 H, CHH’P, Pyr-H and Ar-CH3) ppm. 13C{1H} NMR 
(101 MHz, CDCl3): δ = 152.4/152.3* (s, C=O), 148.6/148.3* (s, Ar-i-C), 139.5-138.8 (m, 
Ph-i-C), 137.0-136.6 (m, Ph’-i-C), 133.4-132.2 (m, Ph-o-CH), 130.8 (br s, Ar-o-C), 
129.0-128.1 (m, Ph/Ph’-CH and Ar-m-CH), 125.4 (s, Ar-p-CH), 56.5-55.8 (m,                
Pyr-2-CH), 47.0* (s, Pyr-5-CH2), 34.5/32.8* (d, 1JC,P = 14 Hz, CH2P), 31.8/30.9* (d, 
3JC,P = 7.8 Hz, Pyr-3-CH2), 24.1/23.3* (s, Pyr-4-CH2), 16.5 (br s, Ar-CH3) ppm. 
31P{1H} NMR (162 MHz, CDCl3): δ = – 21.9/– 22.4* (s) ppm. In the 1H, 13C and 31P 
NMR spectra the title compound can be seen as a mixture of rotamers in a ratio close to 
1:1 and therefore nuclei, which are detected twice are marked with an asterisk. IR (neat): 
ߥ෤ = 3050m, 2971m, 2952m, 2874m, 1708s, 1695s, 1480m, 1432m, 1380s, 1336m, 
1266m, 1165s, 1095m, 1063m, 1026m, 918w, 869w, 848w, 767m, 739m, 697s cm−1. 
MS (EI, 70 eV): m/z (%) = 417 (23, M+), 297 (16), 296 (84), 218 (23), 200 (15), 199 (14), 
187 (13), 186 (18), 185 (100), 183 (57), 174 (20), 105 (13), 84 (14). [ߙ]஽ଶ଴ = − 113.8 
(c = 1.01, CHCl3). HRMS (ESI): calc. for C26H29NO2P ([M+H]+): 418.1930; found: 
418.1923. 
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6.3.2 
Amidophosphines (S)-LA and Precursors 
 
(S)-1-{2-[(Diphenylphosphino)methyl]pyrrolidin-1-yl}-2,2-dimethylpropan-1-
one ((S)-LA1) 
 
Product (S)-LA1 (98%) was prepared according to general procedure 1 from (S)-LC1 
and pivaloyl chloride. 
C22H28NOP (353.44 g·mol−1): 
m.p. 92-93 °C. Rf = 0.35 (SiO2, hexanes/ethyl acetate 9:1). 1H NMR (500 MHz, 
CD2Cl2): δ = 7.64 (“t”, J = 7.1 Hz, 2 H, Ph/Ph’-o-H), 7.41-7.26 (m, 8 H, Ph/Ph’-H), 4.22-
4.15 (m, 1 H, Pyr-2-H), 3.72-3.67 (m, 1 H, Pyr-5-HH’), 3.54-3.49 (m, 1 H, Pyr-5-HH’), 
2.90 (“br d”, J = 12 Hz, 1 H, CHH’P), 2.02-1.89 (m, 4 H, CHH’P, Pyr-4-HH’ and           
Pyr-3-H2), 1.83-1.74 (m, 1 H, Pyr-4-HH’), 1.18 (s, 9 H, tBu-H) ppm. 13C{1H} NMR 
(126 MHz, CD2Cl2): δ = 175.9 (s, C=O), 139.8 (d, 1JC,P = 15 Hz, Ph-i-C), 138.0 (d, 
1JC,P = 13 Hz, Ph’-i-C), 133.1 (d, 2JC,P = 19 Hz, Ph-o-CH), 132.7 (d, 2JC,P = 19 Hz,           
Ph’-o-CH), 128.6 (s, Ph-p-CH), 128.5-128.3 (m, Ph/Ph’-CH), 57.1 (d, 2JC,P = 18 Hz,          
Pyr-2-CH), 48.0 (s, Pyr-5-CH2), 39.0 (s, tBu-C), 32.5 (d, 1JC,P = 13 Hz, CH2P), 29.6 (d, 
3JC,P = 9.2 Hz, Pyr-3-CH2), 27.4 (s, tBu-CH3), 25.5 (s, Pyr-4-CH2) ppm. 31P{1H} NMR 
(162 MHz, CD2Cl2): δ = – 25.3 (s) ppm. IR (KBr): ߥ෤ = 3054m, 2957s, 2876s, 1615s, 
1476m, 1408s, 1372s, 1211m, 1160m, 1091m, 1026w, 995w, 921m, 836w, 785w, 747s, 
698s cm−1. MS (EI, 70 eV): m/z (%) = 353 (2, M+), 296 (13), 201 (28), 183 (23), 
152 (100), 121 (11), 84 (11), 69 (20), 57 (29). [ߙ]஽ଶ଴ = – 88.1 (c = 1.10, CHCl3). 
Elemental analysis: calc. C 74.76%, H 7.98%, N 3.96%; found: C 74.77%, H 7.85%, 
N 3.87%. 
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(S)-1-{2-[(Di-ortho-tolylphosphino)methyl]pyrrolidin-1-yl}-2,2-dimethylpropan-1-
one ((S)-LA2) 
 
Product (S)-LA2 (90%) was prepared according to general procedure 1 from (S)-LC2 
and pivaloyl chloride. 
C24H32NOP (381.49 g·mol−1): 
m.p. 110-112 °C. Rf = 0.48 (SiO2, hexanes/ethyl acetate 4:1). 1H NMR (400 MHz, 
CD2Cl2): δ = 7.93-7.82 (br s, 1 H, oTol-6-H), 7.33-7.23 (m, 2 H, oTol-4-H and oTol-5-H), 
7.20-7.13 (m, 3 H, oTol/oTol’-3-H and oTol’-4-H), 7.09-7.00 (m, 2 H, oTol’-5-H and 
oTol’-6-H), 4.25-4.17 (m, 1 H, Pyr-2-H), 3.72-3.66 (m, 1 H, Pyr-5-HH’), 3.57-3.50 (m, 
1 H, Pyr-5-HH’), 2.88-2.77 (m, 1 H, CHH’P), 2.50 (s, 3 H, oTol-CH3), 2.31 (s, 3 H, 
oTol’-CH3), 2.04-1.94 (m, 3 H, Pyr-3-H2 and Pyr-4-HH’), 1.87-1.77 (m, 1 H, Pyr-4-HH’), 
1.66 (“t”, J = 12 Hz, 1 H, CHH’P), 1.20 (s, 9 H, tBu-CH3) ppm. 13C{1H} NMR 
(101 MHz, CD2Cl2): δ = 176.0 (s, C=O), 142.2 (d, 2JC,P = 25 Hz, oTol-2-C), 141.7 (d, 
2JC,P = 27 Hz, oTol’-2-C), 137.6 (d, 1JC,P = 12 Hz, oTol-1-C), 136.1 (d, 1JC,P = 13 Hz, 
oTol’-1-C), 131.9 (s, oTol-6-CH), 131.8 (s, oTol’-6-CH), 130.0 (d, 3JC,P = 4.6 Hz,       
oTol-3-CH), 129.9 (d, 3JC,P = 5.0 Hz, oTol’-3-CH), 128.5 (s, oTol-4-CH), 128.4 (s,    
oTol’-4-CH), 126.2 (s, oTol-5-CH), 126.1 (s, Tol’-5-CH), 57.1 (d, 2JC,P = 21 Hz,             
Pyr-2-CH), 47.9 (s, Pyr-5-CH2), 39.0 (s, tBu-C), 31.4 (d, 1JC,P = 14 Hz, CH2P), 29.6 (d, 
3JC,P = 10 Hz, Pyr-3-CH2), 27.4 (s, tBu-CH3), 25.5 (d, 4JC,P = 4.2 Hz,  Pyr-4-CH2), 
21.1 (d, 3JC,P = 8.4 Hz, oTol-CH3), 20.8 (d, 3JC,P = 6.9 Hz, oTol’-CH3) ppm. 
31P{1H} NMR (162 MHz, CD2Cl2): δ = – 41.5 (s) ppm. IR (KBr): ߥ෤ = 3046w, 2965s, 
1613s, 1472m, 1460m, 1406s, 1373m, 1265w, 1225m, 1170m, 923w, 877w, 833w, 757s, 
724m cm−1. MS (EI, 70 eV): m/z (%) = 381 (5, M+), 229 (18), 213 (12), 153 (11), 
152 (100), 70 (14), 69 (16), 57 (30). [ߙ]஽ଶ଴ = – 106 (c = 0.980, CHCl3). Elemental 
analysis: calc. C 75.56%, H 8.45%, N 3.67%; found: C 75.41%, H 8.40%, N 3.55%. 
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(S)-1-(2-{[Di(furan-2-yl)phosphino]methyl}pyrrolidin-1-yl)-2,2-dimethylpropan-1-
one ((S)-LA3) 
 
Product (S)-LA3 (86%) was prepared according to general procedure 1 from (S)-LC3 
and pivaloyl chloride. 
C18H24NO3P (333.36 g·mol−1): 
m.p. 108-110 °C. Rf = 0.53 (SiO2, hexanes/ethyl acetate 7:3). 1H NMR (400 MHz, 
CDCl3): δ = 7.62-7.58 (m, 2 H, Fur/Fur’-5-H), 6.85-6.82 (m, 1 H, Fur-3-H), 6.73-6.70 (m, 
1 H, Fur’-3-H), 6.38-6.34 (m, 2 H, Fur/Fur’-4-H), 4.35-4.25 (m, 1 H, Pyr-2-H), 3.72-
3.64 (m, 1 H, Pyr-5-HH’), 3.53-3.43 (m, 1 H, Pyr-5-HH’), 2.82 (br d, J = 12 Hz, 1 H, 
CHH’P), 2.26 (dd, 2JH,P = 13 Hz, 2JH,H = 9.8 Hz, 1 H, CHH’P), 1.97-1.70 (m, 3 H,          
Pyr-H), 1.65-1.52 (m, 1 H, Pyr-H), 1.21 (s, 9 H, tBu-H) ppm. 13C{1H} NMR (101 MHz, 
CDCl3): δ = 1765 (s, C=O), 148.6 (d, 1JC,P = 7.8 Hz, Fur-2-C), 148.0 (d, 1JC,P = 7.7 Hz, 
Fur’-2-C), 147.0 (s, Fur-5-CH), 146.9 (s, Fur’-5-CH), 120.2 (d, 2JC,P = 24 Hz, Fur-3-CH), 
119.7 (d, 2JC,P = 18 Hz, Fur’-3-CH), 110.8 (d, 3JC,P = 2.7 Hz, Fur-4-CH), 110.7 (d, 
3JC,P = 3.6 Hz, Fur’-4-CH), 57.0 (d, 2JC,P = 25 Hz, Pyr-2-CH), 47.9 (s, Pyr-5-CH2), 
39.3 (s, tBu-C), 30.0 (s, Pyr-3-CH2), 29.4 (d, 1JC,P = 7.1 Hz, CH2P), 27.7 (s, tBu-CH3), 
25.6 (s, Pyr-4-CH2) ppm. 31P{1H} NMR (162 MHz, CD2Cl2): δ = – 70.5 (br) ppm. 
IR (KBr): ߥ෤ = 3114m, 2963s, 2924s, 2217w, 1735w, 1604s, 1460m, 1407s, 1367m, 
1258w, 1215w, 1156m, 1112w, 1066w, 1013m, 903w, 831w cm−1. MS (EI, 70 eV): 
m/z (%) = 333 (4, M+), 276 (29), 181 (18), 153 (11), 152 (100), 96 (10), 84 (17), 70 (19), 
69 (27), 57 (48), 41 (15). [ߙ]஽ଶ଴ = – 38.3 (c = 0.989, CHCl3). Elemental analysis: calc. 
C 64.85%, H 7.26%, N 4.20%; found: C 64.61%, H 7.34%, N 3.92%. 
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(S)-1-{2-[(Di-tert-butylphosphino)methyl]pyrrolidin-1-yl}-2,2-dimethylpropan-1-
one borane adduct ((S)-LA4∙BH3) 
 
Product (S)-LA4∙BH3 (24%) was prepared according to general procedure 2 from           
(S)-LC4∙BH3 and pivaloyl chloride. 
C18H39BNOP (327.29 g·mol−1): 
m.p. 99-103 °C. Rf = 0.21 (SiO2, hexanes/ethyl acetate 9:1). 1H NMR (400 MHz, 
CDCl3): δ = 4.40-4.32 (m, 1 H, Pyr-2-H), 3.70-3.64 (m, 1 H, Pyr-5-HH’), 3.58-3.52 (m, 
1 H, Pyr-5-HH’), 2.55 (“td”, J = 15, 2.5 Hz, 1 H, CHH’P), 2.20-2.09 (m, 1 H,                 
Pyr-3-HH’), 2.05-1.96 (m, 1 H, Pyr-3-HH’), 1.96-1.87 (m, 1 H, Pyr-4-HH’), 1.87-
1.77 (m, 1 H, Pyr-4-HH’), 1.40 (d, 3JH,P = 13 Hz, 9 H, PtBu-H), 1.36-1.28 (m, 1 H, 
CHH’P), 1.26 (s, 9 H, CtBu-H), 1.24 (d, 3JH,P = 12 Hz, 9 H, PtBu’-H), 0.94-0.05 (br q, 
3 H, BH3) ppm. 13C{1H} NMR (101 MHz, CDCl3): δ = 176.7 (s, C=O), 57.7 (d, 
2JC,P = 5.0 Hz, Pyr-2-CH), 48.0 (s, Pyr-5-CH2), 39.3 (s, CtBu-C), 33.2 (d, 1JC,P = 27 Hz, 
PtBu-C), 32.1 (d, 1JC,P = 28 Hz, PtBu’-C), 30.6 (s, Pyr-3-CH2), 28.3 (d, 2JC,P = 1.5 Hz, 
PtBu-CH3), 28.0 (d, 1JC,P = 1.2 Hz, PtBu’-CH3), 27.8 (s, CtBu-CH3), 25.3 (s, Pyr-4-CH2), 
21.7 (d, 1JC,P = 24 Hz, CH2P) ppm. 31P{1H} NMR (162 MHz, CDCl3): δ = 40.3 
(br d) ppm. IR (neat): ߥ෤ = 2967m, 2922m, 2874m, 2378m, 1611s, 1471m, 1404m, 1371s, 
1341w, 1208w, 1182w, 1149m, 1069m, 1021m, 929w, 885m, 816m cm−1. MS (FAB, 
NBA + KCl): m/z (%) = 366 (18, [M + K]+), 327 (11), 326 (42, [M –H]+), 314 (16, 
[M − BH2]+), 299 (15), 298 (70), 256 (35), 242 (24), 240 (37), 200 (16), 184 (14), 
128 (11), 57 (100), 41 (23). [ߙ]஽ଶ଴ = – 89.2 (c = 1.05, CHCl3). 
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(S)-1-{2-[(Di-tert-butylphosphino)methyl]pyrrolidin-1-yl}-2,2-dimethylpropan-1-
one ((S)-LA4) 
 
Product (S)-LC4 was prepared according to general procedure 3 from (S)-LC4·BH3. 
C18H36NOP (313.46 g·mol−1): 
31P{1H} NMR (162 MHz, CD2Cl2): δ = 22.2 (s) ppm. 
 
(S)-1-{2-[(Dicyclohexylphosphino)methyl]pyrrolidin-1-yl}-2,2-dimethylpropan-1-
one borane adduct ((S)-LA5∙BH3) 
 
Product (S)-LA5∙BH3 (67%) was prepared according to general procedure 2 from         
(S)-LC5∙BH3 and pivaloyl chloride. 
C22H43BNOP (379.37 g·mol−1): 
Rf = 0.16 (SiO2, hexanes/ethyl acetate 19:1). 1H NMR (400 MHz, CDCl3): δ = 4.35-
4.27 (m, 1 H, Pyr-2-H), 3.69-3.63 (m, 1 H, Pyr-5-HH’), 3.56-3.51 (m, 1 H, Pyr-5-HH’), 
2.39 (“t”, J = 14 Hz, 1 H, CHH’P), 2.09-1.90 (m, 5 H, Pyr-3-H2, Pyr-4-HH’ and             
Cy/Cy’-1-H), 1.89-1.78 (m, 7 H, Pyr-4-HH’ and Cy/Cy’-H), 1.75-1.66 (m, 4 H, Cy/Cy’-
H), 1.53-1.19 (m, 20 H, CHH’P, tBu-H and Cy/Cy’-H), 0.83-0.05 (br m, 3 H, BH3) ppm. 
13C{1H} NMR (101 MHz, CDCl3): δ = 176.5 (s, C=O), 56.3 (d, 2JC,P = 4.6 Hz,             
Pyr-2-CH), 47.9 (s, Pyr-5-CH2), 39.3 (s, tBu-C), 32.7 (d, 1JC,P = 32 Hz, Cy-1-CH), 
32.4 (d, 1JC,P = 35 Hz, Cy’-1-CH), 30.4 (s, Pyr-3-CH2), 27.7 (s, tBu-CH3), 27.3 (d, 
2JC,P = 5.5 Hz, Cy/Cy’-CH2), 27.2 (d, 2JC,P = 5.5 Hz, Cy/Cy’-CH2), 27.0 (s, Cy/Cy’-CH2), 
26.9-26.8 (m, 2 Cy/Cy’-CH2), 26.7 (s, Cy/Cy’-CH2), 26.6 (br s, Cy/Cy’-CH2), 26.4 (br s, 
Cy/Cy’-CH2), 26.2 (br s, Cy/Cy’-CH2), 26.1 (br s, Cy/Cy’-CH2), 25.4 (s, Pyr-4-CH2), 
24.0 (d, 1JC,P = 27 Hz, CH2P) ppm. 31P{1H} NMR (162 MHz, CDCl3): δ = 21.5 
(br d) ppm. IR (neat): ߥ෤ = 2928s, 2852s, 1716m, 1616s, 1581m, 1477m, 1448m, 1402s, 
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1361s, 1205w, 1159m, 1142m, 1064m, 1004m, 923w, 854m cm−1. MS (FAB, 
NBA + KCl): m/z (%) = 418 (24, [M + K]+), 379 (16), 378 (61, [M –H]+), 366 (28, 
[M − BH2]+), 351 (24), 350 (100), 294 (14), 282 (34), 200 (11), 115 (13), 83 (11), 
57 (53), 55 (20), 41 (19). [ߙ]஽ଶ଴ = – 51.5 (c = 0.862, CHCl3). 
 
(S)-1-{2-[(Dicyclohexylphosphino)methyl]pyrrolidin-1-yl}-2,2-dimethylpropan-1-
one ((S)-LA5) 
 
Product (S)-LC5 was prepared according to general procedure 3 from (S)-LC5·BH3. 
C22H40NOP (365.53 g·mol−1): 
31P{1H} NMR (162 MHz, CD2Cl2): δ = −10.4 (s) ppm. 
 
(S)-1-{2-[(Diphenylphosphino)methyl]pyrrolidin-1-yl}-3,3-dimethylbutan-1-one            
((S)-LA6) 
 
Product (S)-LA6 (26%) was prepared according to general procedure 1 from (S)-LC1 
and 3,3-dimethylbutanoyl chloride. 
C23H30NOP (367.46 g·mol−1): 
m.p. 80-84 °C. Rf = 0.31 (SiO2, cyclohexane/ethyl acetate 8:2). 1H NMR (500 MHz, 
CDCl2): δ = 8.11-7.22 (m, 10 H, Ph/Ph’-H), 4.39-4.15 (m, 1 H, Pyr-2-H), 3.57-3.32 (m, 
2 H, Pyr-5-H2), 2.44-1.74 (m, 8 H, CH2P, CH2 and Pyr-H), 1.13-0.71 (m, 9 H,             
tBu-H3) ppm. 13C{1H} NMR (126 MHz, CDCl3): δ = 171.1-170.8 (br s, C=O), 137.9-
137.5 (m, Ph-i-C), 135.6-135.3 (m, Ph’-i-C), 133.9-132.8 (m, Ph/Ph’-CH), 131.9-
130.4 (m, Ph/Ph’-CH), 129.3-128.4 (m, Ph/Ph’-CH), 55.3-55.0 (br d, Pyr-2-CH), 48.3-
47.9 (br d, Pyr-5-CH2), 47.2 (br s, CH2), 34.7-34.4 (br s, tBu-C), 31.8-31.4 (m, CH2P), 
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30.4-29.8 (m, Pyr-3-CH2 and tBu-CH3), 24.5 (s, Pyr-4-CH2) ppm. 31P{1H} NMR 
(162 MHz, CDCl3): δ = − 25.3 (s) ppm. IR (neat): ߥ෤ = 2958m, 2933m, 2867m, 1622s, 
1463w, 1434m, 1413m, 1394m, 1211m, 1190m, 1120w, 995w, 796w, 742m  cm−1. 
MS (EI, 70 eV): m/z (%) = 368 (10, [M + H]+), 285 (18), 284 (100), 217 (15), 215 (25), 
202 (27), 201 (29), 182 (22), 166 (23), 84 (56), 83 (10), 70 (16). [ߙ]஽ଶ଴ = – 22.9 
(c = 0.830, CHCl3). 
 
Adamantan-1-yl {(S)-2-[(diphenylphosphino)methyl]pyrrolidin-1-yl}methanone    
((S)-LA7) 
 
Product (S)-LA7 (96%) was prepared according to general procedure 1 from (S)-Lc1 
and 1-adamantanecarbonyl chloride. 
C28H34NOP (431.55 g·mol−1): 
m.p. 118-120 °C. Rf = 0.49 (SiO2, hexanes/ethyl acetate 4:1). 1H NMR (400 MHz, 
CDCl3): δ = 7.66-7.60 (m, 2 H, Ph/Ph’-H), 7.42-7.26 (m, 8 H, Ph/Ph’-H), 4.36-4.27 (m, 
1 H, Pyr-2-H), 3.89-3.78 (m, 1 H, Pyr-5-HH’), 3.59-3.49 (m, 1 H, Pyr-5-HH’), 2.99-
2.82 (m, 1 H, CHH’P), 2.05-1.81 (m, 13 H, CHH’P, Pyr-4-HH’, Pyr-3-H2 and Adm-H), 
1.80-1.54 (m, 7 H, Pyr-4-HH’ and Adm-H) ppm. 13C{1H} NMR (101 MHz, CDCl3): 
δ = 175.9 (s, C=O), 140.7 (br d, 1JC,P = 15 Hz, Ph-i-C), 137.6 (d, 1JC,P = 12 Hz, Ph’-i-C), 
133.2 (d, 2JC,P = 19 Hz, Ph-o-CH), 132.9 (d, 2JC,P = 20 Hz, Ph’-o-CH), 128.7 (s,                   
Ph-p-CH), 128.7 (d, 3JC,P = 6.9 Hz, Ph-m-CH), 128.6 (s, Ph’-p-CH), 128.5 (d, 
3JC,P = 6.9 Hz, Ph’-m-CH), 57.3 (br d, 2JC,P = 19 Hz, Pyr-2-CH), 48. (br s, Pyr-5-CH2), 
42.0 (s, Adm-1-C), 38.3 (s, Adm-2/8/10-CH2), 36.8 (s, Adm-4/6/9-CH2), 32.8 (d, 
1JC,P = 13 Hz, CH2P), 29.5 (br d, 3JC,P = 10 Hz, Pyr-3-CH2), 28.5 (s, Adm-3/5/7-CH), 
25.9 (s, Pyr-4-CH2) ppm. 31P{1H} NMR (162 MHz, CD2Cl2): δ = − 25.1 (s) ppm. 
IR (KBr): ߥ෤ =  2909m, 2850m, 1689m, 1608s, 1393s, 1166m, 1107m, 749m cm−1. 
MS (EI, 70 eV): m/z (%) = 431 (3, M+), 231 (15), 230 (100), 201 (13), 135 (48), 79 (8). [ߙ]஽ଶ଴ = – 32.0 (c = 1.42, CHCl3). 
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Adamantan-1-yl {(S)-2-[(di-ortho-tolylphosphino)methyl]pyrrolidin-1-yl}methanone 
((S)-LA8) 
 
Product (S)-LA8 (83%) was prepared according to general procedure 1 from (S)-LC2 
and 1-adamantanecarbonyl chloride. 
C30H38NOP (459.60 g·mol−1): 
m.p. 145-147 °C. Rf = 0.47 (SiO2, hexanes/ethyl acetate 4:1). 1H NMR (500 MHz, 
CDCl3): δ = 7.99-7.82 (m, 1 H, oTol-3-H), 7.40-7.29 (m, 1 H, oTol-5-H), 7.24 (“t”, 
2JH,H = 7.4 Hz, 1 H, oTol-4-H), 7.22-7.10 (m, 3 H, oTol’-4-H and oTol/oTol’-6-H), 7.09-
6.95 (m, 2 H, oTol’-3-H and oTol’-5-H), 4.40-4.30 (m, 1 H, Pyr-2-H), 3.89-3.78 (m, 1 H, 
Pyr-5-HH’), 3.63-3.52 (m, 1 H, Pyr-5-HH’), 2.96-2.79 (m, 1 H, CHH’P), 2.53 (br s, 3 H, 
oTol-CH3), 2.30 (br s, 3 H, oTol’-CH3), 2.07-1.52 (m, 20 H, CHH’P, Pyr-H and               
Adm-H) ppm. 13C{1H} NMR (101 MHz, CDCl3): δ = 175.9 (s, C=O), 142.2-141.6 (m, 
oTol-2-C), 141.6 (d, 2JC,P = 27 Hz, oTol’-2-C), 137.4 (d, 1JC,P = 12 Hz, oTol-1-C), 
135.7 (d, 1JC,P = 13 Hz, oTol’-1-C), 132.5-131.6 (m, oTol/oTol’-3-CH), 130.1-129.9 (m, 
oTol/oTol’-6-CH),128.5 (br s, oTol/oTol’-4-CH), 126.7 (s, oTol-5-CH), 126.2 (s,            
oTol’-5-CH), 57.6-57.0 (m, Pyr-2-CH), 48.0 (br s, Pyr-5-CH2), 42.1 (s, Adm-1-C), 
38.4 (s, Adm-2/8/9-CH2), 36.8 (s, Adm-4/6/10-CH2), 31.5-31.2 (m, CH2P), 29.7-29.3 (m, 
Pyr-3-CH2), 28.6 (s, Adm-3/5/7-CH), 26.0 (br s, Pyr-4-CH2), 21.4 (d, 3JC,P = 10 Hz,         
oTol-CH3), 21.2 (d, 3JC,P = 12 Hz, oTol’-CH3) ppm. 31P{1H} NMR (162 MHz, CD2Cl2): 
δ = − 41.0 (s) ppm. IR (neat): ߥ෤ = 2902m, 2853m, 1693w, 1605s, 1450m, 1381s, 1310w, 
1200w, 1161w, 1034w, 878w, 755s cm−1. MS (EI, 70 eV): m/z (%) = 459 (3, M+), 
231 (18), 230 (100), 229 (13), 135 (38). [ߙ]஽ଶ଴ = – 48.4 (c = 0.520, CHCl3). HRMS (ESI): 
calc. for C30H39NOP ([M + H]+): 460.2764; found: 460.2747. 
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Adamantan-1-yl ((S)-2-{[di(furan-2-yl)phosphine]methyl}pyrrolidin-1-yl)methanone 
((S)-LA9) 
 
Product (S)-LA9 (61%) was prepared according to general procedure 1 from (S)-LC3 
and 1-adamantanecarbonyl chloride. 
C24H30NO3P (411.47 g·mol−1): 
m.p. 127-129 °C. Rf = 0.43 (SiO2, dichloromethane/ethyl acetate 200:1). 1H NMR 
(400 MHz, CD2Cl2): δ = 7.63 (‟dd”, 3JH,H = 4.2 Hz, J = 1.7 Hz, 2 H, Fur/Fur’-5-H), 6.89-
6.86 (m, 1 H, Fur-3-H), 6.74-6.71 (m, 1 H, Fur’-3-H), 6.43-6.40 (m, 1 H, Fur-4-H), 6.40-
6.38 (m, 1 H, Fur’-4-H), 4.25-4.13 (m, 1 H, Pyr-2-H), 3.82-3.71 (m, 1 H, Pyr-5-HH’), 
3.57-3.47 (m, 1 H, Pyr-5-HH’), 2.82-2.73 (m, 1 H, CHH’P), 2.10 (ddd, 2JH,P = 13 Hz, 
2JH,H = 10 Hz, 3JH,H = 1.0 Hz, 1 H, CHH’P), 1.99 (br s, 3 H, Adm-3/5/7-H), 1.96-1.57 (m, 
16 H, Pyr-H and Adm-H) ppm. 13C{1H} NMR (101 MHz, CD2Cl2): δ = 175.4 (s, C=O), 
151.8-151.5 (br d, Fur-2-C), 151.1-150.7 (br d, Fur’-2-C), 146.9 (br s, Fur/Fur’-5-CH), 
120.0 (s, Fur-3-CH), 119.8 (s, Fur’-3-CH), 110.7 (s, Fur-4-CH), 110.7 (Fur’-4-CH), 57.1-
56.3 (br m, Pyr-2-CH), 47.9 (s, Pyr-5-CH2), 41.9 (s, Adm-1-C), 38.3 (s, Adm-2/8/9-CH2), 
36.7 (s, Adm-4/6/10-CH2), 30.0-29.8 (br d, CH2P), 29.0 (br s, Pyr-3-CH2), 28.7 (s,            
Adm-3/5/7-CH), 25.8-25.4 (br s, Pyr-4-CH2) ppm. 31P NMR (162 MHz, CD2Cl2): 
δ = − 70.0 (br d) ppm. IR (KBr): ߥ෤ = 2919m, 2847m, 1690m, 1608s, 1393s, 1166m, 
1160m, 1013s cm−1. MS (EI, 70 eV): m/z (%) = 411 (8, M+), 231 (15), 230 (100), 
135 (64). [ߙ]஽ଶ଴ = –51.2 (c = 1.00, CHCl3). 
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Adamantan-1-yl {(S)-2-[(di-tert-butylphosphino)methyl]pyrrolidin-1-yl}methanone 
borane adduct ((S)-LA10·BH3) 
 
Product (S)-LA10·BH3 (43%) was prepared according to general procedure 2 from     
(S)-LC4∙BH3 and 1-adamantanecarbonyl chloride. 
C24H45BNOP (405.40 g·mol−1): 
m.p. 201-203 °C. Rf = 0.32 (hexanes/ethyl acetate 9:1). 1H NMR (400 MHz, CDCl3): 
δ = 4.40-4.32 (m, 1 H, Pyr-2-H), 3.83-3.75 (m, 1 H, Pyr-5-HH’), 3.65-3.57 (m, 1 H,             
Pyr-5-HH’), 2.53 (“td”, J = 14, 2.0 Hz, 1 H, CHH’P), 2.19-2.09 (m, 1 H, Pyr-3-HH’), 
2.03 (“br d”, 3 H, Adm-3/5/7-H), 1.99 (br s, 6 H, Adm-2/8/10-H2), 1.99-1.86 (m, 2 H, 
Pyr-3-HH’ and Pyr-4-HH’), 1.85-1.77 (m, 1 H, Pyr-4-HH’), 1.72 (br s, 6 H,                     
Adm-4/6/9-H2), 1.40 (d, 3JH,P = 13 Hz, 9 H, tBu-H), 1.35-1.25 (m, 1 H, CHH’P), 1.23 (d, 
3JH,P = 12 Hz, 9 H, tBu’-H), 0.83-0.08 (br q, 3 H, BH3) ppm. 13C{1H} NMR (101 MHz, 
CDCl3): δ = 176.2 (s, C=O), 57.9 (d, 2JC,P = 5.4 Hz, Pyr-2-CH), 48.0 (s, Pyr-5-CH2), 
42.2 (s, Adm-1-C), 38.4 (s, Adm-2/8/10-CH2), 36.8 (s, Adm-4/6/9-CH2), 33.2 (d, 
1JC,P = 27 Hz, tBu-C), 32.6 (d, 1JC,P = 28 Hz, tBu’-C), 30.4 (s, Pyr-3-CH2), 28.5 (s, Adm-
3/5/7-CH), 28.3 (d, 2JC,P = 1.5 Hz, tBu-CH3), 28.0 (d, 2JC,P = 1.2 Hz, tBu’-CH3), 25.6 (s, 
Pyr-4-CH2), 21.9 (d, 1JC,P = 24 Hz, CH2P) ppm. 31P{1H} NMR (162 MHz, CDCl3): 
δ = 40.3 (br s) ppm. IR (neat): ߥ෤ = 2902m, 2870m, 2851m, 2378m, 2358m, 1689m, 
1600s, 1468w, 1451w, 1386s, 1366m, 1347w, 1069m, 1023w, 925w, 879w, 815m, 666m, 
623m cm−1. MS (FAB, NBS + KCl): m/z (%) = 444 (28, [M + K]+), 406 (19), 405 (27), 
404 (90, [M – H]+), 403 (24), 392 (34, [M – BH2]+), 377 (27), 376 (98), 334 (36), 
320 (20), 278 (19), 270 (12), 242 (27), 241 (15), 240 (61), 184 (15), 135 (100), 128 (17), 
93 (18), 91 (16), 79 (19), 67 (10), 57 (72), 41 (21). [ߙ]஽ଶ଴ = – 55.5 (c = 0.500, CHCl3). 
Elemental analysis: calc. C 71.10%, H 11.19%, N 3.46%; found: C 71.06%, H 11.01%, 
N 3.38%. 
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Adamantan-1-yl {(S)-2-[(di-tert-butylphosphino)methyl]pyrrolidin-1-yl}methanone 
((S)-LA10) 
 
Product (S)-LA10 was prepared according to general procedure 3 from (S)-LA10·BH3. 
C24H42NOP (391.57 g·mol−1): 
31P{1H} NMR (162 MHz, CD2Cl2): δ = 22.2 (s) ppm. 
 
Adamantan-1-yl {(S)-2-[(dicyclohexylphosphino)methyl]pyrrolidin-1-yl}methanone 
borane adduct ((S)-LA11·BH3) 
 
Product (S)-LA11·BH3 (83%), isolated as a colorless semisolid, was prepared according 
to general procedure 2 from (S)-LC5∙BH3 and 1-adamantanecarbonyl chloride. 
C28H49BNOP (457.48 g·mol−1): 
Rf = 0.10 (SiO2, hexanes/ethyl acetate 19:1). 1H NMR (400 MHz, CDCl3): δ = 4.37-
4.26 (m, 1 H, Pyr-2-H), 3.81-3.73 (m, 1 H, Pyr-5-HH’), 3.63-3.54 (m, 1 H, Pyr-5-HH’), 
2.37 (“t”, J = 15 Hz, 1 H, CHH’P), 2.09-1.62 (m, 29 H), 1.56-1.16 (m, 13 H), 0.82-
0.02 (br q, 3 H, BH3) ppm. 13C{1H} NMR (126 MHz, CDCl3): δ = 176.0 (s, C=O), 
56.4 (br d, 2JC,P = 2.7 Hz, Pyr-2-CH), 46.9 (s, Pyr-5-CH2), 42.1 (s, Adm-1-C), 38.3 (s, 
Adm-2/8/10-CH2), 36.8 (s, Adm-4/6/9-CH2), 32.6 (d, 1JC,P = 32 Hz, Cy-1-CH), 32.4 (d, 
1JC,P = 37 Hz, Cy’-1-CH), 30.1 (s, Pyr-3-CH2), 28.5 (s, Adm-3/5/7-CH), 27.3-26.8 (m, 
Cy/Cy’-CH2), 25.9 (br s, Pyr-4-CH2), 24.1 (d, 1JC,P = 27 Hz, CH2P) ppm. 31P{1H} NMR 
(202 MHz, CDCl3): δ = 21.4 (br s) ppm. IR (neat): ߥ෤ = 2903s, 2861s, 2374m, 1614s, 
1455m, 1377m, 1061m, 1010w, 880m cm−1. MS (FAB, NBA): m/z (%) = 457 (25), 
456 (76, [M – H]+), 455 (18), 444 (29, [M – BH2]+), 429 (30), 428 (100), 426 (12), 
360 (35), 338 (26), 337 (10), 322 (11), 294 (28), 293 (21), 292 (75), 291 (19), 278 (12), 
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230 (14), 147 (12), 135 (86), 115 (21), 107 (10), 97 (12), 95 (15), 93 (24), 91 (22), 
83 (31), 81 (42), 79 (29), 77 (10), 73 (26), 71 (12), 69 (31), 67 (27), 57 (37), 55 (66), 
43 (34), 41 (42). [ߙ]஽ଶ଴ = – 14.7 (c = 0.692, CHCl3). Elemental analysis: calc. C 73.51%, 
H 10.80%, N 3.06%; found: C 73.78%, H 10.60%, N 2.86%.  
 
Adamantan-1-yl {(S)-2-[(dicyclohexylphosphino)methyl]pyrrolidin-1-yl}methanone 
((S)-LA11) 
 
Product (S)-LA11 was prepared according to general procedure 3 from (S)-LA11·BH3. 
C28H46NOP (443.64 g·mol−1): 
31P{1H} NMR (162 MHz, CD2Cl2): δ = – 10.3 (br) ppm. 
 
2-(Adamantan-1-yl)-1-{(S)-2-[(diphenylphosphino)methyl]pyrrolidin-1-yl}ethanone 
((S)-LA12) 
 
Compound (S)-LA12 (48%) was prepared according to general procedure 1 from         
(S)-LC1 and 2-(adamantan-1-yl)acetyl chloride (60, prepared according to general 
procedure 4) and isolated as a colorless semisolid. 
C29H36NOP (445.58 g·mol−1): 
Rf = 0.20 (SiO2, hexanes/ethyl acetate 8:2). 1H NMR (400 MHz, CDCl3): δ = 7.71-
7.62 (m, 1 H, Ph/Ph’-H), 7.57-7.45 (m, 1 H, Ph/Ph’-H), 7.45-7.22 (m, 8 H, Ph/Ph’-H), 
4.37-4.21/3.86-3.66* (m, 1 H, Pyr-2-H); 3.53-3.41 (m, 2 H, Pyr-5-H), 3.41-3.27/3.08-
2.91* (m, 1 H, CHH’P), 2.34-1.24 (m, 22 H, CHH’P, CH2, Pyr-H and Adm-H) ppm. 
13C{1H} NMR (101 MHz, CDCl3): δ = 170.1/169.7* (s, C=O), 139.5-138.8* (m, Ph-i-C), 
137.7-136.9* (m, Ph’-i-C), 133.9* (d, 2JC,P = 20 Hz, Ph-o-CH), 133.2-132.7* (m,             
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Ph/Ph’-CH), 132.1* (d, 2JC,P = 18 Hz, Ph’-o-CH), 129.4-128.1 (m, Ph/Ph’-CH), 
55.8/55.4* (d, 2JC,P = 20 Hz, Pyr-2-CH), 48.7 (s, CH2), 48.4/47.9* (s, Pyr-5-CH2), 
42.9/42.6* (s, Adm-2/8/9-CH2), 37.0/36.9* (s, Adm-4/6/10-CH2), 34.0-32.3* (m, CH2P 
and Adm-1-C), 31.1-30.3* (m, Pyr-3-CH2), 28.6 (br s, Adm-3/5/7-CH), 24.6 (br s,           
Pyr-4-CH2) ppm. 31P{1H} NMR (162 MHz, CDCl3): δ = – 24.6/– 24.9* (s) ppm. In the 
1H, 13C and 31P NMR spectra the title compound can be seen as a mixture of rotamers in a 
ratio close to 2:3 and therefore nuclei, which are detected twice are marked with an 
asterisk. IR (KBr): ߥ෤ = 2897s, 2845m, 1622s, 1446w, 1433m, 1407s, 1360m, 1345w, 
1313w, 1244w, 1183m, 1120w, 1102m, 1095m, 1027w, 987w, 917w, 878w, 790w, 738s, 
693s cm−1. MS (EI, 70 eV): m/z (%) = 445 (3, M+), 284 (18), 245 (18), 244 (100), 
243 (15), 201 (13), 135 (21), 70 (13), 69 (13). [ߙ]஽ଶ଴ = – 21.7 (c = 0.660, CHCl3). 
 
(S)-1-{2-[(Diphenylphosphino)methyl]pyrrolidin-1-yl}-2,2,2-triphenylethanone      
((S)-LA13) 
 
Product (S)-LA13 (96%) was prepared according to general procedure 1 from (S)-LC1 
and 2,2,2-triphenylacetyl chloride (prepared according to general procedure 4). 
C37H34NOP (539.65 g·mol−1): 
m.p. 105-107 °C. Rf = 0.28 (SiO2, hexanes/ethyl acetate 9:1). 1H NMR (500 MHz, 
CDCl3): δ = 7.65 (“t”, J = 7.9 Hz, 2 H, PPh-o-H), 7.41-7.30 (m, 5 H, PPh’-o-H and 
PPh/Ph’-H), 7.29-7.23 (m, 9 H, PPh/Ph’-H, and CPh-m-H), 7.22-7.16 (m, 9 H,                  
CPh-o/p-H), 4.47-4.38 (m, 1 H, Pyr-2-H), 3.34 (“dt”, J = 13, 4.3 Hz, 1 H, CHH’P), 3.00-
2.94 (m, 1 H, Pyr-5-HH’), 2.16-2.10 (m, 1 H, Pyr-5-HH’), 2.02-1.95 (m, 1 H,                  
Pyr-3-HH’), 1.83-1.77 (m, 1 H, CHH’P), 1.71-1.63 (m, 1 H, Pyr-3-HH’), 1.56-1.48 (m, 
1 H, Pyr-4-HH’), 1.40-1.30 (m, 1 H, Pyr-4-HH’) ppm. 13C{1H} NMR (126 MHz, CDCl3): 
δ = 171.0 (s, C=O), 143.0 (s, CPh-i-C), 139.5 (d, 1JC,P = 12 Hz, PPh-i-C), 137.2 (d, 
1JC,P = 13 Hz, PPh’-i-C), 133.3 (d, 2JC,P = 19 Hz, PPh-o-CH), 132.9 (d, 2JC,P = 19 Hz, 
PPh’-o-CH), 130.5 (s, CPh-m-CH), 128.7 (d, 3JC,P = 9.2 Hz, PPh-m-CH), 128.6 (d, 
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3JC,P = 7.3 Hz, PPh’-m-CH), 128.5 (s, PPh-p-CH), 128.4 (s, PPh’-p-CH), 127.8 (s,            
CPh-o-CH), 126.6 (s, CPh-p-CH), 68.0 (s, CPh3), 57.5 (d, 2JC,P = 20 Hz, Pyr-2-CH), 
48.6 (s, Pyr-5-CH2), 32.2 (d, 1JC,P = 15 Hz, CH2P), 30.6 (d, 3JC,P = 10 Hz, Pyr-3-CH2), 
25.1 (s, Pyr-4-CH2) ppm. 31P{1H} NMR (202 MHz, CDCl3): δ = – 21.1 (s) ppm. 
IR (neat): ߥ෤ = 3053m, 2924s, 2850m, 1626s, 1599w, 1489m, 1445m, 1433m, 1381s, 
1205w, 1180w, 1157m, 1086m, 1034w, 999w, 837m, 737s, 694s, 640m cm−1. MS (EI, 
70 eV): m/z (%) = 539 (5, M+), 338 (24), 337 (25), 244 (20), 243 (100), 165 (18). [ߙ]஽ଶ଴ = – 57.2 (c = 0.620, CHCl3). Elemental analysis: calc. C 82.35%, H 6.35%, 
N 2.60%; found: C 82.27%, H 7.36%, N 2.54%. 
 
(S)-1-{2-[(Di-ortho-tolylphosphino)methyl]pyrrolidin-1-yl}-2,2,2-triphenylethanone 
((S)-LA14) 
 
Product (S)-LA14 (67%) was prepared according to general procedure 1 from (S)-LC2 
and 2,2,2-triphenylacetyl chloride (prepared according to general procedure 4). 
C39H38NOP (567.70 g·mol−1): 
m.p. 92-95 °C. Rf = 0.39 (SiO2, hexanes/ethyl acetate 9:1). 1H NMR (500 MHz, CDCl3): 
δ = 7.91-7.88 (m, 1 H, oTol-3-H), 7.33-7.29 (m, 1 H, oTol-6-H), 7.27-7.11 (m, 18 H, 
oTol/oTol’-H and Ph-H), 7.06-7.03 (m, 2 H, oTol’-3-H and oTol’-5-H), 6.95 (d, 
3JH,P = 6.7 Hz, 1 H, oTol’-6-H), 4.49-4.42 (m, 1 H, Pyr-2-H), 3.22 (“dt”, J = 14, 3.8 Hz, 
1 H, CHH’P), 2.95-2.90 (m, 1 H, Pyr-5-HH’), 2.52 (s, 3 H, oTol-CH3), 2.30 (s, 3 H, 
oTol’-CH3), 2.19-2.14 (m, 1 H, Pyr-5-HH’), 2.05-1.98 (m, 1 H, Pyr-3-HH’), 1.78-
1.71 (m, 1 H, Pyr-3-HH’), 1.62 (“td”, J = 13, 2.8 Hz, 1 H, CHH’P), 1.57-1.50 (m, 1 H, 
Pyr-4-HH’), 1.42-1.33 (m, 1 H, Pyr-4-HH’) ppm. 13C{1H} NMR (126 MHz, CDCl3): 
δ = 171.0 (s, C=O), 143.1 (s, Ph-i-C), 142.1 (d, 2JC,P = 26 Hz, oTol-2-C), 141.8 (d, 
2JC,P = 27 Hz, oTol’-2-C), 137.3 (d, 1JC,P = 13 Hz, oTol-1-C), 135.5 (d, 1JC,P = 12 Hz, 
oTol’-1-C), 132.4 (s, oTol-3-CH), 132.1 (s, oTol’-3-CH), 130.6 (s, Ph-m-CH), 130.0-
129.8 (m, oTol/oTol’-6-CH), 128.5 (s, oTol-4-CH), 128.4 (s, oTol’-4-CH), 127.8 (s,           
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Ph-o-CH), 126.6 (s, Ph-p-CH), 126.6 (s, oTol-5-CH), 126.1 (s, oTol’-5-CH), 68.0 (s, 
CPh3), 57.2 (d, 2JC,P = 22 Hz, Pyr-2-CH), 48.4 (s, Pyr-5-CH2), 31.0 (d, 1JC,P = 14 Hz, 
CH2P), 30.7 (d, 3JC,P = 9.6 Hz, Pyr-3-CH2), 25.0 (d, 4JC,P = 1.1 Hz, Pyr-4-CH2), 21.1 (d, 
3JC,P = 6.5 Hz, oTol-CH3), 20.9 (d, 3JC,P = 5.8 Hz, oTol’-CH3) ppm. 31P{1H} NMR 
(162 MHz, CD2Cl2): δ = – 42.4 (s) ppm. IR (neat): ߥ෤ = 2943w, 911w, 1625s, 1595m, 
1491m, 1443s, 1387m, 1178w, 1157m, 1136w, 1031m, 924w, 899w, 871, 740s, 697s, 
641m cm−1. MS (EI, 70 eV): m/z (%) = 567 (4, M+), 338 (23), 337 (23), 244 (21), 
243 (100), 229 (11), 165 (19). [ߙ]஽ଶ଴ = – 36.9 (c = 0.550, CHCl3). 
 
(S)-1-{2-[(Di(furan-2-yl)phosphino]methylpyrrolidin-1-yl}-2,2,2-triphenylethanone 
((S)-LA15) 
 
Product (S)-LA15 (80%) was prepared according to general procedure 1 from (S)-LC3 
and 2,2,2-triphenylacetyl chloride (prepared according to general procedure 4). 
C33H30NO3P (519.57 g·mol−1): 
m.p. 175-179 °C. Rf = 0.19 (SiO2, hexanes/ethyl acetate 9:1). 1H NMR (500 MHz, 
CDCl3): δ = 7.62 (br s, 2 H, Fur/Fur’-5-H), 7.34-7.17 (m, 15 H, Ph-H), 6.82 (s, 1 H,          
Fur-3-H), 6.74 (s, 1 H, Fur’-3-H), 6.38 (s, 2 H, Fur/Fur’-4-H), 4.50-4.39 (m, 1 H,           
Pyr-2-H), 3.22-3.14 (m, 1 H, CHH’P), 2.97-2.87 (m, 1 H, Pyr-5-HH’), 2.19 (dd, 
J = 13 Hz, J = 10 Hz, 1 H, CHH’P), 2.15-2.05 (m, 1 H, Pyr-5-HH’), 1.90-1.80 (m, 1 H, 
Pyr-3-HH’), 1.54-1.44 (m, 1 H, Pyr-4-HH’), 1.41-1.23 (m, 1 H, Pyr-4-HH’), 1.32-
1.22 (m, 1 H, Pyr-3-HH’) ppm. 13C{1H} NMR (126 MHz, CDCl3): δ = 171.2 (C=O), 
151.6 (d, 1JC,P = 18 Hz, Fur-2-C), 151.2 (d, 1JC,P = 13 Hz, Fur’-2-C), 147.1 (2 s,             
Fur/Fur’-5-CH), 143.0 (s, Ph-i-C), 130.6 (s, Ph-m-CH), 127.8 (s, Ph-o-CH), 126.6 (s,         
Ph-p-CH), 120.6 (d, 2JC,P = 27 Hz, Fur-3-CH), 120.0 (d, 2JC,P = 23 Hz, Fur’-3-CH), 
110.8 (d, 3JC,P = 3.6 Hz, Fur-4-CH), 110.8 (d, 3JC,P = 2.6 Hz, Fur’-4-CH), 68.0 (s, CPh3), 
57.6 (d, 2JC,P = 23 Hz,, Pyr-2-CH), 48.6 (s, Pyr-5-CH), 30.0 (d, 1JC,P = 6.3 Hz, CH2P), 
29.6 (d, 3JC,P = 4.1 Hz, Pyr-3-CH2), 25.1 (s, Pyr-4-CH2) ppm. 31P{1H} NMR (162 MHz, 
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CDCl3): δ = − 66.9 (br s) ppm. IR (KBr): ߥ෤ = 3122w, 3087w, 3056w, 3021w, 2972m, 
2873w, 1959w, 1735w, 1627s, 1596m, 1491m, 1445m, 1420w, 1390s, 1346w, 1281w, 
1254w, 1227w, 1211m, 1188w, 1163w, 1153m, 1118w, 1105w, 1074w, 1036w, 1005s, 
943w, 902m, 875m, 838w, 799w,755s, 743s, 702s cm−1. MS (EI, 70 eV): 
m/z (%) = 519 (13, M+), 338 (18), 337 (15), 244 (20), 243 (100), 165 (45). [ߙ]஽ଶ଴ = – 77.9 
(c = 1.00, CHCl3). HRMS (ESI): calc. for C33H31NO3P ([M + H]+): 520.2036; found: 
520.2022. 
 
(S)-1-{2-[(Di-tert-butylphosphino)methyl)]pyrrolidin-1-yl}-2,2,2-triphenylethanone 
borane adduct ((S)-LA16·BH3) 
 
Product (S)-LA16·BH3 (91%) was prepared according to general procedure 2 from     
(S)-LC4∙BH3 and 2,2,2-triphenylacetyl chloride (prepared according to general 
procedure 4). 
C33H45BNOP (513.50 g·mol−1): 
m.p. 207-210 °C. Rf = 0.33 (SiO2, hexanes/ethyl acetate 9:1). 1H NMR (400 MHz, 
CDCl3): δ = 7.32-7.25 (m, 6 H, Ph-o-H), 7.25-7.19 (m, 9 H, Ph-m-H and Ph-p-H), 4.59-
4.52 (m, 1 H, Pyr-2-H), 2.90-2.82 (m, 1 H, Pyr-5-HH’), 2.77 (“td”, J = 14, 2.3 Hz, 1 H, 
CHH’P), 2.24-2.13 (m, 2 H, Pyr-3-HH’ and Pyr-5-HH’), 1.88-1.78 (m, 1 H, Pyr-3-HH’), 
1.60-1.42 (m, 2 H, Pyr-4-H2), 1.41 (d, 3JH,P = 13 Hz, 9 H, tBu-H), 1.29-1.22 (m, 1 H, 
CHH’P), 1.24 (d, 3JH,P = 12 Hz, 9 H, tBu’-H), 0.94-0.07 (br q, 3 H, BH3) ppm. 
13C{1H} NMR (101 MHz, CDCl3): δ = 170.9 (s, C=O), 143.0 (s, Ph-i-C), 130.5 (s,            
Ph-m-CH), 127.8 (s, Ph-o-CH), 126.7 (s, Ph-p-CH), 68.0 (s, CPh3), 57.4 (d, 
2JC,P = 5.0 Hz, Pyr-2-CH), 48.2 (s, Pyr-5-CH2), 33.2 (d, 1JC,P = 27 Hz, tBu-C), 32.2 (d, 
1JC,P = 28 Hz, tBu’-C), 31.3 (s, Pyr-3-CH2), 28.5 (d, 2JC,P = 1.5 Hz, tBu-CH3), 28.0 (d, 
2JC,P = 1.2 Hz, tBu’-CH3), 24.8 (s, Pyr-4-CH2), 21.5 (d, 1JC,P = 24 Hz, CH2P) ppm. 
31P{1H} NMR (162 MHz, CDCl3): δ = 40.1 (“br d”, J = 54 Hz) ppm. IR (neat): 
ߥ෤ = 3055m, 2924m, 2382m, 1620s, 1599w, 1489m, 1445m, 1385s, 1373s, 1252w, 1177w, 
1155m, 1070m, 874w, 750s, 737s, 696s, 640m cm−1. MS (FAB, NBA): m/z (%) = 512 
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(100, [M – H]+), 500 (21, [M – BH2]+), 484 (14), 442 (22), 270 (16), 243 (84), 240 (20), 
184 (20), 165 (34), 128 (12), 57 (23). [ߙ]஽ଶ଴ = – 85.1 (c = 0.700, CHCl3). Elemental 
analysis: calc. C 77.19%, H 8.83%, N 2.73%; found: C 77.02%, H 8.95%, N 2.85%. 
 
(S)-1-{2-[(Di-tert-butylphosphino)methyl]pyrrolidin-1-yl}-2,2,2-triphenylethanone 
((S)-LA16) 
 
Product (S)-LA16 was prepared according to general procedure 3 from (S)-LA16·BH3. 
C33H42NOP (499.67 g·mol−1): 
31P{1H} NMR (162 MHz, CD2Cl2): δ = 20.6 (s) ppm. 
 
(S)-1-{2-([(Dicyclohexylphosphino)methyl]pyrrolidin-1-yl}-2,2,2-triphenylethanone 
borane adduct ((S)-LA17·BH3) 
 
Product (S)-LA17·BH3 (89%) was prepared according to general procedure 2 from      
(S)-LC5∙BH3 and 2,2,2-triphenylacetyl chloride (prepared according to general 
procedure 4). 
C37H49BNOP (565.58 g·mol−1): 
m.p. 100-104 °C. Rf = 0.43 (SiO2, cyclohexane/ethyl acetate 19:1). 1H NMR (400 MHz, 
CDCl3): δ = 7.31-7.18 (m, 15 H, Ph-H), 4.50-4.42 (m, 1 H, Pyr-2-H), 2.89-2.82 (m, 1 H, 
Pyr-5-HH’), 2.71 (“td”, J = 14, 2.3 Hz, 1 H, CHH’P), 2.19-2.09 (m, 2 H, Pyr-5-HH’ and 
Pyr-3-HH’), 2.09-1.98 (m, 2 H, Cy/Cy’-1-H), 1.93-1.78 (m, 6 H, Cy/Cy’-H), 1.78-
1.67 (m, 5 H, Pyr-3-HH’ and Cy/Cy’-H), 1.59-1.38 (m, 4 H, Pyr-4-HH’ and Cy/Cy’-H), 
1.38-1.16 (m, 9 H, CHH’P, Pyr-4-HH’ and Cy/Cy’-H), 0.82-0.07 (br q, 3 H, BH3) ppm. 
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13C{1H} NMR (101 MHz, CDCl3): δ = 171.0 (s, C=O), 143.0 (s, Ph-i-C), 130.5 (s,          
Ph-m-CH), 127.8 (s, Ph-o-CH), 126.7 (s, Ph-p-CH), 68.0 (s, CPh3), 56.4 (d, 
2JC,P = 4.6 Hz, Pyr-2-CH), 48.3 (s, Pyr-5-CH2), 32.6 (d, 1JC,P = 32 Hz, Cy-1-CH), 32.5 (d, 
1JC,P = 34 Hz, Cy’-1-CH), 31.3 (s, Pyr-3-CH2), 27.2-26.8 (m, Cy/Cy’-CH2), 26.8 (s, 
Cy/Cy’-CH2), 26.4 (m, Cy/Cy’-CH2), 26.1 (s, Cy/Cy’-CH2), 25.0 (s, Pyr-4-CH2), 23.7 (d, 
1JC,P = 27 Hz, CH2P) ppm. 31P{1H} NMR (162 MHz, CDCl3): δ = 21.8 (br s) ppm. 
IR (neat): ߥ෤ = 2918s, 2849s, 2372m, 1626s, 1506m, 1489m, 1447m, 1373w, 1354m, 
1339m, 1308m, 1157w, 1067m, 1000w, 891w, 876w, 762m, 746m, 698s cm−1. 
MS (FAB, NBA): m/z (%) = 564 (100, [M – H]+), 552 (25, [M – BH2]+), 468 (17), 
322 (19), 294 (28), 293 (16), 292 (19), 243 (74), 210 (22), 165 (23). [ߙ]஽ଶ଴ = – 61.6 
(c = 0.532, CHCl3). Elemental analysis: calc. C 78.57%, H 8.73%, N 2.48%; found: 
C 78.53%, H 8.98%, N 2.54%. 
 
(S)-1-{2-[(Dicyclohexylphosphino)methyl]pyrrolidin-1-yl}-2,2,2-triphenylethanone 
((S)-LA17) 
 
Product (S)-LA17 was prepared according to general procedure 3 from (S)-LA17·BH3. 
C37H46NOP (551.74 g·mol−1): 
31P{1H} NMR (162 MHz, CD2Cl2): δ = – 10.3 (s) ppm. 
 
(S)-{2-[(Diphenylphosphino)methyl]pyrrolidin-1-yl}(phenyl)methanone ((S)-LA18) 
 
Compound (S)-LA18 (94%) was prepared according to general procedure 1 from             
(S)-LC1 and benzoyl chloride. 
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C24H24NOP (373.43 g·mol−1): 
Rf = 0.30 (SiO2, hexanes/ethyl acetate 7:3). 1H NMR (400 MHz, CDCl3): δ = 7.72- 
7.63 (m, 2 H, CPh-H), 7.48-7.25 (m, 13 H, CPh-H and PPh-H), 4.47-4.36 (m, 1 H,           
Pyr-2-H), 3.51-3.32 (m, 2 H, Pyr-5-H2), 3.14-3.03 (d, 2JH,P = 13 Hz, 1 H, CHH’P), 2.23-
2.13 (m, 5 H, CHH’P and Pyr-H) ppm. 31P{1H} NMR (162 MHz, CDCl3): δ = − 25.9 
(s) ppm. MS (EI, 70 eV): m/z (%) = 373 (14, M+), 248 (13), 206 (12), 202 (12), 201 (33), 
183 (21), 173 (13), 172 (100), 171 (15), 158 (14), 121 (18), 105 (93), 104 (36), 77 (45), 
69 (33). The spectroscopic data are consistent with those reported in the literature.[68f] 
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6.3.3 
Trisubstituted Ureaphosphines (S)-LU3 and Precursors 
 
(S)-N-(tert-Butyl)-2-[(diphenylphosphino)methyl]pyrrolidine-1-carboxamide         
((S)-LU31) 
 
Compound (S)-LU31 (78%) was prepared according to general procedure 1 from              
(S)-LC1 and tert-butyl isocyanate. 
C22H29N2OP (368.45 g·mol−1): 
m.p. 92-95 °C. Rf = 0.26 (SiO2, hexanes/ethyl acetate 7:3). 1H NMR (400 MHz, CDCl3): 
δ = 7.55-7.49 (m, 2 H, Ph-o-H), 7.43-7.38 (m, 2 H, Ph-o’-H), 7.36-7.29 (m, 6 H, Ph-H), 
3.94-3.84 (m, 2 H, Pyr-2-H and NH), 3.30-3.22 (m, 2 H, Pyr-5-H2), 2.63 (“dt”,              
J = 14, 3.7 Hz, 1 H, CHH’P), 2.17-2.10 (m, 1 H, CHH’P), 2.04-1.93 (m, 3 H, Pyr-3-H2 
and Pyr-4-HH’), 1.90-1.80 (m, 1 H, Pyr-4-HH’), 1.27 (s, 9 H, tBu-H) ppm. 
13C{1H} NMR (101 MHz, CDCl3): δ = 156.0 (s, C=O), 138.9 (d, 1JC,P = 12 Hz, Ph-i-CH), 
138.1 (d, 1JC,P = 13 Hz, Ph’-i-CH), 133.2 (d, 2JC,P = 19 Hz, Ph-o-CH), 132.7 (d, 
2JC,P = 19 Hz, Ph’-o-CH), 129.0 (s, Ph-p-CH), 128.8 (d, 3JC,P = 6.9 Hz, Ph-m-CH), 
128.6 (s, Ph’-p-CH), 128.6 (d, 2JC,P = 6.9 Hz, Ph’-m-CH), 55.1 (d, 2JC,P = 20 Hz,             
Pyr-2-CH), 50.7 (s, tBu-C), 46.3 (s, Pyr-5-CH2), 34.0 (d, 1JC,P = 15 Hz, CH2P), 31.5 (d, 
3JC,P = 8.4 Hz, Pyr-3-CH2), 29.8 (s, tBu-CH3), 23.8 (s, Pyr-4-CH2) ppm. 31P{1H} NMR 
(162 MHz, CDCl3): δ = − 21.3 (s) ppm. IR (neat): ߥ෤ = 3480w, 2968m, 2938m, 2919m, 
2837m, 1641s, 1632s, 1507s, 1498m, 1448m, 1434m, 1387m, 1351m, 1342s, 1244w, 
1217m, 1203m, 1182m, 1163w, 1067m, 1025m, 961m, 920m, 879m, 805m, 794m, 756s, 
747s, 737s cm−1. MS (EI, 70 eV): m/z (%) = 368 (24, M+), 353 (16), 202 (14), 201 (17), 
199 (11), 185 (13), 183 (27), 167 (48), 121 (12), 111 (31), 84 (39), 83 (23), 70 (100). [ߙ]஽ଶ଴ = – 53.4 (c = 1.05, CHCl3). HRMS (ESI): calc. for C22H30N2OP ([M+H]+): 
369.2090; found: 369.2087. 
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(S)-N-(tert-Butyl)-2-[(di-ortho-tolylphosphino)methyl]pyrrolidine-1-carboxamide             
((S)-LU32) 
 
Compound (S)-LU32 (56%) was prepared according to general procedure 1 from              
(S)-LC2 and tert-butyl isocyanate. 
C24H33N2OP (396.51 g·mol−1): 
Rf = 0.18 (SiO2, hexanes/ethyl acetate 8:2). 1H NMR (400 MHz, CDCl3): δ = 7.45-
7.37 (m, 1 H, oTol-H), 7.24-7.03 (m, 7 H, oTol/oTol’-H), 3.90 (s, 1 H, NH), 3.85-
3.74 (m, 1 H, Pyr-2-H), 3.36-3.25 (m, 2 H, Pyr-5-H2), 2.56-2.49 (m, 1 H, CHH’P), 
2.49 (s, 3 H, oTol-CH3), 2.37 (s, 3 H, oTol’-CH3), 2.14-2.05 (m, 1 H, CHH’P), 2.02-
1.84 (m, 4 H, Pyr-H), 1.25 (s, 9 H, tBu-H) ppm. 13C{1H} NMR (101 MHz, CDCl3): 
δ = 156.0 (s, C=O), 142.5 (d, 2JC,P = 26 Hz, oTol-2-C), 141.7 (d, 2JC,P = 26 Hz,               
oTol’-2-C), 137.0 (d, 1JC,P = 12 Hz, oTol-1-C), 136.0 (d, 1JC,P = 13 Hz, oTol’-1-C), 
131.8 (s, oTol-6-CH), 131.2 (s, oTol’-6-CH), 130.2 (d, 3JC,P = 4.6 Hz, oTol-3-CH), 
130.2 (d, 3JC,P = 4.7 Hz, oTol’-3-CH), 128.8 (s, oTol-4-CH), 128.5 (s, oTol’-4-CH), 
126.8 (s, oTol-5-CH), 126.2 (s, oTol’-5-CH), 55.0 (d, 2JC,P = 21 Hz, Pyr-2-CH), 50.7 (s, 
tBu-C), 46.1 (s, Pyr-5-CH2), 32.8 (d, 1JC,P = 15 Hz, CH2P), 31.7 (d, 3JC,P = 9.2 Hz,            
Pyr-3-CH2), 29.7 (s, tBu-CH3), 23.7 (s, Pyr-4-CH2), 21.5-21.1 (m, oTol/oTol’-CH3) ppm. 
31P{1H} NMR (162 MHz, CDCl3): δ = − 42.9 (s) ppm. IR (neat): ߥ෤ = 3344w, 2963m, 
2929m, 2869m, 1634s, 1533s, 1447m, 1387m, 1657s, 1286m, 1203s, 1031w, 956w, 
748m cm−1. MS (EI, 70 eV): m/z (%) = 396 (4, M+), 381 (22), 328 (13), 312 (39), 
230 (14), 229 (47), 215 (23), 213 (24), 183 (17), 167 (52), 157 (16), 111 (14), 84 (100), 
83 (21), 70 (84), 58 (96), 57 (17). [ߙ]஽ଶ଴ = – 12.3 (c = 0.470, CHCl3). 
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(S)-N-(tert-Butyl)-2-{[di(furan-2-yl)phosphine]methyl}pyrrolidine-1-carboxamide 
((S)-LU33) 
 
Compound (S)-LU33 (65%) was prepared according to general procedure 1 from           
(S)-LC3 and tert-butyl isocyanate. 
C18H25N2O3P (348.38 g·mol−1): 
m.p. 162-165 °C. Rf = 0.15 (SiO2, hexanes/ethyl acetate 4:1). 1H NMR (500 MHz, 
CDCl3): δ = 7.61 (br s, 2 H, Fur/Fur’-5-H), 6.79 (br s, 1 H, Fur-3-H), 6.72 (br s, 1 H, 
Fur’-3-H), 6.40-6.36 (m, 2 H, Fur/Fur’-4-H), 4.32-4.04 (m, 1 H, NH), 3.89-3.78 (m, 1 H, 
Pyr-2-H), 3.32-3.22 (m, 2 H, Pyr-5-H2), 2.80-2.72 (m, 1 H, CHH’P), 2.24-2.13 (m, 1 H, 
CHH’P), 2.01-1.70 (m, 4 H, Pyr-H), 1.34 (s, 9 H, tBu-H) ppm. 13C{1H} NMR (126 MHz, 
CDCl3): δ = 155.9 (s, C=O), 151.3 (d, 1JC,P = 16 Hz, Fur-2-C), 151.0 (d, 1JC,P = 17 Hz, 
Fur’-2-C), 147.2 (s,  Fur-5-CH), 147.1 (s, Fur’-5-CH), 120.7 (d, 2JC,P = 26 Hz, Fur-3-CH), 
120.2 (d, 2JC,P = 26 Hz, Fur’-3-CH), 111.0 (d, 3JC,P = 6.4 Hz, Fur-4-CH), 110.8 (d, 
3JC,P = 6.4 Hz, Fur’-4-CH), 54.9 (d, 2JC,P = 19 Hz, Pyr-2-CH), 50.8 (s, tBu-C), 46.2 (s, 
Pyr-5-CH2), 31.2 (d, 1JC,P = 6.4 Hz, CH2P), 30.7 (d, 4JC,P = 3.7 Hz, Pyr-3-CH2), 29.7 (s, 
tBu-CH3), 23.6 (s, Pyr-4-CH2) ppm. 31P{1H} NMR (162 MHz, CDCl3): 
δ = −70.0 (s) ppm. IR (KBr): ߥ෤ = 3450m, 3105m, 2966m, 2859m, 1732m, 1639s, 1518s, 
1454m, 1392w, 1350w, 1213s, 1151w, 1065w, 1002m, 960w, 902w, 884w, 834w, 771s, 
713w, 656w cm−1. MS (EI, 70 eV): m/z (%) = 348 (17, M+), 291 (11), 181 (6), 167 (10), 
165 (17), 127 (6), 111 (13), 109 (6), 84 (14), 83 (17), 71 (5), 70 (100), 57 (7), 41 (5). [ߙ]஽ଶ଴ = − 46.6 (c = 1.00, CHCl3). HRMS (ESI): calc. for C18H26N2O3P ([M+H]+): 
349.1676; found: 349.1669. 
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(S)-N-(tert-Butyl)-2-[(di-tert-butylphosphino)methyl]pyrrolidine-1-carboxamide 
borane adduct ((S)-LU34∙BH3) 
 
Compound (S)-LU34∙BH3 (77%) was prepared according to general procedure 2 from 
(S)-LC4∙BH3 and tert-butyl isocyanate. 
C18H40BN2OP (342.31 g·mol−1): 
m.p. 176-178 °C. Rf = 0.25 (SiO2, hexanes/ethyl acetate 4:1). 1H NMR (400 MHz, 
CDCl3): δ = 4.27-4.20 (m, 1 H, Pyr-2-H), 4.10 (s, 1 H, NH), 3.30-3.24 (m, 1 H,             
Pyr-5-HH’), 3.17 (“q”, JH,H = 8.1 Hz, 1 H, Pyr-5-HH’), 2.38 (“td”, J = 14, 1.5 Hz, 1 H, 
CH’HP), 2.21-2.14 (m, 1 H, Pyr-3-HH’), 2.10-1.97 (m, 1 H, Pyr-3-HH’), 1.96-1.88 (m, 
2 H, Pyr-4-H2), 1.50-1.41 (m, 1 H, CHH’P), 1.38 (d, 3JH,P = 13 Hz, 9 H, PtBu-H), 1.35 (s, 
9 H, NtBu-H), 1.24 (d, 3JH,P = 12 Hz, 9 H, PtBu’-H), 0.83-0.03 (br q, 3 H, BH3) ppm. 
13C{1H} NMR (101 MHz, CDCl3): δ = 156.0 (s, C=O), 55.2 (d, 2JC,P = 5.4 Hz,              
Pyr-2-CH), 50.8 (s, NtBu-C), 46.1 (s, Pyr-5-CH2), 33.1 (d, 1JC,P = 28 Hz, PtBu-C), 
32.5 (d, 1JC,P = 27 Hz, PtBu’-C), 31.5 (s, Pyr-3-CH2), 29.8 (s, NtBu-CH3), 28.3 (d, 
2JC,P = 1.5 Hz, PtBu-CH3), 28.0 (d, 2JC,P = 1.5 Hz, PtBu’-CH3), 23.8 (s, Pyr-4-CH2), 
22.4 (d, 1JC,P = 23 Hz, CH2P) ppm. 31P{1H} NMR (162 MHz, CDCl3): δ = 39.9 (“br d”, 
J = 75 Hz) ppm. IR (neat): ߥ෤ = 3420w, 2969m, 2911m, 2871m, 1651s, 1508s, 1460m, 
1452m, 1360s, 1344s, 1243m, 1216m, 1190m, 1149w, 1068m, 1025w, 963w, 918w, 
858w, 814m, 791m, 768m cm−1. MS (EI, 70 eV): m/z (%) = 341 (10, [M – H]+), 272 (15), 
271 (100), 259 (10), 242 (16), 240 (17), 215 (23), 139 (17), 84 (12), 70 (18), 57 (26). [ߙ]஽ଶ଴ = – 66.6 (c = 0.350, CHCl3).  
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(S)-N-(tert-Butyl)-2-[(di-tert-butylphosphino)methyl]pyrrolidine-1-carboxamide     
((S)-LU34) 
 
Product (S)-LU34 was prepared according to general procedure 3 from (S)-LU34∙BH3. 
C18H37N2OP (328.47 g·mol−1): 
31P{1H} NMR (162 MHz, CD2Cl2): δ = 21.7 (s) ppm. 
 
(S)-N-(tert-Butyl)-2-[(dicyclohexylphosphino)methyl]pyrrolidine-1-carboxamide 
borane adduct ((S)-LU35∙BH3) 
 
Compound (S)-LU35∙BH3 (64%) was isolated as a colorless semisolid and prepared 
according to general procedure 2 from (S)-LC5∙BH3 and tert-butyl isocyanate. 
C22H44BN2OP (394.38 g·mol−1): 
Rf = 0.27 (SiO2, hexanes/ethyl acetate 4:1). 1H NMR (400 MHz, CDCl3): δ = 4.18 (br s, 
1 H, NH), 4.16-4.05 (m, 1 H, Pyr-2-H), 3.32-3.25 (m, 1 H, Pyr-5-HH’), 3.24-3.18 (m, 
1 H, Pyr-5-HH’), 2.15 (“t”, J = 14 Hz, 1 H, CHH’P), 2.02-1.62 (m, 15 H, Pyr-3-H2,          
Pyr-4-H2 and Cy/Cy’-H), 1.61-1.52 (m, 1 H, CHH’P), 1.47-1.37 (m, 2 H, Cy/Cy’-H), 
1.35 (br s, 9 H, tBu-H), 1.33-1.22 (m, 9 H, Cy/Cy’-H), 0.76-0.07 (br q, 3 H, BH3) ppm. 
13C{1H} NMR (101 MHz, CDCl3): δ = 155.9 (s, C=O), 53.6 (d, 2JC,P = 4.2 Hz,                
Pyr-2-CH), 51.0 (s, tBu-C), 46.0 (s, Pyr-5-CH2), 32.5 (d, 1JC,P = 33 Hz, Cy-1-CH), 
32.5 (d, 1JC,P = 33 Hz, Cy’-1-CH), 32.0 (s, Pyr-3-CH2), 29.8 (s, tBu-CH3), 27.1-26.7 (m, 
Cy/Cy’-CH2), 26.1 (s, Cy/Cy’-CH2), 24.6 (d, 1JC,P = 26 Hz, CH2P), 23.7 (s,                   
Pyr-4-CH2) ppm. 31P{1H} NMR (162 MHz, CDCl3): δ = 21.9 (“br d”, J = 73 Hz) ppm. 
IR (neat): ߥ෤ = 2963w, 2927s, 2916s, 2851s, 1614s, 1448s, 1415s, 1352m, 1312m, 1242w, 
1221w, 1180m, 1155m, 1121m, 1004m, 894s, 875m, 746s, 719m, 695m cm−1. MS (EI, 
70 eV): m/z (%) = 394 (3), 393 (12, [M – H]+), 311 (10), 298 (19), 297 (100), 294 (34), 
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293 (15), 292 (41), 139 (17), 114 (11), 84 (12), 83 (10), 70 (20), 58 (11), 55 (11). [ߙ]஽ଶ଴ = – 4.3 (c = 0.180, CHCl3). 
 
(S)-N-(tert-Butyl)-2-[(dicyclohexylphosphino)methyl]pyrrolidine-1-carboxamide 
((S)-LU35) 
 
Product (S)-LU35 was prepared according to general procedure 3 from (S)-LU35∙BH3. 
C12H41N2OP (380.55 g·mol−1): 
31P{1H} NMR (162 MHz, CD2Cl2): δ = − 10.2 (s) ppm. 
 
(S)-2-[(Diphenylphosphino)methyl]-N-isopropylpyrrolidine-1-carboxamide           
((S)-LU36) 
 
Compound (S)-LU36 (71%) was prepared according to general procedure 1 from         
(S)-LC1 and isopropyl isocyanate. 
C21H27N2OP (354.43 g·mol−1): 
m.p. 93-95 °C. Rf = 0.16 (SiO2, hexanes/ethyl acetate 7:3). 1H NMR (400 MHz, CDCl3): 
δ = 7.61-7.56 (m, 2 H, Ph-o-H), 7.44-7.27 (m, 8 H, Ph/Ph’-H), 3.97-3.86 (m, 2 H,               
Pyr-2-H and iPr-CH), 3.73 (br d, 1 H, 3JH,H = 7.6 Hz, NH), 3.31-3.19 (m, 2 H, Pyr-5-H2), 
2.73 (“td”, J = 14, 3.6 Hz, 1 H, CHH’P), 2.10-1.94 (m, 4 H, CHH’P, Pyr-4-HH’ and           
Pyr-3-H2), 1.93-1.84 (m, 1 H, Pyr-4-HH’), 1.08 (d, 3JH,H = 6.6 Hz, 3 H, iPr-CH3), 1.04 (d, 
3JH,H = 6.6 Hz, 3 H, iPr-CH3) ppm. 13C{1H} NMR (101 MHz, CDCl3): δ = 156.3 (s, 
C=O), 139.3 (d, 1JC,P = 12 Hz, Ph-i-C), 138.0 (d, 1JC,P = 13 Hz, Ph’-i-C), 133.5 (d, 
2JC,P = 20 Hz, Ph-o-CH), 132.9 (d, 2JC,P =19 Hz, Ph’-o-CH), 129.3 (s, Ph-p-CH), 129.1 (d, 
3JC,P = 6.9 Hz, Ph-m-CH), 128.9 (s, Ph’-p-CH), 128.8 (d, 3JC,P = 6.9 Hz, Ph’-m-CH), 
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55.4 (d, 2JC,P = 20 Hz, Pyr-2-CH), 46.4 (s, Pyr-5-CH2), 42.4 (s, iPr-CH), 34.2 (d, 
1JC,P = 14 Hz, CH2P), 31.5 (d, 3JC,P = 8.4 Hz, Pyr-3-CH2), 24.1 (s, iPr-CH3), 24.0 (s,            
Pyr-4-CH2) ppm. 31P{1H} NMR (162 MHz, CDCl3): δ = – 21.4 (s) ppm. IR (neat): 
ߥ෤ = 3480w, 2969w, 2932m, 2927m, 2918m, 2853m, 1613s, 1521w, 1469w, 1448m, 
1415m, 1369m, 1352m, 1313m, 1306m, 1180m, 1156m, 1120m, 1027w, 1003w, 993w, 
894m, 876m, 773m, 745s, 740s, 719m, 695s cm−1. MS (EI, 70 eV): m/z (%) = 354 (22, 
M+), 277 (12), 201 (14), 199 (10), 185 (12), 183 (26), 153 (97), 84 (47), 83 (19), 70 (100). [ߙ]஽ଶ଴ = – 47.8 (c = 1.03, CHCl3). HRMS (ESI): calc. for C21H28N2OP ([M+H]+): 
355.1934; found: 355.1931. 
 
(S)-N-Cyclohexyl-2-[(diphenylphosphino)methyl]pyrrolidine-1-carboxamide       
((S)-LU37) 
 
Compound (S)-LU37 (76%) was prepared according to general procedure 1 from         
(S)-LC1 and cyclohexyl isocyanate. 
C24H31N2OP (394.49 g·mol−1): 
m.p. 129-131 °C. Rf = 0.11 (SiO2, hexanes/ethyl acetate 4:1). 1H NMR (400 MHz, 
CDCl3): δ = 7.62-7.55 (m, 2 H, Ph-H), 7.43-7.26 (m, 8 H, Ph/Ph’-H), 3.98-3.88 (m, 1 H, 
Pyr-2-H), 3.82 (d, 3JH,H = 7.8 Hz, 1 H, NH), 3.65-3.55 (m, 1 H, Cy-1-H), 3.31-3.21 (m, 
2 H, Pyr-5-H2), 2.79 (“dt”, J = 14, 3.8 Hz, 1 H, CHH’P), 2.11-1.94 (m, 4 H, Pyr-3-H2, 
Pyr-4-HH’ and CHH’P), 1.94-1.79 (m, 3 H, Pyr-4-HH’ and Cy-H), 1.71-1.62 (m, 2 H, 
Cy-H), 1.62-1.53 (m, 1 H, Cy-H), 1.39-1.26 (m, 2 H, Cy-H), 1.15-1.06 (m, 1 H, Cy-H), 
1.06-0.89 (m, 2 H, Cy-H) ppm. 13C{1H} NMR (101 MHz, CDCl3): δ = 156.0 (s, C=O), 
139.1 (d, 1JC,P = 12 Hz, Ph-i-C), 137.7 (d, 1JC,P = 13 Hz, Ph’-i-C), 133.2 (d, 2JC,P = 19 Hz, 
Ph-o-CH), 132.7 (d, 2JC,P = 19 Hz, Ph’-o-CH), 129.0 (s, Ph-p-CH), 128.8 (d, 
3JC,P = 6.9 Hz, Ph-m-CH), 128.6 (s, Ph’-p-CH), 128.5 (d, 3JC,P = 6.5 Hz, Ph’-m-CH), 
55.1 (d, 2JC,P = 20 Hz, Pyr-2-CH), 49.0 (s, Cy-1-CH), 46.1 (s, Pyr-5-CH2), 34.4 (s,         
Cy-CH2), 34.3 (s, Cy-CH2), 33.8 (d, 1JC,P = 14 Hz, CH2P), 31.1 (d, 3JC,P = 8.4 Hz,           
Pyr-3-CH2), 25.8 (s, Cy-CH2), 25.3 (s, Cy-CH2), 25.2 (s, Cy-CH2), 23.9 (s, Pyr-4-CH2) 
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ppm. 31P{1H} NMR (162 MHz, CDCl3): δ = – 21.4 (s) ppm. IR (neat): ߥ෤ = 3315m, 
2926m, 2849m, 1635m, 1608s, 1511s, 1480m, 1447w, 1432m, 1393m, 1353m, 1339m, 
1288w, 1218w, 1190w, 1147w, 1068w, 917w, 871w, 809w, 771m, 737s, 694s cm−1. 
MS (EI, 70 eV): m/z (%) = 394 (10, M+), 317 (16), 285 (11), 284 (54), 216 (10), 201 (16), 
200 (20), 199 (14), 194 (11), 193 (89), 185 (18), 183 (31), 121 (10), 111 (25), 110 (10), 
84 (52), 83 (33), 70 (100). [ߙ]஽ଶ଴ = – 57.6 (c = 1.10, CHCl3). HRMS (ESI): calc. for 
C24H32N2OP ([M+H]+): 395.2247; found: 395.2244. 
 
(S)-N-Cyclohexyl-2-[(di-ortho-tolylphosphino)methyl]pyrrolidine-1-carboxamide 
((S)-LU38) 
 
Compound (S)-LU38 (52%) was prepared according to general procedure 1 from         
(S)-LC2 and cyclohexyl isocyanate. 
C26H35N2OP (422.54 g·mol−1): 
m.p. 145-149 °C. Rf = 0.14 (SiO2, hexanes/ethyl acetate 4:1). 1H NMR (400 MHz, 
CDCl3): δ = 7.66-7.55 (m, 1 H, oTol-H), 7.30-7.09 (m, 7 H, oTol/oTol’-H), 3.94-3.76 (m, 
2 H, Pyr-2-H and NH), 3.69-3.55 (m, 1 H, Cy-1-H), 3.39-3.20 (m, 2 H, Pyr-5-H2), 2.76-
2.64 (m, 1 H, CHH’P), 2.42 (s, 3 H, oTol-CH3), 2.41 (s, 3 H, oTol’-CH3), 2.20-2.11 (m, 
1 H, CHH’P), 2.06-1.76 (m, 6 H, Pyr-H and Cy-H), 1.72-1.51 (m, 3 H, Cy-H), 1.40-
1.22 (m, 2 H, Cy-H), 1.57-0.86 (m, 3 H, Cy-H) ppm. 13C{1H} NMR (101 MHz, CDCl3): 
δ = 155.9 (s, C=O), 142.6 (d, 2JC,P = 26 Hz, oTol-2-C), 141.6 (d, 2JC,P = 25 Hz,             
oTol’-2-C), 136.7-136.4 (br, oTol-1-C), 135.5-135.0 (br, oTol’-1-C), 132.0 (s,              
oTol-6-CH), 131.5 (s, oTol’-6-CH), 130.2 (br s, oTol-3-CH), 130.2 (br s, oTol’-3-CH), 
129.0 (s, oTol-4-CH), 128.7 (s, oTol’-4-CH), 126.9 (s, oTol-5-CH), 126.2 (s,              
oTol’-5-CH), 55.0 (d, 2JC,P = 24 Hz, Pyr-2-CH), 49.0 (s, Cy-1-CH), 46.1 (s, Pyr-5-CH2), 
34.4 (s, Cy-CH2), 34.3 (s, Cy-CH2), 32.5 (d, 1JC,P = 13 Hz, CH2P), 31.3 (d, 3JC,P = 9.0 Hz, 
Pyr-3-CH2), 25.8 (s, Cy-CH2), 25.3 (Cy-CH2), 25.3 (Cy-CH2), 23.8 (s, Pyr-4-CH2), 
21.5 (d, 3JC,P = 19 Hz, oTol-CH3), 21.2 (d, 3JC,P = 19 Hz, oTol’-CH3) ppm. 
31P{1H} NMR (162 MHz, CDCl3): δ = – 42.0 (s) ppm. IR (neat): ߥ෤ = 3307m, 2927m, 
CHAPTER 6 
 
212 
2850m, 1746w, 1615s, 1525s, 1448m, 1390m, 1352m, 1251w, 1197w, 1158w, 1076w, 
1028w, 917w, 890w, 873w, 744s, 720m cm−1. MS (EI, 70 eV): m/z (%) = 422 (7, M+), 
407 (19), 331 (32), 312 (26), 229 (14), 213 (26), 193 (72), 84 (61), 83 (12), 70 (100). [ߙ]஽ଶ଴ = – 59.6 (c = 0.99, CHCl3). 
 
(S)-N-Cyclohexyl-2-[(di-tert-butylphosphino)methyl]pyrrolidine-1-carboxamide 
borane adduct ((S)-LU39∙BH3) 
 
Compound (S)-LU39∙BH3 (63%) was prepared according to general procedure 2 from 
(S)-LC4∙BH3 and cyclohexyl isocyanate. 
C20H42BN2OP (368.35 g·mol−1): 
m.p. 79-83 °C. Rf = 0.20 (SiO2, hexanes/ethyl acetate 4:1). 1H NMR (400 MHz, CDCl3): 
δ = 4.27-4.21 (m, 1 H, Pyr-2-H), 4.08 (d, 3JH,H = 8.1 Hz, 1 H, NH), 3.71-3.61 (m, 1 H, 
Cy-1-H), 3.30-3.25 (m, 1 H, Pyr-5-HH’), 3.15 (“q”, J = 8.0 Hz, 1 H, Pyr-5-HH’), 
2.48 (“t”, J = 14, 2.5 Hz, 1 H, CHH’P), 2.22-2.14 (m, 1 H, Pyr-3-HH’), 2.08-1.98 (m, 
1 H, Pyr-3-HH’), 1.98-1.87 (m, 4 H, Cy-H), 1.76-1.64 (m, 2 H, Cy-H), 1.63-1.54 (m, 1 H, 
Pyr-4-HH’), 1.48-1.40 (m, 1 H, CHH’P), 1.38 (d, 3JH,P = 13 Hz, 9 H, tBu-H), 1.39-
1.28 (m, 2 H, Cy-H), 1.22 (d, 3JH,P = 12 Hz, 9 H, tBu’-H), 1.17-0.91 (m, 3 H, Pyr-4-HH’ 
and Cy-H), 0.81-0.06 (br q, 3 H, BH3) ppm. 13C{1H} NMR (101 MHz, CDCl3): 
δ = 156.1 (s, C=O), 55.6 (d, 2JC,P = 5.8 Hz, Pyr-2-CH), 48.9 (s, Cy-1-CH), 46.0 (s,             
Pyr-5-CH2), 34.6 (s, Cy-CH2), 34.3 (s, Cy-CH2), 33.1 (d, 1JC,P = 27 Hz, tBu-C), 32.0 (d, 
1JC,P = 28 Hz, tBu’-C), 31.5 (s, Pyr-3-CH2), 28.3 (d, 2JC,P = 1.5 Hz, tBu-CH3), 28.0 (d, 
2JC,P = 1.2 Hz, tBu’-CH3), 25.7 (s, Pyr-4-CH2), 25.3 (s, Cy-CH2), 25.2 (s, Cy-CH2), 
23.8 (s, Cy-CH2), 22.5 (d, 1JC,P = 23 Hz, CH2P) ppm. 31P{1H} NMR (162 MHz, CDCl3): 
δ = 39.9 (“br d”, J = 68 Hz) ppm. IR (neat): ߥ෤ = 3324w, 2926m, 2852m, 1617s, 1513s, 
1474m, 1448m, 1391m, 1345s, 1242w, 1188m, 1145m, 1070s, 1021m, 919w, 889w, 
813m, 772m cm−1. MS (EI, eV): m/z (%) =367 (8, [M – H]+), 298 (18), 297 (100), 
242 (13), 241 (13), 240 (12), 221 (12), 70 (13), 57 (11). [ߙ]஽ଶ଴ = – 31.0 (c = 0.581, 
CHCl3). HRMS (ESI): calc. for C20H41BN2OP ([M − H]+): 367.3044; found: 367.3041. 
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(S)-N-Cyclohexyl-2-[(di-tert-butylphosphino)methyl]pyrrolidine-1-carboxamide   
((S)-LU39) 
 
Product (S)-LU39 was prepared according to general procedure 3 from (S)-LU39∙BH3. 
C20H39N2OP (354.51 g·mol−1): 
31P{1H} NMR (162 MHz, CD2Cl2): δ = 21.8 (s) ppm. 
 
(S)-N-Cyclohexyl-2-[(dicyclohexylphosphino)methyl]pyrrolidine-1-carboxamide 
borane adduct ((S)-LU310∙BH3) 
 
Compound (S)-LU310∙BH3 (51%) was prepared according to general procedure 2 from 
(S)-LC5∙BH3 and cyclohexyl isocyanate. 
C24H46BN2OP (420.42 g·mol−1): 
m.p. 128-131 °C. Rf = 0.14 (SiO2, hexanes/ethyl acetate 4:1). 1H NMR (400 MHz, 
CDCl3): δ = 4.22-4.11 (m, 2 H, Pyr-2-H and NH), 3.69-3.60 (m, 1 H, NCy-1-H), 3.32-
3.27 (m, 1 H, Pyr-5-HH’), 3.20 (“q”, J = 8.0 Hz, 1 H, Pyr-5-HH’), 2.28 (“t”, J = 14 Hz, 
1 H, CHH’P), 2.05-1.57 (m, 21 H), 1.57-1.49 (m, 1 H, CHH’P), 1.49-1.05 (m, 15 H), 
0.87-0.05 (br q, 3 H, BH3) ppm. 13C{1H} NMR (101 MHz, CDCl3): δ = 155.9 (s, C=O), 
54.0 (d, 2JC,P = 4.2 Hz, Pyr-2-CH), 49.1 (s, NCy-1-CH), 45.9 (s, Pyr-5-CH2), 34.5 (s, 
NCy-CH2), 34.3 (s, NCy-CH2), 32.6 (d, 1JC,P = 11 Hz, PCy-1-CH), 32.3 (d, 1JC,P = 12 Hz, 
PCy’-1-CH), 31.8 (s, Pyr-3-CH2), 27.2-26.5 (m, PCy/Cy’-CH2), 26.1 (s, PCy/Cy’-CH2), 
25.7 (NCy-4-CH2), 25.4 (s, NCy-CH2), 25.3 (s, NCy-CH2), 24.8 (d, 1JC,P = 26 Hz, CH2P), 
23.8 (s, Pyr-4-CH2) ppm. 31P{1H} NMR (162 MHz, CDCl3): δ = 21.7 (“br d”, 
J = 71 Hz) ppm. IR (neat): ߥ෤ = 3339w, 2924m, 2850m, 1630s, 1516m, 1447m, 1432m, 
1386m, 1349m, 1342m, 1172w, 1066m, 856w, 763m, 752m, 696m cm−1. MS (EI, 
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70 eV): m/z (%) = 420 (2), 419 (9, [M – H]+), 337 (11), 324 (20), 323 (100), 294 (28), 
293 (11), 292 (23), 221 (14), 70 (11). [ߙ]஽ଶ଴ = – 19.3 (c = 0.580, CHCl3).  
 
(S)-N-Cyclohexyl-2-[(dicyclohexylphosphino)methyl]pyrrolidine-1-carboxamide 
((S)-LU310) 
 
Product (S)-LU310 was prepared according to general procedure 3 from (S)-LU310·BH3. 
C24H43N2OP (406.58 g·mol−1): 
31P{1H} NMR (162 MHz, CD2Cl2): δ = −10.5 (s) ppm. 
 
(S)-N-(Adamantan-1-yl)-2-[(diphenylphosphino)methyl]pyrrolidine-1-carboxamide 
((S)-LU311) 
 
Compound (S)-LU311 (94%) was prepared according to general procedure 1 from       
(S)-LC1 and 1-adamantyl isocyanate. 
C28H35N2OP (446.56 g·mol−1): 
m.p. 77-79 °C. Rf = 0.29 (SiO2, hexanes/ethyl acetate 7:3). 1H NMR (400 MHz, 
CD2Cl2): δ = 7.58-7.53 (m, 2 H, Ph-H), 7.42-7.29 (m, 8 H, Ph/Ph’-H), 3.93-3.86 (m, 1 H, 
Pyr-2-H), 3.84 (s, 1 H, NH), 3.25-3.19 (m, 2 H, Pyr-5-H2), 2.69 (“dt”, 2JH,P =13 Hz, 
JH,H = 3.8 Hz, 1 H, CHH’P), 2.06-1.93 (m, 7 H, CHH’P, Pyr-3-H2, Pyr-4-HH’ and          
Adm-3/5/7-H), 1.90 (s, 6 H, Adm-2/8/9-H2), 1.88-1.78 (m, 1 H, Pyr-4-HH’), 1.66 (s, 6 H, 
Adm-4/6/10-H2) ppm. 13C{1H} NMR (101 MHz, CDCl3): δ = 155.7 (s, C=O), 139.0 (d, 
1JC,P = 12 Hz, Ph-i-C), 138.1 (d, 1JC,P = 13 Hz, Ph’-i-C), 133.2 (d, 2JC,P = 19 Hz,            
Ph-o-CH), 132.7 (d, 2JC,P = 19 Hz, Ph’-o-CH), 128.9 (s, Ph-p-CH), 128.8 (d, 
3JC,P = 6.9 Hz, Ph-m-CH), 128.6 (s, Ph’-p-CH), 128.6 (d, 3JC,P = 6.9 Hz, Ph’-m-CH), 
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55.1 (d, 2JC,P = 20 Hz, Pyr-2-CH), 51.2 (s, Adm-1-C), 46.3 (s, Pyr-5-CH2), 42.7 (s,            
Adm-2/8/9-CH2), 36.6 (s, Adm-4/6/10-CH2), 34.0 (d, 1JC,P = 15 Hz, CH2P), 31.4 (d, 
3JC,P = 8.8 Hz, Pyr-3-CH2), 29.7 (s, Adm-3/5/7-CH), 23.8 (s, Pyr-4-CH2) ppm. 
31P{1H} NMR (162 MHz, CD2Cl2): δ = − 21.1 (s) ppm. IR (neat): ߥ෤ = 3441w, 3341m, 
2904s, 2847m, 1640s, 1630s, 1504s, 1480m, 1452w, 1372w, 1352s, 1337m, 1306s, 
1185m, 1160m, 1101w, 1081w, 738s, 715s cm−1. MS (EI, 70 eV): m/z (%) = 446 (27, 
M+), 284 (12), 246 (16), 245 (97), 215 (10), 204 (13), 201 (24), 200 (86), 199 (30), 
185 (19), 183 (30), 177 (26), 151 (14), 135 (61), 121 (17), 120 (50), 94 (23), 93 (12), 
91 (10), 84 (56), 83 (32), 79 (13), 70 (100). [ߙ]஽ଶ଴ = – 34.5 (c = 1.04, CHCl3). 
HRMS (ESI): calc. for C28H36N2OP ([M+H]+): 447.2560; found: 447.2553. 
 
(S)-N-(Adamantan-1-yl)-2-[(di-ortho-tolylphosphino)methyl]pyrrolidine-1-
carboxamide ((S)-LU312) 
 
Compound (S)-LU312 (79%) was prepared according to general procedure 1 from       
(S)-LC2 and 1-adamantyl isocyanate. 
C30H39N2OP (474.62 g·mol−1): 
m.p. 80-84 °C. Rf = 0.33 (SiO2, hexanes/ethyl acetate 8:2). 1H NMR (400 MHz, CDCl3): 
δ = 7.47-7.40 (m, 1 H, oTol-H), 7.24-7.11 (m, 7 H, oTol/oTol’-H), 3.87-3.78 (m, 2 H, 
Pyr-2-H and NH), 3.35-3.26 (m, 2 H, Pyr-5-H2), 2.55 (“dt”, J = 14, 3.2 Hz, 1 H, CHH’P), 
2.44 (s, 3 H, oTol-CH3), 2.38 (s, 3 H, oTol’-CH3), 2.12-1.83 (m, 8 H, CHH’P, Pyr-H and 
Adm-3/5/7-H), 1.87 (s, 6 H, Adm-2/8/9-H2), 1.64 (s, 6 H, Adm-4/6/10-H2) ppm. 
13C{1H} NMR (101 MHz, CDCl3): δ = 155.7 (s, C=O), 142.5 (d, 2JC,P = 26 Hz,                 
oTol-2-C), 141.8 (d, 2JC,P = 26 Hz, oTol’-2-C), 137.1 (d, 1JC,P = 12 Hz, oTol-1-C), 
136.0 (d, 1JC,P = 13 Hz, oTol’-1-C), 131.9 (s, oTol-3-CH), 131.3 (s, oTol’-3-CH), 130.3-
130.1 (m, oTol/oTol’-6-CH), 128.7 (s, oTol-4-CH), 128.5 (s, oTol’-4-CH), 126.8 (s, 
oTol-5-CH), 126.2 (s, oTol’-5-CH), 55.0 (d, 2JC,P = 21 Hz, Pyr-2-CH), 51.2 (s,             
Adm-1-C), 46.1 (s, Pyr-5-CH2), 42.7 (s, Adm-2/8/9-CH2), 36.6 (s, Adm-4/6/10-CH2), 
32.8 (d, 1JC,P = 15 Hz, CH2P), 31.6 (d, 3JC,P = 9.4 Hz, Pyr-3-CH2), 29.7 (s,                        
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Adm-3/5/7-CH), 23.7 (s, Pyr-4-CH2), 21.6-21.1 (m, oTol/oTol’-CH3) ppm. 31P{1H} NMR 
(162 MHz, CDCl3): δ = − 42.1 (s) ppm. IR (neat): ߥ෤ = 3353w, 2902s, 2846s, 1632s, 
1506s, 1450m, 1371m, 1352s, 1338m, 1306m, 1186w, 1159w, 1130w, 1080w, 1031w, 
957w, 919w, 875w, 802w, 745s, 719m cm−1. MS (EI, eV): m/z (%) = 474 (7, M+), 
459 (24), 383 (21), 246 (19), 245 (100), 229 (16), 228 (32), 227 (14), 214 (11), 213 (61), 
177 (16), 151 (17), 135 (49), 120 (29), 94 (23), 93 (12), 84 (68), 83 (16), 79 (12), 70 (95). [ߙ]஽ଶ଴ = – 28.8 (c = 0.600, CHCl3). HRMS (ESI): calc. for C30H40N2OP ([M + H]+): 
475.2873; found: 475.2862. 
 
(S)-N-(Adamantan-1-yl)-2-[(di-tert-butylphosphino)methyl]pyrrolidine-1-
carboxamide borane adduct ((S)-LU313·BH3) 
 
Product (S)-LU313·BH3 (72%) was prepared according to general procedure 2 from          
(S)-LC4∙BH3 and 1-adamantyl isocyanate. 
C24H46BN2OP (420.42 g·mol−1): 
m.p. 98-100 °C. Rf = 0.27 (SiO2, cyclohexane/ethyl acetate 9:1). 1H NMR (400 MHz, 
CDCl3): δ = 4.27-4.18 (m, 1 H, Pyr-2-H), 3.98 (s, 1 H, NH), 3.30-3.24 (m, 1 H,              
Pyr-5-HH’), 3.17 (“q”, JH,H = 8.1 Hz, 1 H, Pyr-5-HH’), 2.36 (“t”, J = 15 Hz, 1 H, 
CH’HP), 2.22-2.14 (m, 1 H, Pyr-3-HH’), 2.05 (br s, 3 H, Adm-3/5/7-H), 1.98 (br s, 7 H, 
Pyr-3-HH’ and Adm-2/8/9-H2), 1.95-1.87 (m, 2 H, Pyr-4-H2), 1.66 (br s, 6 H,                  
Adm-4/6/10-H2), 1.50-1.41 (m, 1 H, CHH’P), 1.37 (d, 3JH,P = 13 Hz, 9 H, tBu-H), 
1.23 (d, 3JH,P = 12 Hz, 9 H, tBu’-H), 0.82-0.13 (br q, 3 H, BH3) ppm. 13C{1H} NMR 
(101 MHz, CDCl3): δ = 155.6 (s, C=O), 55.1 (d, 2JC,P = 5.4 Hz, Pyr-2-CH), 51.4 (s,  
Adm-1-C), 46.2 (s, Pyr-5-CH2), 42.7 (s, Adm-2/8/9-CH2), 36.6 (s, Adm-4/6/10-CH2), 
33.6 (d, 1JC,P = 27 Hz, tBu-C), 32.6 (d, 1JC,P = 27 Hz, tBu’-C), 31.5 (s, Pyr-3-CH2), 
29.7 (s, Adm-3/5/7-CH), 28.4 (d, 2JC,P = 1.5 Hz, tBu-CH3), 28.0 (d, 2JC,P = 1.1 Hz,       
tBu’-CH3), 23.7 (s, Pyr-4-CH2), 22.4 (d, 1JC,P = 23 Hz, CH2P) ppm. 31P{1H} NMR 
(162 MHz, CDCl3): δ = 39.8 (br s) ppm. IR (neat): ߥ෤ = 2904s, 2851m, 2363m, 1644s, 
1510s, 1475m, 1454m, 1351m, 1306m, 1255w, 1191m, 1153w, 1072m, 1020w, 958w, 
926w, 816m, 758m cm−1. MS (FAB, NBS + KCl): m/z (%) = 459 (18, [M + K]+), 
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421 (24), 420 (31), 419 (100, [M − H]+), 418 (27), 407 (23, [M – BH2]+), 349 (17), 
242 (25), 240 (18), 135 (35), 128 (10), 70 (12), 57 (34). [ߙ]஽ଶ଴ = – 48.1 (c = 0.520, 
CHCl3). Elemental analysis: calc. C 68.57%, H 11.03%, N 6.66%; found: C 68.33%, 
H 11.01%, N 6.66%. 
 
(S)-N-(Adamantan-1-yl)-2-[(di-tert-butylphosphino)methyl]pyrrolidine-1-
carboxamide ((S)-LU313) 
 
Product (S)-LU313 was prepared according to general procedure 3 from (S)-LU313·BH3. 
C24H43N2OP (406.58 g·mol−1): 
31P{1H} NMR (162 MHz, CD2Cl2): δ = 21.7 (s) ppm. 
 
(S)-N-(Adamantan-1-yl)-2-[(dicyclohexylphosphino)methyl]pyrrolidine-1-
carboxamide borane adduct ((S)-LU314·BH3) 
 
Product (S)-LU32·BH3 (87%) was prepared according to general procedure 2 from           
(S)-LC5∙BH3 and 1-adamantyl isocyanate. 
C28H50BN2OP (472.49 g·mol−1): 
m.p. 79-82 °C. Rf = 0.19 (SiO2, cyclohexane/ethyl acetate 9:1). 1H NMR (500 MHz, 
CDCl3): δ = 4.16-4.08 (m, 1 H, Pyr-2-H), 4.08 (s, 1 H, NH), 3.30-3.26 (m, 1 H,                 
Pyr-5-HH’), 3.21 (“q”, J = 8.1 Hz, 1 H, Pyr-5-HH’), 2.19-2.12 (m, 1 H, CHH’P), 2.06 (br 
s, 3 H, Adm-3/5/7-H), 2.01-1.75 (m, 19 H, Pyr-H, Adm-2/8/9-H2 and Cy/Cy’-H), 1.73-
1.68 (m, 4 H, Cy/Cy’-H), 1.66 (br s, 6 H, Adm-4/6/10-H2), 1.59-1.53 (m, 1 H, CHH’P), 
1.49-1.37 (m, 2 H, Cy/Cy’-H), 1.37-1.16 (m, 7 H, Cy/Cy’-H), 0.73-0.04 (br q, 3 H, 
BH3) ppm. 13C{1H} NMR (126 MHz, CDCl3): δ = 155.6 (s, C=O), 53.6 (d, 2JC,P = 3.7 Hz, 
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Pyr-2-CH), 51.5 (s, Adm-1-C), 46.0 (s, Pyr-5-CH2), 42.7 (s, Adm-2/8/9-CH2), 36.6 (s, 
Adm-4/6/10-CH2), 32.5 (d, 1JC,P = 34 Hz, Cy-1-CH), 32.4 (d, 1JC,P = 32 Hz, Cy’-1-CH), 
32.0 (s, Pyr-3-CH2), 29.8 (s, Adm-3/5/7-CH), 27.1-26.6 (m, Cy/Cy’-CH2), 26.1 (s, 
Cy/Cy’-CH2), 24.6 (d, 1JC,P = 26 Hz, CH2P), 23.6 (s, Pyr-4-CH2) ppm. 31P{1H} NMR 
(162 MHz, CDCl3): δ = 21.8 (br d) ppm. IR (neat): ߥ෤ = 2907s, 2849s, 2374m, 1651s, 
1506s, 1447m, 1350m, 1339m, 1306m, 1195w, 1065m, 1003w, 854w cm−1. MS (ESI): 
m/z (%) = 483 (46), 481 (100, [M – BH3 + Na]+), 480 (50), 473 (11, [M + H]+), 466 (21), 
399 (17), 322 (13), 321 (16), 304 (37), 281 (30), 253 (25), 252 (78), 224 (11), 184 (29). [ߙ]஽ଶ଴ = – 21.4 (c = 0.186, CHCl3). Elemental analysis: calc. C 71.18%, H 10.67%, 
N 5.93%; found: C 71.20%, H 10.41%, N 6.07%. 
 
(S)-N-(Adamantan-1-yl)-2-[(dicyclohexylphosphino)methyl]pyrrolidine-1-
carboxamide ((S)-LU314) 
 
Product (S)-LU314 was prepared according to general procedure 3 from (S)-LU314·BH3. 
C28H47N2OP (458.66 g·mol−1): 
31P{1H} NMR (162 MHz, CDCl3): δ = – 10.2 (s) ppm. 
 
(S)-2-[(Diphenylphosphino)methyl]-N-tritylpyrrolidine-1-carboxamide ((S)-LU315) 
 
Product (S)-LU315·BH3 (92%), isolated as a colorless semisolid, was prepared according 
to general procedure 1 from (S)-LC1 and triphenylmethyl isocyanate (66).[82] 
C37H35N2OP (554.66 g·mol−1): 
Rf = 0.26 (SiO2, hexanes/ethyl acetate 7:3). 1H NMR (500 MHz, CDCl3): δ = 7.36-
7.11 (m, 25 H, PPh/Ph’-H and CPh-H), 5.42 (s, 1 H, NH), 4.06-3.95 (m, 1 H, Pyr-2-H), 
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3.37-3.21 (m, 2 H, Pyr-5-H2), 3.87 (“dt”, J = 14, 3.8 Hz, 1 H, CHH’P), 2.07 (dd, J = 14, 
9.3 Hz, 1 H, CHH’P), 1.93-1.79 (m, 2 H, Pyr-3-HH’ and Pyr-4-HH’), 1.79-1.69 (m, 2 H, 
Pyr-3-HH’ and Pyr-4-HH’) ppm. 13C{1H} NMR (101 MHz, CDCl3): δ = 155.4 (s, C=O), 
146.0 (s, CPh-i-C), 139.2 (d, 1JC,P = 12 Hz, PPh-i-C), 138.0 (d, 1JC,P = 12 Hz, PPh’-i-C), 
133.0 (d, 2JC,P = 5.6 Hz, PPh-o-CH), 132.8 (d, 2JC,P = 5.6 Hz, PPh’-o-CH), 128.9 (s,            
CPh-o-CH), 128.7-128.4 (m, PPh-CH), 127.9 (s, CPh-m-CH), 126.7 (s, CPh-p-CH), 
70.1 (s, CPh3), 55.9 (d, 2JC,P = 13 Hz, Pyr-2-CH), 46.4 (s, Pyr-5-CH2), 33.8 (d, 
1JC,P = 15 Hz, CH2P), 31.3 (d, 3JC,P = 8.2 Hz, Pyr-3-CH2), 24.0 (s, Pyr-4-CH2) ppm. 
31P{1H} NMR (162 MHz, CDCl3): δ = – 21.6 (s) ppm. IR (neat): ߥ෤ = 3055m, 2920m, 
2864m, 1663s, 1489s, 1474m, 1445m, 1433m, 1339s, 1184m, 1026m, 744m, 696s cm−1. 
MS (ESI): m/z (%) = 577 (20, [M + Na]+), 555 (39, [M + H]+), 244 (22), 243 (100), 
165 (19). [ߙ]஽ଶ଴ = – 28.8 (c = 1.71, CHCl3). Elemental analysis: calc. C 80.12%, 
H 6.36%, N 5.05%; found: C 79.86%, H 6.98%, N 4.65%. 
 
(S)-2-[(Di-ortho-tolylphosphino)methyl]-N-tritylpyrrolidine-1-carboxamide            
((S)-LU316) 
 
Product (S)-LU316 (42%) was prepared according to general procedure 1 from (S)-LC2 
and triphenylmethyl isocyanate (66).[82] 
C39H39N2OP (582.71 g·mol−1): 
Rf = 0.36 (SiO2, cyclohexane/ethyl acetate 8:2). 1H NMR (400 MHz, CDCl3): δ = 7.32-
7.06 (m, 23 H, oTol/oTol’-H and Ph-H), 5.65 (s, 1 H, NH), 4.12-4.02 (m, 1 H, Pyr-2-H), 
3.49-3.39 (m, 1 H, Pyr-5-HH’), 3.88-3.30 (m, 1 H, Pyr-5-HH’), 2.58-2.49 (m, 1 H, 
CHH’P), 2.37 (s, 3 H, oTol-CH3), 2.30 (s, 3 H, oTol’-CH3), 2.01-1.83 (m, 5 H, CHH’P 
and Pyr-H) ppm. 13C{1H} NMR (101 MHz, CDCl3): δ = 155.6 (s, C=O), 146.0 (s,              
Ph-i-C), 142.2 (d, 2JC,P = 7.3 Hz, oTol-2-C), 142.0 (d, 2JC,P = 7.7 Hz, oTol’-2-C), 
136.9 (d, 1JC,P = 12 Hz, oTol-1-C), 135.7 (d, 1JC,P = 12 Hz, oTol’-1-C), 131.6 (br s, 
oTol/oTol’-3-CH), 130.2 (d, 2JC,P = 5.0 Hz, oTol-6-CH), 130.1 (d, 2JC,P = 5.0 Hz,             
oTol’-6-CH), 128.8 (s, Ph-m-CH), 128.6 (s, oTol-4-CH), 128.6 (s, oTol’-4-CH), 127.9 (s, 
CHAPTER 6 
 
220 
Ph-o-CH), 126.7 (s, Ph-p-CH), 126.5 (s, oTol-5-CH), 126.2 (s, oTol’-5-CH), 70.1 (s, 
CPh3), 56.0 (d, 2JC,P = 21 Hz, Pyr-2-CH), 46.2 (s, Pyr-5-CH2), 32.8 (d, 1JC,P = 15 Hz, 
CH2P), 31.8 (d, 3JC,P = 9.2 Hz, Pyr-3-CH2), 23.8 (s, Pyr-4-CH2), 21.4 (d, 3JC,P = 8.4 Hz, 
oTol-CH3), 21.2 (d, 3JC,P = 8.0 Hz, oTol’-CH3) ppm. 31P{1H} NMR (162 MHz, CDCl3): 
δ = – 42.2 (s) ppm. 
 
(S)-2-[(Di-tert-butylphosphino)methyl]-N-tritylpyrrolidine-1-carboxamide borane 
adduct ((S)-LU317·BH3) 
 
Product (S)-LU317·BH3 (88%) was prepared according to general procedure 2 from    
(S)-LC4∙BH3 and triphenylmethyl isocyanate (66).[82] 
C33H46BN2OP (528.52 g·mol−1): 
m.p. 104-107 °C. Rf = 0.43 (SiO2, hexanes/ethyl acetate 4:1). 1H NMR (400 MHz, 
CDCl3): δ = 7.30-7.18 (m, 15 H, Ph-H), 5.40 (s, 1 H, NH), 4.25-4.18 (m, 1 H, Pyr-2-H), 
3.44-3.36 (m, 2 H, Pyr-5-H2), 2.20-1.93 (m, 5 H, Pyr-H and CHH’P), 1.35-1.20 (m, 1 H, 
CHH’P), 1.19 (d, 3JH,P = 12 Hz, 9 H, tBu-H), 1.17 (d, 3JH,P = 13 Hz, 9 H, tBu’-H), 0.88-
0.04 (br q, 3 H, BH3) ppm. 13C{1H} NMR (101 MHz, CDCl3): δ = 155.2 (s, C=O), 
146.0 (s, Ph-i-C), 128.9 (s, Ph-m-CH), 127.9 (s, Ph-o-CH), 126.8 (s, Ph-p-CH), 70.4 (s, 
CPh3), 55.4 (d, 2JC,P = 5.0 Hz, Pyr-2-CH), 46.0 (s, Pyr-5-CH2), 33.5 (d, 1JC,P = 27 Hz, 
tBu-C), 32.0 (d, 1JC,P = 27 Hz, tBu’-C), 31.2 (s, Pyr-3-CH2), 28.2 (d, 2JC,P = 1.5 Hz,              
tBu-CH3), 27.9 (d, 2JC,P = 0.8 Hz, tBu’-CH3), 24.0 (s, Pyr-4-CH2), 22.2 (d, 1JC,P = 23 Hz, 
CH2P) ppm. 31P{1H} NMR (162 MHz, CDCl3): δ = 39.3 (br d, J = 61 Hz) ppm. IR (neat): 
ߥ෤ = 2930m, 2852m, 2372m, 1489s, 1447s, 1339s, 1308m, 1186w, 1157w, 1064m, 1000w, 
748m, 696s cm−1. MS (FAB, NBA): m/z (%) = 527 (16, [M – H]+), 244 (21), 243 (100), 
165 (12), 57 (12). [ߙ]஽ଶ଴ = + 17.0 (c = 0.493, CHCl3). Elemental analysis: calc. 
C 74.99%, H 8.77%, N 5.30%; found: C 74.78%, H 9.00%, N 5.40%. 
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(S)-2-[(Di-tert-butylphosphino)methyl]-N-tritylpyrrolidine-1-carboxamide ((S)-LU317) 
 
Product (S)-LU317 was prepared according to general procedure 3 from (S)-LU317·BH3. 
C33H43N2OP (514.68 g·mol−1): 
31P{1H} NMR (162 MHz, CD2Cl2): δ = 21.8 (s) ppm. 
 
(S)-2-[(Dicyclohexylphosphino)methyl]-N-tritylpyrrolidine-1-carboxamide borane 
adduct ((S)-LU318·BH3) 
 
Product (S)-LU318·BH3 (87%) was prepared according to general procedure 2 from     
(S)-LC5∙BH3 and triphenylmethyl isocyanate (66).[82] 
C37H50BN2OP (580.59 g·mol−1): 
m.p. 58-60 °C. Rf = 0.38 (SiO2, hexanes/ethyl acetate 4:1). 1H NMR (400 MHz, CDCl3): 
δ = 7.33-7.17 (m, 15 H, Ph-H), 5.42 (s, 1 H, NH), 4.17-4.08 (m, 1 H, Pyr-2-H), 3.38 (“t”, 
J = 6.3 Hz, 2 H, Pyr-5-CH2), 2.09-1.04 (m, 28 H, Pyr-H, Cy/Cy’-H and CH2P), 0.80-
0.07 (“br q”, 3 H, BH3) ppm. 13C{1H} NMR (101 MHz, CDCl3): δ = 155.0 (s, C=O), 
145.9 (s, Ph-i-C), 128.9 (s, Ph-m-CH), 127.9 (s, Ph-o-CH), 126.8 (s, Ph-p-CH), 70.3 (s, 
CPh3), 54.1 (br d, 2JC,P = 4.6 Hz, Pyr-2-CH), 45.9 (s, Pyr-5-CH2), 32.5 (d, 1JC,P = 14 Hz, 
Cy-1-CH), 32.2 (d, 1JC,P = 12 Hz, Cy’-1-CH), 31.5 (s, Pyr-3-CH2), 27.1-25.9 (m,           
Cy/Cy’-CH2), 24.0 (s, Pyr-4-CH2) ppm. 31P{1H} NMR (162 MHz, CDCl3): δ = 20.8 (“br 
d”) ppm. IR (neat): ߥ෤ = 2930m, 2918m, 2851m, 2372m, 1655s, 1489s, 1447s, 1339s, 
1308m, 1186w, 1065m, 899m, 746m, 696s cm−1. MS (FAB, NBA): m/z (%) = 580 (11), 
579 (22, [M – H]+), 244 (20), 243 (100), 165 (16), 149 (12). [ߙ]஽ଶ଴ = + 3.0 (c = 1.30, 
CHCl3). Elemental analysis: calc. C 76.54%, H 8.68%, N 4.83%; found: C 76.22%, 
H 8.65%, N 5.05%. 
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(S)-2-[(Dicyclohexylphosphino)methyl]-N-tritylpyrrolidine-1-carboxamide            
((S)-LU318) 
 
Product (S)-LU318 was prepared according to general procedure 3 from (S)-LU318·BH3. 
C37H47N2OP (566.76 g·mol−1): 
31P{1H} NMR (203 MHz, CD2Cl2): δ = – 10.9 (s) ppm. 
 
2,5-Dioxopyrrolidin-1-yl phenyl carbamate (70) 
 
A mixture of aniline (69, 140 μL, 1.52 mmol, 1.0 eq.) and triethylamine (220 μL, 
1.58 mmol, 1.0 eq.) in dichloromethane (16 mL) was added to a solution of                     
N,N’-disuccinimidyl carbonate (DSC, 614 mg, 2.40 mmol, 1.6 eq.) in dichloromethane 
(32 mL) at 0 °C. The reaction mixture was then allowed to stir at room temperature for 
30 minutes, before it was reduced to dryness under reduced pressure. The residue was 
purified by column chromatography on silica gel (3 x 10 cm), eluting with hexanes/ethyl 
acetate (3:5). The title compound 70 (292 mg, 1.25 mmol, 82%) was obtained as a 
colorless solid.  
C11H10N2O4 (234.21 g·mol−1): 
Rf = 0.28 (SiO2, hexanes/ethyl acetate 3:5). 1H NMR (400 MHz, CDCl3): δ = 7.55 (br s, 
1 H, NH), 7.37 (d, 3JH,H = 8.5 Hz, 2 H, Ph-o-H), 7.31 (“t”, 3JH,H = 7.9 Hz, 2 H, Ph-m-H), 
7.13 (d, 3JH,H = 7.3 Hz, 1 H, Ph-p-H), 2.87 (s, 4 H, CH2) ppm. 13C{1H} NMR (101 MHz, 
(CD3)2SO): δ = 171.7 (s, C=O), 150.0 (C=O), 138.1 (s, Ph-i-C), 129.7 (s, Ph-p-CH), 
124.9 (s, Ph-m-CH), 119.6 (s, Ph-o-CH), 26.2 (s, CH2) ppm. 
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(S)-2-[(Diphenylphosphino)methyl]-N-phenylpyrrolidine-1-carboxamide ((S)-LU319) 
 
Compound (S)-LU319 (49%) was prepared according to general procedure 1 from       
(S)-LC1 and 2,5-dioxopyrrolidin-1-yl phenyl carbamate (70). 
C24H25N2OP (388.44 g·mol−1): 
m.p. 166-169 °C. Rf = 0.16 (SiO2, hexanes/ethyl acetate 7:3). 1H NMR (500 MHz, 
CDCl3): δ = 8.56 (s, 1 H, NH), 7.60-7.57 (m, 2 H, PPh-o-H), 7.44-7.40 (m, 2 H,             
PPh’-o-H), 7.39-7.34 (m, 3 H, PPh/Ph’-H), 7.31-7.27 (m, 3 H, NPh-o-H and PPh/Ph’-H), 
7.27-7.24 (m, 4 H, NPh-m-H and PPh/Ph’-H), 7.03-6.97 (m, 1 H, NPh-p-H), 4.13-
4.00 (m, 1 H, Pyr-2-H), 3.42 (“t”, J = 1.6 Hz, 2 H, Pyr-5-H2), 2.79 (“dt”, J = 14, 2.8 Hz, 
1 H, CHH’P), 2.20-2.14 (m, 1 H, CHH’P), 2.14-2.04 (m, 3 H, Pyr-3-H2 and Pyr-4-HH’), 
1.99-1.91 (m, 1 H, Pyr-4-HH’) ppm. 13C{1H} NMR (126 MHz, CDCl3): δ = 153.8 (s, 
C=O), 139.1 (s, NPh-i-C), 138.6 (d, 1JC,P = 12 Hz, PPh-i-C), 137.6 (d, 1JC,P = 12 Hz, 
PPh’-i-C), 133.2 (d, 2JC,P = 19 Hz, PPh-o-CH), 132.7 (d, 2JC,P = 19 Hz, PPh’-o-CH), 
129.1 (s, PPh-p-CH), 128.9 (d, 3JC,P = 6.4 Hz, PPh-m-CH), 128.9 (s, NPh-o-CH), 
128.8 (s, PPh’-p-CH), 128.6 (d, 2JC,P = 6.4 Hz, PPh’-m-CH), 122.9 (s, NPh-p-CH), 
119.8 (s, NPh-m-CH), 55.6 (d, 2JC,P = 20 Hz, Pyr-2-CH), 46.5 (s, Pyr-5-CH2), 33.8 (s, 
1JC,P = 15 Hz, CH2P), 31.4 (d, 3JC,P = 8.2 Hz, Pyr-3-CH2), 24.0 (s, Pyr-4-CH2) ppm. 
31P{1H} NMR (162 MHz, CDCl3): δ = − 22.3 (s) ppm. IR (neat): ߥ෤ = 3270m, 2945w, 
2906w, 2880w, 1627s, 1592m, 1523s, 1497m, 1432s, 1379s, 1353m, 1293w, 1242m, 
1215m, 1190m, 1093w, 1027w, 918w, 880w, 842w, 736s, 692s cm−1. MS (EI, 70 eV): 
m/z (%) = 388 (10, M+), 387 (10), 296 (11), 201 (18), 200 (52), 199 (20), 188 (13), 
187 (100), 185 (28), 183 (31), 119 (20), 91 (11), 84 (49), 83 (10), 70 (78). [ߙ]஽ଶ଴ = – 31.8 
(c = 0.592, CHCl3). HRMS (ESI): calc. for C24H26N2OP ([M+H]+): 389.1777; found: 
389.1772. 
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(S)-2-{[Di(furan-2-yl)phosphine]methyl}-N-phenylpyrrolidine-1-carboxamide       
((S)-LU320) 
 
Compound (S)-LU320 (61%) was prepared according to general procedure 1 from          
(S)-LC3 and 2,5-dioxopyrrolidin-1-yl phenyl carbamate (70). 
C20H21N2O3P (368.37 g·mol−1): 
m.p. 97-99 °C. Rf = 0.18 (SiO2, cyclohexane/ethyl acetate 4:1). 1H NMR (400 MHz, 
(CD3)2CO): δ = 8.34 (s, 1 H, NH), 7.86 (d, J = 9.8 Hz, 1 H, Fur-H), 7.70-7.58 (m, 3 H, 
Fur/Fur’-H and Ph/Ph’-H), 7.41-7.26 (m, 4 H, Fur/Fur’-H and Ph/Ph’-H), 7.12-7.00 (m, 
2 H, Fur/Fur’-H and Ph/Ph’-H), 6.57 (d, J = 16 Hz, 1 H, Fur’-H), 4.37-4.22 (m, 1 H,           
Pyr-2-H), 3.69-3.51 (m, 2 H, Pyr-5-H2), 3.06-2.97 (m, 1 H, CHH’P), 2.41 (dd, 
2JH,P = 13 Hz, J = 10 Hz 1 H, CHH’P), 2.18-1.97 (m, 3 H, Pyr-3-H2 and Pyr-4-HH’), 
1.89-1.78 (m, 1 H, Pyr-4-HH’) ppm. 13C{1H} NMR (101 MHz, (CD3)2CO): δ = 155.7 (s, 
C=O), 153.7-153.4 (br, Ph-1-C), 149.2-149.0 (m, Fur/Fur’-2-C), 142.6 (s, Fur-5-CH), 
142.1 (Fur’-5-CH), 130.6/130.2* (s, Ph-m-CH), 123.9/123.7* (s, Ph-p-CH), 121.5 (d, 
2JC,P = 25 Hz, Fur-3-CH), 121.1 (d, 2JC,P = 19 Hz, Fur’-3-CH), 121.3/120.4* (s,                
Ph-o-CH), 112.7-112.5 (m, Fur/Fur’-4-CH), 57.2 (d, 2JC,P = 22 Hz, Pyr-2-CH), 48.0 (s, 
Pyr-5-CH2), 32.3 (d, 3JC,P = 3.4 Hz, Pyr-3-CH2), 32.1 (d, 1JC,P = 6.9 Hz, CH2P), 25.8 (s, 
Pyr-4-CH2) ppm. In the 13C NMR spectra the title compound can be seen as a mixture of 
rotamers in a ratio close to 1:1 and therefore nuclei, which are detected twice are marked 
with an asterisk. 31P{1H} NMR (162 MHz, (CD3)2CO): δ = − 66.8 (“br d”) ppm. 
IR (KBr): ߥ෤ = 3286m, 3110w, 2958w, 2871w, 1945w, 1872w, 1719m, 1655s, 1598s, 
1534s, 1495m, 1441s, 1366m, 1308s, 1231s, 1150m, 1070m, 1010m, 894m, 840w, 
752s cm−1. MS (EI, 70 eV): m/z (%) = 368 (5, M+), 276 (37), 212 (22), 187 (10), 
165 (16), 119 (12), 94 (7), 93 (100), 92 (9), 77 (11), 70 (46), 65 (10). [ߙ]஽ଶ଴ = − 29.2 
(c = 0.200, CHCl3). HRMS (ESI): calc. for C20H22N2O3P ([M+H]+): 369.1363; found: 
369.1358. 
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(S)-2-[(Diphenylphosphino)methyl]-N-mesitylpyrrolidine-1-carboxamide ((S)-LU321) 
 
Product (S)-LU321 (82%) was prepared according to general procedure 1 from (S)-LC1 
and 2,4,6-trimethylphenyl isocyanate. 
C27H31N2OP (430.52 g·mol−1): 
m.p. 163-166 °C. Rf = 0.14 (SiO2, hexanes/ethyl acetate 4:1). 1H NMR (400 MHz, 
CDCl3): δ = 7.59 (“dt”, J = 7.7, 1.5 Hz, 2 H, Ph-o-H), 7.42-7.38 (m, 2 H, Ph’-o-H), 7.32-
7.23 (m, 6 H, Ph/Ph’-H), 6.85 (br s, 2 H, Mes-H), 5.26 (br s, 1 H, NH), 4.08-3.95 (m, 1 H, 
Pyr-2-H), 3.51-3.40 (m, 2 H, Pyr-5-H2), 2.91 (“dt”, J = 14, 3.6 Hz, 1 H, CHH’P), 2.25 (s, 
3 H, Mes-4-CH3), 2.15 (s, 6 H, Mes-2/6-CH3), 2.10-2.01 (m, 4 H, CHH’P, Pyr-3-H2 and 
Pyr-4-HH’), 2.01-1.83 (m, 1 H, Pyr-4-HH’) ppm. 13C{1H} NMR (126 MHz, CDCl3): 
δ = 154.7 (s, C=O), 139.1 (d, 1JC,P = 12 Hz, Ph-i-C), 137.4 (d, 1JC,P = 13 Hz, Ph’-i-C), 
136.1 (s, Mes-4-C), 135.5 (s, Mes-2/6-C), 133.3 (d, 2JC,P = 19 Hz, Ph-o-CH), 132.6 (d, 
2JC,P = 19 Hz, Ph’-o-CH), 132.6 (s, Mes-1-C), 129.1 (s, Ph-p-CH), 128.9 (s,                 
Mes-3/5-CH), 128.8 (d, 3JC,P = 6.3 Hz, Ph-m-CH), 128.6 (s, Ph’-p-CH), 128.6 (d, 
3JC,P = 6.9 Hz, Ph’-m-CH), 55.6 (d, 2JC,P = 21 Hz, Pyr-2-CH), 46.5 (s, Pyr-5-CH2), 
34.1 (d, 1JC,P = 14 Hz, CH2P), 31.5 (d, 3JC,P = 7.3 Hz, Pyr-3-CH2), 24.1 (s, Pyr-4-CH2), 
21.0 (s, Mes-4-CH3), 18.7 (s, Mes-2/6-CH3) ppm. 31P{1H} NMR (162 MHz, CDCl3): 
δ = − 21.1 (s) ppm. IR (neat): ߥ෤ = 3271m, 970m, 2949m, 2922m, 1735m, 1622s, 1608m, 
1505s, 1482m, 1433m, 1418m, 1362s, 1235m, 1210m, 1121w, 1094w, 1068w, 845m, 
747s, 736s, 694s cm−1. MS (EI, 70 eV): m/z (%) = 430 (4, M+), 415 (10), 353 (12), 
286 (35), 284 (14), 229 (17), 215 (18), 201 (22), 200 (100), 199 (32), 185 (23), 183 (38), 
161 (45), 146 (30), 133 (10), 91 (12), 84 (45), 83 (38), 70 (99). [ߙ]஽ଶ଴ = – 76.4 (c = 0.372, 
CHCl3).  
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(S)-2-[(Di-ortho-tolylphosphino)methyl]-N-mesitylpyrrolidine-1-carboxamide       
((S)-LU322) 
 
Product (S)-LU322 (67%) was prepared according to general procedure 1 from (S)-LC2 
and 2,4,6-trimethylphenyl isocyanate. 
C29H35N2OP (458.57 g·mol−1): 
m.p. 169-173 °C. Rf = 0.15 (SiO2, hexanes/ethyl acetate 4:1). 1H NMR (400 MHz, 
CDCl3): δ = 7.58-7.50 (m, 1 H, oTol-H), 7.24-7.00 (m, 7 H, oTol/oTol’-H), 6.84 (s, 2 H, 
Mes-H), 5.13 (s, 1 H, NH), 3.98-3.87 (m, 1 H, Pyr-2-H), 3.55-3.40 (m, 2 H, Pyr-5-H2), 
2.84-2.75 (m, 1 H, CHH’P), 2.44 (s, 3 H, oTol-CH3), 2.41 (s, 3 H, oTol’-CH3), 2.24 (s, 
3 H, Mes-4-CH3), 2.20-1.87 (m, 5 H, Pyr-H and CHH’P), 2.13 (s, 6 H,                        
Mes-2/6-CH3) ppm. 13C{1H} NMR (126 MHz, CDCl3): δ = 154.6 (s, C=O), 142.6 (d, 
2JC,P = 26 Hz, oTol-2-C), 41.6 (d, 2JC,P = 25 Hz, oTol’-2-C), 137.1 (d, 1JC,P = 12 Hz, 
oTol-1-C), 136.1 (s, Mes-4-C), 135.7 (d, 1JC,P = 13 Hz, oTol’-1-C), 135.5 (s, Mes-2/6-C), 
132.6 (s, Mes-1-C), 131.9 (s, oTol-3-CH), 131.3 (s, oTol’-3-C), 130.3-130.0 (m, 
oTol/oTol’-6-CH), 128.9 (s, Mes-3/5-CH), 128.9 (s, oTol-4-CH), 128.6 (s, oTol’-4-CH), 
126.8 (s, oTol-5-CH), 126.3 (s, oTol’-5-CH), 55.3 (d, 2JC,P = 22 Hz, Pyr-2-CH), 46.5 (s, 
Pyr-5-CH2), 33.1 (d, 1JC,P = 15 Hz, CH2P), 31.6 (d, 3JC,P = 6.9 Hz, Pyr-3-CH2), 24.0 (s, 
Pyr-4-CH2), 21.6-21.1 (m, oTol/oTol’-CH3), 21.0 (s, Mes-4-CH3), 18.6 (s,                        
Mes-2/6-CH3) ppm. 31P{1H} NMR (162 MHz, CDCl3): δ = − 42.3 (s) ppm. IR (neat): 
ߥ෤ = 32559m, 2962m, 2922m, 2874m, 1623s, 1609m, 1502s, 1498s, 1450m, 1352s, 
1235m, 1202m, 1070w, 1029w, 947w, 917w, 844m, 755s, 742s cm−1. MS (EI, 70 eV): 
m/z (%) = 458 (8, M+), 443 (17), 367 (35), 314 (30), 312 (12), 229 (60), 228 (45), 
227 (19), 214 (14), 213 (80), 161 (33), 146 (21), 91 (12), 84 (74), 83 (21), 70 (100). [ߙ]஽ଶ଴ = – 30.5 (c = 0.322, CHCl3). 
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(S)-2-[(Di-tert-butylphosphino)methyl]-N-mesitylpyrrolidine-1-carboxamide borane 
adduct ((S)-LU323·BH3) 
 
Product (S)-LU323·BH3 (90%) was prepared according to general procedure 2 from      
(S)-LC4∙BH3 and 2,4,6-trimethylphenyl isocyanate. 
C23H42BN2OP (404.38 g·mol−1): 
m.p. 206-208 °C. Rf = 0.19 (SiO2, hexanes/ethyl acetate 4:1). 1H NMR (500 MHz, 
CDCl3): δ = 6.87 (s, 2 H, Mes-H), 5.55 (br s, 1 H, NH), 4.40-4.27 (m, 1 H, Pyr-2-H), 
3.54-3.44 (m, 1 H, Pyr-5-HH’), 3.44-3.36 (m, 1 H, Pyr-5-HH’), 2.57 (“t”, J = 15 Hz, 1 H, 
CHH’P), 2.24 (s, 3 H, Mes-4-CH3), 2.22 (s, 6 H, Mes-2/6-CH3), 2.21-2.11 (m, 2 H,             
Pyr-3-H2), 2.06-1.98 (m, 2 H, Pyr-4-H2), 1.54-1.44 (m, 1 H, CHH’P), 1.35 (d, 
3JH,P = 13 Hz, 9 H, tBu-H), 1.25 (d, 3JH,P = 13 Hz, 9 H, tBu’-H), 0.90-0.06 (br q, 3 H, 
BH3) ppm. 13C{1H} NMR (126 MHz, CDCl3): δ = 154.7 (s, C=O), 136.3 (s, Mes-4-C), 
135.5 (s, Mes-2/6-C), 132.4 (s, Mes-1-C), 129.1 (s, Mes-3/5-CH), 55.9 (d, 2JC,P = 5.5 Hz, 
Pyr-2-CH), 46.4 (s, Pyr-5-CH2), 33.2 (d, 1JC,P = 27 Hz, tBu-C), 32.0 (d, 1JC,P = 27 Hz, 
tBu’-C), 31.6 (s, Pyr-3-CH2), 28.2 (br s, tBu-CH3), 28.0 (br s, tBu’-CH3), 24.1 (s,              
Pyr-4-CH2), 22.4 (d, 1JC,P = 24 Hz, CH2P), 21.0 (s, Mes-4-CH3), 18.6 (s, Mes-2/6-CH3) 
ppm. 31P{1H} NMR (162 MHz, CDCl3): δ = – 39.8 (“br d”, J = 67 Hz) ppm. IR (neat): 
ߥ෤ = 2926m, 2852m, 2376m, 1620s, 1514s, 1475m, 1450w, 1389m, 1346s, 1236w, 
1190m, 1147m, 1070m, 1020m, 813m cm−1. MS (FAB, NBA): m/z (%) = 405 (23), 
404 (32), 403 (100, [M – H]+), 402 (25), 391 (15, [M – BH2]+), 333 (22), 277 (12), 
270 (36), 242 (21), 186 (12), 128 (10), 70 (15), 57 (46). [ߙ]஽ଶ଴ = – 56.2 (c = 1.01, CHCl3). 
Elemental analysis: calc. C 68.31%, H 10.47%, N 6.93%; found: C 68.33%, H 10.32%, 
N 7.00%. 
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(S)-2-[(Di-tert-butylphosphino)methyl]-N-mesitylpyrrolidine-1-carboxamide         
((S)-LU323) 
 
Product (S)-LU323 was prepared according to general procedure 3 from (S)-LU323·BH3. 
C23H39N2OP (390.54 g·mol−1): 
31P{1H} NMR (162 MHz, CD2Cl2): δ = 21.3 (s) ppm. 
 
(S)-2-[(Dicyclohexylphosphino)methyl]-N-mesitylpyrrolidine-1-carboxamide borane 
adduct ((S)-LU324·BH3) 
 
Product (S)-LU324·BH3 (82%) was prepared according to general procedure 2 from          
(S)-LC5∙BH3 and 2,4,6-trimethylphenyl isocyanate. 
C27H46BN2OP (456.45 g·mol−1): 
m.p. 141-143 °C. Rf = 0.23 (SiO2, hexanes/ethyl acetate 4:1). 1H NMR (500 MHz, 
CDCl3): δ = 6.68 (s, 2 H, Mes-H), 5.65 (s, 1 H, NH), 4.29-4.22 (m, 1 H, Pyr-2-H), 3.48-
3.43 (m, 1 H, Pyr-5-HH’), 3.93 (“q”, 1 H, J = 7.9 Hz, Pyr-5-HH’), 2.38 (“t”, J = 14 Hz, 
1 H, CHH’P), 2.24 (s, 3 H, Mes-4-CH3), 2.21 (s, 6 H, Mes-2/6-CH3), 2.14-2.08 (m, 1 H, 
Pyr-3-HH’), 2.09-1.93 (m, 5 H, Pyr-H and Cy/Cy’-1-H), 1.92-1.64 (m, 10 H, Cy/Cy’-H), 
1.58 (“q”, J = 11 Hz, 1 H, CHH’P), 1.48-1.38 (m, 2 H, Cy/Cy’-H), 1.38-1.28 (m, 2 H, 
Cy/Cy’-H), 1.28-1.18 (m, 6 H, Cy/Cy’-H), 0.78-0.06 (br q, 3 H, BH3) ppm. 
13C{1H} NMR (126 MHz, CDCl3): δ = 154.5 (s, C=O), 136.1 (s, Mes-1-C), 135.5 (s, 
Mes-2/6-C), 132.4 (s, Mes-4-C), 129.0 (s, Mes-3/5-CH), 54.4 (br s, Pyr-2-CH), 46.3 (s, 
Pyr-5-CH2), 32.5 (d, 1JC,P = 29 Hz, Cy-1-CH), 32.2 (d, 1JC,P = 29 Hz, Cy’-1-CH), 31.9 (br 
s, Pyr-3-CH2), 27.1 (s, Cy/Cy-CH2), 27.0 (s, Cy/Cy-CH2), 26.9 (d, J = 3.7 Hz,              
Cy/Cy’-CH2), 26.8 (d, J = 5.5 Hz, Cy/Cy’-CH2), 26.8 (s, Cy/Cy’-CH2), 26.7 (s,              
Cy/Cy’-CH2), 26.5 (br s, Cy/Cy’-CH2), 26.4 (br d, J = 1.8 Hz, Cy/Cy’-CH2), 26.1 (s,         
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Cy-4-CH2), 26.0 (s, Cy’-4-CH2), 24.6 (d, 1JC,P = 27 Hz, CH2P), 24.0 (s, Pyr-4-CH2), 
21.0 (s, Mes-4-CH3), 18.6 (s, Mes-2/6-CH3) ppm. 31P{1H} NMR (162 MHz, CDCl3): 
δ = 21.8 (br s) ppm. IR (neat): ߥ෤ = 2928m, 2851m, 2372m, 1653s, 1628s, 1504m, 1489s, 
1447m, 1339m, 1186w, 1065m, 746m, 696s cm−1. MS (FAB, NBA): m/z (%) = 457 (28), 
456 (42), 455 (100, [M – H]+), 454 (31), 443 (18, [M – BH2]+), 359 (24), 322 (42), 
294 (38), 293 (11), 292 (18), 277 (10), 70 (10), 55 (12). [ߙ]஽ଶ଴ = – 35.5 (c = 0.774, 
CHCl3). Elemental analysis: calc. C 71.05%, H 10.16%, N 6.14%; found: C 70.90%, 
H 10.08%, N 6.07%. 
 
(S)-2-[(Dicyclohexylphosphino)methyl]-N-mesitylpyrrolidine-1-carboxamide       
((S)-LU324) 
 
Product (S)-LU324 was prepared according to general procedure 3 from (S)-LU324·BH3. 
C27H43N2OP (442.31 g·mol−1): 
31P{1H} NMR (203 MHz, CD2Cl2): δ = – 10.1 (s) ppm. 
 
2,4,6-Tri-tert-butylmethylphenyl isocyanate (68)[83] 
 
A solution of di-tert-butyl carbonate (339 mg, 1.55 mmol, 1.4 eq.) in acetonitrile (2 mL) 
was successively with a solution of 4-(dimethylamino)pyridine (DMAP, 136 mg, 
1.11 mmol, 1.0 eq.) in acetonitrile (3 mL) and a solution of 2,4,6-tri-tert-butylaniline (67, 
290 mg, 1.11 mmol, 1.0 eq.) in acetonitrile (2 mL). The resulting yellowish mixture was 
stirred at room temperature for 10 minutes. The reaction mixture was treated with 
H2SO4 (7.0 eq.) as a 40% solution in acetonitrile and then stirred for 5 minutes. The 
mixture was extracted with n-hexanes (3 x 30 mL). The combined hexanes layers were 
dried over MgSO4 and the solvent was evaporated under reduced pressure, to afford 
68 (225 mg, 783 μmol, 71%) as a yellowish solid. The compound was used without 
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further purification. The spectroscopic data were consistent with those reported in the 
literature.[135] 
 
(S)-2-[(Diphenylphosphino)methyl]-N-(2,4,6-tri-tert-butylphenyl)pyrrolidine-1-
carboxamide ((S)-LU325) 
 
Product (S)-LU325 (34%) was prepared according to general procedure 1 from (S)-LC1 
and 2,4,6-tri-tert-butylmethylphenyl isocyanate (68). 
C36H49N2OP (556.76 g·mol−1): 
m.p. 186-188 °C. Rf = 0.34 (SiO2, hexanes/ethyl acetate 4:1). 1H NMR (400 MHz, 
CD2Cl2): δ = 7.65 (“t“, 3JH,H = 7.1 Hz, 2 H, Ph-o-H), 7.44 (s, 2 H, Ar-3/5-H), 7.43-
7.27 (m, 8 H, Ph/Ph’-H), 5.56 (s, 1 H, NH), 4.14-4.03 (m, 1 H, Pyr-2-H), 3.58-3.43 (m, 
2 H, Pyr-5-H2), 2.98 (br d, J = 13 Hz, 1 H, CHH’P), 2.20-1.97 (m, 4 H, Pyr-H), 1.97-
1.83 (m, 1 H, CHH’P), 1.37 (s, 18 H, tBu/tBu’-H3), 1.35 (s, 9 H, tBu’’-H3) ppm. 
13C{1H} NMR (126 MHz, CD2Cl2): δ = 155.8 (s, C=O), 149.2 (s, Ar-4-C), 149.0 (s,          
Ar-2/6-C), 148.8 (s, Ar-2/6-C), 139.7 (br s, Ph-i-C), 137.6 (d, 1JC,P = 13 Hz, Ph’-i-C), 
133.0 (d, 2JC,P = 19 Hz, Ph-o-CH), 132.6 (d, 2JC,P = 19 Hz, Ph’-o-CH), 132.4 (s, Ar-1-C), 
128.7 (s, Ph-p-CH), 128.5 (d, 3JC,P = 6.8 Hz, Ph-m-CH), 128.5 (Ph’-p-CH), 128.4 (d, 
3JC,P = 7.0 Hz, Ph’-m-CH), 123.0 (2s, Ar-3/5-CH), 55.6 (d, 2JC,P = 22 Hz, Pyr-2-CH), 
46.1 (s, Pyr-5-CH2), 36.4 (s, tBu-C), 36.3 (s, tBu’-C), 34.9 (s, tBu’’-C), 33.5 (br d, 
1JC,P = 14 Hz, CH2P), 31.9 (s, tBu/tBu’-CH3), 31.2 (s, tBu’’-CH3), 30.7 (br s, Pyr-3-CH2), 
24.3 (s, Pyr-4-CH2) ppm. 31P{1H} NMR (162 MHz, CD2Cl2): δ = − 22.0 (s) ppm. 
IR (neat): ߥ෤ = 3305w, 2959m, 2904m, 2867m, 1740m, 1628s, 1598m, 1516s, 1507s, 
1474m, 1433m, 1361s, 1349s, 1217m, 1204m, 1085w, 1030w, 913w, 876m, 738s, 
696s cm−1. MS (EI, 70 eV): m/z (%) = 556 (1, M+), 500 (14), 499 (42), 479 (19), 
355 (25), 273 (21), 272 (100), 256 (11), 216 (11), 201 (11), 200 (38), 199 (11), 185 (23), 
183 (20), 84 (40), 83 (28), 70 (44), 57 (18). [ߙ]஽ଶ଴ = – 70.9 (c = 1.18, CHCl3). 
 
                                                             
[135] J. F. W. Keana, A. P. Guzikowski, D. D. Ward, C. Morat, F. L. Van Nice, J. Org. Chem. 1983, 48, 2654-
2660. 
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(S)-2-[(Diphenylphosphino)methyl]-N-(naphthalene-1-yl)pyrrolidine-1-carboxamide 
((S)-LU326) 
 
Product (S)-LU326 (81%) was prepared according to general procedure 1 from (S)-LC1 
and 1-naphthyl isocyanate. 
C28H27N2OP (438.50 g·mol−1): 
Rf = 0.19 (SiO2, hexanes/ethyl acetate 4:1). 1H NMR (400 MHz, CDCl3): δ = 7.88-
7.81 (m, 1 H, Naph-2-H), 7.80-7.70 (m, 2 H, Ar-H), 7.66-7.56 (m, 3 H, Ar-H), 7.50-
7.40 (m, 5 H, Ar-H), 7.33-7.22 (m, 6 H, Naph-8-H and Ph/Ph’-H), 6.38 (s, 1 H, NH), 
4.28-4.18 (m, 1 H, Pyr-2-H), 3.57-3.48 (m, 2 H, Pyr-5-H2), 2.97-2.89 (m, 1 H, CHH’P), 
2.27-2.19 (m, 1 H, CHH’P), 2.19-2.07 (m, 3 H, Pyr-3-H2 and Pyr-4-HH’), 2.05-1.96 (m, 
1H, Pyr-4-HH’) ppm. 13C{1H} NMR (126 MHz, CDCl3): δ = 154.5 (s, C=O), 138.5 (br d, 
1JC,P = 12 Hz, Ph-i-CH), 137.1 (d, 1JC,P = 10 Hz, Ph’-i-CH), 134.3 (s, Naph-1-C), 
133.7 (s, Naph-5a-C), 133.1 (d, 2JC,P = 19 Hz, Ph-o-CH), 132.7 (d, 2JC,P = 19 Hz,             
Ph’-o-CH), 129.1 (s, Ph-p-CH), 129.2-128.9 (m, Ph’-p-CH, Ph-m-CH and Naph-CH), 
128.9 (d, 3JC,P = 7.2 Hz, Ph’-m-CH), 127.9 (s, Naph-1a-C), 126.6 (br s, 2 Naph-CH), 
125.8 (s, Naph-CH), 124.7 (s, Naph-CH), 121.0 (s, Naph-CH), 120.6 (s, Naph-CH), 
56.0 (d, 2JC,P = 19 Hz, Pyr-2-CH), 46.6 (s, Pyr-5-CH2), 33.7 (d, 1JC,P = 13 Hz, CH2P), 
31.3 (d, 3JC,P = 8.9 Hz, Pyr-3-CH2), 24.2 (s, Pyr-4-CH2) ppm. 31P{1H} NMR (162 MHz, 
CDCl3): δ = − 21.5 (s) ppm. IR (neat): ߥ෤ = 3239w, 3049w, 2938w, 2874w, 1622s, 1596m, 
1524m, 14945m, 1480m, 1432m, 1372m, 1328m, 1271m, 1243w, 1184w, 1117w, 1070w, 
1016w, 926w, 851w, 784s, 766s, 756m, 740s, 694s cm−1. MS (EI, 70 eV): 
m/z (%) = 438 (3, M+), 237 (16), 201 (17), 200 (100), 199 (29), 185 (14), 183 (23), 
170 (10), 169 (77), 141 (19), 140 (18), 70 (69). [ߙ]஽ଶ଴ = – 48.3 (c = 0.582, CHCl3). 
HRMS (ESI): calc. for C28H28N2OP ([M+H]+): 439.1934; found: 439.1927. The 
spectroscopic data were consistent with those reported in the literature.[68f] 
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6.3.4 
Tetrasubstituted Ureaphosphines (S)-LU4 and Precursors 
 
(S)-2[(Diphenylphosphino)methyl]-N,N-di-isopropylpyrrolidine-1-carboxamide         
((S)-LU41) 
 
Compound (S)-LU41 (75%), isolated as a colorless semisolid, was prepared according to 
general procedure 1 from (S)-LC1 and N,N-di-isopropylcarbamoyl chloride. 
C24H33N2OP (396.51 g·mol−1): 
Rf = 0.21 (SiO2, hexanes/ethyl acetate 9:1). 1H NMR (400 MHz, CDCl3): δ = 7.50-
7.44 (m, 2 H, Ph-o-H), 7.43-7.38 (m, 2 H, Ph’-o-H), 7.34-7.25 (m, 6 H, Ph/Ph’-H), 4.29-
4.19 (m, 1 H, Pyr-2-H), 3.56 (sept, 3JH,H = 6.7 Hz, 2 H, iPr/iPr’-CH), 3.38-3.30 (m, 1 H, 
Pyr-5-HH’), 3.23-3.15 (m, 1 H, Pyr-5-HH’), 2.52 (“dt”, J = 14, 3.9 Hz, 1 H, CHH’P), 
2.30 (dd, 2JH,P = 14 Hz, 2JH,H = 8.1 Hz, 1 H, CHH’P), 2.07-1.99 (m, 1 H, Pyr-H), 1.85-
1.77 (m, 1 H, Pyr-H), 1.75-1.62 (m, 2 H, Pyr-H), 1.20 (d, 3JH,H = 6.6 Hz, 6 H, iPr-CH3), 
1.18 (d, 3JH,H = 6.8 Hz, 6 H, iPr’-CH3) ppm. 13C{1H} NMR (101 MHz, CDCl3): 
δ = 162.6 (C=O), 139.9 (d, 1JC,P = 13 Hz, Ph-i-C), 139.5 (d, 1JC,P = 12Hz, Ph’-i-C), 
133.1 (d, 2JC,P = 20 Hz, Ph-o-CH), 132.8 (d, 2JC,P = 19 Hz, Ph’-o-CH), 128.6-128.3 (m, 
Ph/Ph’-m/p-CH), 56.3 (d, 2JC,P = 19 Hz, Pyr-2-CH), 51.3 (s, Pyr-5-CH2), 47.1 (s,           
iPr/iPr’-CH), 34.2 (d, 1JC,P = 12 Hz, CH2P), 32.3 (d, 3JC,P = 9.6 Hz, Pyr-3-CH2), 25.6 (s, 
Pyr-4-CH2), 22.5 (s, iPr-CH3), 21.1 (s, iPr’-CH3) ppm. 31P{1H} NMR (162 MHz, CDCl3): 
δ = − 22.7 (s) ppm. IR (neat): ߥ෤ = 3051w, 2961m, 2925m, 2869m, 1623s, 1424s, 1374m, 
1337s, 1315s, 1205m, 1156m, 1129m, 1071m, 1037m, 908w, 873w, 776m, 737s, 
694s cm−1. MS (FAB, NBA): m/z (%) = 398 (21), 397 (55, [M + H]+), 354 (20), 353 (74), 
319 (10), 312 (18), 311 (21), 296 (40), 286 (11), 284 (11), 217 (13), 201 (26), 196 (13), 
195 (89), 185 (42), 153 (10), 128 (72), 91 (12), 86 (100), 73 (33), 70 (23), 43 (65). Partial 
oxidation was observed while measuring. [ߙ]஽ଶ଴ = + 34.8 (c = 0.642, CHCl3). 
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(S)-2-[(Di-ortho-tolylphosphino)methyl]-N,N-di-isopropylpyrrolidine-1-carboxamide 
((S)-LU42) 
 
Product (S)-LU42 (93%), isolated as a colorless semisolid, was prepared according to 
general procedure 1 from (S)-LC2 and N,N-di-isopropylcarbamoyl chloride. 
C26H37N2OP (424.56 g·mol−1): 
Rf = 0.43 (SiO2, hexanes/ethyl acetate 4:1). 1H NMR (400 MHz, CDCl3): δ = 7.47-
7.44 (m, 1 H, oTol-H), 7.23-7.07 (m, 7 H, oTol/oTol’-H), 4.24-4.15 (m, 1 H, Pyr-2-H), 
3.56 (sept, 3JH,H = 6.6 Hz, 2 H, iPr/iPr’-CH), 3.38-3.32 (m, 1 H, Pyr-5-HH’), 3.21-
3.15 (m, 1 H, Pyr-5-HH’), 2.47-2.43 (m, 1 H, CHH’P), 2.46 (s, 3 H, oTol-CH3), 2.37 (s, 
3 H, oTol’-CH3), 2.11-2.02 (m, 2 H, Pyr-3-H2), 1.86-1.78 (m, 1 H, Pyr-4-HH’), 1.74-
1.63 (m, 2 H, Pyr-4-HH’ and CHH’P), 1.22 (d, 3JH,H = 6.6 Hz, 6 H, iPr-CH3), 1.18 (d, 
3JH,H = 6.9 Hz, 6 H, iPr’-CH3) ppm. 13C{1H} NMR (101 MHz, CDCl3): δ = 162.7 (s, 
C=O), 142.1-141.7 (m, oTol/oTol’-2-C), 137.6 (d, 1JC,P = 13 Hz, oTol-1-C), 137.1 (d, 
1JC,P = 13 Hz, oTol’-1-C), 131.9 (s, oTol-3-CH), 131.8 (s, oTol’-3-CH), 130.0 (br s,  
oTol-6-CH), 129.9 (br s oTol’-6-CH), 128.3 (s, oTol-4-CH), 128.3 (s, oTol’-4-CH), 
126.3 (s, oTol-5-CH), 126.2 (s, oTol’-5-CH), 56.3 (d, 2JC,P = 20 Hz, Pyr-2-CH), 51.1 (s, 
Pyr-5-CH2), 47.1 (s, iPr/iPr’-CH), 32.6 (d, 1JC,P = 13 Hz, CH2P), 32.4 (d, 3JC,P = 10 Hz, 
Pyr-3-CH2), 25.4 (s, Pyr-4-CH2), 22.5 (s, iPr-CH3), 21.4 (d, 3JC,P = 9.1 Hz, oTol-CH3), 
21.3 (d, 3JC,P = 8.2 Hz, oTol’-CH3), 21.1 (s, iPr’-CH3) ppm. 31P{1H} NMR (162 MHz, 
CDCl3): δ = – 43.0 (s) ppm. IR (neat): ߥ෤ = 3051w, 2962m, 2867m, 1626s, 1423s, 1337s, 
1315m, 1204w, 1157m, 1128m, 1072w, 1036w, 746s cm−1. MS (EI, 70 eV): 
m/z (%) = 424 (1, M+), 382 (24), 381 (100), 340 (31), 339 (50), 324 (31), 312 (10), 
229 (40), 213 (26), 211 (11), 196 (11), 195 (92), 128 (44), 86 (41), 84 (11), 70 (14), 
43 (31). [ߙ]஽ଶ଴ = + 13.7 (c = 0.881, CHCl3). Elemental analysis: calc. C 73.55%, 
H 8.78%, N 6.60%; found: C 73.57%, H 8.85%, N 6.38%. 
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(S)-2-[(Di-tert-butylphosphino)methyl]-N,N-di-isopropylpyrrolidine-1-carboxamide 
borane adduct ((S)-LU43·BH3) 
 
Product (S)-LU43·BH3 (47%) was prepared according to general procedure 2 from      
(S)-LC4∙BH3 and N,N-di-isopropylcarbamoyl chloride. 
C20H44BN2OP (370.36 g·mol−1): 
m.p. 144-146 °C. Rf = 0.37 (SiO2, hexanes/ethyl acetate 9:1). 1H NMR (400 MHz, 
CDCl3): δ = 4.23-4.14 (m, 1 H, Pyr-2-H), 3.64 (sept, 3JH,H = 6.7 Hz, 2 H, iPr/iPr’-CH), 
3.30 (ddd, 2JH,H = 16 Hz, 3JH,H = 10, 6.4 Hz, 1 H, Pyr-5-HH’), 3.13 (“t”, J = 8.7 Hz, 1 H, 
Pyr-5-HH’), 2.55 (“q”, J = 6.2 Hz, 1 H, Pyr-3-HH’), 2.29 (“td”, J = 15, 2.5 Hz, 1 H, 
CHH’P), 1.86-1.67 (m, 2 H, Pyr-4-H2), 1.54-1.44 (m, 1 H, Pyr-3-HH’), 1.44-1.37 (m, 
1 H, CHH’P), 1.35 (d, 3JH,P = 13 Hz, 9 H, tBu-H), 1.31 (d, 3JH,H = 6.5 Hz, 6 H, iPr-CH3), 
1.23 (d, 3JH,P = 12 Hz, 9 H, tBu’-H), 1.22 (d, 3JH,H = 6.2 Hz, 6 H, iPr’-CH3) 0.93-0.06 (br 
q, 3 H, BH3) ppm. 13C{1H} NMR (101 MHz, CDCl3): δ = 162.4 (s, C=O), 56.4 (d, 
2JC,P = 5.4 Hz, Pyr-2-CH), 50.8 (s, Pyr-5-CH2), 47.1 (s, iPr/iPr’-CH), 33.4 (s, Pyr-3-CH2), 
33.0 (d, 1JC,P = 27 Hz, tBu-C), 32.1 (d, 1JC,P = 28 Hz, tBu’-C), 28.3 (d, 2JC,P = 1.5 Hz, 
tBu-CH3), 28.0 (d, 2JC,P = 1.5 Hz, tBu’-CH3), 25.9 (s, Pyr-4-CH2), 24.2 (d, 1JC,P = 25 Hz, 
CH2P), 22.5 (s, iPr-CH3), 21.1 (s, iPr’-CH3) ppm. 31P{1H} NMR (162 MHz, CDCl3): 
δ = 39.6 (“br d”, J = 77 Hz) ppm. IR (neat): ߥ෤ = 2967m, 2947m, 2931m, 2870m, 2394w, 
2362m, 2342m, 1623s, 1470w, 1426m, 1369m, 1340s, 1317m, 1206m, 1157m, 1132m, 
1070m, 1021m, 879w, 814w cm−1. MS (EI, 70 eV): m/z (%) = 369 (11, [M – H]+), 
300 (18), 299 (100), 271 (13), 270 (78), 269 (20), 243 (11), 242 (44), 241 (14), 240 (14), 
128 (44), 86 (50), 57 (21), 43 (24). [ߙ]஽ଶ଴ = – 25.4 (c = 0.520, CHCl3). Elemental 
analysis: calc. C 64.86%, H 11.97%, N 7.56%; found: C 65.10%, H 11.76%, N 7.49%. 
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(S)-2-[(Di-tert-butylphosphino)methyl]-N,N-di-isopropylpyrrolidine-1-carboxamide 
((S)-LU43) 
 
Product (S)-LU43 was prepared according to general procedure 3 from (S)-LU43·BH3. 
C20H41N2OP (356.53 g·mol−1): 
31P{1H} NMR (162 MHz, CD2Cl2): δ = 21.0 (s) ppm. 
 
(S)-2-[(Dicyclohexylphosphino)methyl]-N,N-di-isopropylpyrrolidine-1-carboxamide 
borane adduct ((S)-LU44·BH3) 
 
Product (S)-LU44·BH3 (86%) was prepared according to general procedure 2 from       
(S)-LC5∙BH3 and N,N-di-isopropylcarbamoyl chloride. 
C24H48BN2OP (422.44 g·mol−1): 
m.p. 127-129 °C. Rf = 0.38 (SiO2, cyclohexane/ethyl acetate 9:1). 1H NMR (400 MHz, 
CDCl3): δ = 4.21-4.11 (m, 1 H, Pyr-2-H), 3.64 (sept, 3JH,H = 6.7 Hz, 2 H, iPr/iPr’-CH), 
3.36-3.29 (m, 1 H, Pyr-5-HH’), 3.12 (“t”, J = 8.4 Hz, 1 H, Pyr-5-HH’), 2.32-2.23 (m, 1 H, 
Pyr-3-HH’), 2.06 (“td”, J = 14, 2.9 Hz, 1 H, CHH’P), 1.98-1.53 (m, 15 H, Pyr-4-H2,           
Pyr-3-HH’ and Cy/Cy’-H), 1.48-1.14 (m, 11 H, CHH’P and Cy/Cy’-H), 1.31 (d, 
3JH,H = 6.6 Hz, 6 H, iPr-CH3), 1.21 (d, 3JH,H = 6.7 Hz, 6 H, iPr’-CH3), 0.88-0.04 (br q, 
3 H, BH3) ppm. 13C{1H} NMR (101 MHz, CDCl3): δ = 162.4 (s, C=O), 55.1 (d, 
2JC,P = 3.2 Hz, Pyr-2-CH), 50.8 (s, iPr-CH), 47.0 (s, Pyr-5-CH2), 33.0 (s, Pyr-3-CH2), 
32.7 (d, 1JC,P = 27 Hz, Cy-1-CH), 32.3 (d, 1JC,P = 29 Hz, Cy’-1-CH), 27.2-26.4 (m, 
Cy/Cy’-CH2), 26.2 (s, Cy/Cy’-CH2), 26.1 (s, Cy/Cy’-CH2), 25.7 (s, Pyr-4-CH2), 25.3 (d, 
1JC,P = 28 Hz, CH2P), 22.6 (s, iPr-CH3), 21.1 (s, iPr’-CH3) ppm. 31P{1H} NMR 
(162 MHz, CDCl3): δ = 20.8 (“br d”, J = 75 Hz) ppm. IR (neat): ߥ෤ = 2962m, 2920s, 
2853m, 2382m, 2338w, 1663m, 1622s, 1489m, 1445m, 1431m, 1339s, 1313m, 1202w, 
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1157m, 1065m, 1038m, 1002w, 916w, 748m, 696s cm−1. MS (ESI): m/z (%) = 423 (100, 
[M + H]+), 410 (13), 409 (17, [M – BH2]+), 257 (10). [ߙ]஽ଶ଴ = – 48.0 (c = 0.510, CHCl3). 
Elemental analysis: calc. C 68.24%, H 11.45%, N 6.63%; found: C 68.49%, H 11.27%, 
N 6.47%. 
 
(S)-2-[(Dicyclohexylphosphino)methyl]-N,N-di-isopropylpyrrolidine-1-carboxamide 
((S)-LU44) 
 
Product (S)-LU44 was prepared according to general procedure 3 from (S)-LU44·BH3. 
C24H45N2OP (408.60 g·mol−1): 
31P{1H} NMR (162 MHz, CD2Cl2): δ = – 12.6 (s) ppm. 
 
N,N-Dicyclohexylcarbamoyl chloride (72) 
 
Dicyclohexylcarbamoyl chloride was prepared in analogy to the procedure reported for 
the synthesis of di-isopropylcarbamoyl chloride.[85] To a solution of bis(trichloromethyl) 
carbonate (451 mg, 1.52 mmol, 0.33 eq.) in abs. toluene (5 mL) was added 
dicyclohexylamine (71, 1.00 mL, 5.02 mmol, 1.1 eq.) drop wise at – 5° C. The mixture 
was then stirred for 48 hours at room temperature. The solids were filtered of and washed 
with toluene (3 x 10 mL). The filtrate was reduced to dryness under reduced pressure to 
afford dicyclohexylcarbamoyl chloride (72, 549 mg, 2.07 mmol, 45%) as a colorless 
solid, which was used without further purification. 
C13H22ClNO (243.77 g·mol−1): 
1H NMR (400 MHz, CDCl3): δ = 4.21-3.99 (m, 1 H, Cy-1-H), 3.21-2.94 (m, 1 H,              
Cy’-1-H), 2.30-2.07 (m, 2 H, Cy-H), 1.89-1.01 (m, 18 H, Cy-H) ppm. MS (ESI): 
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m/z (%) = 243 (7, M+), 208 (18), 162 (37), 126 (36), 118 (15), 83 (52), 82 (50), 67 (36), 
55 (100), 54 (27), 41 (84). 
 
(S)-N,N-Dicyclohexyl-2-[(diphenylphosphino)methyl]pyrrolidine-1-carboxamide 
((S)-LU45) 
 
Compound (S)-LU45 (83%) was prepared according to general procedure 1 from        
(S)-LC1 and N,N-dicyclohexylcarbamoyl chloride (72). 
C30H41N2OP (476.63 g·mol−1): 
m.p. 142-143 °C. Rf = 0.39 (SiO2, hexanes/ethyl acetate 4:1). 1H NMR (500 MHz, 
CDCl3): δ = 7.41-7.34 (m, 4 H, Ph/Ph’-o-H), 7.26-7.18 (m, 6 H, Ph/Ph’-H), 4.20-4.12 (m, 
1 H, Pyr-2-H), 3.27-3.22 (m, 1 H, Pyr-5-HH’), 3.12 (‘”t”, J = 8.4 Hz, 1 H, Pyr-5-HH’), 
2.98-2.92 (m, 2 H, Cy/Cy’-1-H), 2.38 (“dt”, J = 14, 3.6 Hz, 1 H, CHH’P), 2.31 (ddd, 
2JH,P = 14 Hz, 3JH,H = 7.9 Hz, 3JH,H = 1.9 Hz, 1 H, CHH’P), 1.99-1.95 (m, 1 H,                 
Pyr-3-HH’), 1.89-1.81 (m, 2 H, Cy-H), 1.78-1.56 (m, 9 H, Pyr-3-HH’, Pyr-4-H2 and 
Cy/Cy’-H), 1.54-1.49 (m, 2 H, Cy/Cy’-H), 1.49-1.43 (m, 2 H, Cy/Cy’-H), 1.38-1.33 (m, 
2 H, Cy/Cy’-H), 1.23-1.13 (m, 2 H, Cy/Cy’-H), 1.11-0.99 (m, 4 H, Cy/Cy’-H) ppm. 
13C{1H} NMR (126 MHz, CDCl3): δ = 162.8 (s, C=O), 139.8 (d, 1JC,P = 12 Hz, Ph-i-C), 
139.5 (d, 1JC,P = 13 Hz, Ph’-i-C), 133.0 (d, 2JC,P = 19 Hz, Ph-o-CH), 132.8 (d, 
2JC,P = 19 Hz, Ph’-o-CH), 128.5 (d, 3JC,P = 7.3 Hz, Ph-m-CH), 128.4 (d, 3JC,P = 7.3 Hz, 
Ph’-m-CH), 128.4 (s, Ph/Ph’-p-CH), 56.9 (s, Cy/Cy’-1-CH), 56.5 (d, 2JC,P = 19 Hz,          
Pyr-2-CH), 51.4 (s, Pyr-5-CH2), 33.7 (d, 1JC,P = 12 Hz, CH2P), 32.8 (s, Cy/Cy’-CH2), 
32.3 (d, 3JC,P = 10 Hz, Pyr-3-CH2), 31.3 (s, Cy/Cy’-CH2), 26.8 (s, Cy/Cy’-CH2), 25.7 (s, 
Cy/Cy’-CH2), 25.5 (s, Pyr-4-CH2) ppm. 31P{1H} NMR (162 MHz, CDCl3): δ = − 23.1 
(s) ppm. IR (KBr): ߥ෤ = 3051w, 2923s, 2849s, 1741w, 1626s, 1583m, 1481m, 1451m, 
1421s, 1365s, 1341s, 1315s, 1243m, 1182s, 1124m, 1071w, 1026m, 1004m, 894m, 871m, 
750s, 715m, 697s cm−1. MS (FAB, NBA): m/z (%) = 477 (22, [M + H]+), 393 (11), 
296 (14), 275 (27), 208 (13), 201 (12), 193 (14), 192 (45), 185 (24), 183 (11), 126 (26), 
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84 (16), 83 (100), 81 (10), 70 (20), 55 (35), 41 (14). Partial oxidation was observed while 
measuring. [ߙ]஽ଶ଴ = + 52.6 (c = 0.510, CHCl3). Elemental analysis: calc. C 75.60%, 
H 8.67%, N 5.88%; found: C 75.31%, H 8.64%, N 5.78%. 
 
(S)-N,N-Dicyclohexyl-2-[(di-ortho-tolylphosphino)methyl]pyrrolidine-1-
carboxamide ((S)-LU46) 
 
Compound (S)-LU46 (81%) was prepared according to general procedure 1 from         
(S)-LC2 and N,N-dicyclohexylcarbamoyl chloride (72). 
C32H45N2OP (504.69 g·mol−1): 
m.p. 134-136 °C. Rf = 0.51 (SiO2, hexanes/ethyl acetate 4:1). 1H NMR (400 MHz, 
CDCl3): δ = 7.36-7.32 (m, 1 H, oTol-6-H), 7.25-7.20 (m, 1 H, oTol’-6-H), 7.20-7.15 (m, 
3 H, oTol/oTol’-H), 7.15-7.08 (m, 3 H, oTol/oTol’-H), 4.24-4.15 (m, 1 H, Pyr-2-H), 3.37-
3.28 (m, 1 H, Pyr-5-HH’), 3.19 (“t”, J = 8.1 Hz, 1 H, Pyr-5-HH’), 3.01 (m, 2 H,           
Cy/Cy’-1-H), 2.43 (s, 3 H, oTol-CH3), 2.40 (s, 3 H, oTol’-CH3), 2.35 (“dt”, J = 14, 
3.3 Hz, 1 H, CHH’P), 2.16 (dd, 2JH,P = 14 Hz, 3JH,H = 8.6 Hz, 1 H, CHH’P), 2.12-2.04 (m, 
1 H, Pyr-3-HH’), 1.99-1.86 (m, 2 H, Cy/Cy’-H), 1.85-1.61 (m, 9 H, Pyr-3-HH’, Pyr-4-H2 
and Cy/Cy’-H), 1.61-1.53 (m, 2 H, Cy/Cy’-H), 1.53-1.39 (m, 4 H, Cy/Cy’-H), 1.30-
1.19 (m, 2 H, Cy/Cy’-H), 1.19-1.05 (m, 4 H, Cy/Cy’-H) ppm. 13C{1H} NMR (101 MHz, 
CDCl3): δ = 163.0 (s, C=O), 141.9 (d, 2JC,P = 25 Hz, oTol-2-C), 141.8 (d, 2JC,P = 25 Hz, 
oTol’-2-C), 137.5 (d, 1JC,P = 13 Hz, oTol-1-C), 137.4 (d, 1JC,P = 13 Hz, oTol’-1-C), 
132.1 (s, oTol-6-CH), 131.7 (s, oTol’-6-CH), 130.0 (s, oTol-3-CH), 129.9 (s,               
oTol’-3-CH), 128.3 (s, oTol-4-CH), 128.2 (s, oTol’-4-CH), 126.3 (s, oTol-5-CH), 
126.2 (s, oTol’-5-CH), 57.0 (s, Cy/Cy’-1-CH), 56.5 (s, 2JC,P = 20 Hz, Pyr-2-CH), 51.2 (s, 
Pyr-5-CH2), 32.9 (s, Cy/Cy’-CH2), 32.4 (d, 3JC,P = 9.6 Hz, Pyr-3-CH2), 32.2 (d, 
1JC,P = 13 Hz, CH2P), 31.3 (s, Cy/Cy’-CH2), 26.9 (s, Cy/Cy’-CH2), 26.8 (s, Cy/Cy’-CH2), 
25.8 (s, Cy/Cy’-CH2), 25.4 (s, Pyr-4-CH2), 21.5 (d, 3JC,P = 1.2 Hz, oTol-CH3), 21.3 (d, 
3JC,P = 1.9 Hz, oTol’-CH3) ppm. 31P{1H} NMR (162 MHz, CDCl3): δ = − 43.8 (s) ppm. 
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IR (neat): ߥ෤ = 2968w, 2927m, 2915m, 2852m, 1615s, 1448m, 1416s, 1369m, 1310s, 
1242w, 1179m, 1155m, 1121m, 1028w, 1003w, 893m, 746s, 719m, 695m cm−1. MS (EI, 
70 eV): m/z (%) = 504 (1, M+), 423 (3), 422 (20), 421 (65), 339 (19), 324 (16), 276 (16), 
275 (80), 229 (17), 213 (23), 193 (46), 192 (100), 84 (19), 83 (38), 70 (15), 55 (18). [ߙ]஽ଶ଴ = + 41.3 (c = 1.13, CHCl3).  
 
(S)-N,N-Dicyclohexyl-2-[(di-tert-butylphosphino)methyl]pyrrolidine-1-carboxamide 
borane adduct ((S)-LU47·BH3) 
 
Product (S)-LU47·BH3 (69%) was prepared according to general procedure 2 from       
(S)-LC4∙BH3 and N,N-dicyclohexylcarbamoyl chloride (72). 
C26H52BN2OP (450.49 g·mol−1): 
m.p. 117-118 °C. Rf = 0.47 (SiO2, hexanes/ethyl acetate 9:1). 1H NMR (400 MHz, 
CDCl3): δ = 4.24-4.13 (m, 1 H, Pyr-2-H), 3.31-3.23 (m, 1 H, Pyr-5-HH’), 3.18-3.07 (m, 
3 H, Pyr-5-HH’ and Cy/Cy’-1-H), 2.57-2.48 (m, 1 H, Pyr-3-HH’), 2.27 (“td”, J = 14, 
2.7 Hz, 1 H, CHH’P), 2.08-1.96 (m, 2 H, Cy/Cy’-H), 1.87-1.53 (m, 14 H, Pyr-4-H2 and 
Cy/Cy’-H), 1.53-1.46 (m, 1 H, Pyr-3-HH’), 1.46-1.09 (m, 25 H, tBu/tBu’-H, CHH’P and 
Cy/Cy’-H), 0.80-0.08 (br q, 3 H, BH3) ppm. 13C{1H} NMR (101 MHz, CDCl3): 
δ = 162.8 (s, C=O), 57.0 (s, Cy/Cy’-1-CH), 56.4 (d, 2JC,P = 5.4 Hz, Pyr-2-CH), 50.8 (s, 
Pyr-5-CH2), 33.3 (s, Pyr-3-CH2), 33.0 (d, 1JC,P = 27 Hz, tBu-C), 32.9 (s, Cy/Cy’-CH2), 
32.1 (d, 1JC,P = 28 Hz, tBu’-C), 31.2 (s, Cy/Cy’-CH2), 28.3 (d, 2JC,P = 1.5 Hz, tBu-CH3), 
28.0 (d, 2JC,P = 1.2 Hz, tBu’CH3), 26.8 (s, Cy/Cy’-CH2), 26.7 (s, Cy/Cy’-CH2), 25.9 (s, 
Pyr-4-CH2), 25.7 (s, Cy/Cy’-CH2), 24.1 (d, 1JC,P = 25 Hz, CH2P) ppm. 31P{1H} NMR 
(162 MHz, CDCl3): δ = 39.7 (br s) ppm. IR (neat): ߥ෤ = 2928s, 2860m, 2393m, 2364m, 
1625s, 1451w, 1419m, 1365m, 1311s, 1243w, 1236w, 1181m, 1157w,1068m, 1024w, 
999w, 894m, 871m, 813m cm−1. MS (EI, 70 eV): m/z (%) = 449 (6, [M – H]+), 379 (82), 
270 (100), 242 (31), 208 (11), 126 (15), 83 (34), 57 (15). [ߙ]஽ଶ଴ = + 0.6 (c = 0.500, 
CHCl3). Elemental analysis: calc. C 69.32%, H 11.63%, N 6.22%; found: C 69.30%, 
H 11.60%, N 6.00%. 
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(S)-N,N-Dicyclohexyl-2-[(di-tert-butylphosphino)methyl]pyrrolidine-1-carboxamide 
((S)-LU47) 
 
Product (S)-LU47 was prepared according to general procedure 3 from (S)-LU47·BH3. 
C26H49N2OP (436.65 g·mol−1): 
31P{1H} NMR (162 MHz, CD2Cl2): δ = 21.1 (s) ppm. 
 
(S)-N,N-Dicyclohexyl-2-[(dicyclohexylphosphino)methyl]pyrrolidine-1-carboxamide 
borane adduct ((S)-LU48·BH3) 
 
Product (S)-LU48·BH3 (61%), isolated as a colorless semisolid, was prepared according to 
general procedure 2 from (S)-LC5∙BH3 and N,N-dicyclohexylcarbamoyl chloride (72). 
C30H56BN2OP (502.56 g·mol−1): 
m.p. 54-57 °C. Rf = 0.28 (SiO2, hexanes/ethyl acetate 9:1). 1H NMR (500 MHz, CDCl3): 
δ = 4.23-4.03 (m, 1 H, Pyr-2-H), 3.37-3.24 (m, 1 H, Pyr-5-HH’), 3.19-3.05 (m, 3 H,           
Pyr-5-HH’ and NCy/Cy’-1-H), 2.32-2.19 (m, 1 H, Pyr-3-HH’), 2.11-1.04 (m, 47 H), 0.83-
0.10 (br q, 3 H, BH3) ppm. 13C{1H} NMR (101 MHz, CDCl3): δ = 162.7 (s, C=O), 
56.8 (s, NCy/Cy’-1-CH), 55.2 (br d, 2JC,P = 3.0 Hz, Pyr-2-CH), 50.8 (s, Pyr-5-CH2), 
33.0 (s, NCy/Cy’-CH2), 33.9 (s, Pyr-3-CH2), 32.7 (d, 1JC,P = 22 Hz, PCy-1-CH), 32.4 (d, 
1JC,P = 23 Hz, PCy’-1-CH), 31.3 (s, CH2), 27.2-26.1 (m, CH2), 25.7 (s, CH2), 25.1 (d, 
1JC,P = 28 Hz, CH2P) ppm. 31P{1H} NMR (162 MHz, CDCl3): δ = 20.7 (br s) ppm. 
IR (neat): ߥ෤ = 2924s, 2851m, 2370m, 1691m, 1628s, 1448m, 1421m, 1360m, 1310s, 
1180w, 1065m, 1005w, 893m, 854m cm−1. MS (EI, 70 eV): m/z (%) = 501 (3, [M – H]+), 
406 (27), 407 (100), 323 (22), 322 (65), 321 (17), 294 (44), 293 (16), 292 (34), 242 (28), 
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83 (16), 55 (9). [ߙ]஽ଶ଴ = + 8.5 (c = 0.961, CHCl3). Elemental analysis: calc. C 71.70%, 
H 11.23%, N 5.57%; found: C 71.73%, H 11.16%, N 5.54%. 
 
(S)-N,N-Dicyclohexyl-2-[(dicyclohexylphosphino)methyl]pyrrolidine-1-carboxamide 
((S)-LU48) 
 
Product (S)-LU48 was prepared according to general procedure 3 from (S)-LU48·BH3. 
C30H53N2OP (488.73 g·mol−1): 
31P{1H} NMR (162 MHz, CD2Cl2): δ = – 12.5 (s) ppm. 
 
(S)-2-[(Diphenylphosphino)methyl]-N,N-diphenylpyrrolidine-1-carboxamide           
((S)-LU49) 
 
Compound (S)-LU49 (77%) was prepared according to general procedure 1 from         
(S)-LC1 and diphenylcarbamoyl chloride. 
C30H29N2OP (464.54 g·mol−1): 
m.p. 128-129 °C. Rf = 0.30 (hexanes/ethyl acetate 4:1). 1H NMR (400 MHz, CDCl3): 
δ = 7.62 (t, J = 7.8 Hz, 2 H, PPh-o-H), 7.46-7.40 (m, 2 H, PPh’-o-H), 7.36-7.26 (m, 10 H, 
NPh/Ph’-m-H, PPh/Ph’-m-H and PPh/Ph’-p-H), 7.12 (“t”, 3JH,H = 7.5 Hz, 2 H,             
NPh/Ph’-p-H), 7.06 (d, 3JH,H = 8.5 Hz, 4 H, NPh/Ph’-o-H), 4.20-4.09 (m, 1 H, Pyr-2-H), 
3.34-3.21 (m, 2 H, Pyr-5-H’H and CH’HP), 2.68-2.58 (m, 1 H, Pyr-5-H’H), 2.19-2.09 (m, 
1 H, Pyr-3-H’H), 1.93-1.86 (m, 1 H, CH’HP), 1.76-1.61 (m, 3 H, Pyr-3-H’H and           
Pyr-4-CH2) ppm. 13C{1H} NMR (101 MHz, CDCl3): δ = 158.7 (s, C=O), 144.8 (s, 
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NPh/Ph’-i-C), 139.5 (d, 1JC,P = 12 Hz, PPh-i-C), 137.2 (d, 1JC,P = 12 Hz, PPh’-i-C), 
133.2 (d, 2JC,P = 19 Hz, PPh-o-CH), 132.9 (d, 2JC,P = 20 Hz, PPh’-o-CH), 129.3 (s, 
NPh/Ph’-m-CH), 128.8 (d, 3JC,P = 8.1 Hz, PPh-m-CH), 128.7 (s, PPh/Ph’-p-CH), 
128.6 (d, 3JC,P = 7.0 Hz, PPh’-m-CH), 126.0 (s, NPh/Ph’-o-CH), 124.9 (s,                
NPh/Ph’-p-CH), 56.9 (d, 2JC,P = 21 Hz, Pyr-2-CH), 49.3 (s, Pyr-5-CH2), 33.2 (d, 
1JC,P = 14 Hz, CH2P), 32.2 (d, 3JC,P = 9.2 Hz, Pyr-3-CH2), 25.2 (s, Pyr-4-CH2) ppm. 
31P{1H} NMR (162 MHz, CDCl3): δ = – 25.7 (s) ppm. IR (KBr): ߥ෤ = 3050m, 2981m, 
2913m, 2880m, 1647s, 1592m, 1491m, 1389s, 1288w, 1234m, 1170w, 1095w, 1030w, 903w, 
741m cm−1. MS (EI, 70 eV): m/z (%) = 464 (14, M+), 463 (27), 297 (20), 296 (100), 
264 (16), 263 (75), 232 (14), 223 (27), 201 (14), 196 (47), 195 (16), 185 (49), 183 (52), 
180 (12), 173 (12), 169 (27), 168 (34), 167 (19), 77 (13). [ߙ]஽ଶ଴ = + 282.6 (c = 0.993, 
CHCl3). Elemental analysis: calc. C 77.57%, H 6.29%, N 6.03%; found: C 77.37%, 
H 6.55%, N 6.06%. 
 
(S)-2-[(Di-ortho-tolylphosphino)methyl]-N,N-diphenylpyrrolidine-1-carboxamide 
((S)-LU410) 
 
Compound (S)-LU410 (61%) was prepared according to general procedure 1 from         
(S)-LC2 and diphenylcarbamoyl chloride. 
C32H33N2OP (492.59 g·mol−1): 
m.p. 193-197 °C. Rf = 0.38 (hexanes/ethyl acetate 4:1). 1H NMR (400 MHz, CDCl3): 
δ = 7.82-7.76 (m, 1 H, oTol-6-CH), 7.31-7.25 (m, 5 H, oTol-5-CH and Ph/Ph’-m-CH), 
7.24-7.15 (m, 3 H, oTol-3/4-CH and oTol’-4-CH), 7.14-7.07 (m, 5 H, oTol’-3/5/6-CH 
and Ph/Ph’-p-CH), 7.05 (d, 3JH,H = 7.3 Hz, 4 H, Ph/Ph’-o-CH), 4.26-4.16 (m, 1 H,           
Pyr-2-CH), 3.34-3.25 (m, 1 H, Pyr-5-CHH’), 3.12 (“dt”, J = 14, 3.6 Hz, 1 H, CHH’P), 
2.71-2.61 (m, 1 H, Pyr-5-CHH’P), 2.53 (s, 3 H, oTol-CH3), 2.31 (s, 3 H, oTol’-CH3), 
2.24-2.14 (m, 1 H, CHH’P), 1.79-1.64 (m, 4 H, Pyr-H) ppm. 13C{1H} NMR (101 MHz, 
CDCl3): δ = 158.7 (s, C=O), 144.8 (s, Ph/Ph’-i-C), 142.1 (d, 2JC,P = 24 Hz, oTol-2-C), 
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141.9 (d, 2JC,P = 25 Hz, oTol’-2-C), 137.3 (d, 1JC,P = 12 Hz, oTol-1-C), 135.6 (d, 
1JC,P = 13 Hz, oTol’-1-C), 132.2 (s, oTol-6-CH), 131.8 (s, oTol’-6-CH), 130.1 (d, 
3JC,P =5.0 Hz, oTol-3-CH), 130.0 (d, 3JC,P = 5.0 Hz, oTol’-3-CH), 129.3 (s,                
Ph/Ph’-m-CH), 128.6 (s, oTol-4-CH), 128.5 (s, oTol’-4-CH), 126.7 (s, oTol-5-CH), 
126.3 (s, oTol’-5-CH), 126.0 (s, Ph/Ph’-o-CH), 124.8 (s, Ph/Ph’-p-CH), 56.9 (d, 
2JC,P = 21 Hz, Pyr-2-CH), 49.2 (s, Pyr-5-CH2), 32.3 (d, 3JC,P = 9.6 Hz, Pyr-3-CH2), 
31.9 (d, 1JC,P = 14 Hz, CH2P), 252 (s, Pyr-4-CH2), 21.4 (d, 3JC,P = 19 Hz, oTol-CH3), 
21.2 (d, 3JC,P = 18 Hz, oTol’-CH3) ppm. 31P{1H} NMR (162 MHz, CDCl3):                          
δ = – 42.5 ppm. IR (neat): ߥ෤ = 3057w, 2911m, 1637m, 1601m, 1489m, 1448m, 1382s, 
1345s, 1235m, 1164m, 1029w, 759s, 695m cm−1. MS (EI, 70 eV): m/z (%) = 492 (12, M+), 
491 (24), 477 (20), 401 (21), 325 (21), 324 (97), 264 (19), 263 (100), 246 (19), 213 (31), 
197 (12), 196 (98), 169 (11), 167 (12). [ߙ]஽ଶ଴ = + 241.0 (c = 1.04, CHCl3). 
 
(S)-2-[(Di-tert-butyl-phosphino)methyl]-N,N-diphenylpyrrolidine-1-carboxamide 
borane adduct ((S)-LU411∙BH3) 
 
Compound (S)-LU411 (43%) was prepared according to general procedure 2 from        
(S)-LC4∙BH3 and diphenylcarbamoyl chloride. 
C26H40BN2OP (438.39 g·mol−1): 
m.p. 154-155 °C. Rf = 0.14 (SiO2, hexanes/ethyl acetate 9:1). 1H NMR (400 MHz, 
CDCl3): δ = 7.31 (dd, 3JH,H = 7.5 Hz, 4 H, Ph/Ph’-m-H), 7.12 (“t”, 3JH,H = 7.5 Hz, 2 H, 
Ph/Ph’-p-H), 7.06 (dd, 3JH,H = 8.5 Hz,  4JH,H = 1.3 Hz,  4 H, Ph/Ph’-o-H), 4.39-4.30 (m, 
1 H, Pyr-2-H), 3.28-3.22 (m, 1 H, Pyr-5-HH’), 2.82 (td, J = 15 Hz, J = 2.3 Hz, 1 H, 
CHH’P), 2.62-2.47 (m, 2 H, Pyr-5-HH’ and Pyr-3-HH’), 1.76-1.57 (m, 3 H, Pyr-3-HH’ 
and Pyr-4-H2), 1.45-1.34 (m, 1 H, CHH’P), 1.38 (d, 3JH,P = 13 Hz, 9 H, tBu-H3), 1.27 (d, 
3JH,P = 12 Hz, 9 H, tBu’-H3), 0.92-0.03 (br q, 3 H, BH3) ppm. 13C{1H} NMR (101 MHz, 
CDCl3): δ = 158.8 (s, C=O), 144.7 (s, Ph/Ph’-i-C), 129.4 (s, Ph/Ph’-m-CH), 125.7 (s, 
Ph/Ph’-o-CH), 124.9 (s, Ph/Ph’-p-CH), 57.1 (d, 2JC,P = 5.6 Hz, Pyr-2-CH), 49.2 (s,            
Pyr-5-CH2), 33.3 (d, 1JC,P = 27 Hz, tBu-C), 33.3 (s, Pyr-3-CH2), 32.1 (d, 1JC,P = 28 Hz, 
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tBu’-C), 28.3.3 (d, 2JC,P = 1.5 Hz, tBu-CH3), 28.0 (d, 2JC,P = 1.2 Hz, tBu’-CH3), 25.3 (s, 
Pyr-4-CH2), 22.7 (d, 1JC,P = 24 Hz, CH2P) ppm. 31P NMR (162 MHz, CDCl3, 300 K): 
δ = 40.0 (br s) ppm. IR (neat): ߥ෤ = 2956m, 2943m, 2870m, 1648s, 1588m, 1488m, 
1471m, 1378s, 1342m, 1285w, 1226m, 1174m, 1150w, 1068m, 1021w, 902w, 876m, 
817m, 755s, 697s cm−1. MS (EI, 70 eV): m/z (%) = 437 (6, [M − H]+), 367 (100), 
311 (16), 270 (52), 242 (12), 196 (19), 168 (17), 57 (14). [ߙ]஽ଶ଴ = + 217.0 (c = 0.550, 
CHCl3). Elemental analysis: calc. C 71.23%, H 9.20%, N 6.39%; found: C 71.19%, 
H 9.40%, N 6.35%. 
 
(S)-2-[(Di-tert-butylphosphino)methyl]-N,N-diphenylpyrrolidine-1-carboxamide        
((S)-LU411) 
 
Product (S)-LU411 was prepared according to general procedure 3 from (S)-LU411·BH3. 
C26H37N2OP (424.56 g·mol−1): 
31P{1H} NMR (162 MHz, CDCl3): δ = 21.0 (s) ppm. 
 
(S)-2-[(Dicyclohexylphosphino)methyl]-N,N-diphenylpyrrolidine-1-carboxamide 
borane adduct ((S)-LU412∙BH3) 
 
Compound (S)-LU412∙BH3 (92%) was prepared according to general procedure 2 from 
(S)-LC5∙BH3 and diphenylcarbamoyl chloride. 
C30H44BN2OP (490.47 g·mol−1): 
Rf = 0.20 (SiO2, hexanes/ethyl acetate 9:1). 1H NMR (500 MHz, CDCl3): δ = 7.31 (“t”, 
2JH,H = 7.8 Hz, 4 H, Ph/Ph’-m-H), 7.14 (“t”, 2JH,H = 7.5 Hz, 2 H, Ph/Ph’-p-H), 7.06 (“t”, 
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2JH,H = 7.5 Hz, 4 H, Ph/Ph’-o-H), 4.28-4.20 (m, 1 H, Pyr-2-H), 3.25-3.19 (m, 1 H,             
Pyr-5-HH’), 2.75-2.67 (m, 1 H, CHH’P), 2.60-2.53 (m, 1 H, Pyr-5-HH’), 2.40-2.30 (m, 
1 H, Pyr-3-HH’), 2.05-1.15 (m, 26 H, CHH’P, Pyr-3-HH’, Pyr-4-H2 and Cy/Cy’-H), 0.75-
0.04 (br q, 3 H, BH3) ppm. 13C{1H} NMR (126 MHz, CDCl3): δ = 158.6 (s, C=O), 
144.6 (s, Ph/Ph’-i-C), 129.4 (s, Ph/Ph’-o-CH), 125.9 (s, Ph/Ph’-m-CH), 125.0 (s,           
Ph/Ph’-p-CH), 56.1 (d, 2JC,P = 4.6 Hz, Pyr-2-CH), 49.1 (s, Pyr-5-CH2), 33.0 (s,             
Pyr-3-CH2), 32.7 (d, 1JC,P = 29 Hz, Cy-1-CH), 32.5 (d, 1JC,P = 31 Hz, Cy’-1-CH), 27.2-
26.0 (m, Cy/Cy’-CH2), 25.3 (s, Pyr-4-CH2), 24.5 (d, 1JC,P = 27 Hz, CH2P) ppm. 
31P{1H} NMR (162 MHz, CDCl3): δ = 21.5 (br s) ppm. 
 
(S)-2-[(Dicyclohexylphosphino)methyl]-N,N-diphenylpyrrolidine-1-carboxamide    
((S)-LU412) 
 
Product (S)-LU412 was prepared according to general procedure 3 from (S)-LU412∙BH3. 
C30H41N2OP (476.63 g·mol−1): 
31P{1H} NMR (162 MHz, CDCl3): δ =− 10.5 (s) ppm. 
 
(S)-{2-[(Diphenylphosphino)methyl]pyrrolidin-1-yl}(morpholino)methanone        
((S)-LU413) 
 
Compound (S)-LU413 (60%) was prepared according to general procedure 1 from        
(S)-LC1 and 4-morpholinocarbonyl chloride. 
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C22H27N2O2P (382.44 g·mol−1): 
m.p. 113-114 °C. Rf = 0.31 (hexanes/ethyl acetate 1:1). 1H NMR (500 MHz, CDCl3): 
δ = 7.53-7.50 (m, 2 H, Ph-o-H), 7.44-7.40 (m, 2 H, Ph’-o-H), 7.35-7.26 (m, 6 H,           
Ph/Ph’-H), 4.25-4.18 (m, 1 H, Pyr-2-H), 3.67-3.60 (m, 2 H, Morph-H), 3.54-3.50 (m, 2 H, 
Morph-H), 3.36-3.31 (m, 2 H, Pyr-5-H2), 3.20 (“ddd”, 2JH,H = 13 Hz, 3JH,H = 6.6, 2.8 Hz, 
2 H, Morph-H), 2.99 (“ddd”, 2JH,H = 13 Hz, 3JH,H = 6.4, 2.8 Hz, 2 H, Morph-H), 
2.65 (“dt”, 2JH,P = 14 Hz, JH,H = 3.4 Hz, 1 H, CHH’P), 2.26 (dd, 2JH,P = 14 Hz, 
JH,H = 8.8 Hz, 1 H, CHH’P), 2.20-2.16 (m, 1 H, Pyr-H), 1.88-1.63 (m, 3 H, Pyr-H) ppm. 
13C{1H} NMR (126 MHz, CDCl3): δ = 162.8 (C=O), 139.4 (d, 1JC,P = 12 Hz, Ph-i-C), 
138.6 (d, 1JC,P = 12 Hz, Ph’-i-C), 133.8 (d, 2JC,P = 19 Hz, Ph-o-CH), 133.0 (d, 
2JC,P = 19 Hz, Ph’-o-CH), 128.9 (s, Ph-p-CH), 128.9 (s, Ph’-p-CH), 128.8 (d, 
3JC,P = 6.8 Hz, Ph-m-CH), 128.7 (d, 3JC,P = 7.1 Hz, Ph’-m-CH), 67.0 (s, Morph-2/6-CH2), 
56.9 (d, 2JC,P = 18 Hz, Pyr-2-CH), 51.4 (s, Pyr-5-CH2), 46.6 (s, Morph-3/5-CH3), 34.0 (d, 
1JC,P = 13 Hz, CH2P), 32.5 (d, 3JC,P = 9.7 Hz, Pyr-3-CH2), 26.1 (s, Pyr-4-CH2) ppm. 
31P{1H} NMR (162 MHz, CDCl3): δ = – 27.4 (s) ppm. IR (KBr): ߥ෤ = 3045m, 2977m, 
2895m, 2855m, 1967w, 1635s, 1569w, 1480m, 1413s, 1351m, 1306m, 1265m, 1215m, 
1178m, 1115s, 1025m, 948m, 872m, 785m, 744s, 699s, 607m cm−1. MS (FAB, NBA): 
m/z (%) = 383 (100, [M + H]+), 312 (16), 296 (59), 185 (73), 181 (92), 114 (95), 70 (73), 
39 (14). [ߙ]஽ଶ଴ = + 1.6 (c = 1.01, CHCl3). Elemental analysis: calc. C 69.09%, H 7.12%, 
N 7.33%; found: C 69.13%, H 7.09%, N 7.25%. 
 
(S)-2-[(Diphenylphosphino)methyl]-N-methyl-N-phenylpyrrolidine-1-carboxamide 
((S)-LU414) 
 
Compound (S)-LU414 (39%) was prepared according to general procedure 1 from       
(S)-LC1 and N-methyl-N-phenylcarbamoyl chloride. 
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C25H27N2OP (402.47 g·mol−1): 
m.p. 139-141 °C. Rf = 0.25 (hexanes/ethyl acetate 4:1). 1H NMR (400 MHz, CD2Cl2): 
δ = 7.66-7.60 (m, 2 H, NPh-o-H), 7.47-7.25 (m, 10 H, PPh/Ph’-H), 7.13-7.07 (m, 3 H, 
NPh-H), 4.09-3.97 (m, 1 H, Pyr-2-H), 3.17 (s, 3 H, CH3), 3.08-3.10 (m, 2 H, Pyr-5-HH’ 
and CHH’P), 2.55-2.46 (m, 1 H, Pyr-5-HH’), 2.11-2.01 (m, 1 H, Pyr-3-HH’), 1.96-
1.88 (m, 1 H, CHH’P), 1.66-1.49 (m, 3 H, Pyr-3-HH’ and Pyr-4-H2) ppm. 
13C{1H} NMR (101 MHz, CD2Cl2): δ = 159.6 (s, C=O), 146.6 (s, NPh-i-C), 139.8 (d, 
1JC,P = 13 Hz, PPh-i-C), 138.2 (d, 1JC,P = 14 Hz, PPh’-i-C), 133.0 (d, 2JC,P = 19 Hz,           
PPh-o-CH), 132.7 (d, 2JC,P = 19 Hz, PPh’-o-CH), 129.3 (s, NPh-m-CH), 128.7 (s,              
PPh-p-CH), 128.5 (d, 3JC,P = 2.6 Hz, PPh-m-CH), 128.4 (d, 2JC,P = 1.6 Hz, PPh’-m-CH), 
128.4 (s, PPh’-p-CH), 124.8 (s, NPh-o-CH), 124.2 (s, NPh-p-CH), 56.7 (d, 2JC,P = 21 Hz, 
Pyr-2-CH), 49.4 (s, Pyr-5-CH2), 39.2 (s, CH3), 33.6 (d, 1JC,P = 14 Hz, CH2P), 32.1 (d, 
3JC,P = 8.1 Hz, Pyr-3-CH2), 25.2 (s, Pyr-4-CH2 ) ppm. 31P{1H} NMR (162 MHz, CD2Cl2): 
δ = − 22.1 (s) ppm. IR (neat): ߥ෤ = 2975w, 2943w, 2905w, 2881w, 1634s, 1595m, 1581m, 
1492m, 1432s, 1386s, 1351m, 1334m, 1298m, 1165m, 1108m, 1073m, 1025m, 998w, 
932w, 906w, 875w, 851w, 763m, 752s, 696s cm−1. MS (EI, 70 eV): m/z (%) = 402 (12, 
M+), 401 (12), 401 (25), 325 (11), 296 (42), 203 (18), 202 (14), 201 (100), 199 (11), 
183 (31), 161 (29), 134 (83), 133 (14), 106 (21), 77 (15). [ߙ]஽ଶ଴ = + 169.7 (c = 0.623, 
CHCl3).  
 
(S)-2-[(Diphenylphosphino)methyl]-N,N-bis((R)-1-phenylethyl)pyrrolidine-1-
carboxamide ((S,R,R)-LU415) 
 
To a solution of (+)-bis[(R)-1-phenylethyl]amine ((R,R)-73, 100 μL, 437 μmol, 1.00 eq.) 
in abs. tetrahydrofuran (5 mL) was added drop wise a 1.6 M solution of                                   
n-butyllithium (300 μL, 480 μmol, 1.1 eq.) at −78 °C in a dry ice/acetone bath. The 
resulting solution was allowed to stir for 30 minutes at – 78 °C and then for 1 hour at 0 °C 
in an ice bath, before a solution of bis(trichloromethyl)carbonate (45.4 mg, 153 μmol, 
0.35 eq.) in abs. tetrahydrofuran (3 mL) was added at 0 °C. The reaction mixture was 
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allowed to warm to room temperature over 12 hours, before the solvent was removed in 
vacuo. The residual colorless solid was again dissolved in abs. tetrahydrofuran (2 mL). 
Triethylamine (400 μL, 2.87 mmol, 6.6 eq.) and a solution of (S)-2-
[(diphenylphosphino)methyl]pyrrolidine hydrochloride ((S)-52∙HCl, 170 mg, 458 μmol, 
1.0 eq.) in tetrahydrofuran (2 mL) were then added successively at 0 °C. The resulting 
mixture was allowed to warm to room temperature over 20 hours, before it was reduced 
to dryness in vacuo. The crude was purified by column chromatography on silica 
gel (3 x 15 cm), eluting with hexanes/ethyl acetate (9:1). The product (S,R,R)-LU415 was 
isolated as yellowish semisolid (54.4 mg, 104 μmol, 24%). 
C34H37N2OP (520.64 g·mol−1): 
Rf = 0.18 (SiO2, hexanes/ethyl acetate 9:1). 1H NMR (400 MHz, CDCl3): δ = 7.73-
6.97 (m, 20 H, PPh/Ph’-H and C/C’Ph-H), 4.58-4.39 (m, 2 H, NC/C’H), 4.23-4.07 (m, 
1 H, Pyr-2-H), 3.50-3.22 (m, 2 H, Pyr-5-H2), 2.60 (d, 2JH,P = 13 Hz, 1 H, CHH’P), 2.01-
1.36 (m, 11 H, CHH’P, Pyr-H and CH3/CH3’) ppm. 13C{1H} NMR (101 MHz, CDCl3): 
δ = 163.1 (C=O), 143.3 (s, C/C’Ph-i-C), 140.0 (d, 1JC,P = 12 Hz, PPh-i-C), 138.7 (d, 
1JC,P = 13 Hz, PPh’-i-C), 133.2 (d, 2JC,P = 19 Hz, PPh-o-CH), 133.2 (d, 2JC,P = 19 Hz, 
PPh’-o-CH), 128.8 (d, 3JC,P = 6.9 Hz, PPh-m-CH), 128.8 (s, PPh-p-CH), 128.7 (s,            
PPh’-p-CH), 128.7 (d, 3JC,P = 6.9 Hz, PPh’-m-CH), 128.4 (s, C/C’Ph-m-CH), 127.8 (s, 
C/C’Ph-o-CH), 127.1 (s, C/C’Ph-p-CH), 56.9 (s, NC/C’H), 56.4 (d, 2JC,P = 20 Hz,          
Pyr-2-CH), 50.8 (s, Pyr-5-CH2), 33.6 (d, 1JC,P = 13 Hz, CH2P), 32.1 (d, 3JC,P = 9.0 Hz, 
Pyr-3-CH2), 25.6 (s, Pyr-4-CH2), 21.2 (s, CH3/CH3’) ppm. 31P{1H} NMR (162 MHz, 
CDCl3): δ = − 26.0 (s) ppm. IR (KBr): ߥ෤ = 3058w, 3028w, 2969m, 2868m, 1633s, 
1493m, 1446m, 1433m, 1410s, 1368m, 1333m, 1282m, 1184m, 1156w, 1118w, 1071w, 
1025m, 908m, 794w, 739s, 693s cm−1. MS (FAB, NBA): m/z (%) = 521 (20, [M + H]+), 
433 (9), 415 (46), 311 (24), 286 (19), 185 (21), 105 (100), 57 (7). [ߙ]஽ଶ଴ = + 30.9 
(c = 1.00, CHCl3). 
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(S)-2-[(Diphenylphosphino)methyl]-N,N-bis((S)-1-phenylethyl)pyrrolidine-1-
carboxamide ((S,S,S)-LU415) 
 
A 1.6 M solution of phosgene in toluene (600 μL, 960 μmol, 1.1 eq.) was added drop wise 
to a stirred solution of (−)-bis[(S)-1-phenylethyl]amine ((S,S)-73, 200 μL, 876 μmol, 
1.0 eq.) and N-ethyldiisopropylamine (500 μL, 2.58 mmol, 3.0 eq.) in toluene (3 mL) at 
0 °C under argon atmosphere. Stirring was continued for 1 hour before addition of a 
solution of (S)-2-[(diphenylphosphino)methyl]pyrrolidine hydrochloride ((S)-52∙HCl, 
299 mg, 976 μmol, 1.1 eq.) in dichloromethane (2 mL) and 4-(dimethylamino)pyridine 
(DMAP, 21.4 mg, 175 μmol, 0.20 eq.). The reaction mixture was then heated at reflux for 
22 hours. After cooling to room temperature, H2O (20 mL) and conc. HCl (2 mL) were 
added. The phases were separated and the aqueous layer was extracted with 
toluene (20 mL). The combined organic extracts were washed with H2O (20 mL), dried 
over Mg2SO4 and concentrated under reduced pressure. The residue was purified by 
column chromatography on silica gel (3 x 18 cm, pre-treated with 10% NEt3), eluting 
with dichloromethane (100%). The product (S,S,S)-LU415 was obtained as yellowish 
semisolid (121 mg, 323 μmol, 27%). 
C34H37N2OP (520.64 g·mol−1): 
Rf = 0.75 (SiO2, dichloromethane 100%). 1H NMR (400 MHz, CDCl3): δ = 7.57 (“t”, 
3JH,H = 7.3 Hz, 2 H, Ar-H), 7.40-7.30 (m, 5 H, Ar-H), 7.30-7.26 (m, 3 H, Ar-H), 7.24-
7.10 (m, 10 H, Ar-H), 4.85 (q, 3JH,H = 7.1 Hz, 2 H, NC/C’H), 4.21-4.10 (m, 1 H,             
Pyr-2-H), 3.57-3.48 (m, 1 H, Pyr-5-HH’), 3.34-3.23 (m, 1 H, Pyr-5-HH’), 2.89 (“dt”, 
J = 14, 4.0 Hz, 1 H, CHH’P), 2.07-1.97 (m, 1 H, Pyr-H), 1.94 (“dd”, J = 13, 10 Hz, 1 H, 
CHH’P), 1.86-1.76 (m, 1 H, Pyr-H), 1.71-1.48 (m, 2 H, Pyr-H), 1.50 (s, 3 H, CH3), 
1.48 (s, 3 H, CH3’) ppm. 13C{1H} NMR (101 MHz, CDCl3): δ = 163.6 (s, C=O), 143.8 (s, 
CPh-i-C), 139.8 (d, 1JC,P = 13 Hz, C’PPh-i-C), 138.2 (d, 1JC,P = 12 Hz, PPh’-i-C), 
133.1 (d, 2JC,P = 19 Hz, PPh-o-CH), 132.9 (d, 2JC,P = 19 Hz, PPh’-o-CH), 128.7 (s,            
PPh-p-CH), 128.6 (d, 3JC,P = 4.0 Hz, PPh-m-CH), 128.5 (s, PPh’-p-CH), 128.4 (d, 
3JC,P = 8.4 Hz, PPh’-m-CH), 128.1 (s, C/C’Ph-m-CH), 127.6 (s, C/C’Ph-o-CH), 126.7 (s, 
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C/C’Ph-p-CH), 56.7 (d, 2JC,P = 20 Hz, Pyr-2-CH), 55.8 (s, NC/C’H), 50.5 (s, Pyr-5-CH2), 
33.7 (d, 1JC,P = 14 Hz, CH2P), 32.1 (d, 3JC,P = 8.7 Hz, Pyr-3-CH2), 25.5 (s, Pyr-4-CH2), 
19.8 (s, CH3/CH3’) ppm. 31P{1H} NMR (162 MHz, CDCl3): δ = − 25.9 (s) ppm. IR 
(neat): ߥ෤ = 3056w, 3025w, 2969m, 2935w, 2866w, 1623s, 1415m, 1375m, 1340m, 1310m, 
1199m, 1181m, 1170m, 1091m, 1070m, 1025m, 997w, 907m, 873m, 794m, 739s, 693s cm−1. 
MS (FAB, NBA): m/z (%) = 521 (20, [M + H]+), 433 (9), 415 (46), 311 (24), 286 (19), 
185 (21), 105 (100), 57 (7). [ߙ]஽ଶ଴ = + 2.9 (c = 1.28, CHCl3). 
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6.4 
Proline-Based P,O Ligand/Iridium Complexes: Preparation and 
Analytical Data 
 
[(η4-1,5-Cyclooctadiene)-((R)-1-{2-[(Diphenylphosphino)methyl]pyrrolidin-1-yl}-2,2-
dimethylpropan-1-one)-iridium(I)]-tetrakis[3,5-bis(trifluoromethyl)phenyl]borate 
((R)-CA1) 
 
Complex (R)-CA1 (98%) was prepared according to general procedure 5 from ligand 
(R)-LA1 and [Ir(cod)2]BArF.[73] Crystals suitable for X-ray diffraction were obtained by 
crystallization from dichloromethane layered with n-pentane in an NMR tube. 
C62H52NOPIrBF24 (1517.03 g·mol−1): 
m.p. 98-102 °C. 1H NMR (500 MHz, CD2Cl2): δ = 7.96-7.90 (m, 1 H, Ph-o-H), 7.76 (s, 
8 H, ArF-o-H), 7.69-7.33 (m, 12 H, Ph/Ph’-H and ArF-p-H), 7.05-6.96 (m, 1 H, Ph’-m-H), 
5.38-5.28 (m, 1 H, Pyr-2-H), 5.25-5.16 (m, 1 H, cod-CH), 5.11-5.04 (m, 1 H, cod-CH), 
3.78-3.69 (m, 1 H, Pyr-5-HH’), 3.31-3.22 (m, 1 H, Pyr-5-HH’), 3.12-3.00 (m, 1 H, 
CHH’P), 2.97-2.85 (m, 2 H, cod-CH), 2.85-2.77 (m, 1 H, CHH’P), 2.50-2.39 (m, 2 H, 
cod-CH2), 2.31-1.73 (m, 9 H, cod-CH2 and Pyr-H), 1.60-1.48 (m, 1 H, Pyr-3-HH’), 
0.84 (s, 9 H, tBu-H) ppm. 13C{1H} NMR (126 MHz, CD2Cl2): δ = 184.7 (s, C=O), 
161.9 (q, 1JC,B = 50 Hz, ArF-i-C), 134.9 (s, ArF-o-CH), 134.7 (d, 2JC,P = 13 Hz, Ph-o-CH), 
132.9 (s, Ph-p-CH), 131.3 (d, 3JC,P = 9.4 Hz, Ph-m-H), 131.2 (s, Ph’-p-CH), 130.3 (d, 
1JC,P = 51 Hz, Ph-i-C), 129.9 (d, 2JC,P = 11 Hz, Ph’-o-CH), 129.5-128.5 (m, ArF-m-C and 
Ph’-m-CH), 125.3 (d, 1JC,P = 53 Hz, Ph’-i-C), 124.7 (q, 1JC,F = 272 Hz, ArF-CF3), 117.8-
117.4 (m, ArF-p-CH), 69.1 (s, tBu-C), 59.4 (d, 2JC,P = 4.2 Hz, Pyr-2-CH), 52.3 (s,             
cod-CH), 51.5 (s, cod-CH), 48.6 (s, Pyr-5-CH2), 36.9 (d, 1JC,P = 30 Hz, CH2P), 35.3 (br d, 
3JC,P = 3.8 Hz, cod-CH2), 31.9 (br d, 3JC,P = 2.1 Hz, cod-CH2), 31.5 (d, 3JC,P = 14 Hz,           
Pyr-3-CH2), 29.7 (br s, cod-CH2), 27.2 (br s, cod-CH2), 26.7 (s, tBu-CH3), 23.4 (s,          
Pyr-4-CH2) ppm. 31P{1H} NMR (162 MHz, CDCl3): δ = 9.1 (s) ppm. 19F{1H} NMR 
(377 MHz, CDCl3): δ = − 63.5 (s) ppm. IR (KBr): ߥ෤ = 2974m, 1781w, 1612s, 1535s, 
1487m, 1438s, 1358s, 1279s, 1131s, 1000w, 950w, 926w, 888s, 839m cm−1. MS (FAB, 
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NBA): m/z (%) = 655 (13), 654 (36, [M + H]+), 652 (25), 488 (27), 486 (21), 458 (12), 
456 (10). [ߙ]஽ଶ଴ = + 9.3 (c = 1.10, CHCl3). Elemental analysis: calc. C 49.09%, H 3.45%, 
N 0.92%; found: C 49.16%, H 3.47%, N 0.85%. 
 
[(η4-1,5-Cyclooctadiene)-((S)-Adamantan-1-yl {(S)-2-[(diphenylphosphino)methyl] 
pyrrolidin-1-yl}methanone)-iridium(I)]-tetrakis[3,5-bis(trifluoromethyl)phenyl]borate 
((S)-CA7) 
 
Complex (S)-CA7 (98%) was prepared according to general procedure 5 from ligand 
(S)-LA7 and [Ir(cod)2]BArF.[73] 
C68H58NOPIrBF24 (1595.16 g·mol−1): 
m.p. 89-91 °C. 1H NMR (400 MHz, CDCl3): δ = 7.96-7.88 (m, 1 H, Ph-H), 7.73 (s, 8 H, 
ArF-o-H), 7.69-7.24 (m, 12 H, ArF-p-H and Ph/Ph’-H), 7.04-6.95 (m, 1 H, Ph’-H), 5.41-
5.32 (m, 1 H, Pyr-2-H), 5.27-5.18 (m, 1 H, cod-CH), 5.12-5.03 (m, 1 H, cod-CH), 4.00-
3.88 (m, 1 H, Pyr-5-HH’), 3.39-3.24 (m, 1 H, Pyr-5-HH’), 3.11-2.95 (m, 1 H, CHH’P), 
2.95-2.83 (m, 2 H, cod-CH), 2.83-2.72 (m, 1 H, CHH’P), 2.54-2.38 (m, 2 H, cod-H), 
2.34-1.15 (m, 25 H, cod-H, Pyr-H and Adm-H) ppm. 13C{1H} NMR (126 MHz, CD2Cl2): 
δ = 183.6 (s, C=O), 161.9 (q, 1JC,B = 50 Hz, ArF-i-C), 134.9 (s, ArF-o-CH), 134.7 (s,      
Ph-o-CH), 131.7-130.5 (m, Ph-m-CH, Ph/Ph’-p-CH and Ph-i-C), 129.9 (d, 2JC,P = 11 Hz, 
Ph’-o-CH), 129.6-128.0 (m, Ph’-m-CH and ArF-m-C), 124.7 (q, 1JC,F = 272 Hz, ArF-CF3), 
125.3 (br d, Ph’-i-C), 117.5 (br s, ArF-p-CH), 99.2 (d, 2JC,P = 13 Hz, cod-CH), 98.8 (d, 
2JC,P = 13 Hz, cod-CH), 59.2 (br d, 2JC,P = 20 Hz, Pyr-2-CH), 52.1 (s, cod-CH), 51.3 (s, 
cod-CH), 48.5 (s, Pyr-5-CH2), 43.8 (s, Adm-1-C), 37.1 (s, Adm-2/8/10-CH2), 36.0 (br s,         
cod-CH2), 35.9 (s, Adm-4/6/9-CH2), 33.1 (d, 1JC,P = 35 Hz, CH2P), 31.9 (br d, cod-CH2), 
31.3 (d, 3JC,P = 8.1 Hz, Pyr-3-CH2), 29.8 (s, cod-CH2), 28.0 (s, Adm-3/5/7-CH), 27.2 (s, 
cod-CH2), 23.6 (s, Pyr-4-CH2) ppm. 31P{1H} NMR (162 MHz, CDCl3): δ = 12.5 (s) ppm. 
19F{1H} NMR (377 MHz, CDCl3): δ = − 62.3 (s) ppm. IR (neat):  ߥ෤ = 2912m, 2856m, 
1734m, 1610w, 1522m, 1436m, 1354s, 1271s, 1112s, 885m, 839m, 744m, 711m, 680s, 
667m cm−1. MS (ESI): m/z (%) = 732 (100, M+). [ߙ]஽ଶ଴ = − 3 (c = 0.270, CHCl3). 
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[(η4-1,5-Cyclooctadiene)-((S)-1-{2-[(Diphenylphosphino)methyl]pyrrolidin-1-yl}-
2,2,2-triphenylethanone)-iridium(I)]-tetrakis[3,5-bis(trifluoromethyl)phenyl]borate 
((S)-CA13) 
 
 
Complex (S)-CA13 (99%) was prepared according to general procedure 5 from ligand 
(S)-LA13 and [Ir(cod)2]BArF.[73] 
C77H58NOPIrBF24 (1703.25 g·mol−1): 
m.p. 80-84 °C. 1H NMR (400 MHz, CD2Cl2): δ = 8.10-8.01 (m, 2 H, Ph-H), 7.81-
7.01 (m, 30 H, Ph/Ph’-H, CPh-H and ArF-H), 6.80-6.70 (m, 5 H, PPh/Ph’-H), 5.50-
5.39 (m, 1 H, Pyr-2-H), 4.81-4.73 (m, 1 H, cod-CH), 4.26-4.17 (m, 1 H, cod-CH), 3.18-
3.03 (m, 3 H, Pyr-5-H2 and CHH’P), 2.92-2.79 (m, 2 H, cod-CH), 2.65-2.54 (m, 1 H, 
CHH’P), 2.42-0.94 (m, 12 H, Pyr-H and cod-H) ppm. 13C{1H} NMR (126 MHz, 
CD2Cl2): δ = 178.7 (s, C=O), 161.8 (q, 1JC,B = 50 Hz, ArF-i-C), 140.4 (s, CPh-i-C), 
135.8 (d, 2JC,P = 11 Hz, PPh-o-CH), 134.9 (s, ArF-o-CH), 133.3 (s, PPh-p-CH), 131.5 (d, 
3JC,P = 11 Hz, PPh-m-CH), 131.2 (s, PPh’-p-CH), 131.1 (br d, PPh-i-C), 130.0 (d, 
3JC,P = 10 Hz, PPh’-m-CH), 129.8 (s, CPh-m-CH), 129.5-128.4 (m, PPh’-o-CH,            
CPh-o-CH and ArF-m-C), 127.5 (s, CPh-p-CH), 125.9 (br d, PPh’-i-C), 124.7 (q, 
1JC,F = 272 Hz, ArF-CF3), 117.7-117.4 (m, ArF-p-CH), 100.7 (d, 2JC,P = 12 Hz, cod-CH), 
98.0 (d, 2JC,P = 12 Hz, cod-CH), 69.8 (s, CPh3), 60.1 (d, 2JC,P = 6.8 Hz, Pyr-2-CH), 
53.7 (s, cod-CH), 53.5 (s, cod-CH), 51.6 (s, Pyr-5-CH2), 43.0 (d, 1JC,P = 28 Hz, CH2P), 
34.5 (s, cod-CH2), 33.1 (d, 3JC,P = 14 Hz, Pyr-3-CH2), 38.4 (s, cod-CH2), 29.2 (s,               
cod-CH2), 27.5 (s, cod-CH2), 23.3 (s, Pyr-4-CH2) ppm. 31P{1H} NMR (162 MHz, 
CD2Cl2): δ = 14.9 (s) ppm. 19F{1H} NMR (377 MHz, CD2Cl2): δ = − 62.8 (s) ppm. 
IR (neat):  ߥ෤ = 2927m, 2854m, 1610m, 1552m, 1488m, 1438m, 1354s, 1273s, 1115s, 
1000m, 929w, 885m, 839m, 742m, 700m, 680s cm−1. MS (ESI): m/z (%) = 840 (100, 
M+). [ߙ]஽ଶ଴ = + 6.1 (c = 1.271, CHCl3). 
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[(η4-1,5-Cyclooctadiene)-((S)-1-{2-[(di-tert-butylphosphino)methyl]pyrrolidin-1-yl}-
2,2,2-triphenylethanone)-iridium(I)]-tetrakis[3,5-bis(trifluoromethyl)phenyl]borate             
((S)-CA16) 
 
Complex (S)-CA16 (99%) was prepared according to general procedure 5 from ligand 
(S)-LA16 and [Ir(cod)2]BArF.[73] 
C73H66NOPIrBF24 (1663.27 g·mol−1): 
m.p. 66-70 °C. 1H NMR (500 MHz, CDCl3): δ = 7.70 (s, 8 H, ArF-o-H), 7.51 (s, 4 H, 
ArF-p-H), 7.38-6.97 (m, 15 H, Ph-H), 5.03-4.93 (m, 1 H, Pyr-2-H), 4.24-4.16 (m, 1 H, 
cod-CH), 4.16-4.07 (m, 1 H, cod-CH), 4.07-4.00 (m, 1 H, cod-CH), 3.48-3.39 (m, 1 H, 
cod-CH), 3.10-2.98 (m, 1 H, Pyr-5-HH’), 2.81-2.70 (m, 1 H, CHH’P), 2.30-2.07 (m, 5 H, 
Pyr-5-HH’ and cod-CH2), 2.07-1.96 (m, 1 H, CHH’P), 1.83-1.45 (m, 8 H, Pyr-H and  
cod-CH2), 1.32 (d, 3JH,P = 13 Hz, 9 H, tBu-H), 1.19 (d, 3JH,P = 13 Hz, 9 H, tBu’-H) ppm. 
13C{1H} NMR (126 MHz, CDCl3): δ = 174.7 (s, C=O), 161.8 (q, 1JC,B = 50 Hz, ArF-i-C), 
140.5 (br s, Ph-i-C), 134.9 (s, ArF-o-CH), 130.1 (s, Ph-m-CH), 129.4-128.6 (m, ArF-m-C), 
128.6 (s, Ph-o-CH), 128.2 (s, Ph-p-CH), 124.7 (q, 1JC,F = 273 Hz, ArF-CF3), 117.7-
117.4 (m, ArF-p-CH), 95.9 (d, 2JC,P = 11 Hz, cod-CH), 90.8 (d, 2JC,P = 13 Hz, cod-CH), 
69.1 (s, CPh3), 60.2 (d, 2JC,P = 9.3 Hz, Pyr-2-CH), 52.4 (s, Pyr-5-CH2), 52.2 (s, cod-CH), 
50.5 (s, cod-CH), 39.6 (d, 1JC,P = 19 Hz, tBu-C), 37.5 (d, 1JC,P = 20 Hz, CH2P), 36.5 (d, 
1JC,P = 17 Hz, tBu’-C), 34.7 (s, cod-CH2), 34.3 (s, cod-CH2), 33.4 (s, Pyr-3-CH2), 30.5 (d, 
2JC,P = 4.0 Hz, tBu-CH3), 28.9 (br s, tBu’-CH3), 28.0 (s, cod-CH2), 26.8 (s, cod-CH2), 
25.2 (s, Pyr-4-CH2) ppm. 31P{1H} NMR (202 MHz, CDCl3): δ = 55.8 (s) ppm. 
19F{1H} NMR (377 MHz, CDCl3): δ = − 62.6 (s) ppm. IR (neat):  ߥ෤ = 2966w, 2889w, 
1553m, 1353s, 1272s, 1115s, 1095m, 884m, 838m cm−1. MS (FAB, NBA): 
m/z (%) = 801 (43), 800 (100, [M + H]+), 799 (28), 798 (59), 392 (11), 360 (16), 244 (10), 
243 (47), 165 (22). [ߙ]஽ଶ଴ = + 7.8 (c = 0.460, CHCl3). Elemental analysis: calc. 
C 52.72%, H 4.00%, N 0.84%; found: C 52.54%, H 4.02%, N 0.95%.  
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[(η4-1,5-Cyclooctadiene)-((S)-1-{2-[(dicyclohexylphosphino)methyl]pyrrolidin-1-yl}-
2,2,2-triphenylethanone)-iridium(I)]-tetrakis[3,5-bis(trifluoromethyl)phenyl]borate             
((S)-CA17) 
 
Complex (S)-CA17 (97%) was prepared according to general procedure 5 from ligand 
(S)-LA17 and [Ir(cod)2]BArF.[73] 
C77H70NOPIrBF24 (1715.35 g·mol−1): 
m.p. 88-93 °C. 1H NMR (400 MHz, CDCl3): δ = 7.70 (s, 8 H, ArF-o-H), 7.25 (m, 4 H, 
ArF-p-H), 7.26-6.96 (m, 15 H, Ph-H), 4.82-4.66 (m, 1 H, cod-CH), 4.44-4.29 (m, 1 H, 
Pyr-2-H), 3.76-3.68 (m, 1 H, cod-CH), 3.50-3.33 (m, 2 H, cod-CH), 3.14-2.98 (m, 1 H, 
Pyr-5-HH’), 2.98-0.76 (m, 37 H, CH2P, Pyr-H, cod-H and Cy/Cy’-H) ppm. 
31P{1H} NMR (162 MHz, CDCl3): δ = 35.9 (s) ppm. 19F{1H} NMR (377 MHz, CDCl3): 
δ = − 62.8 (s) ppm. IR (neat):  ߥ෤ = 2945m, 2869m, 1606m, 1481m, 1434m, 1352m, 
1272s, 1122s, 1105s, 1054m, 1027m, 999m, 885m, 732m, 703m, 669m cm−1. MS (ESI): 
m/z (%) = 852 (100, M+). [ߙ]஽ଶ଴ = − 7.0 (c = 0.300, CHCl3). 
 
[(η4-1,5-Cyclooctadiene)-((S)-{2-[(diphenylphosphino)methyl]-N-tritylpyrrolidine-1-
carboxamide}-2,2,2-triphenylethanone)-iridium(I)]-tetrakis[3,5-bis(trifluoromethyl) 
phenyl]borate ((S)-CU315) 
 
Complex (S)-CU315 (97%) was prepared according to general procedure 5 from ligand 
(S)-LU315 and [Ir(cod)2]BArF.[73] [((S)-LU315)Ir(cod)]PF6 was prepared from (S)-LU315 
and [Ir(cod)2]PF6. Crystals suitable for X-ray diffraction were obtained by crystallization 
from dichloromethane layered with n-pentane in an NMR tube. 
C77H59N2OPIrBF24 (1718.26 g·mol−1): 
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m.p. 84-88 °C. 1H NMR (400 MHz, CD2Cl2): δ = 8.00-6.97 (m, 37 H, PPh/Ph’-H, CPh-H 
and ArF-H), 5.56 (s, 1 H, NH), 4.76-4.67 (m, 1 H, Pyr-2-H), 4.47-4.39 (m, 1 H, cod-CH), 
3.76-3.64 (m, 1 H, cod-CH), 3.21-3.13 (m, 1 H, Pyr-5-HH’), 3.09-2.93 (m, 2 H,              
Pyr-5-HH’ and CHH’P), 2.82-2.74 (m, 1 H, cod-CH), 2.68-2.53 (m, 2 H, CHH’P and 
cod-CH), 2.36-2.09 (m, 3 H, cod-CH2), 2.08-1.79 (m, 5 H, Pyr-H and cod-CH2), 1.75-
1.22 (m, 4 H, cod-CH2) ppm. 13C{1H} NMR (126 MHz, CDCl3): δ = 163.7 (s, C=O), 
161.8 (q, 1JC,B = 50 Hz, ArF-i-C), 143.6 (s, CPh-i-C), 135.0 (s, ArF-o-CH), 133.9 (d, 
2JC,P = 12 Hz, PPh-o-CH), 132.8 (d, 4JC,P = 2.3 Hz, PPh-p-CH), 131.5 (d, 3JC,P = 9.0 Hz, 
PPh-m-CH), 131.3 (br d, 4JC,P = 2.2 Hz, PPh’-p-CH), 130.1 (d, 1JC,P = 50 Hz, PPh-i-C), 
129.7 (d, 2JC,P = 10 Hz, PPh’-o-CH), 129.6-128.5 (m, ArF-m-C and PPh’-m-CH), 128.5 (s, 
CPh-m-CH), 128.3 (s, CPh-o-CH), 128.0 (s, CPh-p-CH), 125.4 (d, 1JC,P = 50 Hz,            
PPh’-i-C), 124.7 (q, 1JC,F = 273 Hz, ArF-CF3), 117.7-117.5 (m, ArF-p-CH), 99.7 (d, 
2JC,P = 12 Hz, cod-CH), 99.6 (d, 2JC,P = 13 Hz, cod-CH), 72.2 (s, CPh3), 57.6 (d, 
2JC,P = 3.0 Hz, Pyr-2-CH), 51.3 (s, cod-CH), 50.7 (s, cod-CH), 47.4 (s, Pyr-5-CH2), 
35.3 (d, 2JC,P = 4.4 Hz, cod-CH2), 34.4 (d, 1JC,P = 31 Hz, CH2P), 32.7 (d, 2JC,P = 12 Hz, 
Pyr-3-CH2), 31.5 (br d, 2JC,P = 2,5 Hz, cod-CH2), 29.6 (br s, cod-CH2), 26.8 (br s,          
cod-CH2), 23.5 (s, Pyr-4-CH2) ppm. 31P{1H} NMR (162 MHz, CDCl3): δ = 11.2 (s) ppm. 
19F{1H} NMR (377 MHz, CDCl3): δ = − 62.6 (s) ppm. IR (neat): ߥ෤ = 3450w, 2959w, 
1572m, 1569m, 1486w, 1436w, 1353s, 1272s, 1115s, 1036m, 885m, 839m cm−1. 
MS (FAB, NBA): m/z (%) = 856 (21), 855 (45, [M + H]+), 854 (14), 853 (27), 244 (21), 
243 (100), 165 (34). [ߙ]஽ଶ଴ = – 37.7 (c = 0.700, CHCl3). HRMS (ESI): calc. for 
C45H47N2OIrP (M+): 855.3050; found: 855.3063. 
 
[(η4-1,5-Cyclooctadiene)-{(S)-N,N-Dicyclohexyl-2-[(diphenylphosphino)methyl] 
pyrrolidine-1-carboxamide}-iridium(I)]-tetrakis[3,5-bis(trifluoromethyl)phenyl] 
borate ((S)-CU45) 
 
Complex (S)-CU45 (97%) was prepared according to general procedure 5 from ligand 
(S)-LU45 and [Ir(cod)2]BArF.[73] 
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C70H65N2OPIrBF24 (1640.24 g·mol−1): 
m.p. 80-84 °C. 1H NMR (400 MHz, CD2Cl2): δ = 7.98-7.89 (m, 2 H, Ph-o-H), 7.72 (s, 
8 H, ArF-o-H), 7.64-7.51 (m, 7 H, ArF-p-H and Ph/Ph’-H), 7.40-7.32 (m, 3 H, Ph/Ph’-H), 
6.99-6.91 (m, 2 H, Ph-m-H), 5.32-5.20 (m, 1 H, Pyr-2-H), 5.18-5.11 (m, 1 H, cod-CH), 
5.11-4.97 (m, 1 H, cod-CH), 3.47-3.38 (m, 1 H, Pyr-5-HH’), 3.33-3.25 (m, 1 H,             
Pyr-5-HH’), 2.96-2.67 (m, 5 H), 2.62-2.42 (m, 3 H), 2.25-1.93 (m, 4 H), 1.86-1.39 (m, 
17 H), 1.33-1.04 (m, 3 H), 1.11-0.95 (m, 4 H), 0.73-0.62 (m, 2 H) ppm. 13C{1H} NMR 
(126 MHz, CD2Cl2): δ = 168.4 (s, C=O), 161.8 (q, 1JC,B = 50 Hz, ArF-i-C), 135.5 (d, 
2JC,P = 12 Hz, Ph-o-CH), 134.9 (s, ArF-o-CH), 134.2 (s, Ph-p-CH), 131.3 (d, 
2JC,P = 10 Hz, Ph’-o-CH), 130.9 (br d, 3JC,P = 2.6 Hz, Ph-m-CH), 130.3 (s, Ph’-p-CH), 
130.1-128.3 (m, Ph-i-C, Ph’-m-CH and ArF-m-C), 124.4 (br d, Ph’-i-C), 124.7 (q, 
1JC,F = 273 Hz, ArF-CF3),117.7-117.4 (m, ArF-p-CH), 97.2 (d, 2JC,P = 10 Hz, cod-CH), 
96.2 (d, 2JC,P = 13 Hz, cod-CH), 59.2 (br d, Pyr-2-CH), 58.9 (br s, Cy/Cy’-1-CH), 55.1 (s, 
Pyr-5-CH2), 51.4 (s, cod-CH), 49.7 (s, cod-CH), 35.9 (br s, cod-CH2), 35.0 (br d,           
Pyr-3-CH2), 32.6 (s, Cy/Cy’-CH2), 31.1 (br s, cod-CH2), 30.4 (s, Cy/Cy’-CH2), 30.3 (br s, 
cod-CH2), 26.8 (br s, cod-CH2), 26.3 (s, Cy/Cy’-CH2), 26.2 (s, Cy/Cy’-CH2), 25.4 (s,  
Pyr-4-CH2), 25.3 (s, Cy/Cy’-CH2) ppm. 31P{1H} NMR (162 MHz, CDCl3): δ = 14.6 
(s) ppm. 19F{1H} NMR (377 MHz, CDCl3): δ = − 62.4 (s) ppm. IR (neat): ߥ෤ = 2939m, 
2862m, 1733w, 1610w, 1521m, 1452m, 1436m, 1353s, 1271s, 1113s, 1093s, 1000m, 
885m, 836m, 742m, 711m, 680s, 669m cm−1. MS (ESI): m/z (%) = 777 (100, M+). [ߙ]஽ଶ଴ = + 36.5 (c = 0.320, CHCl3). 
 
[(η4-1,5-Cyclooctadiene)-{(S)-N,N-Dicyclohexyl-2-[(dicyclohexylphosphino)methyl] 
pyrrolidine-1-carboxamide}-iridium(I)]-tetrakis[3,5-bis(trifluoromethyl)phenyl] 
borate ((S)-CU48) 
 
Complex (S)-CU48 (98%) was prepared according to general procedure 5 from ligand 
(S)-LU48 and [Ir(cod)2]BArF.[73] 
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C70H77N2OPIrBF24 (1652.33 g·mol−1): 
m.p. 83-87 °C. 1H NMR (400 MHz, CD2Cl2): δ = 7.72 (s, 8 H, ArF-o-H), 7.56 (s, 4 H, 
ArF-p-H), 5.05-4.94 (m, 1 H, cod-CH), 4.84-4.76 (m, 1 H, cod-CH), 4.49-4.36 (m, 1 H, 
Pyr-2-H), 3.77-3.69 (m, 1 H, cod-CH), 3.58-3.48 (m, 1 H, Pyr-5-HH’), 3.33-3.26 (m, 1 H, 
Pyr-5-HH’), 3.25-3.09 (m, 3 H, cod-CH and Cy-H), 2.54-1.07 (m, 56 H) ppm. 
13C{1H} NMR (126 MHz, CDCl3): δ = 165.1 (s, C=O), 161.8 (q, 1JC,B = 50 Hz, ArF-i-C), 
134.9 (s, ArF-o-CH), 129.3-128.6 (m, ArF-m-C), 124.7 (q, 1JC,F = 273 Hz, ArF-CF3), 
117.7-117.5 (m, ArF-p-CH), 93.2 (m, 2 cod-CH), 59.9 (d, 2JC,P = 9.0 Hz, Pyr-2-CH), 
59.0 (br s, NCy/Cy’-1-CH), 53.0 (s, Pyr-5-CH2), 51.9 (s, cod-CH), 49.2 (s, cod-CH), 
37.0-36.3 (m, PCy/Cy’-1-CH and cod-CH2), 34.5 (d, 3JC,P = 10 Hz, Pyr-3-CH2), 33.5 (s, 
Cy/Cy’-CH2), 30.9-29.4 (m, Cy/Cy’-CH2 and cod-CH2), 28.1 (d, 1JC,P = 28 Hz, CH2P), 
26.8-25.1 (m, Pyr-4-CH2, Cy/Cy’-CH2 and cod-CH2) ppm. 31P{1H} NMR (202 MHz, 
CDCl3): δ = 26.6 (s) ppm. 19F{1H} NMR (377 MHz, CDCl3): δ = − 62.6 (s) ppm. 
IR (neat):  ߥ෤ = 2935m, 2858m, 1533m, 1448w, 1353s, 1271s, 1113s, 884m, 839m  cm−1. 
MS (FAB, NBA): m/z (%) = 790 (41), 789 (100, [M + H]+), 788 (28), 787 (64), 677 (15), 
675 (18), 501 (15), 470 (17), 468 (18), 466 (18), 386 (16), 384 (14), 302 (11), 126 (14), 
83 (51), 55 (25). [ߙ]஽ଶ଴ = + 62.3 (c = 0.591, CHCl3). Elemental analysis: calc. C 50.88%, 
H 4.70%, N 1.70%; found: C 50.59%, H 4.73%, N 1.81%. 
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6.5 
Proline-Based P,N Ligands: Preparation and Analytical Data 
 
6.5.1 
Benzoxazole phosphines (S)-LOx and Precursors 
 
(S)-2-{2-[(Diphenylphosphino)methyl]pyrrolidin-1-yl}benzo[d]oxazole ((S)-LOx1) 
 
Compound (S)-LOx1 (82%) was prepared according to general procedure 6 from        
(S)-LC1 and 2-chlorobenzoxazole (81). 
C24H23N2OP (386.43 g·mol−1): 
m.p. 87-89 °C. Rf = 0.26 (SiO2, cyclohexane/ethyl acetate 8:2). 1H NMR (400 MHz, 
CDCl3): δ = 7.68-7.59 (m, 2 H, Ph-H), 7.45-7.33 (m, 6 H, BzOx-7-H and Ph-H), 7.26-
7.20 (m, 3 H, Ph-H), 7.20-7.10 (m, 2 H, BzOx-4-H and BzOx-5-H), 6.99 (“t”, 
3JH,H = 7.7 Hz, 1 H, BzOx-6-H), 4.31-4.16 (m, 1 H, Pyr-2-H), 3.72-3.56 (m, 2 H,               
Pyr-5-H2), 2.86 (“dt”, J = 14, 3.0 Hz, 1 H, CHH’P), 2.33 (“t”, J = 12 Hz, 1 H, CHH’P), 
2.23-2.05 (m, 3 H, Pyr-3-H2 and Pyr-4-HH’), 2.05-1.91 (m, 1 H, Pyr-4-HH’) ppm. 
13C{1H} NMR (101 MHz, CDCl3): δ = 160.5 (s, BzOx-2-C), 148.9 (s, BzOx-7a-C), 
143.4 (br s, BzOx-3a-C), 138.6 (d, 1JC,P = 12 Hz, Ph-i-C), 137.7 (d, 1JC,P = 12 Hz,           
Ph’-i-C), 133.1 (d, 2JC,P = 19 Hz, Ph-o-CH), 132.7 (d, 2JC,P = 19 Hz, Ph’-o-CH), 129.0 (s, 
Ph-p-CH), 128.7 (d, 3JC,P = 7.0 Hz, Ph-m-CH), 128.6 (s, Ph’-p-CH), 128.5 (d, 
3JC,P = 7.0 Hz, Ph’-m-CH), 123.9 (s, BzOx-5-CH), 120.2 (s, BzOx-6-CH), 116.2 (s, 
BzOx-4-CH), 108.6 (s, BzOx-7-CH), 57.5 (d, 2JC,P = 21 Hz, Pyr-2-CH), 48.4 (s, Pyr-5-
CH2), 33.7 (d, 1JC,P = 15 Hz, CH2P), 31.7 (d, 3JC,P = 7.6 Hz, Pyr-3-CH2), 24.1 (br s,          
Pyr-4-CH2) ppm. 31P{1H} NMR (162 MHz, CDCl3): δ = − 22.8 (s) ppm. IR (neat): 
ߥ෤ = 3054w, 2951w, 2875w, 1636s, 1576s, 1458m, 1383m, 1355m, 1243m, 1149w, 
1002w, 912m, 794w, 736s, 695s cm−1. MS (EI, 70 eV): m/z (%) = 386 (4, M+), 310 (20), 
309 (100), 187 (27). [ߙ]஽ଶ଴ = − 85.2 (c = 0.520, CHCl3).  
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(S)-[1-(Benzo[d]oxazol-2-yl)pyrrolidin-2-yl]methanol ((S)-90) 
 
(S)-2-{[(tert-butyldimethylsilyl)oxy]methyl}pyrrolidine[106] ((S)-87, 1.00 g, 4.64 mmol, 
1.0 eq.) was dissolved in tetrahydrofuran (15 mL) and a 1.6 M solution of n-butyllithium 
(3.30 mL, 5.28 mmol, 1.1 eq.) in hexanes was slowly added at – 78 °C in a acetone/dry 
ice bath. The resulting solution was then stirred for 30 minutes at – 78 °C and for 1 hour 
at room temperature. After cooling the solution again to – 78 °C,                                            
2-chlorobenzoxazole (81, 700 μL, 6.13 mmol, 1.3 eq.) was added and the reaction 
mixture was allowed to warm to room temperature over 14 hours. At 0 °C in an ice bath, 
aqueous saturated NaHCO3 (10 mL) was added drop wise. Ethyl acetate (30 mL) was 
added and the layers were separated. The aqueous layer was extracted with ethyl 
acetate (2 x 30 mL). The combined organic layers were washed with brine (40 mL) and 
dried over MgSO4. The solvents were evaporated under reduced pressure and the crude 
product, (S)-2-(2-{[(tert-butyldimethylsilyl)oxy]methyl}pyrrolidin-1-yl)benzo[d]oxazole 
((S)-88), was dried in vacuo. The residue was then dissolved in tetrahydrofuran (10 mL) 
and tetrabutylammonium fluoride trihydrate (TBAF∙3 H2O, 2.93 g, 9.29 mmol, 2.0 eq.) 
was added portion wise, at 0 °C in an ice bath. The resulting mixture was allowed to stir 
at room temperature for 3 hours. Ethyl acetate (30 mL) and H2O (50 mL) were added. 
The resulting layers were separated and the aqueous layer was extracted with ethyl 
acetate (3 x 50 mL). The organic extracts were combined, washed with brine (70 mL) and 
dried over MgSO4. The solvents were removed under reduced pressure and the residue 
was filtered over a plug of silica gel (5 x 5 cm), eluting with ethyl acetate (100%). After 
evaporation of the solvent the product was purified by column chromatography on silica 
gel (5 x 15 cm), eluting with cyclohexane/ethyl acetate (1:1 → 3:7). The title compound 
(S)-90 was obtained as a yellowish semisolid (576 mg, 2.64 mmol, 57%). 
C12H14N2O2 (218.25 g·mol−1): 
Rf = 0.11 (SiO2, cyclohexane/ethyl acetate 7:3). 1H NMR (400 MHz, CDCl3): 
δ = 7.31 (d, 3JH,H = 7.8 Hz, 1 H, BzOx-7-H), 7.24 (d, 3JH,H = 8.0 Hz, 1 H, BzOx-4-H), 
7.15 (“t”, 3JH,H = 7.8 Hz, 1 H, BzOx-6-H), 7.00 (“t”, 3JH,H = 7.8 Hz, 1 H, BzOx-5-H), 
5.99-5.76 (br s, 1 H, OH), 4.19-4.08 (m, 1 H, Pyr-2-H), 3.86-3.71 (m, 3 H, CH2O and 
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Pyr-5-HH’), 3.70-3.59 (m, 1 H, Pyr-5-HH’), 2.24-2.14 (m, 1 H, Pyr-H), 2.09-1.99 (m, 
1 H, Pyr-H), 1.99-1.89 (m, 1 H, Pyr-H), 1.82-1.68 (m, 1 H, Pyr-H) ppm. 
13C{1H} NMR (101 MHz, CDCl3): δ = 162.0 (s, BzOx-2-C), 148.9 (s, BzOx-7a-C), 
142.4 (s, BzOx-3a-C), 124.2 (s, BzOx-5-CH), 120.7 (s, BzOx-6-CH), 116.1 (s,             
BzOx-4-CH), 108.9 (s, BzOx-7-CH), 66.6 (s, Pyr-2-CH), 63.1 (s, CH2O), 48.8 (s,            
Pyr-5-CH2), 29.6 (s, Pyr-4-CH2), 24.4 (s, Pyr-3-CH2) ppm. IR (neat): ߥ෤ = 3270w, 2929w, 
2873m, 1631s, 1573s, 1458s, 1386m, 1354m, 1242s, 1168w, 1151w, 1052m, 1003m, 
962w, 912m, 793w, 753m, 737s cm−1. MS (EI, 70 eV): m/z (%) = 218 (20, M+), 188 (20), 
187 (100). [ߙ]஽ଶ଴ = − 70.6 (c = 0.720, CHCl3). 
 
(S)-2-[2-(Bromomethyl)pyrrolidin-1-yl]benzo[d]oxazole ((S)-92) 
 
(S)-90 (336 mg, 1.54 mmol, 1.0 eq.), tetrabromomethane (765 mg, 2.31 mmol, 1.5 eq.) 
and triphenylphosphine (605 mg, 2.31 mmol, 1.5 eq.) were mixed in 
dichloromethane (10 mL) at 0 °C in an ice bath. The resulting mixture was allowed to 
warm to room temperature overnight. The solvent was evaporated and the crude was 
purified by column chromatography on silica gel (4 x 17 cm), eluting with 
cyclohexane/ethyl acetate (8:2). The title compound (S)-92 was obtained as a colorless 
solid (417 mg, 1.48 mmol, 96%). 
C12H13BrN2O (281.15 g·mol−1): 
m.p. 51-54 °C. Rf = 0.25 (SiO2, cyclohexane/ethyl acetate 8:2). 1H NMR (400 MHz, 
CDCl3): δ = 7.38 (d, 3JH,H = 8.3 Hz, 1 H, BzOx-4-H), 7.28 (d, 3JH,H = 7.9 Hz, 1 H,           
BzOx-7-H), 7.17 (“td”, 3JH,H = 7.7 Hz, 4JH,H = 1.0 Hz, 1 H, BzOx-5-H), 7.02 (“td”, 
3JH,H = 7.8 Hz, 4JH,H = 1.1 Hz, 1 H, BzOx-6-H), 4.39-4.31 (m, 1 H, Pyr-2-H), 3.79-
3.67 (m, 3 H, Pyr-5-H2 and CHH’Br), 3.61 (dd, 2JH,H = 9.9 Hz, 3JH,H = 8.3 Hz, 1 H, 
CHH’Br), 2.24-1.95 (m, 4 H, Pyr-H) ppm. 13C{1H} NMR (101 MHz, CDCl3): δ = 160.5 
(s, BzOx-2-C), 149.0 (s, BzOx-7a-C), 143.3 (s, BzOx-3a-C), 124.1 (s, BzOx-5-CH), 
120.8 (s, BzOx-6-CH), 116.5 (s, BzOx-4-CH), 109.9 (s, BzOx-7-CH), 59.6 (s, Pyr-2-CH), 
49.0 (s, Pyr-5-CH2), 34.4 (s, CH2Br), 30.2 (s, Pyr-4-CH2), 23.8 (s, Pyr-3-CH2) ppm. 
IR (neat): ߥ෤ = 2956w, 2875w, 1630s, 1569s, 1456s, 1435m, 1381m, 1345m, 1328m, 
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1281m, 1244s, 1224m, 1203m, 1189m, 1137m, 1085w, 1004m, 902m, 824m, 795m, 
739s, 644s cm−1. MS (EI, 70 eV): m/z (%) = 282 (17), 280 (17, M+), 201 (20), 188 (13), 
187 (100). [ߙ]஽ଶ଴ = − 59.1 (c = 0.981, CHCl3). 
 
(S)-2-{2-[(Di-ortho-tolylphosphino)methyl]pyrrolidin-1-yl}benzo[d]oxazole ((S)-LOx2) 
 
Product (S)-LOx2 (83%) was prepared according to general procedure 7 from        
bromide (S)-92 and di-ortho-tolylphosphine (94) and isolated as a colorless semisolid. 
C26H27N2OP (414.48 g·mol−1): 
Rf = 0.35 (SiO2, cyclohexane/ethyl acetate 8:2). 1H NMR (500 MHz, CDCl3): δ = 7.78-
7.73 (m, 1 H, oTol-H), 7.38-7.28 (m, 3 H, BzOx-7-H and oTol/oTol’-H), 7.22-7.10 (m, 
6 H, BzOx-4-H, BzOx-5-H and oTol/oTol’-H), 7.08-6.97 (m, 2 H, BzOx-6-H and 
oTol/oTol’-H), 4.28-4.16 (m, 1 H, Pyr-2-H), 3.77-3.69 (m, 1 H, Pyr-5-HH’), 3.68-
3.61 (m, 1 H, Pyr-5-HH’), 2.87-2.80 (m, 1 H, CHH’P), 2.49 (s, 3 H, oTol-CH3), 2.44 (s, 
3 H, oTol’-CH3), 2.39-1.96 (m, 5 H, CHH’P and Pyr-H) ppm. 13C{1H} NMR (101 MHz, 
CDCl3): δ = 160.6 (s, BzOx-2-C), 148.9 (s, BzOx-7a-C), 143.4 (s, BzOx-3a-C), 142.6 (d, 
2JC,P = 26 Hz, oTol-2-C), 141.8 (d, 2JC,P = 26 Hz, oTol’-2-C), 136.6 (d, 1JC,P = 12 Hz, 
oTol-1-C), 135.6 (d, 1JC,P = 13 Hz, oTol’-1-C), 131.8 (s, oTol-6-CH), 131.6 (s,           
oTol’-6-CH), 130.2 (d, 3JC,P = 4.8 Hz, oTol-3-CH), 130.1 (d, 3JC,P = 5.0 Hz, oTol’-3-CH), 
128.8 (s, oTol-4-CH), 128.6 (s, oTol’-4-CH), 126.3 (s, oTol-5-CH), 126.1 (s,               
oTol’-5-CH), 123.9 (s, BzOx-5-CH), 120.2 (s, BzOx-6-CH), 116.2 (s, BzOx-4-CH), 
108.6 (s, BzOx-7-CH), 57.4 (d, 2JC,P = 23 Hz, 1 H, Pyr-2-CH), 48.2 (s, Pyr-5-CH2), 
32.7 (d, 1JC,P = 15 Hz, CH2P), 31.6 (d, 3JC,P = 7.7 Hz, Pyr-3-CH2), 24.0 (s, Pyr-4-CH2), 
21.4 (d, 3JC,P = 5.9 Hz, oTol-CH3), 21.2 (s, oTol’-CH3) ppm. 31P{1H} NMR (162 MHz, 
CDCl3): δ = − 43.2 (s) ppm. IR (neat): ߥ෤ = 3054w, 2969w, 2875w, 1636s, 1576s, 1457s, 
1381m, 1355m, 1283w, 1243m, 1148w, 1031w, 1003w, 917m, 739s cm−1. MS (EI, 
70 eV): m/z (%) = 414 (5, M+), 324 (21), 323 (100), 187 (27). [ߙ]஽ଶ଴ = − 87.1 (c = 0.421, 
CHCl3). 
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(S)-2-{2-[(Di-tert-butylphosphino)methyl]pyrrolidin-1-yl}benzo[d]oxazole borane 
adduct ((S)-LOx3∙BH3) 
 
Compound (S)-LOx3∙BH3 (89%) was prepared according to general procedure 7 from        
(S)-92 and di-tert-butylphosphine borane adduct (50∙BH3). 
C20H34BN2OP (360.28 g·mol−1): 
m.p. 52-56 °C. Rf = 0.36 (SiO2, cyclohexane/ethyl acetate 8:2). 1H NMR (400 MHz, 
CDCl3): δ = 7.33 (d, 3JH,H = 7.7 Hz, 1 H, BzOx-7-H), 7.20 (d, 3JH,H = 7.8 Hz, 1 H,          
BzOx-4-H), 7.17-7.10 (m, 1 H, BzOx-5-H), 7.03-6.94 (m, 1 H, BzOx-6-H), 4.44-4.32 (m, 
1 H, Pyr-2-H), 3.77-3.67 (m, 1 H, Pyr-5-HH’), 3.67-3.56 (m, 1 H, Pyr-5-HH’), 2.64 (“t”, 
J = 14 Hz, 1 H, CHH’P), 2.37-2.26 (m, 1 H, Pyr-3-HH’), 2.26-2.24 (m, 1 H, Pyr-3-HH’), 
2.06-1.94 (m, 2 H, Pyr-4-H2), 1.63-1.51 (m, 1 H, CHH’P), 1.45 (d, 3JH,P = 13 Hz, 9 H, 
tBu-H), 1.25 (d, 3JH,P = 13 Hz, 9 H, tBu’-H), 0.93-0.08 (br m, 3 H, BH3) ppm. 
13C{1H} NMR (101 MHz, CDCl3): δ = 160.5 (s, BzOx-2-C), 148.9 (s, BzOx-7a-C), 
143.6 (s, BzOx-3a-C), 124.0 (s, BzOx-5-CH), 120.4 (s, BzOx-6-CH), 116.3 (s,             
BzOx-4-CH), 108.5 (s, BzOx-7-CH), 57.3 (d, 2JC,P = 6.2 Hz, Pyr-2-CH), 48.1 (s,          
Pyr-5-CH2), 33.4 (d, 1JC,P = 29 Hz, tBu-C), 32.8 (s, Pyr-3-CH), 32.1 (d, 1JC,P = 27 Hz, 
tBu’-C), 28.2 (br s, tBu-CH3), 27.9 (br s, tBu’-CH3), 23.6 (s, Pyr-4-CH2), 21.9 (d, 
1JC,P = 23 Hz, CH2P) ppm. 31P{1H} NMR (162 MHz, CDCl3): δ = 39.8 (br d, 
1JP,B = 68 Hz) ppm. IR (neat): ߥ෤ = 2953m, 2874m, 1637s, 1578s, 1458m, 1382m, 1373m, 
1284w, 1244m, 1147w, 1072m, 1023w, 919w, 813m, 740s cm−1. MS (EI, 70 eV): 
m/z (%) = 360 (14), 359 (22, [M – H]+), 343 (32), 303 (33), 290 (17), 289 (100), 247 (27), 
245 (17), 233 (26), 232 (15), 213 (14), 201 (22), 187 (21), 178 (10), 57 (28). [ߙ]஽ଶ଴ = − 68.4 (c = 0.252, CHCl3). Elemental analysis: calc. C 66.67%, H 9.51%, 
N 7.78%; found: C 66.39%, H 9.52%, N 7.30%. 
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(S)-2-{2-[(Di-tert-butylphosphino)methyl]pyrrolidin-1-yl}benzo[d]oxazole ((S)-LOx3) 
 
Product (S)-LOx3 was prepared according to general procedure 3 from (S)-LOx3·BH3. 
C20H31N2OP (346.45 g·mol−1): 
31P{1H} NMR (162 MHz, CD2Cl2): δ = 21.2 (s) ppm. 
 
(S)-2-{2-[(Dicyclohexylphosphino)methyl]pyrrolidin-1-yl}benzo[d]oxazole borane 
adduct ((S)-LOx4∙BH3) 
 
Compound (S)-LOx4∙BH3 (78%) was prepared according to general procedure 7 from        
(S)-92 and dicyclohexylphosphine borane adduct (51∙BH3). 
C24H38BN2OP (412.36 g·mol−1): 
m.p. 159-162 °C. Rf = 0.16 (SiO2, cyclohexane/ethyl acetate 9:1). 1H NMR (400 MHz, 
CDCl3): δ = 7.33 (d, 3JH,H = 7.7 Hz, 1 H, BzOx-7-H), 7.21 (d, 3JH,H = 7.9 Hz, 1 H, BzOx-
4-H), 7.15 (“td”, 3JH,H = 7.7 Hz, 4JH,H = 1.0 Hz, 1 H, BzOx-5-H), 7.00 (“td”, 
3JH,H = 7.7 Hz, 4JH,H = 1.1 Hz, 1 H, BzOx-6-H), 4.37-4.25 (m, 1 H, Pyr-2-H), 3.75-
3.69 (m, 1 H, Pyr-5-HH’), 3.63-3.56 (m, 1 H, Pyr-5-HH’), 2.41 (“t”, J =15 Hz, 1 H, 
CHH’P), 2.32-1.17 (m, 27 H, CHH’P, Pyr-H and Cy/Cy’-H), 0.82-0.05 (br q, 3 H, 
BH3) ppm. 13C{1H} NMR (101 MHz, CDCl3): δ = 160.4 (s, BzOx-2-C), 149.0 (s,            
BzOx-7a-C), 143.5 (s, BzOx-3a-C), 124.1 (s, BzOx-5-CH), 120.4 (s, BzOx-6-CH), 
116.3 (s, BzOx-4-CH), 108.6 (s, BzOx-7-CH), 56.4 (d, 2JC,P = 6.3 Hz, 1 H, Pyr-2-CH), 
48.1 (s, Pyr-5-CH2), 33.1 (d, 1JC,P = 33 Hz, 1 H, Cy-1-CH), 32.8 (s, Pyr-3-CH2), 31.9 (d, 
1JC,P = 34 Hz, 1 H, Cy’-1-CH), 27.3-26.0 (m, Cy/Cy’-CH2), 23.9 (d, 1JC,P = 26 Hz, 
CH2P), 23.7 (s, Pyr-4-CH2) ppm. 31P{1H} NMR (162 MHz, CDCl3): δ = 21.0 (br d) ppm. 
IR (neat): ߥ෤ = 3288m, 2926m, 2849m, 1635s, 1627s, 1593m, 1523s, 1516s, 1493m, 
1381m, 1355m, 1346m, 1331w, 1240m, 1217w, 1192w, 1174m, 1068w, 951w, 916w, 
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8816w, 737s, 692s cm−1. MS (EI, 70 eV): m/z (%) = 412 (17, M+), 411 (29, [M – H]+), 
396 (13), 395 (50), 394 (12), 329 (11), 316 (20), 315 (100), 313 (25), 292 (10), 247 (11), 
233 (13), 215 (17), 213 (17), 201 (12), 187 (13). [ߙ]஽ଶ଴ = − 60.7 (c = 0.560, CHCl3). 
 
(S)-2-{2-[(Dicyclohexylphosphino)methyl]pyrrolidin-1-yl}benzo[d]oxazole ((S)-LOx4) 
 
Product (S)-LOx4 was prepared according to general procedure 3 from (S)-LOx4·BH3. 
C24H35N2OP (398.52 g·mol−1): 
31P{1H} NMR (162 MHz, CDCl3): δ = − 11.2 (s) ppm. 
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6.5.2 
Benzothiazole phosphines (S)-LTh and Precursors 
 
(S)-2-{2-[(Diphenylphosphino)methyl]pyrrolidin-1-yl}benzo[d]thiazole ((S)-LTh1) 
 
Compound (S)-LTh1 (75%) was prepared according to general procedure 6 from        
(S)-LC1 and 2-chlorobenzothiazole (82). 
C24H23N2PS (402.49 g·mol−1): 
m.p. 101-105 °C. Rf = 0.23 (SiO2, cyclohexane/ethyl acetate 8:2). 1H NMR (500 MHz, 
CDCl3): δ = 7.70 (m, 2 H, Ph-o-H), 7.57 (d, 2JH,H = 8.0 Hz, 1 H, BzTh-4-H), 7.54 (d, 
2JH,H = 7.8 Hz, 1 H, BzTh-7-H), 7.45-7.34 (m, 5 H, Ph/Ph’-H), 7.28 (m, 1 H, BzTh-5-H), 
7.24 (m, 3 H, Ph/Ph’-H), 7.03 (m, 1 H, BzTh-6-H), 4.02-4.08 (m, 1 H, Pyr-2-H), 3.62-
3.44 (m, 2 H, Pyr-5-H2), 2.99 (br d, 2JH,P = 14 Hz, 1 H, CHH’P), 2.24-2.09 (m, 4 H, 
CHH’P and Pyr-3-H2 and Pyr-4-HH’), 2.02 (m, 1 H, Pyr-4-HH’) ppm. 13C{1H} NMR 
(126 MHz, CDCl3): δ = 164.6 (s, BzTh-2-C), 153.1 (s, BzTh-3a-C), 138.6 (d, 
1JC,P = 12 Hz, Ph-i-C), 137.4 (d, 1JC,P = 12 Hz, Ph’-i-C), 133.4 (d, 2JC,P = 19 Hz,            
Ph-o-CH), 132.7 (d, 2JC,P = 19 Hz, Ph’-o-CH), 130.7 (s, BzTh-7a-C), 128.9-128.5 (m, 
Ph/Ph’-CH), 125.8 (s, BzTh-5-CH), 120.8 (d, BzTh-6-CH), 120.7 (BzTh-7-CH), 118.8 (s, 
BzTh-4-CH), 59.3 (d, 2JC,P = 21 Hz, Pyr-2-CH), 50.2 (s, Pyr-5-CH2), 32.3 (d, 
1JC,P = 15 Hz, CH2P), 31.4 (d, 3JC,P = 7.5 Hz, Pyr-3-CH2), 23.9 (s, Pyr-4-CH2) ppm. 
31P{1H} NMR (202 MHz, CDCl3): δ = − 21.6 (s) ppm. IR (neat): ߥ෤ = 3066w, 2964w, 
2918w, 2867w, 1595m, 1564m, 1533s, 1481m, 1452m, 1441s, 1431m, 1363m, 1313m, 
1269m, 1254w, 1186w, 1124m, 1066m, 1018m, 914m, 852m, 734s cm−1. MS (ESI): 
m/z (%) = 403 (100, [M + H]+). Partial oxidation was observed while measuring. [ߙ]஽ଶ଴ = − 61.6 (c = 0.530, CHCl3).  
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(S)-2-(2-{[(tert-Butyldimethylsilyl)oxy]methyl}pyrrolidin-1-yl)benzo[d]thiazole           
((S)-89) 
 
(S)-2-{[(tert-butyldimethylsilyl)oxy]methyl}pyrrolidine[106] ((S)-87, 750 mg, 3.48 mmol, 
1.0 eq.) was dissolved in tetrahydrofuran (5 mL) and a 1.6 M solution of n-butyllithium 
(2.50 mL, 4.00 mmol, 1.2 eq.) in hexanes was slowly added at – 78 °C in a acetone/dry 
ice bath. The resulting solution was then stirred for 30 minutes at – 78 °C and for 1 hour 
at room temperature. After cooling the solution again to – 78 °C,                                             
2-chlorobenzothiazole (82, 540 μL, 4.15 mmol, 1.2 eq.) was added and the reaction 
mixture was allowed to warm to room temperature over 14 hours. At 0 °C in an ice bath, 
aqueous saturated NaHCO3 (10 mL) was added drop wise. Ethyl acetate (20 mL) was 
added and the layers were separated. The aqueous layer was extracted with ethyl 
acetate (2 x 20 mL). The combined organic extracts were washed with brine (30 mL) and 
dried over MgSO4. The solvents were evaporated under reduced pressure and the crude 
was purified by column chromatography on silica gel (4 x 15 cm), eluting with 
cyclohexane/ethyl acetate (19:1). The title compound (S)-89 was obtained as a colorless 
semisolid (837 mg, 2.64 mmol, 69%). 
C18H28N2OSSi (348.58 g·mol−1): 
Rf = 0.31 (SiO2, cyclohexane/ethyl acetate 19:1). 1H NMR (400 MHz, CDCl3): δ = 7.62-
7.53 (m, 2 H, BzTh-4-H and BzTh-7-H), 7.31-7.25 (m, 1 H, BzTh-5-H), 7.09-7.00 (m, 
1 H, BzTh-6-H), 4.12-4.00 (m, 1 H, Pyr-2-H), 3.87-3.78 (m, 2 H, CH2O), 3.66-3.57 (m, 
1 H, Pyr-5-HH’), 3.57-3.47 (m, 1 H, Pyr-5-HH’), 2.22-1.93 (m, 4 H, Pyr-H), 0.88 (s, 9 H, 
tBu-H), 0.05 (s, 3 H, CH3), 0.00 (s, 3 H, CH3’) ppm. 13C{1H} NMR (101 MHz, CDCl3): 
δ = 165.4 (s, BzTh-2-C), 153.4 (s, BzTh-3a-C), 130.9 (s, BzTh-7a-C), 125.9 (s,              
BzTh-5-CH), 120.9 (s, BzTh-6-CH), 120.7 (s, BzTh-7-CH), 118.9 (s, BzTh-4-CH), 
62.9 (s, CH2O), 62.7 (s, Pyr-2-CH), 50.9 (s, Pyr-5-CH2), 28.6 (s, Pyr-4-CH2), 26.1 (s, 
tBu-CH3), 24.0 (s, Pyr-3-CH2), 18.4 (s, tBu-C), − 5.2 (2 s, CH3/CH3’) ppm. IR (neat): 
ߥ෤ = 2953m, 2929m, 2856m, 1597m, 1535s, 1445m, 1362m, 1277m, 1252m, 1096m, 
1016w, 835s, 776m, 750s, 724m cm−1. MS (EI, 70 eV): m/z (%) = 348 (11, M+), 291 (37), 
216 (12), 204 (14), 203 (100). [ߙ]஽ଶ଴ = − 100 (c = 0.100, CHCl3). 
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(S)-[1-(Benzo[d]thiazol-2-yl)pyrrolidin-2-yl]methanol ((S)-91) 
 
(S)-89 (331 mg, 949 μmol, 1.0 eq.) was dissolved in tetrahydrofuran (7 mL) and 
tetrabutylammonium fluoride trihydrate (TBAF∙3 H2O, 599 mg, 1.90 mmol, 2.0 eq.) was 
added at 0 °C in an ice bath. The resulting mixture was allowed to stir at room 
temperature for 3 hours. Ethyl acetate (10 mL) and H2O (20 mL) were added. The layers 
were separated and the aqueous layer was extracted with ethyl acetate (3 x 10 mL). The 
organic layers were combined, washed with brine (15 mL) and dried over MgSO4 and the 
solvent was removed under reduced pressure. The product was purified by column 
chromatography on silica gel (4 x 10 cm), eluting with cyclohexane/ethyl acetate (1:1), to 
afford (S)-91 (199 mg, 849 μmol, 89%) as a yellowish semisolid. 
C12H14N2OS (234.32 g·mol−1): 
Rf = 0.24 (SiO2, cyclohexane/ethyl acetate 1:1). 1H NMR (400 MHz, CDCl3): 
δ = 7.60 (d, 3JH,H = 7.9 Hz, 1 H, BzTh-4-H), 7.54 (d, 3JH,H = 8.1 Hz, 1 H, BzTh-7-H), 
7.31 (“t”, 3JH,H = 7.7 Hz, 1 H, BzTh-5-H), 7.09 (“t”, 3JH,H = 7.7 Hz, 1 H, BzTh-6-H), 
6.65-6.45 (br s, 1 H, OH), 4.30-4.20 (m, 1 H, Pyr-2-H), 3.86-3.71 (m, 2 H, CH2O), 3.60-
3.51 (m, 1 H, Pyr-5-HH’), 3.50-3.40 (m, 1 H, Pyr-5-HH’), 2.27-2.16 (m, 1 H, Pyr-H), 
2.13-2.193 (m, 2 H, Pyr-H), 1.83-1.70 (m, 1 H, Pyr-H) ppm. 13C{1H} NMR (101 MHz, 
CDCl3): δ = 167.2 (s, BzTh-2-C), 151.7 (s, BzTh-3a-C), 130.2 (s, BzTh-7a-C), 130.2 
(BzTh-5-CH), 126.1 (s, BzTh-6-CH), 120.7 (s, BzTh-7-CH), 118.6 (s, BzTh-4-CH), 
66.8 (s, Pyr-2-CH), 64.8 (s, CH2O), 51.8 (s, Pyr-5-CH2), 29.8 (s, Pyr-4-CH2), 21.0 (s, 
Pyr-3-CH2) ppm. IR (neat): ߥ෤ = 3265m, 2906m, 2869m, 1594m, 1564m, 1528s, 1473w, 
1442s, 1359s, 1314m, 1274m, 1253m, 1238m, 1185w, 1153w, 1124w, 1067w, 1047m, 
1016m, 925w, 902w, 848w, 749s, 724s, 684w cm−1. MS (EI, 70 eV): m/z (%) = 234 (20, 
M+), 204 (21), 203 (100). [ߙ]஽ଶ଴ = − 104 (c = 0.989, CHCl3). 
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(S)-2-[2-(Bromomethyl)pyrrolidin-1-yl]benzo[d]thiazole ((S)-93) 
 
(S)-91 (321 mg, 1.37 mmol, 1.0 eq.), tetrabromomethane (683 mg, 2.06 mmol, 1.5 eq.) 
and triphenylphosphine (539 mg, 2.05 mmol, 1.5 eq.) were mixed in 
dichloromethane (8 mL) at 0 °C in an ice bath. The resulting mixture was allowed to 
warm to room temperature overnight. The solvent was evaporated and the crude was 
purified by column chromatography on silica gel (4 x 17 cm), eluting with 
cyclohexane/ethyl acetate (8:2). The title compound (S)-93 was obtained as a colorless 
solid (180 mg, 606 μmol, 44%). 
C12H13BrN2S (297.21 g·mol−1): 
m.p. 130-133 °C. Rf = 0.47 (SiO2, cyclohexane/ethyl acetate 8:2). 1H NMR (400 MHz, 
CDCl3): δ = 7.53 (“t”, 3JH,H = 7.4 Hz, 2 H, BzTh-H), 7.27-7.16 (m, 1 H, BzTh-H), 
7.00 (“t”, 3JH,H = 7.4 Hz, 1 H, BzTh-H), 4.38-4.25 (m, 1 H, Pyr-2-H), 5.76 (d, J = 9.8 Hz, 
1 H, CHH’Br), 3.62-3.52 (m, 2 H, CHH’Br and Pyr-5-HH’), 3.47-3.38 (m, 1 H,              
Pyr-5-HH’), 2.20-1.98 (m, 4 H, Pyr-H) ppm. 13C{1H} NMR (101 MHz, CDCl3): 
δ = 164.9 (s, BzTh-2-C), 153.0 (s, BzTh-3a-C), 130.8 (s, BzTh-7a-C), 126.1 (s, BzTh-5-
CH), 121.3 (s, BzTh-6-CH), 120.8 (s, BzTh-7-CH), 119.2 (s, BzTh-4-CH), 61.3 (s,           
Pyr-2-CH), 51.2 (s, Pyr-5-CH2), 34.0 (s, CH2Br), 30.1 (s, Pyr-3-CH2), 23.8 (s,                
Pyr-4-CH2) ppm. IR (neat): ߥ෤ = 3439w, 2959w, 2872w, 1594m, 1558m, 1530s, 1473m, 
1442m, 1418m, 1358m, 1325m, 1269m, 1246m, 1120m, 1065w, 1017w, 912w, 880w, 
751s, 727s, 684m cm−1. MS (EI, 70 eV): m/z (%) = 298 (17), 296 (17, M+), 217 (30), 
216 (18), 204 (13), 203 (100). [ߙ]஽ଶ଴ = − 113 (c = 0.123, CHCl3). 
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(S)-2-{2-[(Di-ortho-tolylphosphino)methyl]pyrrolidin-1-yl}benzo[d]thiazole ((S)-LTh2) 
 
Compound (S)-LTh2 (59%) was prepared according to general procedure 7 from        
bromide (S)-93 and di-ortho-tolylphosphine (94). 
C26H27N2PS (430.54 g·mol−1): 
m.p. 114-118 °C. Rf = 0.47 (SiO2, cyclohexane/ethyl acetate 8:2). 1H NMR (500 MHz, 
CDCl3): δ = 7.99-7.91 (m, 1 H, oTol-6-H), 7.62 (d, 3JH,H = 8.1 Hz, 1 H, BzTh-7-H), 
7.57 (d, 3JH,H = 7.8 Hz, 1 H, BzTh-4-H), 7.40 (“t”, J = 7.2 Hz, 1 H, oTol-5-H), 7.36-
7.29 (m, 2 H, oTol-4-H and BzTh-6-H), 7.24-7.20 (m, 1 H, oTol-3-H), 7.20-7.14 (m, 3 H, 
oTol’-3/4/6-H), 7.10-7.07 (m, 1 H, oTol’-5-H), 7.07-7.03 (m, 1 H, BzTh-5-H), 4.23-
4.09 (m, 1 H, Pyr-2-H), 3.67-3.60 (m, 1 H, Pyr-5-HH’), 3.56-3.47 (m, 1 H, Pyr-5-HH’), 
3.04-2.95 (m, 1 H, CHH’P), 2.49 (s, 3 H, oTol-H3), 2.46 (s, 3 H, oTol’-H3), 2.31-2.24 (m, 
1 H, Pyr-3-HH’), 2.22-2.13 (m, 2 H, Pyr-3-HH’ and Pyr-4-HH’), 2.10-2.01 (m, 1 H,           
Pyr-4-HH’), 1.99-1.91 (m, 1 H, CHH’P) ppm. 13C{1H} NMR (101 MHz, CDCl3): 
δ = 164.7 (s, BzTh-2-C), 153.3 (s, BzTh-7a-C), 142. (d, 2JC,P = 26 Hz, oTol-2-C), 
141.7 (d, 2JC,P = 26 Hz, oTol’-2-C), 137.0 (d, 1JC,P = 12 Hz, oTol-1-C), 135.6 (d, 
1JC,P = 13 Hz, oTol’-1-C), 132.5 (s, oTol-6-CH), 131.6 (s, oTol’-6-CH), 131.0 (s,             
BzTh-3a-C), 130.2-130.1 (m, oTol/oTol’-3-CH), 128.8 (s, oTol-4-CH), 128.6 (s,             
oTol’4-CH), 126.4 (s, oTol-5-CH), 126.2 (s, oTol’-5-CH), 125.9 (s, BzTh-6-CH), 
120.8 (s, BzTh-5-CH), 120.7 (s, BzTh-4-CH), 118.9 (s, BzTh-7-CH), 59.4 (d, 
2JC,P = 23 Hz, Pyr-2-CH), 50.1 (s, Pyr-5-CH2), 31.4 (d, 3JC,P = 7.9 Hz, Pyr-3-CH2), 
31.2 (d, 1JC,P = 15 Hz, CH2P), 24.0 (s, Pyr-4-CH2), 21.4 (d, 3JC,P = 12 Hz, oTol-CH3), 
21.3 (d, 3JC,P = 12 Hz, oTol’-CH3) ppm. 31P{1H} NMR (162 MHz, CDCl3): δ = − 42.5 (s) 
ppm. IR (neat): ߥ෤ = 3055w, 2966w, 2930w, 2874w, 1593m, 1560m, 1531s, 1444s, 
1359m, 1318m, 1272m, 1254m, 1184w, 1141w, 1065w, 1016m, 925m, 909m, 847m, 
754s, 748s, 725m, 680m cm−1. MS (EI, 70 eV): m/z (%) = 430 (6, M+), 340 (22), 
339 (100), 267 (13), 217 (13), 215 (11), 203 (61). [ߙ]஽ଶ଴ = − 80.7 (c = 0.851, CHCl3). 
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(S)-2-{2-[(Di-tert-butylphosphino)methyl]pyrrolidin-1-yl}benzo[d]thiazole borane 
adduct ((S)-LTh3∙BH3) 
 
Compound (S)-LTh3∙BH3 (81%) was prepared according to general procedure 7 from        
(S)-93 and di-tert-butylphosphine borane adduct (50∙BH3). 
C20H34BN2PS (376.35 g·mol−1): 
m.p. 171-176 °C. Rf = 0.54 (SiO2, cyclohexane/ethyl acetate 8:2). 1H NMR (400 MHz, 
CDCl3): δ = 7.61 (d, 3JH,H = 7.7 Hz, 1 H, BzTh-7-H), 7.48 (d, 3JH,H = 7.8 Hz, 1 H,           
BzTh-4-H), 7.31-7.22 (m, 1 H, BzTh-6-H), 7.05 (“t”, 1JH,H = 7.4 Hz, 1 H, BzTh-5-H), 
4.52-4.39 (m, 1 H, Pyr-2-H), 3.60-3.47 (m, 1 H, Pyr-5-HH’), 3.46-3.33 (m, 1 H,                
Pyr-5-HH’), 3.06-2.91 (m, 1 H, CHH’P), 2.41-2.19 (m, 2 H, Pyr-H), 2.13-1.97 (m, 2 H, 
Pyr-H), 1.62-1.37 (m, 1 H, CHH’P), 1.52 (d, 3JH,P = 13 Hz, 9 H, tBu-H), 1.25 (d, 
3JH,P = 12 Hz, 9 H, tBu’-H), 0.93-0.12 (br q, 3 H, BH3) ppm. 13C{1H} NMR (101 MHz, 
CDCl3): δ = 164.5 (s, BzTh-2-C), 153.4 (s, BzTh-3a-C), 131.0 (s, BzTh-7a-C), 126.0 (s, 
BzTh-6-CH), 120.9 (s, BzTh-5-CH), 120.9 (s, BzTh-7-CH), 118.8 (s, BzTh-4-CH), 
59.3 (d, 2JC,P = 5.7 Hz, Pyr-2-CH), 50.5 (s, Pyr-5-CH2), 33.7 (d, 1JC,P = 27 Hz, tBu-C), 
32.7 (s, Pyr-3-CH2), 32.2 (d, 1JC,P = 27 Hz, tBu’-C), 28.4 (br s, tBu-CH3), 28.0 (br s,    
tBu’-CH3), 23.9 (s, Pyr-4-CH2), 20.7 (d, 1JC,P = 23 Hz, CH2P) ppm. 31P{1H} NMR 
(162 MHz, CDCl3): δ = 39.7 (br d) ppm. IR (neat): ߥ෤ = 2948m, 2906m, 2871m, 1597m, 
1538s, 1444s, 1393w, 1354m, 1316w, 1274m, 1184m, 1147m, 1123m, 1070s, 1019m, 
921m, 815m, 753s, 678m cm−1. MS (EI, 70 eV): m/z (%) = 376 (24), 375 (63, [M – H]+), 
374 (14), 343 (12), 320 (12), 319 (60), 318 (14), 306 (18), 305 (100), 263 (21), 261 (13), 
249 (30), 248 (15), 231 (15), 229 (17), 217 (20), 215 (13), 203 (33), 57 (24). [ߙ]஽ଶ଴ = − 120 (c = 0.210, CHCl3).  
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(S)-2-{2-[(Di-tert-butylphosphino)methyl]pyrrolidin-1-yl}benzo[d]thiazole ((S)-LTh3) 
 
Product (S)-LTh3 was prepared according to general procedure 3 from (S)-LTh3·BH3. 
C20H31N2PS (362.51 g·mol−1): 
31P{1H} NMR (162 MHz, CDCl3): δ = 20.8 (s) ppm. 
 
(S)-2-{2-[(Dicyclohexylphosphino)methyl]pyrrolidin-1-yl}benzo[d]thiazole borane 
adduct ((S)-LTh4∙BH3) 
 
Compound (S)-LTh4∙BH3 (66%) was prepared according to general procedure 7 from        
(S)-93 and dicyclohexylphosphine borane adduct (51∙BH3). 
C24H38BN2PS (428.42 g·mol−1): 
m.p. 120-123 °C. Rf = 0.40 (SiO2, cyclohexane/ethyl acetate 9:1). 1H NMR (400 MHz, 
CDCl3): δ = 7.61 (d, 3JH,H = 7.7 Hz, 1 H, BzTh-7-H), 7.50 (d, 3JH,H = 7.3 Hz, 1 H,           
BzTh-4-H), 7.29 (“t”, 3JH,H = 7.8 Hz, 1 H, BzTh-6-H), 7.06 (“t”, 3JH,H = 7.5 Hz, 1 H, 
BzTh-5-H), 4.46-4.33 (m, 1 H, Pyr-2-H), 3.61-3.48 (m, 1 H, Pyr-5-HH’), 3.48-3.34 (m, 
1 H, Pyr-5-HH’), 2.72-2.58 (m, 1 H, CHH’P), 2.33-1.11 (m, 27 H, CHH’P, Pyr-H and 
Cy/Cy’-H), 0.79-0.10 (br q, 3 H, BH3) ppm. 13C{1H} NMR (101 MHz, CDCl3): 
δ = 164.5 (s, BzTh-2-C), 153.4 (s, BzTh-3a-C), 131.0 (s, BzTh-7a-C), 126.1 (s,           
BzTh-6-CH), 121.0 (s, BzTh-5-CH), 120.9 (s, BzTh-7-CH), 118.8 (s, BzTh-4-CH), 
58.1 (br s, Pyr-2-CH), 50.4 (s, Pyr-5-CH2), 33.2 (d, 1JC,P = 32 Hz, Cy-1-CH), 32.6 (s,   
Pyr-3-CH2), 32.0 (d, 1JC,P = 33 Hz, Cy’-1-CH), 27.4-25.9 (m, Cy/Cy’-CH2), 23.8 (s,     
Pyr-4-CH2), 22.8 (d, 1JC,P = 27 Hz, CH2P) ppm. 31P{1H} NMR (162 MHz, CDCl3): 
δ = 21.5 (br) ppm. IR (neat): ߥ෤ = 2922m, 2915m, 2849m, 2369m, 1595m, 1560w, 1536s, 
1442s, 1361m, 1318m, 1272m, 1252m, 1180w, 1125m, 1067m, 1016m, 1006m, 931m, 
858m, 801m, 754s, 726s, 6778m cm−1. MS (EI, 70 eV): m/z (%) = 428 (26), 427 (85, 
EXPERIMENTAL PART 
 
273 
[M – H]+), 426 (19), 395 (17), 345 (14), 332 (21), 331 (100), 292 (12), 249 (11), 231 (20), 
217 (13), 203 (18). [ߙ]஽ଶ଴ = − 53.8 (c = 0.131, CHCl3). 
 
(S)-2-{2-[(Dicyclohexylphosphino)methyl]pyrrolidin-1-yl}benzo[d]thiazole ((S)-LTh4) 
 
Product (S)-LTh4 was prepared according to general procedure 3 from (S)-LTh4·BH3. 
C24H35N2PS (414.59 g·mol−1): 
31P{1H} NMR (162 MHz, CDCl3): δ = − 10.9 (s) ppm. 
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6.5.3 
Benzimidazole phosphines (S)-LIm 
 
(S)-2-{2-[(Diphenylphosphino)methyl]pyrrolidin-1-yl}-1-methyl-1H-
benzo[d]imidazole ((S)-LIm1) 
 
Compound (S)-LIm1 (83%) was prepared according to general procedure 6 from        
(S)-LC1 and 2-chlorobenzimidazole (83).[105] 
C25H26N3P (399.47 g·mol−1): 
Rf = 0.17 (SiO2, cyclohexane/ethyl acetate 8:2). 1H NMR (400 MHz, CDCl3): 
δ = 7.54 (d, 3JH,H = 7.7 Hz, 1 H, BzIm-4-H), 7.46-7.38 (m, 2 H, Ph/Ph’-H), 7.33-7.23 (m, 
7 H, Ph/Ph’-H), 7.17-7.06 (m, 2 H, Ph/Ph’-H and BzIm-H), 7.02-6.92 (m, 2 H, BzIm-H), 
4.61-4.48 (m, 1 H, Pyr-2-H), 3.75-3.66 (m, 1 H, Pyr-5-HH’), 3.49 (s, 3 H, NCH3), 3.34-
3.26 (m, 1 H, Pyr-5-HH’), 2.82-2.71 (m, 1 H, CHH’P), 2.38 (br d, 2JH,P = 14 Hz, 1 H, 
CHH’P), 2.30-2.12 (m, 2 H, Pyr-H), 2.09-1.98 (m, 1 H, Pyr-H), 1.96-1.84 (m, 1 H,      
Pyr-H) ppm. 13C{1H} NMR (101 MHz, CDCl3): δ = 160.0 (s, BzIm-2-C), 143.1 (s,       
BzIm-3a-C), 138.6 (d, 1JC,P = 12 Hz, Ph-i-C), 137.5 (d, 1JC,P = 12 Hz, Ph’-i-C), 133.9 (s, 
BzIm-7a-C), 133.2 (d, 2JC,P = 19 Hz, Ph-o-CH), 132.7 (d, 2JC,P = 19 Hz, Ph’-o-CH), 
129.0-128.5 (m, Ph/Ph’-CH), 122.9 (s, BzIm-CH), 121.0 (s, BzIm-CH), 118.4 (s,           
BzIm-4-CH), 109.7 (s, BzIm-7-CH), 63.3 (d, 2JC,P = 19 Hz, Pyr-2-CH), 52.2 (s,            
Pyr-5-CH2), 35.1 (d, 1JC,P = 15 Hz, CH2P), 33.8 (s, CH3), 31.5 (d, 3JC,P = 7.7 Hz,             
Pyr-3-CH2), 28.8 (s, Pyr-4-CH2) ppm. 31P{1H} NMR (162 MHz, CDCl3): δ = − 23.2 (s) 
ppm. 
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6.6 
Proline-Based P,N Ligand/Iridium Complexes: Preparation and 
Analytical Data 
 
[(η4-1,5-Cyclooctadiene)-((S)-2-{2-[(diphenylphosphino)methyl]pyrrolidin-1-
yl}benzo[d]oxazole)-iridium(I)]-tetrakis[3,5-bis(trifluoromethyl)phenyl]borate       
((S)-COx1) 
 
Complex (S)-COx1 (89%) was prepared according to general procedure 8 from ligand 
(S)-LOx1 and [Ir(cod)Cl]2. 
C64H47N2OPIrBF24 (1550.05 g·mol−1): 
m.p. 131-133 °C. 1H NMR (500 MHz, CD2Cl2): δ = 7.76 (br s, 9 H, BzOx-4-H and           
ArF-o-H), 7.58 (br s, 4 H, ArF-p-H), 7.50-7.44 (m, 2 H, Ph-o-H), 7.44-7.38 (m, 4 H, 
BzOx-5-H and Ph/Ph’-H), 7.32-7.27 (m, 1 H, Ph/Ph’-p-H), 7.23-7.11 (m, 6 H,                
BzOx-6/7-H and Ph/Ph’-H), 5.87-5.77 (m, 1 H, Pyr-2-H), 5.13-5.06 (m, 1 H, cod-CH), 
4.97-4.88 (m, 1 H, cod-CH), 3.96-3.88 (m, 1 H, cod-CH), 3.74-3.65 (m, 1 H, Pyr-5-HH’), 
3.65-3.56 (m, 1 H, Pyr-5-HH’), 3.31 (ddd, J = 15, 10, 2.2 Hz, 1 H, CHH’P), 3.10-2.98 (m, 
2 H, CHH’P and cod-CH), 2.71-2.56 (m, 2 H, Pyr-3-HH’ and cod-H), 2.44-2.36 (m, 1 H, 
cod-H), 2.33-2.08 (m, 7 H, Pyr-4-H2, Pyr-3-HH’ and cod-H), 1.75-1.65 (m, 1 H, cod-H), 
1.65-1.56 (m, 1 H, cod-H) ppm. 13C{1H} NMR (101 MHz, CD2Cl2): δ = 161.9 (q, 
1JC,B = 50 Hz, ArF-i-C), 158.9 (s, BzOx-2-C), 147.6 (s, BzOx-7a-C), 138.7 (s,                
BzOx-3a-C), 134.9 (s, ArF-o-CH), 133.6 (d, 2JC,P = 13 Hz, Ph-o-CH), 131.9 (d, 
4JC,P = 2.3 Hz, Ph-p-CH), 131.2 (d, 4JC,P = 2.5 Hz, Ph’-p-CH), 130.9 (d, 3JC,P = 9.4 Hz, 
Ph-m-CH), 130.4 (d, 1JC,P = 51 Hz, Ph-i-C), 129.5-128.5 (m, Ph’-CH and ArF-m-C), 
127.4 (d, 1JC,P = 50 Hz, Ph’-i-C), 125.4 (s, BzOx-5-CH), 124.7 (q, 1JC,F = 272 Hz,             
ArF-CF3), 123.7 (s, BzOx-6-CH), 117.7-117.4 (m, ArF-p-CH), 117.4 (s, BzOx-4-CH), 
110.3 (s, BzOx-7-CH), 97.7 (d, 2JC,P = 9.6 Hz, cod-CH), 88.1 (d, 2JC,P = 15 Hz, cod-CH), 
66.1 (s, cod-CH), 61.1 (s, cod-CH), 60.5 (d, 2JC,P = 5.8 Hz, Pyr-2-CH), 49.9 (s,               
Pyr-5-CH2), 41.1 (d, 1JC,P = 29 Hz, CH2P), 36.1 (d,3JC,P = 4.3 Hz, cod-CH2), 34.8 (d, 
3JC,P = 13 Hz, Pyr-3-CH2), 33.5 (s, cod-CH2), 29.2 (d, 3JC,P = 1.6 Hz, cod-CH2), 26.2 (d, 
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3JC,P = 2.6 Hz, cod-CH2), 23.5 (s, Pyr-4-CH2) ppm. 31P{1H} NMR (162 MHz, CD2Cl2): 
δ = 15.6 (s) ppm. 19F{1H} NMR (377 MHz, CD2Cl2): δ = − 62.8 (s) ppm. IR (neat): 
ߥ෤ = 2928w, 2848w, 1643m, 1618m, 1589m, 1467m, 1436w, 1402w, 1353s, 1271s, 
1251m, 1113s, 999w, 885m, 838m, 742m, 711m, 680s, 667s cm−1. MS (FAB, NBA): 
m/z (%) = 688 (34), 687 (100, M+), 686 (27), 685 (67), 577 (23), 575 (23), 573 (10). [ߙ]஽ଶ଴ = − 36.3 (c = 0.860, CHCl3). Elemental analysis: calc. C 49.59%, H 3.06%, 
N 1.81%; found: C 49.40%, H 3.39%, N 1.81%. 
 
[(η4-1,5-Cyclooctadiene)-((S)-2-{2-[(di-ortho-tolylphosphino)methyl]pyrrolidin-1-
yl}benzo[d]oxazole)-iridium(I)]-tetrakis[3,5-bis(trifluoromethyl)phenyl]borate      
((S)-COx2) 
 
Complex (S)-COx2 (55%) was prepared according to general procedure 9 from ligand 
(S)-LOx2 and [Ir(cod)2]BArF. 
C66H51N2OPIrBF24 (1578.31 g·mol−1): 
m.p. 72-77 °C. 1H NMR (400 MHz, CD2Cl2): δ = 8.32-8.19 (br m, 1 H, oTol-6-H), 
7.81 (d, 3JH,H = 7.8 Hz, 1 H, BzOx-4-H), 7.73 (br s, 8 H, ArF-o-H), 7.56 (s, 4 H, ArF-p-H), 
7.48-6.80 (m, 10 H, oTol/oTol’-H and BzOx-H), 5.96-5.85 (m, 1 H, Pyr-2-H), 4.98-
4.89 (m, 1 H, cod-CH), 4.68-4.53 (m, 1 H, cod-CH), 3.98-3.89 (m, 1 H, cod-CH), 3.89-
3.74 (m, 2 H, cod-H), 3.61-3.52 (m, 1 H, CHH’P), 2.77-2.58 (m, 3 H, CHH’P, Pyr-5-HH’ 
and Pyr-3-HH’), 2.58-1.98 (m, 11 H, cod-CH, cod-H, Pyr-H and oTol-H3), 1.93 (s, 3 H, 
oTol’-H3), 1.67-1.43 (m, 3 H, Pyr-4-HH’ and cod-H) ppm. 13C{1H} NMR (101 MHz, 
CD2Cl2): δ = 161.8 (q, 1JC,B = 50 Hz, ArF-i-C), 158.0 (s, BzOx-2-C), 147.7 (s,                  
BzOx-7a-C), 141.7 (br, oTol-2-C), 141.2 (br, oTol’-2-C), 140.3 (br d, oTol-6-CH), 
138.8 (s, BzOx-3a-C), 134.9 (s, ArF-o-CH), 132.8-132.3 (m, oTol-4-CH,                    
oTol/oTol’-3-CH), 131.6 (br s, oTol’-6-CH),130.0 (br, oTol-1-C), 129.3-128.4 (m,        
ArF-m-C), 128.4 (q, 1JC,F = 272 Hz, ArF-CF3), 127.9-125.0 (m, oTol’-1-C, oTol’-4-CH, 
oTol/oTol’-5-CH and BzOx-5-CH), 123.7 (s, BzOx-6-CH), 117.8-117.4 (m, ArF-p-CH 
and BzOx-4-CH), 110.4 (s, BzOx-7-CH), 96.9 (br d, cod-CH), 87.2 (d, 2JC,P = 15 Hz, 
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cod-CH), 66.7 (s, cod-CH), 62.6 (s, cod-CH), 59.6 (br d, 2JC,P = 4.0 Hz, Pyr-2-CH), 
50.0 (s, cod-CH2), 43.9 (d, 1JC,P = 26 Hz, CH2P), 36.8 (br s, Pyr-5-CH2), 36.0 (d, 
3JC,P = 11 Hz, Pyr-3-CH2), 33.9 (s, cod-CH2), 28.4 (s, cod-CH2), 25.6 (s, Pyr-4-CH2), 
24.0 (br s, oTol-CH3), 23.1 (s, cod-CH2), 21.8 (br s, oTol’-CH3) ppm. 31P{1H} NMR 
(162 MHz, CD2Cl2): δ = 26.1/10.2*(br s) ppm. In 31P NMR spectra the title compound 
can be seen as a mixture of rotamers in a ratio close to 25:1. 19F{1H} NMR (377 MHz, 
CD2Cl2): δ = − 62.8 (s) ppm. IR (neat): ߥ෤ = 2965w, 2888w, 1647m, 1620m, 1468m, 
1404w, 1355m, 1274s, 1117s, 1003w, 887m, 840m, 745m, 713m, 680m cm−1. MS (ESI): 
m/z (%) = 715 (100, M+). [ߙ]஽ଶ଴ = − 37 (c = 0.140, CHCl3). Elemental analysis: calc. 
C 50.23%, H 3.26%, N 1.78%; found: C 50.69%, H 3.94%, N 1.93%. 
 
[(η4-1,5-Cyclooctadiene)-((S)-2-{2-[(di-tert-butylphosphino)methyl]pyrrolidin-1-
yl}benzo[d]oxazole)-iridium(I)]-tetrakis[3,5-bis(trifluoromethyl)phenyl]borate      
((S)-COx3) 
 
Complex (S)-COx3 (95%) was prepared according to general procedure 9 from ligand 
(S)-LOx3 and [Ir(cod)2]BArF. 
C60H55N2OPIrBF24 (1510.05 g·mol−1): 
m.p. 210-213 °C. 1H NMR (400 MHz, CD2Cl2): δ = 7.73 (br s, 8 H, ArF-o-H), 7.59-
7.52 (m, 5 H, ArF-p-H and BzOx-4-H), 7.40-7.33 (m, 2 H, BzOx-5-H and BzOx-7-H), 
7.23 (“td”, 3JH,H = 7.8 Hz, 4JH,H = 1.1 Hz, 1 H, BzOx-6-H), 5.32-5.20 (m, 2 H, cod-CH), 
4.45-4.37 (m, 1 H, cod-CH), 4.13-4.05 (m, 1 H, Pyr-2-H), 3.97-3.76 (m, 3 H, Pyr-5-H2 
and cod-CH), 2.82 (ddd, 2JH,P = 16 Hz, 2JH,H = 12 Hz, JH,H = 1.8 Hz, 1 H, CHH’P), 2.70-
2.57 (m, 2 H, cod-H), 2.42-2.34 (m, 1 H, cod-H), 2.34-2.22 (m, 1 H, Pyr-3-HH’), 2.20-
1.95 (m, 5 H, Pyr-3-HH’, Pyr-4-H2 and cod-H), 1.95-1.77 (m, 2 H, CHH’P and cod-H), 
1.46-1.22 (m, 11 H, tBu-H and cod-H), 1.17 (d, 3JH,P = 14 Hz, 9 H, tBu’-H) ppm. 
13C{1H} NMR (101 MHz, CD2Cl2): δ = 161.8 (q, 1JC,B = 50 Hz, ArF-i-C), 157.5 (s,  
BzOx-2-C), 148.0 (s, BzOx-7a-C), 138.9 (s, BzOx-3a-C), 134.9 (s, ArF-o-CH), 129.5-
128.4 (m, ArF-m-C), 125.2 (s, BzOx-5-CH), 124.7 (q, 1JC,F = 272 Hz, ArF-CF3), 123.8 (s, 
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BzOx-6-CH), 118.8 (s, BzOx-4-CH), 117.5 (br s, ArF-p-CH), 110.4 (s, BzOx-7-CH), 
92.0 (d, 2JC,P = 8.5 Hz, cod-CH), 82.9 (d, 2JC,P = 15 Hz, cod-CH), 65.7 (s, cod-CH), 
58.5 (s, cod-CH), 57.9 (d, 2JC,P = 7.4 Hz, Pyr-2-CH), 49.7 (s, Pyr-5-CH2), 38.5 (d, 
3JC,P = 4.2 Hz, cod-CH2), 38.3 (d, 1JC,P = 17 Hz, tBu-C), 36.5 (d, 3JC,P = 8.1 Hz,           
cod-CH2), 36.0 (d, 1JC,P = 18 Hz, tBu’-C), 34.3 (d, 1JC,P = 21 Hz, CH2P), 33.7 (s,              
Pyr-3-CH2), 30.7 (d, 2JC,P = 4.5 Hz, tBu-CH3), 30.0-29.2 (br m, tBu’-CH3), 28.8 (s,           
cod-CH2), 24.6 (s, Pyr-4-CH2), 24.1 (s, cod-CH2) ppm. 31P{1H} NMR (162 MHz, 
CD2Cl2): δ = 46.8 (s) ppm. 19F{1H} NMR (377 MHz, CD2Cl2): δ = − 62.9 (s) ppm. 
IR (neat): ߥ෤ = 2968w, 2892w, 1650m, 1622m, 1469m, 1406w, 1354m, 1272s, 1162s, 
1121s, 1005w, 887m, 840m, 714m cm−1. MS (FAB, NBA): m/z (%) = 648 (32), 647 (100, 
M+), 646 (21), 645 (61), 537 (12), 423 (12). [ߙ]஽ଶ଴ = + 7.1 (c = 0.220, CHCl3). 
 
[(η4-1,5-Cyclooctadiene)-((S)-2-{2-[(dicyclohexylphosphino)methyl]pyrrolidin-1-
yl}benzo[d]oxazole)-iridium(I)]-tetrakis[3,5-bis(trifluoromethyl)phenyl]borate       
((S)-COx4) 
 
Complex (S)-COx4 (84%) was prepared according to general procedure 9 from ligand 
(S)-LOx4 and [Ir(cod)2]BArF. 
C64H59N2OPIrBF24 (1562.13 g·mol−1): 
m.p. 142-146 °C. 1H NMR (400 MHz, CD2Cl2): δ = 7.74 (s, 8 H, ArF-m-H), 7.61 (d, 
2JH,H= 8.0 Hz, 1 H, BzOx-4-H), 7.57 (s, 4 H, ArF-p-H), 7.40-7.34 (m, 2 H, BzOx-5-H and 
BzOx-7-H), 7.24 (“td”, 2JH,H= 7.9 Hz, 3JH,H= 1.1 Hz, 1 H, BzOx-6-H), 5.21-5.08 (m, 1 H, 
Pyr-2-H), 4.77-4.70 (m, 1 H, cod-CH), 4.70-4.62 (m, 1 H, cod-CH), 4.20-4.10 (m, 1 H, 
cod-CH), 3.93-3.77 (m, 2 H, Pyr-5-H2), 3.54-3.44 (m, 1 H, cod-CH), 2.66-2.54 (m, 3 H, 
CHH’P and cod-H), 2.40-2.24 (m, 2 H, Pyr-3-HH’ and cod-H), 2.21-1.84 (m, 11 H, 
CHH’P, Pyr-H, cod-H and Cy/Cy’-H), 1.84-1.67 (m, 5 H, Cy/Cy’-H), 1.64-1.01 (m, 
14 H, cod-H and Cy/Cy’-H), 0.95-0.82 (m, 1 H, cod-H) ppm. 13C{1H} NMR (101 MHz, 
CD2Cl2): δ = 161.8 (q, 1JC,B = 50 Hz, ArF-i-C), 158.0 (s, BzOx-2-C), 147.8 (s,                 
BzOx-7a-C), 138.8 (s, BzOx-3a-C), 134.9 (s, ArF-o-CH), 129.6-128.4 (m, ArF-m-CH), 
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125.4 (s, BzOx-5-CH), 124.6 (q, 1JC,F = 272 Hz, ArF-CF3), 123.9 (s, BzOx-6-CH), 
118.0 (s, BzOx-4-CH), 117.6 (br s, ArF-p-CH), 110.4 (s, BzOx-7-CH), 95.3 (d, 
2JC,P = 9.5 Hz, cod-CH), 86.8 (d, 2JC,P = 15 Hz, cod-CH), 65.8 (s, cod-CH), 58.8 (s            
cod-CH), 58.8 (d, 2JC,P = 6.1 Hz, Pyr-2-CH), 49.9 (s, Pyr-5-CH2), 37.5 (d, 3JC,P = 3.9 Hz, 
cod-CH2), 37.0 (d, 1JC,B = 26 Hz, Cy-1-CH), 35.9 (d, 3JC,P = 10 Hz, cod-CH2), 33.4 (s, 
Pyr-3-CH2), 33.0 (d, 1JC,P = 26 Hz, CH2P), 31.6 (d, 1JC,B = 26 Hz, Cy’-1-CH), 30.1 (s, 
Cy/Cy’-CH2), 29.8 (s, Cy/Cy’-CH2), 29.5 (s, Cy/Cy’-CH2), 29.0 (s, Cy/Cy’-CH2), 26.9-
26.7 (m, cod-CH2 and Cy/Cy’-CH2), 26.1 (s, Cy/Cy’-CH2), 25.9 (s, Cy/Cy’-CH2), 24.8 (d, 
3JC,P = 2.5 Hz, cod-CH2), 24.3 (s, Pyr-4-CH2) ppm. 31P{1H} NMR (162 MHz, CD2Cl2): 
δ = 24.9 (s) ppm. 19F{1H} NMR (377 MHz, CD2Cl2): δ = − 62.7 (s) ppm. IR (neat): 
ߥ෤ = 2937w, 2860w, 1648m, 1620w, 1596w, 1467w, 1402w, 1354m, 1273s, 1119s, 
1005w, 887m, 840w, 745m, 713m, 681m cm−1. MS (FAB, NBA): m/z (%) = 700 (34), 
699 (100, M+), 698 (25), 697 (62), 587 (18), 585 (11). [ߙ]஽ଶ଴ = + 60.9 (c = 0.330, CHCl3). 
Elemental analysis: calc. C 49.21%, H 3.81%, N 1.79%; found: C 48.89%, H 4.11%, 
N 1.73%. 
 
[(η4-1,5-Cyclooctadiene)-((S)-2-{2-[(diphenylphosphino)methyl]pyrrolidin-1-yl} 
benzo[d]thiazole)-iridium(I)]-tetrakis[3,5-bis(trifluoromethyl)phenyl]borate          
((S)-CTh1) 
 
Complex (S)-CTh1 (81%) was prepared according to general procedure 8 from ligand 
(S)-LTh1 and [Ir(cod)Cl]2. 
C64H47N2PSIrBF24 (1566.10 g·mol−1): 
m.p. 69-71 °C. 1H NMR (500 MHz, CDCl3): δ = 8.34 (d, 2JH,H = 8.2 Hz, 1 H,             
BzTh-4-H), 7.77 (s, 8 H, ArF-m-H), 7.56 (s, 4 H, ArF-p-H), 7.55-7.51 (m, 1 H,            
BzTh-5-H), 7.49 (d, 2JH,H = 7.9 Hz, 1 H, BzTh-7-H), 7.47-7.37 (m, 5 H, Ph/Ph’-H), 7.32-
7.28 (m, 1 H, Ph/Ph’-H), 7.28-7.22 (m, 1 H, BzTh-6-H), 7.20-7.10 (m, 4 H, Ph/Ph’-H), 
6.35-6.22 (m, 1 H, Pyr-2-H), 4.85-4.77 (m, 1 H, cod-CH), 4.51-4.42 (m, 1 H, cod-CH), 
4.12-4.06 (m, 1 H, cod-CH), 3.52-3.34 (m, 3 H, Pyr-5-H2 and CHH’P), 3.02-2.87 (m, 
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2 H, CHH’P and cod-CH), 2.78-2.63 (m, 2 H, Pyr-3-HH’ and cod-H), 2.36-2.10 (m, 7 H, 
Pyr-3-HH’, Pyr-4-H2 and cod-H), 2.10-1.97 (m, 1 H, cod-H), 1.63-1.45 (m, 2 H,           
cod-H) ppm. 13C{1H} NMR (101 MHz, CDCl3): δ = 165.8 (s, BzTh-2-C), 162.0 (q, 
1JC,B = 50 Hz, ArF-i-C), 148.6 (s, BzTh-3a-C), 135.0 (s, ArF-o-CH), 133.2 (d, 
2JC,P = 13 Hz, Ph-o-CH), 132.1 (s, Ph-p-CH), 131.5 (s, Ph’-p-CH), 130.7 (d, 
3JC,P = 9.4 Hz, Ph-m-CH), 130.1 (d, 1JC,P = 51 Hz, Ph-i-C), 129.5-128.6 (m, Ph’-o-CH, 
Ph’-m-CH and ArF-m-C), 128.0 (d, 1JC,P = 50 Hz, Ph’-i-C), 127.1 (s, BzTh-5-CH), 
126.8 (s, BzTh-7a-C), 128.4 (q, 1JC,F = 272 Hz, ArF-CF3), 124.2 (s, BzTh-6-CH), 
122.1 (s, BzTh-4-CH), 121.9 (s, BzTh-7-CH), 117.1 (s, ArF-p-CH), 97.3 (d, 
2JC,P = 9.4 Hz, cod-CH), 89.6 (d, 2JC,P = 15 Hz, cod-CH), 65.3 (s, cod-CH), 61.9 (s,           
cod-CH), 61.9 (d, 2JC,P = 6.7 Hz, Pyr-2-CH), 53.5 (s, Pyr-5-CH2), 40.8 (d, 1JC,P = 31 Hz, 
CH2P), 36.7 (d, 3JC,P = 3.6 Hz, cod-CH2), 35.8 (d, 3JC,P = 13 Hz, Pyr-3-CH2), 33.6 (s,  
cod-CH2), 28.7 (s, cod-CH2), 25.9 (s, cod-CH2), 23.8 (s, Pyr-4-CH2) ppm. 31P{1H} NMR 
(162 MHz, CD2Cl2): δ = 15.6 (s) ppm. 19F{1H} NMR (377 MHz, CD2Cl2): δ = − 62.8 
(s) ppm. IR (neat): ߥ෤ = 2889w, 1610w, 1534m, 1452m, 1352s, 1272s, 1113s, 1024w, 
999w, 937w, 885m, 838m, 744m, 711m, 686m, 669m cm−1. MS (FAB, NBA): 
m/z (%) = 705 (11), 704 (37), 703 (100), 702 (27), 701 (60), 595 (12), 594 (16), 593 (30), 
592 (10), 591 (18). [ߙ]஽ଶ଴ = + 17.9 (c = 1.08, CHCl3). Elemental analysis: calc. 
C 49.08%, H 3.02%, N 1.79%; found: C 49.06%, H 2.94%, N 2.02%. 
 
[(η4-1,5-Cyclooctadiene)-((S)-2-{2-[(di-ortho-tolylphosphino)methyl]pyrrolidin-1-
yl}benzo[d]thiazole)-iridium(I)]-tetrakis[3,5-bis(trifluoromethyl)phenyl]borate     
((S)-CTh2) 
 
Complex (S)-CTh2 (97%) was prepared according to general procedure 9 from ligand 
(S)-LTh2 and [Ir(cod)2]BArF. 
C66H51N2PSIrBF24 (1594.15 g·mol−1): 
m.p. 118-121 °C. 1H NMR (400 MHz, CD2Cl2): δ = 8.52 (d, 3JH,H = 8.3 Hz, 1 H,            
BzTh-4-H), 8.18-8.08 (m, 1 H, oTol-6-H), 7.75 (s, 8 H, ArF-o-H), 7.69-7.60 (m, 2 H, 
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BzTh-5-H and BzTh-7-H), 7.57 (s, 4 H, ArF-p-H), 7.44-7.22 (m, 5 H, BzTh-6-H,       
oTol’-6-H, oTol-5-H, oTol-4-H and oTol-3-H), 7.18-7.10 (m, 1 H, oTol’-3-H), 7.08-
6.95 (m, 1 H, oTol’-4-H), 6.94-6.85 (m, 1 H, oTol’-5-H), 6.54-6.41 (m, 1 H, Pyr-2-H), 
4.82-4.72 (m, 1 H, cod-CH), 4.31-4.20 (m, 1 H, cod-CH), 4.14-4.05 (m, 1 H, cod-CH), 
3.77-3.64 (m, 1 H, CHH’P), 3.63-3.52 (m, 2 H, cod-H), 2.85-2.65 (m, 3 H, Pyr-5-H2 and 
CHH’P), 2.65-2.55 (m, 1 H, cod-CH), 2.46-2.15 (m, 9 H, Pyr-3-H2, Pyr-4-H2, oTol-H3 
and cod-H), 2.15-1.95 (m, 3 H, cod-H), 1.90 (s, 3 H, oTol’-H3), 1.57-1.44 (m, 1 H,       
cod-H) ppm. 13C{1H} NMR (101 MHz, CD2Cl2): δ = 165.2 (s, BzTh-2-C), 161.8 (q, 
1JC,B = 50 Hz, ArF-i-C), 148.8 (s, BzTh-3a-C), 141.5 (br s, oTol-2-C), 140.6 (br d,           
oTol’-2-C), 139.4 (d, 2JC,P = 30 Hz, oTol-6-CH), 134.9 (s, ArF-o-CH), 132.7-132.3 (m, 
oTol-4-CH, oTol/oTol’-3-CH), 131.5 (br s, oTol’-6-CH), 131.0 (br s, oTol’-4-CH), 
130.3 (br d, oTol-1-C), 129.5-128.4 (m, ArF-m-C), 127.2 (s, BzTh-7a-C), 127.0 (s,            
BzTh-5-CH), 126.7 (d, 3JC,P = 9.6 Hz, oTol-5-CH), 125.6 (d, 3JC,P = 9.6 Hz, oTol’-5-CH), 
125.0 (q, 1JC,F = 272 Hz, ArF-CF3), 125.2 (br d, oTol’-1-C), 124.0 (s, BzTh-6-CH), 
120.6 (s, BzTh-7-CH), 121.8 (s, BzTh-4-CH), 117.7-117.4 (m, ArF-p-CH), 96.2 (d, 
2JC,P = 8.1 Hz, cod-CH), 87.9 (d, 2JC,P = 16 Hz, cod-CH), 66.3 (s, cod-CH), 63.1 (s,           
cod-CH), 62.2 (d, 2JC,P = 9.0 Hz, Pyr-2-CH), 53.9 (s, cod-CH2), 43.7 (d, 1JC,P = 29 Hz, 
CH2P), 37.2 (br s, Pyr-5-CH2), 36.7 (d, 3JC,P = 13 Hz, Pyr-3-CH2), 34.0 (s, cod-CH2), 
28.3 (s, cod-CH2), 25.5 (s, cod-CH2), 24.3 (s, Pyr-4-CH2), 23.0 (d, 3JC,P = 5.6 Hz,           
oTol-CH3), 21.6 (br s, oTol’-CH3) ppm. 31P{1H} NMR (162 MHz, CD2Cl2): 
δ = 22.4/3.32* (br s) ppm. In 31P NMR spectra the title compound can be seen as a 
mixture of rotamers in a ratio close to 17:1. 19F{1H} NMR (377 MHz, CD2Cl2): 
δ = − 62.8 (s) ppm. IR (neat): ߥ෤ = 3064w, 2964w, 2889w, 1787w, 1545m, 1453m, 
1355m, 1275s, 1116s, 888m, 839m, 744m, 714m, 681m cm−1. MS (FAB, NBA): 
m/z (%) = 733 (12), 732 (38), 731 (100, M+), 730 (24), 729 (59), 623 (11), 622 (11), 
621 (21), 620 (11), 619 (19), 617 (13). [ߙ]஽ଶ଴ = − 1.0 (c = 0.271, CHCl3). 
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[(η4-1,5-Cyclooctadiene)-((S)-2-{2-[(di-tert-butylphosphino)methyl]pyrrolidin-1-
yl}benzo[d]thiazole)-iridium(I)]-tetrakis[3,5-bis(trifluoromethyl)phenyl]borate     
((S)-CTh3) 
 
Complex (S)-CTh3 (94%) was prepared according to general procedure 9 from ligand 
(S)-LTh3 and [Ir(cod)2]BArF. 
C60H55N2PSIrBF24 (1526.12 g·mol−1): 
m.p. 228-231 °C. 1H NMR (400 MHz, CD2Cl2): δ = 8.35 (d, 3JH,H = 8.2 Hz, 1 H,           
BzTh-4-H), 7.73 (br s, 8 H, ArF-o-H), 7.65 (d, 3JH,H = 7.9 Hz, 1 H, BzTh-7-H), 7.59-
7.51 (m, 5 H, BzTh-5-H and ArF-p-H), 7.30 (“t”, 3JH,H = 7.7 Hz, 1 H, BzTh-6-H), 5.76-
5.65 (m, 1 H, Pyr-2-H), 5.37-5.29 (m, 1 H, cod-CH), 4.43-4.34 (m, 1 H, cod-CH), 4.07-
3.97 (m, 1 H, cod-CH), 3.78-3.58 (m, 2 H, Pyr-5-H2), 3.37-3.26 (m, 1 H, cod-CH), 
2.86 (ddd, 2JH,P = 16 Hz, 2JH,H = 11 Hz, 3JH,H = 1.9 Hz, 1 H, CHH’P), 2.75-2.62 (m, 2 H, 
cod-H), 2.33-2.16 (m, 3 H, Pyr-3-HH’, Pyr-4-HH’ and cod-H), 2.16-1.91 (m, 5 H, 
CHH’P, Pyr-3-HH’, Pyr-4-HH’ and cod-H), 1.82-1.71 (m, 1 H, cod-H), 1.50-1.17 (m, 
11 H, tBu-H and cod-H), 1.11 (d, 3JH,P = 14 Hz, 9 H, tBu’-H) ppm. 13C{1H} NMR 
(101 MHz, CD2Cl2): δ = 164.6 (s, BzTh-2-C), 161.8 (q, 1JC,B = 50 Hz, ArF-i-C), 149.2 (s, 
BzTh-3a-C), 134.9 (s, ArF-o-CH), 129.5-128.2 (m, ArF-m-CH), 127.2 (s, BzTh-7a-C), 
126.8 (s, BzTh-5-CH), 124.7 (q, 1JC,F = 272 Hz, ArF-CF3), 124.0 (s, BzTh-6-CH), 
123.5 (s, BzTh-4-CH), 121.7 (s, BzTh-7-CH), 117.5 (br s, ArF-p-CH), 91.2 (d, 
2JC,P = 7.6 Hz, cod-CH), 83.8 (d, 2JC,P = 16 Hz, cod-CH), 67.3 (s, cod-CH), 59.6 (d, 
2JC,P = 7.7 Hz, Pyr-2-CH), 57.5 (s, cod-CH), 53.4 (s, Pyr-5-CH2), 38.7 (d, 3JC,P = 4.4 Hz, 
cod-CH2), 37.6 (d, 1JC,P = 16 Hz, tBu-C), 37.3 (d, 3JC,P = 8.1 Hz, cod-CH2), 35.7 (d, 
1JC,P = 18 Hz, tBu’-C), 34.2 (s, Pyr-3-CH2), 34.0 (d, 1JC,P = 21 Hz, CH2P), 30.4 (d, 
2JC,P = 4.6 Hz, tBu-CH3), 28.3 (br s, tBu’-CH3), 27.0 (s, cod-CH2), 24.8 (s, Pyr-4-CH2), 
24.0 (d, 3JC,P = 2.9 Hz, cod-CH2) ppm. 31P{1H} NMR (162 MHz, CD2Cl2): δ = 46.7 
(s) ppm. 19F{1H} NMR (377 MHz, CD2Cl2): δ = − 62.7 (s) ppm. IR (neat): ߥ෤ = 2962w, 
2888w, 1611w, 1546m, 1455w, 1353m, 1272s, 1163s, 1122s, 1021w, 887m, 839w, 747w, 
714m,681m cm−1. MS (FAB, NBA): m/z (%) = 664 (31), 663 (100, M+), 662 (21), 
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661 (59), 555 (11), 553 (15), 497 (12), 441 (11), 439 (14). [ߙ]஽ଶ଴ = + 140 (c = 1.30, 
CHCl3). Elemental analysis: calc. C 47.22%, H 3.63%, N 1.84%; found: C 46.78%, 
H 3.92%, N 1.91%. 
 
[(η4-1,5-Cyclooctadiene)-((S)-2-{2-[(dicyclohexylphosphino)methyl]pyrrolidin-1-
yl}benzo[d]thiazole)-iridium(I)]-tetrakis[3,5-bis(trifluoromethyl)phenyl]borate       
((S)-CTh4) 
 
Complex (S)-CTh4 (98%) was prepared according to general procedure 9 from ligand 
(S)-LTh4 and [Ir(cod)2]BArF. 
C64H59N2PSIrBF24 (1578.20 g·mol−1): 
m.p. 120-124 °C. 1H NMR (400 MHz, CD2Cl2): δ = 8.29 (d, 2JH,H = 8.1 Hz, 1 H,            
BzTh-4-H), 7.74 (br s, 8 H, ArF-o-H), 7.66 (d, 2JH,H = 7.9 Hz, 1 H, BzTh-7-H), 7.62-
7.50 (m, 5 H, BzTh-5-H and ArF-p-H), 7.31 (“t”, 2JH,H = 8.1 Hz, 1 H, BzTh-6-H), 5.63-
5.51 (m, 1 H, Pyr-2-H), 4.89-4.80 (m, 1 H, cod-CH), 4.58-4.50 (m, 1 H, cod-CH), 3.71-
3.52 (m, 4 H, Pyr-5-H2 and cod-CH), 2.74-2.54 (m, 3 H, CHH’P and cod-H), 2.38-
2.22 (m, 2 H, Pyr-3-HH’ and cod-H), 2.22-1.82 (m, 11 H, CHH’P, Pyr-3-HH’, Pyr-4-H2, 
cod-H and Cy/Cy’-H), 1.82-1.55 (m, 7 H, Cy/Cy’-H), 1.55-1.45 (m, 2 H, cod-H and 
Cy/Cy’-H), 1.45-1.20 (m, 8 H, cod-H and Cy/Cy’-H), 1.20-1.02 (m, 2 H, Cy/Cy’-H), 
0.97-0.81 (m, 1 H, cod-H) ppm. 13C{1H} NMR (101 MHz, CD2Cl2): δ = 165.2 (s,          
BzTh-2-C), 161.8 (q, 1JC,B = 50 Hz, ArF-i-C), 148.8 (s, BzTh-3a-C), 134.9 (s, ArF-m-CH), 
129.6-128.3 (m, ArF-m-CH), 127.0 (s, BzTh-5-CH), 127.0 (s, BzTh-7a-C), 124.7 (q, 
1JC,F = 272 Hz, ArF-CF3), 124.1 (s, BzTh-6-CH), 122.2 (s, BzTh-4-CH), 121.7 (s,           
BzTh-7-CH), 117.6 (s, ArF-p-CH), 94.4 (d, 2JC,P = 9.2 Hz, cod-CH), 92.9 (d, 
2JC,P = 14 Hz, cod-CH), 65.7 (s, cod-CH), 60.9 (d, 2JC,P = 6.4 Hz, Pyr-2-CH), 58.1 (s, 
cod-CH), 53.6 (s, Pyr-5-CH2), 37.7 (d, 3JC,P = 3.8 Hz, cod-CH2), 37.2 (d, 1JC,P = 25 Hz, 
Cy-1-CH), 36.7 (d, 3JC,P = 10 Hz, cod-CH2), 33.6 (s, Pyr-3-CH2), 32.9 (d, 1JC,P = 27 Hz, 
CH2P), 32.2 (d, 1JC,P = 25 Hz, Cy’-1-CH), 29.5-29.2 (m, Cy/Cy’-CH2), 28.8 (s,            
Cy/Cy’-CH2), 27.2-26.6 (m, cod-CH2 and Cy/Cy’-CH2), 26.1 (s, Cy/Cy’-CH2), 25.8 (s, 
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Cy/Cy’-CH2), 24.8 (br d, 3JC,P = 2.4 Hz, cod-CH2), 24.6 (s, Pyr-4-CH2) ppm. 
31P{1H} NMR (162 MHz, CD2Cl2): δ = 22.9 (s) ppm. 19F{1H} NMR (377 MHz, CD2Cl2): 
δ = − 62.8 (s) ppm. IR (neat): ߥ෤ = 2936m, 2859m, 1611w, 1544m, 1453m, 1354s, 1273s, 
1115s, 1003w, 887m, 839m, 747m, 713m, 680m cm−1. MS (FAB, NBA): m/z (%) = 
716 (36), 715 (100, M+), 714 (23), 713 (59), 605 (13), 604 (14), 603 (27), 601 (16). [ߙ]஽ଶ଴ = + 123 (c = 0.450, CHCl3). Elemental analysis: calc. C 48.71%, H 3.77%, 
N 1.78%; found: C 48.78%, H 4.06%, N 1.91%. 
 
[(η4-1,5-Cyclooctadiene)-((S)-2-{2-[(diphenylphosphino)methyl]pyrrolidin-1-yl}-1-
methyl-1H-benzo[d]imidazole)-iridium(I)]-tetrakis[3,5-bis(trifluoromethyl)phenyl] 
borate ((S)-CIm1) 
 
Complex (S)-CIm1 (92%) was prepared according to general procedure 8 from ligand 
(S)-LIm1 and [Ir(cod)Cl]2. 
C65H50N3PIrBF24 (1563.08 g·mol−1): 
m.p. 88-91 °C. 1H NMR (400 MHz, CD2Cl2): δ = 7.95 (d, 3JH,H = 8.0 Hz, 1 H,             
BzIm-4-H), 7.73 (br s, 8 H, ArF-o-H), 7.58-7.51 (m, 6 H, Ph-o-H and ArF-p-H), 7.47-
7.40 (m, 3 H, Ph’-o-H and Ph-p-H), 7.38-7.29 (m, 2 H, Ph’-p-H and BzIm-5-H), 7.29-
7.19 (m, 3 H, Ph-m-H and BzIm-6-H), 7.18-7.08 (m, 3 H, Ph’-m-H and BzTh-7-H), 5.89-
5.76 (m, 1 H, Pyr-2-H), 4.71-4.63 (m, 1 H, cod-CH), 4.63-4.55 (m, 1 H, cod-CH), 4.13-
4.02 (m, 2 H, Pyr-5-HH’ and cod-CH), 3.54 (s, 3 H, NCH3), 3.56-3.41 (m, 2 H,             
Pyr-5-HH’ and CHH’P), 2.82-2.67 (m, 3 H, Pyr-3-HH’, cod-CH and cod-H), 2.54-
2.44 (m, 1 H, CHH’P), 2.43-2.34 (m, 1 H, cod-H), 2.34-2.21 (m, 3 H, Pyr-4-HH’ and 
cod-H), 2.19-1.93 (m, 4 H, Pyr-3-HH’, Pyr-4-HH’ and cod-H), 1.64-1.41 (m, 2 H,         
cod-H) ppm. 13C{1H} NMR (101 MHz, CD2Cl2): δ = 161.8 (q, 1JC,B = 50 Hz, ArF-i-C), 
154.5 (s, BzIm-2-C), 138.0 (s, BzIm-3a-C), 134.9 (s, ArF-o-CH), 134.6 (s, BzIm-7a-C), 
133.9 (d, 2JC,P = 13 Hz, Ph-o-CH), 131.8 (s, Ph-p-CH), 131.2-130.3 (m, Ph’-p-CH,          
Ph-m-CH and Ph-i-C), 129.7-128.2 (m, Ph’-i-C, Ph’-o-CH, Ph’-m-CH, and ArF-m-CH), 
124.6 (q, 1JC,F = 272 Hz, ArF-CF3), 123.4 (s, BzIm-6-CH), 123.3 (s, BzIm-5-CH), 
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119.3 (s, BzIm-4-CH), 117.6 (br s, ArF-p-CH), 109.6 (s, BzIm-7-CH), 95.6 (d, 
2JC,P = 10 Hz, cod-CH), 88.7 (d, 2JC,P = 15 Hz, cod-CH), 64.2 (s, cod-CH), 
62.0 (2JC,P = 10 Hz, Pyr-2-CH), 60.9 (d, cod-CH), 53.4 (s, Pyr-5-CH2), 37.4 (d, 
1JC,P = 34 Hz, CH2P), 36.8 (s, cod-CH2), 35.1 (d, 3JC,P = 12 Hz, Pyr-3-CH2), 33.9 (s,          
cod-CH2), 32.3 (s, NCH3), 28.6 (s, cod-CH2), 26.0 (s, cod-CH2), 24.9 (s, Pyr-4-CH2) ppm. 
31P{1H} NMR (162 MHz, CD2Cl2): δ = 18.6 (s) ppm. 19F{1H} NMR (377 MHz, CD2Cl2): 
δ = − 62.6 (s) ppm. IR (neat): ߥ෤ = 2970w, 2883w, 1610w, 1541m, 1481m, 1456w, 1352s, 
1273s, 1115s, 999w, 885m, 838m, 742m, 711m cm−1. MS (FAB, NBA): 
m/z (%) = 701 (39), 700 (100, M+), 699 (25), 698 (63), 590 (21), 589 (15), 588 (37), 
587 (13), 586 (32), 585 (11), 584 (13), 508 (12). [ߙ]஽ଶ଴ = + 15.8 (c = 1.13, CHCl3). 
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6.7 
Phosphinohydrazones and Precursors: Preparation and 
Analytical Data 
 
(S)-2-(Bromomethyl)-1-nitrosopyrrolidine ((S)-123) 
 
(S)-(1-Nitrosopyrrolidin-2-yl)methanol[118] (6.30 g, 48.4 mmol, 1.0 eq.) and 
tetrabromomethane (24.6 g, 74.2 mmol, 1.5 eq.) were mixed in dichloromethane  (95 mL) 
at 0 °C in an ice bath. Triphenylphosphine (19.0 g, 72.4 mmol, 1.5 eq.) was then added 
portion wise. The yellowish reaction mixture was then allowed to warm to room 
temperature overnight, where it turned brownish. The mixture was reduced to dryness 
under rotatory evaporation. The crude was purified by column chromatography on silica 
gel (7.5 x 19 cm), eluting with cyclohexane/ethyl acetate (8:2). The product (S)-123 was 
isolated as a yellowish solid (8.50 g, 44.0 mmol, 91%). 
C5H9BrN2O (193.04 g·mol−1): 
m.p. 45-47 °C. Rf = 0.18 (SiO2, cyclohexane/ethyl acetate 8:2). 1H NMR (400 MHz, 
CDCl3): δ = 4.76-4.66/4.52-4.44* (m, 1 H, Pyr-2-H), 4.44-4.36/3.87-3.82* (m, 1 H, 
CHH’Br), 4.14-4.04/3.72-3.66* (m, 1 H, CHH’Br), 3.75-3.70/3.60-3.50* (m, 1 H,          
Pyr-5-HH’), 3.57-3.52 (m, 1 H, Pyr-5-HH’), 2.87-1.82 (m, 4 H, Pyr-H) ppm. 
13C{1H} NMR (101 MHz, CDCl3): δ = 60.9/56.8* (Pyr-2-CH), 51.0/46.2* (s,               
Pyr-5-CH2), 34.3/32.1* (s, CH2Br), 29.2/28.5 (s, Pyr-3-CH2), 22.5/20.7* (s,                     
Pyr-4-CH2) ppm. In the 1H and 13C NMR spectra the title compound can be seen as a 
mixture of rotamers in a ratio close to 1:1 and therefore nuclei, which are detected twice 
are marked with an asterisk. IR (neat): ߥ෤ = 2986m, 2953m, 2934m, 2884m, 1472m, 
1417m, 1399s, 1364s, 1336s, 1319m, 1272s, 1196m, 1170m, 1138m, 1007s, 963m, 
927m, 878m, 809s, 706s cm−1. MS (EI, 70 eV): m/z (%) = 194 (18), 192 (18, M+), 
113 (100), 99 (97), 83 (22), 82 (32), 69 (28), 68 (12), 55 (30), 42 (11), 41 (20), 39 (11). [ߙ]஽ଶ଴ = − 103 (c = 2.04, CHCl3). 
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(S)-2-[(Diphenylphosphino)methyl]-1-nitrosopyrrolidine ((S)-122) 
 
To a solution of (S)-2-(bromomethyl)-1-nitrosopyrrolidine ((S)-123, 500 mg, 2.59 mmol, 
1.0 eq.) in abs. tetrahydrofuran (5 mL) was added under argon atmosphere a 0.5 M 
solution of potassium diphenylphosphide in tetrahydrofuran (6.70 mL, 3.37 mmol, 
1.3 eq.) at 0 °C in an ice bath. The reaction mixture was then allowed to stir at 0 °C for 
30 minutes before it was filtered through celite under inert atmosphere. The solvent was 
removed in vacuo and the residue was purified by column chromatography on silica gel 
(4 x 17 cm), eluting with cyclohexane/ethyl acetate (8:2). The title compound (S)-122 
was obtained as a colorless semisolid (698 mg, 2.34 mmol, 90%). 
C17H19N2OP (298.32 g·mol−1): 
Rf = 0.26 (SiO2, cyclohexane/ethyl acetate 8:2). 1H NMR (400 MHz, CDCl3): δ = 7.66-
7.27 (m, 10 H, Ph/Ph’-H), 4.49-4.36 (m, 1 H, Pyr-2-H), 4.36-4.26/3.74-3.62* (m, 1 H, 
Pyr-5-HH’), 4.18-4.08/3.56-3.46* (m, 1 H, Pyr-5-HH’), 3.22-3.14/2.96-2.89* (m, 1 H, 
CHH’P), 2.38-1.79 (m, 5 H, CHH’P and Pyr-H) ppm. 13C{1H} NMR (101 MHz, CDCl3): 
δ = 138.0 (d, 1JC,P = 11 Hz, Ph-i-C), 136.8 (d, 1JC,P = 12 Hz, Ph’-i-C), 133.1/133.0* (d, 
2JC,P = 19 Hz, Ph-o-CH), 132.7/132.6* (d, 2JC,P = 19 Hz, Ph’-o-CH), 129.2/129.3* (s,   
Ph-p-CH), 129.1-128.5 (m, Ph/Ph’-CH), 59.8/55.3* (d, 2JC,P = 22 Hz, Pyr-2-CH), 
50.4/45.7* (s, Pyr-5-CH2), 34.6/30.9* (d, 1JC,P = 15 Hz, CH2P), 31.2/30.1* (d, 
3JC,P = 7.4/8.4 Hz, Pyr-3-CH2), 22.8/21.1* (s, Pyr-4-CH2) ppm. 31P{1H} NMR (162 MHz, 
CDCl3): δ = – 22.2/– 22.8* (s) ppm. In the 1H, 13C and 31P NMR spectra the title 
compound can be seen as a mixture of rotamers in a ratio close to 1:5 and therefore 
nuclei, which are detected twice are marked with an asterisk. IR (neat): ߥ෤ = 3052w, 
2967m, 2943m, 2877m, 1480, 1432s, 1413s, 1301s, 1271s, 1167w, 1095w, 999w, 740m, 
696s  cm−1. MS (EI, 70 eV): m/z (%) =298 (1, M+), 268 (20), 202 (19), 201 (100), 
199 (21), 183 (29), 121 (35). [ߙ]஽ଶ଴ = − 67.8 (c = 1.56, CHCl3).  
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(S)-2-[(Diphenylphosphino)methyl]pyrrolidin-1-amine ((S)-114) 
 
To a solution of (S)-122 (200 mg, 670 μmol, 1.0 eq.) in abs. tetrahydrofuran (8 mL) was 
added drop wise at 0°C in an ice bath, under argon atmosphere, a 1 M solution of LiAlH4 
(2.00 mL, 2.00 mmol, 3.0 eq.) in tetrahydrofuran. The mixture was allowed to warm up to 
room temperature overnight (18 hours). Aqueous saturated Na2SO4 (8 mL) was added 
drop wise at 0°C and the biphasic mixture was stirred for 15 minutes at room 
temperature. The solids were filtered off and washed with tetrahydrofuran (3 x 10 mL). 
The filtrate was concentrated under reduced pressure to afford (S)-114 as a colorless 
semisolid in quantitative yield. The title compound was used in the next step without 
further purification. 
C17H21N2P (284.34 g·mol−1): 
1H NMR (400 MHz, CDCl3): δ = 7.45-7.12 (m, 10 H, Ph/Ph’-H), 3.19-3.10 (m, 1 H,  
Pyr-2-H), 2.80 (br s, 2 H, NH2), 2.65 (br d, 2JH,P = 13 Hz, 1 H, CHH’P), 2.20-2.03 (m, 
2 H, Pyr-5-H2), 2.01-1.80 (m, 2 H, CHH’P and Pyr-4-HH’), 1.70-1.48 (m, 2 H,               
Pyr-4-HH’ and Pyr-3-HH’), 1.47-1.35 (m, 1 H, Pyr-3-HH’) ppm. 13C{1H} NMR 
(101 MHz, CDCl3): δ = 139.2 (d, 1JC,P = 12 Hz, Ph-i-C), 138.6 (d, 1JC,P = 13 Hz, Ph’-i-C), 
132.9 (d, 2JC,P = 19 Hz, Ph-o-CH), 132.7 (d, 2JC,P = 19 Hz, Ph’-o-CH), 128.8-128.2 (m, 
Ph/Ph’-CH), 66.9 (d, 2JC,P = 18 Hz, Pyr-2-CH), 60.0 (s, Pyr-5-CH2), 32.9 (d, 
1JC,P = 12 Hz, CH2P), 30.1 (d, 3JC,P = 6.7 Hz, Pyr-3-CH2), 20.1 (s, Pyr-4-CH2) ppm. 
31P{1H} NMR (162 MHz, CDCl3): δ = – 21.6 (s) ppm. MS (EI, 70 eV): m/z (%) = 
285 (18), 284 (100, M+), 217 (10), 215 (15), 202 (17), 201 (41), 98 (40), 85 (30), 77 (13). 
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(S)-N-Cyclohexylidene-2-[(diphenylphosphino)methyl]pyrrolidin-1-amine ((S)-LH1) 
 
(S)-2-[(Diphenylphosphino)methyl]pyrrolidin-1-amine ((S)-114, 95.3 mg, 335 μmol, 
1.0 eq.) and cyclohexanone (100 μL, 965 μmol, 2.9 eq.) were mixed in abs. 
tetrahydrofuran (1 mL) in a flame-dried Young tube. The resulting mixture was then 
heated at reflux for 17 hours, before the solvent was removed in vacuo. The crude was 
purified by column chromatography on silica gel (2 x 15 cm), eluting with 
cyclohexane/ethyl acetate (9:1 → 8:2). The title compound (S)-LH1 was obtained as a 
colorless semisolid (98.0 mg, 269 μmol, 80%). 
C23H29N2P (364.46 g·mol−1): 
Rf = 0.37 (SiO2, cyclohexane/ethyl acetate 8:2). 1H NMR (500 MHz, CDCl3): δ = 7.52-
7.37 (m, 4 H, Ph/Ph’-o-H), 7.37-7.23 (m, 6 H, Ph/Ph’-H), 3.11-2.33 (m, 2 H, Pyr-5-HH’ 
and Pyr-2-H), 2.55-2.40 (m, 2 H, CHH’P and Cy-H), 2.37-2.10 (m, 4 H, Pyr-5-HH’ and 
Cy-H), 2.10-1.89 (m, 2 H, CHH’P and Pyr-3-HH’), 1.82-1.33 (m, 9 H, Pyr-3-HH’,       
Pyr-4-H2 and Cy-H) ppm. 13C{1H} NMR (101 MHz, CDCl3): δ = 168.6/162.5* (s, C=N), 
140.1/139.9* (d, 1JC,P = 14 Hz, Ph-i-C), 139.6/139.5* (d, 1JC,P = 14 Hz, Ph’-i-C), 
132.8 (br d, 2JC,P = 19 Hz, Ph-o-CH), 132.8 (br d, 2JC,P = 19 Hz, Ph’-o-CH), 128.5-
128.1 (m, Ph/Ph’-CH), 64.9 (br d, 2JC,P = 19 Hz, Pyr-2-CH), 54.1/53.7* (s, Pyr-5-CH2), 
36.2/35.9* (s, Cy-2/6-CH2), 33.9 (br d, 1JC,P = 12 Hz, CH2P), 29.8 (br d, 3JC,P = 7.2 Hz, 
Pyr-3-CH2), 29.4/29.1* (s, Cy-2/6-CH2), 28.4/27.7* (Cy-3/5-CH2), 26.6 (s, Cy-4-CH2), 
25.6/25.0* (s, Cy-3/5-CH2), 21.7/21.5* (s, Pyr-4-CH2) ppm. 31P{1H} NMR (162 MHz, 
CDCl3): δ = – 21.8/– 22.1* (s) ppm. In the 13C and 31P NMR spectra the title compound 
can be seen as a mixture of rotamers in a ratio close to 4:1 and therefore nuclei, which are 
detected twice are marked with an asterisk. IR (neat): ߥ෤ = 2930m, 2854m, 2835m, 
1695w, 1635w, 1447m, 1433s, 1184m, 1119m, 1037w, 906w, 740m, 696s cm−1. MS (EI, 
70 eV): m/z (%) = 364 (4, M+), 322 (25), 321 (100), 295 (39), 294 (51), 285 (15), 
284 (86), 282 (20), 281 (64), 280 (24), 268 (19), 201 (35), 200 (54), 199 (10), 185 (26), 
183 (39), 172 (19), 165 (63), 121 (13), 96 (58), 91 (12), 70 (16), 69 (17), 55 (23), 41 (14). [ߙ]஽ଶ଴ = + 91.1 (c = 0.320, CHCl3). 
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(S)-2-[(Diphenylphosphino)methyl]-N-[1-(4-methoxyphenyl)ethylidene]pyrrolidin-1-
amine ((S)-LH2) 
 
(S)-2-[(Diphenylphosphino)methyl]pyrrolidin-1-amine ((S)-114, 167 mg, 587 μmol, 
1.0 eq.) and para-methoxyacetophenone (106 mg, 706 μmol, 2.2 eq.) were mixed in abs. 
toluene (4 mL) in a flame-dried Young tube charged with molecular sieves. A tip of a 
spatula of para-toluenesulfonic acid was added and the resulting mixture was heated at 
reflux for 2 days. The solids were then filtered of and the solvent was evaporated in 
vacuo. The crude was purified by column chromatography on silica gel (2 x 15 cm), 
eluting with cyclohexane/ethyl acetate (19:1) to afford product (S)-LH2 (41.0 mg, 
98.4 μmol, 17%), as a colorless semisolid. 
C26H29N2OP (416.50 g·mol−1): 
Rf = 0.20 (SiO2, cyclohexane/ethyl acetate 19:1). 1H NMR (400 MHz, CD2Cl2): 
δ = 7.70 (d, 3JH,H = 8.9 Hz, 2 H, OPh-3/5-H), 7.58-7.51 (m, 2 H, PPh-o-H), 7.47-7.40 (m, 
2 H, PPh’-o-H), 7.38-7.23 (m, 6 H, PPh/Ph’-H), 6.84 (d, 3JH,H = 8.9 Hz, 2 H, OPh-2/6-H), 
3.83 (s, 3 H, OCH3), 3.43-3.26 (m, 2 H, Pyr-2-H and Pyr-5-HH’), 2.64 (“dt”, J = 14, 
3.3 Hz, 1 H, CHH’P), 2.45-2.35 (m, 1 H, Pyr-5-HH’), 2.17-2.03 (m, 5 H, CHH’P,             
Pyr-H and CH3), 1.96-1.74 (m, 2 H, Pyr-H), 1.72-1.58 (m, 1 H, Pyr-H) ppm. 
13C{1H} NMR (101 MHz, CD2Cl2): δ = 160.3 (s, OPh-1-C), 157.5 (s, C=N), 140.0 (d, 
1JC,P = 13 Hz, PPh-i-C), 139.4 (d, 1JC,P = 14 Hz, PPh’-i-C), 132.9 (d, 2JC,P = 19 Hz,           
PPh-o-CH), 132.8 (d, 2JC,P = 19 Hz, PPh’-o-CH), 132.2 (s, OPh-4-C), 128.4-128.1 (m, 
PPh/PPh’-CH), 127.4 (s, OPh-3/5-CH), 113.4 (s, OPh-2/6-CH), 65.5 (d, 2JC,P = 18 Hz, 
Pyr-2-CH), 55.3 (s, OCH3), 53.9 (s, Pyr-5-CH2), 34.2 (d, 1JC,P = 12 Hz, CH2P), 30.0 (d, 
3JC,P = 7.2 Hz, Pyr-3-CH2), 22.3 (s, Pyr-4-CH2), 15.9 (s, CH3) ppm. 31P{1H} NMR 
(162 MHz, CD2Cl2): δ = – 22.2 (s) ppm. IR (neat): ߥ෤ = 2997w, 2954m, 2933m, 2833m, 
1735m, 1606m, 1510s, 1433m, 1360m, 1308m, 1247s, 1174m, 1089w, 1032m, 831m, 
739m, 696m cm−1. MS (ESI): m/z (%) = 418 (30), 417 (100, [M + H]+), 297 (21), 
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295 (56), 282 (17), 228 (19), 216 (49), 172 (37), 161 (70), 156 (24). Partial oxidation was 
observed while measuring. [ߙ]஽ଶ଴ = + 311 (c = 0.270, CHCl3). 
 
(S)-(1-Aminopyrrolidin-2-yl)methanol ((S)-131) 
 
A solution of (S)-(1-nitrosopyrrolidin-2-yl)methanol[118] (640 mg, 4.92 mmol, 1.0 eq.) in 
abs. tetrahydrofuran (2 mL) was added drop wise to a suspension of LiAlH4 (380 mg, 
10.0 mmol, 2.0 eq.) in abs. tetrahydrofuran (17 mL) at 0°C in an ice bath, under argon 
atmosphere. The mixture was allowed to stir at 0°C for 30 minutes and then at room 
temperature for 3 hours. Aqueous saturated Na2SO4 (40 mL) was added drop wise at 0°C 
and the biphasic mixture was allowed to stir for 15 minutes at room temperature, where it 
turned colorless. The solids were filtered off and washed with tetrahydrofuran 
(3 x 20 mL). The filtrate was concentrated under reduced pressure to afford (S)-131 as a 
colorless solid, which was used in the next step without further purification. 
C5H12N2O (116.16 g·mol−1): 
1H NMR (400 MHz, CDCl3): δ = 4.60-4.61 (m, 2 H, NH2), 3.80-3.72 (m, 1 H, CHH’O), 
3.65-3.57 (m, 1 H, CHH’O), 3.30-3.21 (m, 1 H, Pyr-2-H), 3.20-3.08 (m, 1 H, OH), 2.57-
2.47 (m, 1 H, Pyr-5-HH’), 2.33-2.23 (m, 1 H, Pyr-5-HH’), 1.86-1.71 (m, 3 H, Pyr-H), 
1.48-1.36 (m, 1 H, Pyr-H) ppm. The spectroscopic data were consistent with those 
reported.[136] 
 
(S)-{1-[(2,4,6-Trimethylbenzylidene)amino]pyrrolidin-2-yl}methanol ((S)-134) 
 
2,4,6-Trimethylbenzaldehyde (400 μL, 2.71 mmol, 1.6 eq.) and (S)-(1-aminopyrrolidin-2-
yl)methanol ((S)-131, 191 mg, 1.64 mmol, 1.0 eq.) were mixed in abs. toluene (6 mL) and 
                                                             
[136] S. E. Denmark, J. P. Edwards, T. Weber, D. W. Piotrowski, Tetrahedron: Asymmetry, 2010, 21, 1278-
1302. 
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heated at reflux overnight. The mixture was reduced to dryness under reduced pressure 
and purified by column chromatography on silica gel (4 x 15 cm), eluting with 
cyclohexane/ethyl acetate (9:1). The title compound was obtained as a colorless semisolid 
(199 mg, 808 μmol, 49%). 
C15H22N2O (246.35 g·mol−1): 
Rf = 0.12 (SiO2, cyclohexane/ethyl acetate 9:1). 1H NMR (400 MHz, CDCl3): δ = 7.42 (s, 
1 H, CH=N), 6.86 (s, 2 H, Mes-H), 3.92-3.82 (m, 1 H, OH), 3.80-3.64 (m, 2 H,             
Pyr-2-H and CHH’O), 3.62-3.47 (m, 2 H, CHH’O and Pyr-5-HH’), 3.07-2.96 (m, 1 H, 
Pyr-5-HH’), 2.38 (s, 6 H, Mes-2/6-H3), 2.27 (s, 3 H, Mes-4-H3), 2.12-1.90 (m, 3 H,         
Pyr-H), 1.68-1.55 (m, 1 H, Pyr-H) ppm. 13C{1H} NMR (101 MHz, CDCl3): δ = 136.9 (s, 
Mes-4-C), 136.2 (s, Mes-2/6-C), 134.6 (s, CH=N), 130.5 (s, Mes-1-C), 129.5 (s,          
Mes-3/5-CH), 66.7 (s, CH2O), 64.6 (Pyr-2-CH), 48.8 (Pyr-5-CH2), 25.8 (s, Pyr-3-CH2), 
22.0 (s, Pyr-4-CH2), 21.3 (s, Mes-2/6-CH3), 21.1 (s, Mes-4-CH3) ppm. IR (neat): 
ߥ෤ = 3346m, 3261m, 2949m, 2914m, 2875m, 2808m, 1679m, 1610m, 1583m, 1431s, 
1369s, 1339s, 1298m, 1236m, 1194m, 1141m, 1105m, 1020s, 993m, 889s, 854s, 
729m cm−1. MS (ESI): m/z (%) = 248 (17), 247 (100, [M + H]+), 235 (27), 229 (11). [ߙ]஽ଶ଴ = − 147 (c = 1.10, CHCl3). 
 
(S)-2-(Bromomethyl)-N-(2,4,6-trimethylbenzylidene)pyrrolidin-1-amine ((S)-135) 
 
(S)-{1-[(2,4,6-Trimethylbenzylidene)amino]pyrrolidin-2-yl}methanol ((S)-134, 160 mg, 
649 μmol, 1.0 eq.) and tetrabromomethane (323 mg, 974 μmol, 1.5 eq.) were mixed in 
dichloromethane  (7 mL) at 0 °C in an ice bath. Triphenylphosphine (356 mg, 976 μmol, 
1.5 eq.) was added and the resulting yellowish reaction mixture was stirred at room 
temperature for 3 hours. The mixture was then reduced to dryness under rotatory 
evaporation. The crude was purified by column chromatography on silica gel (4 x 17 cm), 
eluting with cyclohexane/ethyl acetate (100:0 → 19:1) to afford product (S)-135 (139 mg, 
449 mmol, 69%). 
EXPERIMENTAL PART 
 
293 
C15H21BrN2 (309.24 g·mol−1): 
Rf = 0.61 (SiO2, cyclohexane/ethyl acetate 19:1). 1H NMR (400 MHz, CDCl3): 
δ = 7.42 (s, 1 H, CH=N), 6.85 (s, 2 H, Mes-H), 3.77-3.66 (m, 2 H, Pyr-2-H and CHH’Br), 
3.58-3.45 (m, 2 H, CHH’P and Pyr-5-HH’), 3.10-3.00 (m, 1 H, Pyr-5-HH’), 2.39 (s, 6 H, 
Mes-2/6-H3), 2.26 (s, 3 H, Mes-4-H3), 2.16-1.81 (m, 4 H, Pyr-H) ppm. 
 
(S)-2-[(Diphenylphosphino)methyl]-N-(2,4,6-trimethylbenzylidene)pyrrolidin-1-
amine ((S)-LH4) 
 
To a solution of (S)-2-(bromomethyl)-N-(2,4,6-trimethylbenzylidene)pyrrolidin-1-
amine ((S)-135, 120 mg, 388 μmol, 1.0 eq.) in abs. tetrahydrofuran (2 mL) was added 
under argon atmosphere a 0.5 M solution of potassium diphenylphosphide in 
tetrahydrofuran (1.00 mL, 500 μmol, 1.3 eq.) at 0 °C. The reaction mixture was allowed 
to stir at 0 °C for 1 hour before the solvent was removed in vacuo. The residue was 
purified by column chromatography on silica gel (3 x 17 cm), eluting with 
cyclohexane/ethyl acetate (30:1). The product (S)-LH4 was isolated as a colorless 
semisolid (155 mg, 374 μmol, 96%). 
Compound (S)-LH4 (62%) was as well prepared according to general procedure 10 from 
(S)-114 and 2,4,6-trimethylbenzaldehyde. 
C27H31N2P (414.52 g·mol−1): 
Rf = 0.25 (SiO2, cyclohexane/ethyl acetate 30:1). 1H NMR (400 MHz, CD2Cl2): δ = 7.55-
7.48 (m, 2 H, Ph-o-H), 7.47-7.39 (m, 2 H, Ph’-o-H), 7.37-7.26 (m, 7 H, Ph/Ph’-H and 
NCH), 6.83 (s, 2 H, Mes-H), 3.48-3.34 (m, 2 H, Pyr-2-H and Pyr-5-HH’), 3.03 (“dt”, 
J = 13, 3.5 Hz, 1 H, CHH’P), 2.98-2.89 (m, 1 H, Pyr-5-HH’), 2.37 (s, 6 H, Mes-2/6-CH3), 
2.25 (s, 3 H, Mes-4-CH3), 2.12-1.97 (m, 3 H, CHH’P, Pyr-3-HH’ and Pyr-4-HH’), 1.97-
1.84 (m, 1 H, Pyr-4-HH’), 1.77-1.64 (m, 1 H, Pyr-3-HH’) ppm. 13C{1H} NMR 
(101 MHz, CD2Cl2): δ = 139.7 (d, 1JC,P = 13 Hz, Ph-i-C), 138.6 (d, 1JC,P = 14 Hz,             
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Ph’-i-C), 136.0 (s, Mes-4-C), 135.9 (s, Mes-2/6-C), 132.9 (d, 2JC,P = 19 Hz, Ph-o-CH), 
132.9 (s, CH=N), 132.6 (d, 2JC,P = 19 Hz, Ph’-o-CH), 130.9 (s, Mes-1-C), 129.3 (s,           
Mes-3/5-CH), 128.6 (s, Ph-p-CH), 128.4 (d, 3JC,P = 6.9 Hz, Ph-m-CH), 128.4 (s,               
Ph’-p-CH), 128.3 (d, 3JC,P = 6.6 Hz, Ph’-m-CH), 62.2 (d, 1JC,P = 21 Hz, Pyr-2-CH), 
48.2 (s, Pyr-5-CH2), 33.6 (d, 1JC,P = 13 Hz, CH2P), 30.1 (d, 3JC,P = 6.5 Hz, Pyr-3-CH2), 
21.8 (s, Pyr-4-CH2), 21.5 (s, Mes-2/6-CH3), 20.7 (s, Mes-4-CH3) ppm. 31P{1H} NMR 
(162 MHz, CD2Cl2): δ = – 22.7 (s) ppm. IR (neat): ߥ෤ = 3069w, 2961m, 2911m, 2850w, 
1584w, 1480m, 1457m, 1432s, 1336w, 1319m, 1259w, 1240w, 1197w, 1164w, 1120m, 
1094m, 1027m, 743m, 674m cm−1. MS (ESI): m/z (%) = 415 (100, [M + H]+). [ߙ]஽ଶ଴ = − 11.2 (c = 0.501, CHCl3). 
 
(S)-N-(2,2-Dimethylpropylidene)-2-[(diphenylphosphino)methyl]pyrrolidin-1-
amine ((S)-LH5) 
 
Product (S)-LH5 (51%), isolated as a colorless semisolid, was prepared according to 
general procedure 10 from (S)-114 and trimethylacetaldehyde. 
C22H29N2P (352.45 g·mol−1): 
Rf = 0.22 (SiO2, cyclohexane/ethyl acetate 30:1). 1H NMR (400 MHz, CDCl3): δ = 7.60-
7.53 (m, 2 H, Ph-o-H), 7.46-7.38 (m, 2 H, Ph’-o-H), 7.38-7.24 (m, 6 H, Ph/Ph’-H), 
6.50 (s, 1 H, CH=N), 3.29-3.21 (m, 1 H, Pyr-5-HH’), 3.15-3.04 (m, 1 H, Pyr-2-H), 
3.01 (“dt”, J = 13, 3.1 Hz, 1 H, CHH’P), 2.63-2.53 (m, 1 H, Pyr-5-HH’), 2.04-1.86 (m, 
3 H, CHH’P, Pyr-3-HH’ and Pyr-4-HH’), 1.86-1.73 (m, 1 H, Pyr-4-HH’), 1.66-1.52 (m, 
1 H, Pyr-3-HH’), 1.07 (s, 9 H, tBu-H3) ppm. 13C{1H} NMR (101 MHz, CD2Cl2): 
δ = 146.8 (s, CH=N), 140.1 (d, 1JC,P = 13 Hz, Ph-i-C), 138.7 (d, 1JC,P = 14 Hz, Ph’-i-C), 
133.0 (d, 2JC,P = 19 Hz, Ph-o-CH), 132.6 (d, 2JC,P = 19 Hz, Ph’-o-CH), 128.5 (s,               
Ph-p-CH), 128.4 (d, 3JC,P = 6.7 Hz, Ph-m-CH), 128.3 (d, 3JC,P = 6.6 Hz, Ph’-m-CH), 
128.3 (s, Ph’-p-CH), 62.6 (d, 2JC,P = 20 Hz, Pyr-2-CH), 49.0 (s, Pyr-5-CH2), 34.5 (s,          
tBu-C), 33.0 (d, 1JC,P = 12 Hz, CH2P), 30.0 (d, 3JC,P = 5.7 Hz, Pyr-3-CH2), 28.2 (s,             
tBu-CH3), 21.4 (s, Pyr-4-CH2) ppm. 31P{1H} NMR (162 MHz, CD2Cl2): δ = – 22.4 
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(s) ppm. IR (neat): ߥ෤ = 2953m, 2898m, 2862m, 2820m, 1593m, 1435s, 1362m, 1371m, 
1186m, 1117m, 1109m, 1070m, 1027m, 736s, 692s cm−1. MS (ESI): m/z (%) = 353 (36, 
[M + H]+), 334 (23), 333 (100). Partial oxidation was observed while measuring. [ߙ]஽ଶ଴ = − 67.8 (c = 0.310, CHCl3). 
 
(S)-N-(Cyclohexylmethylene)-2-[(diphenylphosphino)methyl]pyrrolidin-1-
amine ((S)-LH6) 
 
Product (S)-LH6 (49%), isolated as a colorless semisolid, was prepared according to 
general procedure 10 from (S)-114 and cyclohexanecarboxaldehyde. 
C24H31N2P (378.49 g·mol−1): 
Rf = 0.23 (SiO2, cyclohexane/ethyl acetate 30:1). 1H NMR (400 MHz, CDCl3): δ = 7.57-
7.49 (m, 2 H, Ph-o-H), 7.47-7.38 (m, 2 H, Ph’-o-H), 7.37-7.24 (m, 6 H, Ph/Ph’-H), 
6.43 (“d”, 1 H, CH=N), 3.28-3.19 (m, 1 H, Pyr-5-HH’), 3.17-3.07 (m, 1 H, Pyr-2-H), 
2.95-2.87 (m, 1 H, CHH’P), 2.64-2.52 (m, 1 H, Pyr-5-HH’), 2.17-2.06 (m, 1 H, Cy-1-H), 
2.06-1.53 (m, 10 H, CHH’P, Pyr-H and Cy-H), 1.38-1.11 (m, 5 H, Cy-H) ppm. 
13C{1H} NMR (101 MHz, CD2Cl2): δ = 144.3 (s, CH=N), 140.3-139.3 (br, Ph-i-C), 
139.0-138.0 (br, Ph’-i-C), 133.1 (d, 2JC,P = 19 Hz, Ph-o-CH), 132.9 (d, 2JC,P = 19 Hz, Ph’-
o-CH), 128.9-127.9 (m, Ph/Ph’-CH), 62.4 (br d, 2JC,P = 21 Hz, Pyr-2-CH), 49.6 (s,            
Pyr-5-CH2), 41.4 (s, Cy-CH), 33.2 (br d, 1JC,P = 13 Hz, CH2P), 31.4 (br d, 3JC,P = 5.5 Hz, 
Pyr-3-CH2), 30.1 (s, Cy-CH2), 26.3 (s, Cy-CH2), 25.9 (br s, Cy-CH2), 21.5 (br s,            
Pyr-4-CH2) ppm. 31P{1H} NMR (162 MHz, CD2Cl2): δ = – 19.9/− 22.2* (s) ppm. In the 
31P NMR spectra the title compound can be seen as a mixture of rotamers in a ratio close 
to 1:5. IR (neat): ߥ෤ = 2920m, 2849m, 1373m, 1229m, 1206m, 1089m, 783m, 738m, 
696m cm−1. MS (ESI): m/z (%) = 380 (23), 379 (100, [M + H]+), 235 (18), 193 (25), 
149 (12), 130 (11). [ߙ]஽ଶ଴ = − 36.4 (c = 0.420, CHCl3). 
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6.8 
Hydrogenation Reactions: Procedures and Analytical Data 
 
6.8.1 
General Information, Working Techniques, and Standard Procedures 
 
General Information: 
The product yields obtained in the hydrogenation of any substrate presented in this thesis 
were determined by GC analysis and the products were not isolated. 
 
Working Techniques: 
The hydrogenation experiments were set up in a glove box, except otherwise noted below 
the respective table showing the hydrogenation results. In these cases the hydrogenations 
were prepared in air. The standard procedure is described below. When the temperature, 
the concentration, the reaction time, the pressure (5 bar) or the solvent was varied, the 
same procedure was followed taking into account the changes in reaction conditions. For 
reactions at elevated temperature the autoclave containing the reaction vials was 
immersed in a pre-heated oil bath for 5 minutes prior to the exposure to hydrogen. The 
solvents used for hydrogenation experiments were stored over aluminium oxide and 
filtered through a syringe filter prior to usage. 
 
Standard procedure for catalytic hydrogenations at elevated pressure (50 bar): 
The preparation of the reactions was carried out in a glove box under inert atmosphere. A 
stock solution of the individual ligand and [Ir(cod)2]BArF (1:1) or of the precatalyst was 
prepared in dichloromethane (5 mM in precatalyst). The substrate (250 µmol) was 
weighed into a separate vial and 0.5 mL of the stock solution (1 mol% of precatalyst) 
were added. A stir bar was added and four vials (1.5 mL) were placed into a 60-mL 
autoclave (Premex AG, Lengnau, Switzerland) which was closed in the glove box. The 
autoclave was purged, pressurized with H2 gas (Carbagas, Switzerland, 99.995%) and 
placed on a stirring plate. The mixtures were stirred at room temperature for 2 hours. 
After pressure release, the solution was concentrated in a stream of nitrogen and taken up 
in n-heptane (3 mL) and filtered through a short plug of silica gel (0.5 x 6 cm), eluting 
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with n-heptane/isopropanol (7:3). The filtrates were analyzed by GC and HPLC (see 
below for detailed analytical procedures). 
 
Standard procedure for catalytic hydrogenations at ambient pressure: 
The preparation of the reactions was carried out in a glove box under inert atmosphere 
and the reaction mixtures were prepared like in the procedure described above. The four 
vials (1.5 mL) were then placed into a flask equipped with a 24/40 joint which was closed 
with a rubber septum. A H2-filled balloon equipped with a needle was put on the septum, 
the flask was flushed with H2 by pulling vacuum and placed on a stirring plate. The 
mixtures were stirred at room temperature for the indicated time. After pressure release, 
the workup and analysis were carried out as described above. 
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6.8.2 
Hydrogenation Substrates and Products 
 
(E)-1,2-Diphenyl-1-propene (S1) 
 
The enantiomeric excess was determined by HPLC analysis on a chiral stationary phase 
and the conversion was determined by GC analysis.[60a] 
HPLC (Daicel Chiracel OJ, n-heptane/isopropanol 99:1, 0.5 mL∙min−1, 20 °C, 212 nm): 
tR = 14.1 min ((R)-P1), tR = 23.1 min ((S)-P1). 
GC (Restek Rxt-1701, 0.25 mm x 0.25 µm x 30 m, 60 kPa He, 100 °C/2 min, 7 °C∙min−1, 
250 °C/10 min): tR = 18.2 min (P1), tR = 21.0 min (S1). 
Substrate S1 is commercially available. 
 
6-Methoxy-1-methyl-3,4-dihydronaphthalene (S2) 
 
The enantiomeric excess was determined by HPLC analysis on a chiral stationary phase 
and the conversion was determined by GC analysis.[60a] 
HPLC* (Daicel Chiracel OD-H, n-heptane 100%, 0.5 mL∙min−1, 20 °C, 212 nm): 
tR = 20.4 min ((R)-P2), tR = 27.0 min ((S)-P2). 
GC (Restek Rxt-1701, 0.25 mm x 0.25 µm x 30 m, 60 kPa He, 100 °C/2 min, 7 °C∙min−1, 
250 °C/10 min): tR = 16.9 min (P1), tR = 18.3 min (S1). 
Substrate S2 was synthesized according to the reported procedure.[137] 
 
 
 
 
                                                             
[137] P. Schnider, Dissertation, University of Basel, 1996, pp.149-149. 
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(E)- and (Z)-2-(4-methoxyphenyl)-2-butene ((E)- and (Z)-S3) 
 
The enantiomeric excess was determined by HPLC or GC analysis on a chiral stationary 
phase and the conversion was determined by GC analysis.[60a] 
HPLC* (Daicel Chiracel OD-H, n-heptane 100%, 0.5 mL∙min−1, 20 °C, 220 nm): 
tR = 12.9 min ((S)-P3), tR = 14.3 min ((R)-P3). 
GC* (Chiraldex γ-cyclodextrin TFA G-TA, 0.25 mm x 0.12 µm x 30 m, 60 kPa H2, 
60 °C/30 min, 5 °C∙min−1, 100 °C, 20 °C∙min−1, 160 °C/10 min) : tR = 38.6 min ((R)-P3), 
tR = 38.4 min ((S)-P3). 
GC (Restek Rxt-1701, 0.25 mm x 0.25 µm x 30 m, 60 kPa He, 100 °C/2 min, 7 °C∙min−1, 
250 °C/10 min): tR = 11.9 min (P3), tR = 11.8 min ((Z)-S3), tR = 14.2 min ((E)-S3). 
Substrates (E)- and (Z)-S3 were synthesized according to the reported procedure.[138] 
 
(E)-Ethyl 3-phenylbut-2-enoate (S4) 
 
The enantiomeric excess was determined by GC analysis on a chiral stationary phase and 
the conversion was determined by GC analysis.[60a] 
GC* (Chiraldex γ-cyclodextrin TFA G-TA, 0.25 mm x 0.12 µm x 30 m, 100 kPa H2, 
85 °C/50 min, 10 °C∙min−1, 160 °C/10 min) : tR = 41.4 min ((R)-P4), tR = 43.2 min           
((S)-P4). 
GC (Restek Rxt-1701, 0.25 mm x 0.25 µm x 30 m, 60 kPa He, 100 °C/2 min, 7 °C∙min−1, 
250 °C/10 min): tR = 15.0 min (P4), tR = 17.2 min (S4). 
Substrate S4 is commercially available. 
 
 
 
                                                             
[138] P. Schnider, Dissertation, University of Basel, 1996, pp.147-147. 
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(E)-2-Methyl-3-phenylprop-2-en-1-ol (S5) 
 
The enantiomeric excess was determined by HPLC analysis on a chiral stationary 
phase.[139] The conversion was determined by GC analysis.[60a] 
HPLC* (Daicel Chiracel OD-H, n-heptane/isopropanol 95:5, 0.5 mL∙min−1, 40 °C, 
205 nm): tR = 14.8 min ((R)-P5), tR = 16.8 min ((S)-P5). 
GC (Restek Rxt-1701, 0.25 mm x 0.25 µm x 30 m, 60 kPa He, 100 °C/2 min, 7 °C∙min−1, 
250 °C/10 min): tR = 14.0 min (P5), tR = 15.7 min (S5). 
Substrate S5 is commercially available. 
 
(E)-Ethyl 2-methyl-3-phenylacrylate (S6a) 
 
The enantiomeric excess was determined by HPLC analysis on a chiral stationary 
phase.[140] The conversion was determined by GC analysis.[95a] 
HPLC* (Daicel Chiracel OB-H, n-heptane 100%, 0.5 mL∙min−1, 20 °C, 210 nm): 
tR = 22.7 min ((R)-P6a), tR = 25.3 min ((S)-P6a). 
GC (Restek Rxt-1701, 0.25 mm x 0.25 µm x 30 m, 60 kPa He, 100 °C/2 min, 7 °C∙min−1, 
250 °C/10 min): tR = 14.5 min (P6a), tR = 17.2 min (S6a). 
The synthesis of substrate S6a is reported.[95a] 
 
 
 
 
 
 
                                                             
[139] The absolute configuration of the products was assigned according to: G. Fronza, C. Fuganti, S. Serra, 
Eur. J. Org. Chem. 2009, 6160-6171. 
[140] The absolute configuration of the products was assigned according to: D. J. Shermer, P. A. Slatford, 
D. D. Edney, J. M. J. Williams, Tetrahedron: Asymmetry 2007, 18, 2845-2848. 
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(E)-Isopropyl 2-methyl-3-phenylacrylate (S6b) 
*
 
The enantiomeric excess was determined by HPLC analysis on a chiral stationary phase 
the absolute configuration of the products was assigned by correlation with previously 
reported data.[80] The conversion was determined by GC analysis. 
HPLC* (Daicel Chiracel OB-H, n-heptane 100%, 0.5 mL∙min−1, 20 °C, 210 nm): 
tR = 15.2 min ((R)-P6b), tR = 17.1 min ((S)-P6b). 
GC (Restek Rxt-1701, 0.25 mm x 0.25 µm x 30 m, 60 kPa He, 100 °C/2 min, 7 °C∙min−1, 
250 °C/10 min): tR = 15.3 min (P6b), tR = 18.5 min (S6b). 
 
(E)-Ethyl 2-methyl-5-phenylpent-2-enoate (S7) 
 
The enantiomeric excess was determined by HPLC analysis on a chiral stationary phase 
and the conversion was determined by GC analysis.[80] 
HPLC* (Daicel Chiracel OB-H, n-heptane/isopropanol 97:3, 0.8 mL∙min−1, 20 °C, 
210 nm): tR = 9.7 min ((+)-P7), tR = 13.8 min ((–)-P7). 
GC (Restek Rxt-1701, 0.25 mm x 0.25 µm x 30 m, 60 kPa He, 100 °C/2 min, 7 °C∙min−1, 
250 °C/10 min): tR = 19.1 min (P7), tR = 20.9 min (S7). 
The synthesis of substrate S7 is reported.[80] 
 
(E)-Ethyl 3-methyl-5-phenylpent-2-enoate (S8) 
 
The enantiomeric excess was determined by HPLC analysis on a chiral stationary phase 
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 and the conversion was determined by GC analysis.[80,95] 
HPLC* (Daicel Chiracel OJ-H, n-heptane/isopropanol 98:2, 0.5 mL∙min−1, 20 °C, 
210 nm): tR = 15.2 min ((R)-P8), tR = 16.3 min ((S)-P8). 
GC (Restek Rxt-1701, 0.25 mm x 0.25 µm x 30 m, 60 kPa He, 100 °C/2 min, 7 °C∙min−1, 
250 °C/10 min): tR = 19.5 min (P8). 
The synthesis of substrate S8 is reported.[80,95] 
 
(E)-Ethyl 2,3-diphenylacrylate (S9) 
 
The enantiomeric excess was determined by HPLC analysis on a chiral stationary phase 
and the conversion was determined by GC analysis. 
HPLC* (Daicel Chiracel OD-H, n-heptane/isopropanol 99:1, 0.5 mL∙min−1, 20 °C, 
254 nm): tR = 12.6 min ((–)-P9), tR = 15.0 min ((+)-97).  [ߙ]஽ଶ଴ = + 50.7 (c = 1.31, CHCl3) 
for 56% ee. 
GC (Restek Rxt-1701, 0.25 mm x 0.25 µm x 30 m, 60 kPa He, 100 °C/2 min, 7 °C∙min−1, 
250 °C/10 min): tR = 24.3 min (P9), tR = 25.9 min (S9). 
(E)-Ethyl 2,3-diphenylacrylate (S9): α-phenylcinnamic acid (2.00 g, 8.92 mmol) was 
mixed with ethanol (3 mL), a drop of H2SO4 and a tip of a spatula of MgSO4 were added, 
before the mixture was heated at reflux overnight. The excess ethanol was evaporated, the 
residue was dissolved in diethyl ether (30 mL) and washed with aqueous saturated 
NaHCO3 (2 x 30 mL). The ethereal solution was dried over MgSO4 and reduced to 
dryness. Column chromatography on silica gel (4 x 18 cm), eluting with 
cyclohexane/ethyl acetate (19:1), afforded the compound as an oil (1.73 g, 6.85 mmol, 
77%). The spectroscopic data were consistent with those reported.[141] 
 
 
 
 
                                                             
[141] L. Boros, K. Felföldi, I. Pálinko, Molecules 2004, 9, 256-263. 
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(E)-4-Phenylpent-3-en-2-one (S10a) 
 
The enantiomeric excess was determined by HPLC analysis on a chiral stationary phase 
and the absolute configuration of the products was assigned by correlation with 
previously reported data.[34d] The conversion was determined by GC analysis. 
HPLC* (Daicel Chiracel AS-H, n-heptane/isopropanol 99.3:0.7, 0.5 mL∙min−1, 20 °C, 
210 nm): tR = 20.5 min ((S)-P10a), tR = 24.7 min ((R)-P10a) tR = 26.6/31.2/34.2 min 
(P10’). 
GC (Restek Rxt-1701, 0.25 mm x 0.25 µm x 30 m, 60 kPa He, 100 °C/2 min, 7 °C∙min−1, 
250 °C/10 min): tR = 13.9 min (P10a), tR = 16.0 min (S10a), tR = 13.7/14.3 min (P10’). 
The synthesis of substrate S10a was carried out according to the reported procedure.[34d] 
 
(E)-1,3-Diphenylbut-2-en-1-one (S10b) 
 
The enantiomeric excess was determined by HPLC analysis on a chiral stationary phase 
and the absolute configuration of the products was assigned according to previously 
reported data.[34d] The conversion was determined by GC-analysis. 
HPLC* (Daicel Chiracel AD-H, n-heptane/isopropanol 97:3, 0.5 mL∙min−1, 20 °C, 
230 nm): tR = 13.4 min ((S)-P10b), tR = 15.7 min ((R)-P10b). 
GC (Restek Rxt-1701, 0.25 mm x 0.25 µm x 30 m, 60 kPa He, 100 °C/2 min, 7 °C∙min−1, 
250 °C/10 min): tR = 25.2 min (P10b), tR = 28.2 min (S10b). 
The synthesis of substrate S10b was carried out according to the reported procedure.[34d] 
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N-(1-Phenylethylidene)-aniline (S11) 
 
The enantiomeric excess was determined by HPLC analysis on a chiral stationary phase 
and the conversion was determined by GC analysis.[60a] 
HPLC* (Daicel Chiracel OD-H, n-heptane/isopropanol 99:1, 0.5 mL∙min−1, 20 °C, 
210 nm): tR = 24.6 min ((S)-P11), tR = 33.0 min ((R)-P11). 
GC (Macherey-Nagel Optima 5-Amin, 0.25 mm x 0.25 µm x 30 m, 60 kPa He, 
100 °C/8 min, 5 °C∙min−1, 250 °C/10 min): tR = 35.3 min (P1), tR = 36.0 min (S11). 
Substrate S11 is commercially available. 
 
2-(4-Methoxyphenyl)-1-butene (S12) 
 
The enantiomeric excess was determined by HPLC on a chiral stationary phase and the 
conversion was determined by GC analysis.[60a] 
HPLC* (Daicel Chiracel OD-H, n-heptane 100%, 0.5 mL∙min−1, 20 °C, 220 nm): 
tR = 12.9 min ((S)-P3), tR = 14.3 min ((R)-P3). 
GC (Restek Rxt-1701, 0.25 mm x 0.25 µm x 30 m, 60 kPa He, 100 °C/2 min, 7 °C∙min−1, 
250 °C/10 min): tR = 11.9 min (P3), tR = 13.0 min (S12). 
Substrate S12 was synthesized according to the reported procedure.[142] 
 
 
 
 
 
                                                             
[142] P. Schnider, Dissertation, University of Basel, 1996, pp.148-148. 
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(E)-3-Benzylidenedihydrofuran-2(3H)-one (S13) 
 
The enantiomeric excess was determined by HPLC analysis on a chiral stationary 
phase.[34e] The conversion was determined by GC analysis. 
HPLC* (Daicel Chiracel OB-H, n-heptane/isopropanol 90:10, 0.8 mL∙min−1, 35 °C, 
210 nm): tR = 21.3 min ((+)-P13), tR = 23.7 min ((−)-P13). 
GC (Restek Rxt-1701, 0.25 mm x 0.25 µm x 30 m, 60 kPa He, 100 °C/2 min, 7 °C∙min−1, 
250 °C/10 min): tR = 22.5 min (P13), tR = 26.5 min (S13). 
The synthesis of substrate S13 is reported.[34e] 
 
1-Methoxy-4-(3-methylbut-2-en-2-yl)-benzene (S16) 
 
The enantiomeric excess was determined by GC analysis on a chiral stationary phase and 
the conversion was determined by GC analysis.[32] 
GC* (Brechbühler β-cyclodextrin DEtTButSil (SE54), 0.25 mm x 0.25 µm x 25 m, 
60 kPa H2, 80 °C/0 min, 1 °C∙min−1, 120 °C/0 min, 10 °C∙min−1, 180 °C/2 min): 
tR = 14.1 min ((+)-P16), tR = 14.4 min ((−)-P16). 
GC (Restek Rxt-1701, 0.25 mm x 0.25 µm x 30 m, 60 kPa He, 100 °C/2 min, 7 °C∙min−1, 
250 °C/10 min): tR = 13.6 min (P16), tR = 14.1 min (S16). 
Substrate S16 was synthesized according to the reported procedure.[32,143] 
 
 
 
 
 
 
                                                             
[143] M. V. Troutman, D. H. Appella, S. L. Buchwald, J. Am. Chem. Soc. 1999, 121, 4916-4917. 
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6.9 
Allylic Alkylation Reactions: Procedures and Analytical Data 
 
6.9.1 
Standard Procedure 
 
Standard procedure for catalytic allylic alkylation reactions: 
A solution of [(π-C3H5)PdCl]2 (2.50 mol%) and the individual ligand (2.50 mol%) in 
dichloromethane (2.0 mL) was degassed in a Young tube by three freeze-pump-thaw 
cycles and afterwards stirred at 50 °C for 2 hours. In a second Young tube the desired 
allylic alkylation substrate (200-300 μmol, 1.0 eq.) was dissolved in dichloromethane 
(250 μM). To this solution N,O-Bis(trimethylsilyl)acetamide (BSA, 3.0 eq.), the 
nucleophile (109 or 138, 3.0 eq.) and catalytic amounts of KOAc were added. After three 
freeze-pump-thaw cycles the catalyst solution was added via syringe and the resulting 
mixture was stirred at room temperature for the indicated time. After this time, the 
reaction was diluted with diethyl ether (20 mL) and washed with ice-cold aqueous 
saturated NH4Cl (10 mL).The aqueous phase was extracted with diethyl ether (3 x20 mL), 
the combined organic extracts were dried over MgSO4 and the solvent was removed 
under reduced pressure. The products were purified by column chromatography on silica 
gel, eluting with hexanes/ethyl acetate/NEt3 (18:1:1).[144] 
 
6.9.2 
Allylic Alkylation Substrates and Products 
 
Allylic Alkylation of (E)-1,3-di-phenylallyl acetate (S22) 
 
The enantiomeric excess was determined by HPLC analysis on a chiral stationary phase. 
HPLC* (Daicel Chiracel AD-H, n-heptane/isopropanol 97:3, 1.0 mL∙min−1, 20 °C, 
254 nm): tR = 22.7 min ((R)-P22a), tR = 32.8 min ((S)-P22a). 
                                                             
[144] C. Ebner, Dissertation, University of Basel 2012, pp 146-146. 
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HPLC* (Daicel Chiracel AD-H, n-heptane/isopropanol 97:3, 0.9 mL∙min−1, 20 °C, 
254 nm): tR = 16.3 min ((R)-P22b), tR = 18.0 min ((S)-P22b). 
Substrate S22 is commercially available. 
 
Allylic Alkylation of (E)-1,3-di-para-tolylallyl benzoate (S23) 
 
The enantiomeric excess was determined by HPLC analysis on a chiral stationary 
phase.[144] 
HPLC* (Daicel Chiracel AD-H, n-heptane/isopropanol 97:3, 0.9 mL∙min−1, 20 °C, 
254 nm): tR = 16.2 min ((R)-P23), tR = 17.5 min ((S)-P23). 
The synthesis of substrate S23 is reported.[144] 
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6.10 
Crystallographic Data 
 
The X-ray structures were measured by DR. MARKUS NEUBURGER and DR. SILVIA 
SCHAFFNER at the Department of Chemistry of the University of Basel. Data collection 
was performed with a Nonius KappaCCD, Brucker Kappa Apex2 or Area diffractometer 
using graphite-monochromated Mo Kα-radiation. The structure was solved with 
SIR92[145] and refined with Crystals.[146] Chebychev polynominal weights were used to 
complete the refinement.[147] Hydrogen were added geometrically. The absolute 
configuration and enantiopurity was determined by refinement of the flack parameter.[148] 
Plots were produced using Mercury. 
Compound (R)-CA1 [((S)-LU315)Ir(cod)]PF6 (S)-CH6 
molecular formula C63H54BF24IrNOP C45H47F6IrN2OP2 C64H55BF24IrN2P 
molecular weight [g∙mol−1] 1601.99 1000.04 1542.10 
shape plate block block 
color red orange orange 
temperature [K] 173 123 123 
radiation Mo Kα Mo Kα Mo Kα 
wavelength [Å] 0.71073 0.71073 0.71073 
crystal system monoclinic monoclinic trigonal 
space group P 21 P 21 P 31 
crystal size [mm3] 0.02 x 0.12 0.29 0.13 x 0.17 x 0.23 0.060 x 0.140 x 0.240 
a [Å] 12.4504(5) 10.5337(4) 13.0070(3) 
b [Å] 17.8211(7) 17.8052(7) 13.0070(3) 
c [Å] 14.5518(6) 10.5342(4) 31.8014(8) 
α [°] 90 90 90 
β [°] 91.605 96.692(2) 90 
γ [°] 90 90 120 
unit cell volume [Å3] 3227.5(2) 1962.28(13) 4659.41(19) 
Z 2 2 3 
F(000) 1588 1000 2298 
θ-range for data 
collection [°] 26.829 39.388 32.575 
calculated 
density [Mg∙cm−3] 1.648 1.692 1.649 
adsorption 
coefficient μ [mm−1] 2.288 3.552 2.290 
measured reflections 27501 92339 46182 
independent reflexions 13056 22164 20770 
used reflections 9783 20688 13566 
parameter refined 920 515 839 
R[a] 0.0344 0.0124 0.0452 
Rw[b] 0.0505 0.0135 0.0582 
goodness-of-fit 1.2318 1.0832 1.0898 
Flack parameter 0.004(6) 0.0069(13) − 0.008(5) 
[a] R = ƩǀǀF0ǀ−ǀFCǀǀ/ƩǀF0ǀ; [b] Rw = {Ʃ[w(F0−FC)2]/Ʃ[w(F0)2]}1/2 
                                                             
[145] A. Altomare, G. Cascarno, C. Giacovazzo, A. Guagliardi, J. Appl. Crystallogr. 1993, 26, 343-350. 
[146] D. Watkin, R. Cooper, C. K. Prout, Z. Kristallogr. 2002, 217, 429-430. 
[147] J. R. Carruthers, D. J. Watkin, Acta Crystallogr., Sect. A. Found Crystallogr. 1979, A35, 698-699. 
[148] H. D. Flack, G. Bernardinelli, J. Appl. Crystallogr. 2000, 33, 1143-1148. 
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Iridium complexes with chiral P,N ligands are highly efficient catalysts for the 
asymmetric hydrogenation of a broad range of substrates. Since the highest 
enantioselectivities achieved vary strongly depending on the substrate type, it is important 
to developed new ligands, which have various features, even if many catalysts have 
already been designed. Herein were presented various proline-based ligands, which 
coordinate to iridium in a bidentate fashion involving two different coordinating atoms. 
First were described proline-based P,O ligands followed by two types of proline-based 
P,N ligands (Figure 29). 
 
In chapter 2, proline-based P,O ligands were investigated as ligands for the iridium-
catalyzed asymmetric hydrogenation. These ligands were clearly identified to coordinate 
in a bidentate fashion to iridium, forming a seven-membered metallacycle upon binding 
of both the carbonyl oxygen atom and the phosphorus atom. L-Proline proved to be a 
convenient enantiopure modular scaffold and allowed to prepare in a few steps a broad 
library of chiral compounds in good yields, possessing a wide range of steric and 
electronic properties. Three subclasses of these ligands were developed and investigated: 
carbamatophosphines, amidophosphines and ureaphosphines.  
 
These P,O ligand/iridium complexes were evaluated in the asymmetric hydrogenation of 
a series of substrates spanning a range of coordinating properties. Especially trisubstituted 
functionalized and unfunctionalized alkenes were reduced with good enantioselectivities 
within short reaction times. Depending on both the structure of the coordinating carbonyl 
substituent and the phosphine substituents, moderate to high enantioselectivities were 
achieved. The catalysts, which were identified to allow for the highest enantioselectivities 
in the asymmetric hydrogenation of routinely tested substrates (e.g. (E)-1,2-diphenyl-1-
propene, (E)-ethyl 3-phenylbut-2-enoate, (E)-2-methyl-3-phenylprop-2-en-1-ol) were also 
tested in the asymmetric hydrogenation of more challenging prochiral trisubstituted 
alkenes, such as α,β-unsaturated carboxylic esters and ketones. Excellent conversions and 
enantiomeric excesses up to 95% were obtained when amidophosphines or 
ureaphosphines were employed as ligands in the iridium-catalyzed asymmetric 
hydrogenation of trisubstituted α,β-unsaturated, α-substituted carboxylic esters 
(see Figure 29). Even more impressive is the level of enantioselectivity obtained for             
α,β-unsaturated ketones, which were reduced with several catalysts that afforded 
enantioselectivities much higher than previously reported P,N-based systems. 
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Inspired by the structure of these P,O ligands, analogous proline-based P,N ligands were 
investigated. It was thought to combine two features: the well known chelation of 
P,N ligands to iridium and the proline-based structure. Also these P,N ligands were easily 
prepared and steric and electronic properties were studied by varying the substituents at 
the phosphorus atom and the pyrrolidine nitrogen. These P,N ligands form a seven-
membered metallacycle when bound to iridium. Previous reports suggest that the size of 
the metallacycle strongly influences the enantioselectivity of the asymmetric reduction, 
therefore these ligands were investigated. These novel complexes showed excellent 
activities in the asymmetric reduction of unfunctionalized and functionalized 
trisubstituted standard substrates, albeit with slightly lower enantioselectivities than those 
achieved with P,O ligand/iridium complexes. 
 
Furthermore, a second type of proline-based P,N ligand was investigated (Figure 29). 
This scaffold involves a hydrazone moiety in combination with a phosphorus donor and 
forms a six-membered metallacycle, upon binding to iridium. The synthesis of these 
ligands proved to be more difficult. Only aldhydrazones could be synthesized efficiently 
and complexed to iridium. These complexes were tested as catalysts for the 
hydrogenation of alkenes and proved to be quite unstable. Nevertheless, these complexes 
reduced some substrates with full conversions, but fluctuating enantioselectivities. 
 
Finally, in chapter 5, the proline-based P,O ligands presented in chapter 1 were 
investigated as chiral ligands for the palladium-catalyzed allylic alkylation reaction. This 
project was carried out in collaboration with DR. CHRISTIAN EBNER. Good activities were 
achieved but the enantioselectivities were low and can not compete with previously 
reported ligands for this transformation. 
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Figure 29. Proline-based ligands and iridium complexes investigated herein. 
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